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“Well, in our country,” said Alice, still panting a little, “you’d generally 
get to somewhere else—if  you run very fast for a long time, as we’ve 
been doing.”
“A slow sort of  country!” said the Queen. “Now, here, you see, it takes 
all the running you can do, to keep in the same place. If  you want to 
get somewhere else, you must run at least twice as fast as that!”
— Lewis Carrol, Alice in Wonderland
Malaria is conventionally controlled using drugs to kill the parasite that causes the disease, 
and insecticides and nets to prevent the parasites transmission to and from mosquitoes. One 
report estimates that in Africa 663 million cases of  malaria were averted by control efforts 
between 2000 and 2015 [1]. It seems logical that gains of  the same scale could continue if  we 
were to apply the same control with greater coverage and intensity. Yet hundreds of  millions 
are spent improving our control tools, seeking alternatives, and striving to better understand 
the malaria parasite and its vector. This begs questions: Is too much money funnelled into 
novel malaria research? Is malaria a problem of  politics and misdirected funding?
 Malaria control is currently effective because we so recently developed our latest 
controls that the parasite has not yet adapted to coexist with them. There is no denying 
this adaptation has begun though. Along the east African coast mosquitoes that once bit 
exclusively at night and indoors are now biting earlier and outdoors [2, 3]. Where mosquitoes 
with a strict preference for human blood have been wiped out by indoor insecticides, other 
less picky species are maintaining transmission by feeding on cattle as well as humans 
[4]. Perhaps more concerning are the changes that have been observed in mosquito and 
parasite physiology. Mosquito resistance to pyrethroid insecticides, which dominate the 
market because of  their use in insecticide treated nets, is now widespread [5, 6]. In border 
regions of  Thailand, Myanmar and Cambodia derivatives of  Artemisinin, the latest and 
best antimalarial treatment, are becoming less effective against local parasite strains [7]. 
 Our current arsenal of  treatments and vector controls are variations on approaches 
used throughout history; avoid being bitten, kill the mosquito, and treat the infection. 
Though fundamentally these approaches have changed very little, the effectiveness of  
our tools current iterations is the product of  an historic struggle against mosquito and 
parasite evolution. Resistance to quinine, used in various forms since the 17th century, has 
been repeatedly observed but develops slowly and sporadically [8], whereas Chloroquine 
and Sulphadoxine-pyrimethamine resistance emerged rapidly in the 1960’s and 1990’s 
respectively, and now appear fixed in many parasite populations [9]. The same pattern has 
been observed with insecticides, with mosquitoes becoming resistant in a matter of  years to 
each generation of  compounds since resistance to DDT emerged in the 1950’s [6]. 
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We have been running to stand still in the fight against malaria, and only in recent years do 
we appear to be outpacing it. By continuing to explore the biology and epidemiology of  the 
parasite and its vector, scientists hope to reveal vulnerabilities to exploit with new drugs, 
vaccines, and insecticides. Without continued research, fundamental and applied, the 
potency of  our current approaches will fall and the hard-won gains of  the last two decades 
will slow and reverse. Investing to ensure these tools continue to be effective is, simply put – 
fine. With this approach we can hope to keep controlling malaria, and continue its decline 
to an extent. To get ‘somewhere else’ though, we must bring new weapons to the fight. 
Plasmodium, parasitism, and transmission
The organisms that cause malaria in humans belong to the phylum Apicomplexa, and the 
genus Plasmodium. Apicomplexans evolved from a photosynthetic ancestor, diverging from 
colpodellids (marine predators) and chromerids (coral like photoautotrophs) by adopting 
obligate parasitism [10]. The phylum is divided into two classes; the Conoidasida, which 
are monoxenic parasites, meaning they require a single host, and the dixenic Aconoidasida, 
which need two hosts to complete their life cycle. Plasmodium belongs to the latter group, its 
life cycle being complete after development in both a female mosquito and a vertebrate host. 
The life stages emerging in each are essential, but the mosquito is the parasite’s definitive 
host, in which it reaches sexual maturity.
 The transmission event for Plasmodium is the mosquito bite. With the exception of  
Toxorhynchites mosquitoes, which form their own subfamily, females in all mosquito genera 
feed on vertebrate blood [11]. This is not because they require blood for survival (females 
get their basic nutrients from sugar and water, as males do) but because it is required for egg 
development. When mating, the female mosquito stores the male’s sperm in a specialised 
structure called a spermathecae, so that afterwards she may produce eggs continually. Egg 
development (the gonotrophic cycle) takes three days, and as long as she feeds at least 
once in each cycle, an inseminated female mosquito may lay for the rest of  her life. The 
malaria parasite appears to take advantage of  this behaviour, so from our point of  view 
it’s easy to think of  mosquitoes as the parasites tool; an insect used as a middle-man to get 
between infected and uninfected vertebrates. From a parasitological viewpoint, however, 
the vertebrate is the tool, serving only as a reservoir for parasites attempting the jump 
from one mosquito to the next. The term ‘vector’ then is epidemiological. A vector of  
human pathogens is an animal or object which carries a pathological agent and facilitates 
its transmission to humans. If  a good vector is one regularly exposed to humans, increasing 
the chance of  pathogen transmission, then blood-feeding (or haematophagous) vectors are 
exceptional. The parasite’s aim, to gain entry to its secondary host, aligns precisely with 
that of  the vector, which is to regularly feed. Because of  the obvious efficiency of  this 
vector-parasite system, blood-feeding animals have evolved to co-exist with an array of  
vertebrate viruses, microbes and parasites. These vary widely in medical importance, but 
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mosquitoes receive particular notoriety as sources of  disease. In 2014 Bill Gates announced 
on his web-blog that mosquitoes were the ‘deadliest of  all animals’, killing more people than 
humans and the next 13 most dangerous animals combined [12]. News of  the Zika fever 
virus disease epidemic in South America has recently put Aedes aegypti and Aedes albopictus 
in the spotlight; mosquitoes otherwise infamous as vectors of  the yellow fever, dengue 
fever, and chikungunya fever viruses. Medically important species in the genera Culex also 
transmit deadly arboviruses, including West Nile and Japanese encephalitis, as well as the 
worm Wucheria bancrofti, which causes lymphatic filariasis. Collectively, mosquito borne 
diseases are responsible for approximately 725,000 deaths every year [12]. Of  these, more 
than half  are the result of  infection with malaria parasites [13]. Though Culex mosquitoes, 
as well as Aedes, Mansonia, and Culiseta, host a range of  Plasmodium species, none develop 
fully or cause pathology in humans [14]. Only mosquitoes in the genus Anopheles transmit 
the parasites that cause human malaria, and of  the 461 described Anopheles species, 41 are 
thought to be medically important, because they host species able to infect and develop in 
humans and because of  their at least partial preference for our blood [15]. 
 Five Plasmodium species cause malaria in humans: Plasmodium malariae, Plasmodium 
ovale, Plasmodium knowlesi, Plasmodium vivax and Plasmodium falciparum. P. malariae is 
widespread in areas of  sub-Saharan Africa and the southwest Pacific (prevalence in these 
areas has exceeded 15-30%) but elsewhere the parasite occurs only at low frequency (1-2%) 
[16, 17]. P. ovale is uncommon, accounting for around 1-3% of  reported cases in areas of  
West Africa and Southeast Asia [16], though molecular surveillance put its prevalence in 
some regions closer to 5-10% [16, 18]. P. knowlesi, the rarest of  the five species, is a monkey 
parasite, and its infection of  humans is a by-product of  only partially overlapping biology 
with human infecting species, which makes humans paratenic (or accidental) hosts, from 
which it cannot be transmitted back to mosquitoes. P. knowlesi infection is viewed as an 
emerging public health issue because of  its severe pathology and the increasing exposure 
of  forest workers to mosquitoes that typically feed on the parasites primary reservoir; 
long- and pig-tailed macaques [19]. Because passage through this reservoir is thought to be 
essential for the parasites development, the impact of  P. knowlesi is restricted geographically 
to macaque habitats in South-east Asia.
 The most important Plasmodium species, in terms of  their public health impact and 
economic burden, are P. vivax and P. falciparum. These have the widest distribution of  the 
five species, and together account for the majority of  the diseases’ total annual incidence. P. 
vivax causes what was once termed ‘benign’ malaria, because though causing severe disease 
the parasite rarely kills [20]. There were an estimated 13.8 million cases of  vivax infection 
in 2015, distributed through Central and South America, South Asia, areas of  East Africa, 
and the South Pacific, where the parasite is transmitted by a wide variety of  Anopheles 
vectors [13, 21]. P. falciparum is responsible for almost all global malaria related mortality. 
It is transmitted in all sub-tropical regions, but is most abundant in sub-Saharan Africa, 
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where its dominant vectors are mosquitoes of  the Anopheles gambiae species complex. The 
WHO estimates that in 2015 there were 212 million (148-304 million) malaria cases and 
429,000 (235,000-639,000) deaths due to malaria [13, 22]. Factors that contribute to these 
figures include the likelihood of  being bitten by an infected vector, the organism’s complex 
pathology in humans, and the outcome of  our attempts to control the parasite on both these 
fronts. On the other hand the number of  people at risk of  infection, cited as 3.2 billion, is 
simply a product of  the distribution and competence of  mosquito vectors [23]. The impact 
of  malaria today therefore reflects the remarkable efficiency and adaptability of  Anopheles 
mosquitoes. In his book The Creation: An Appeal to Save Life on Earth Professor Emeritus and 
Pulitzer Prize winning naturalist E. O. Wilson wrote: “It would be a mistake to let even 
one species out of  the millions on earth go extinct”. For A. gambiae, he reconsidered: “Keep 
their DNA for future research…and let them go” [24, 25].
 Anopheles thrive in harsh conditions. They lay their eggs on the surface of  multiple and 
often temporary pools of  water such as collect in pots, animal troughs, and tyre tracks, 
ensuring genetic variability (by reducing the chance their offspring all hatch from and 
breed around one site), safety from predation, and rapid population growth even when 
rainfall is sporadic [26-28]. Breeding site preference, and behaviour during feeding and 
resting vary between species. The most efficient vectors are specialised to feed on humans 
(anthropophily), though many prefer to feed on non-human animals (zoophily) or do so 
only when humans are scarce or vector controls force a behavioural shift in primary host 
choice [29]. Anopheles gambiae sensu stricto is anthropophilic, and enhances its chances of  
reproduction by biting indoors (endophagy) at times when humans are likely to be asleep, 
and defenceless. Other vectors show more plasticity in host choice or biting behaviour, 
making them more robust to the effects of  indoor controls like insecticide treated nets and 
walls [2-4, 29, 30]. Like most blood feeding insects, to facilitate blood-feeding Anopheles 
secrete a mixture of  proteins and pharmacologic substances into the skin before and during 
feeding, many of  which are specific to the mosquito’s genus and even to the gambiae complex 
[31-33]. Anti-inflammatory and analgesic compounds decrease swelling, redness and pain 
to maximise the chances of  feeding undisturbed [34], while anti-platelet aggregators and 
vasodilators ensure that blood-flow is unimpeded until the insect has finished feeding. 
 A vectors efficiency is traditionally defined as its ‘vectorial capacity’ (C) [35], which is 
an estimate of  the number of  mosquitoes that would bite and become infected daily from a 
single, perfectly infective human. A vectors efficiency may also be considered part of  a larger 
equation describing the efficiency of  the parasite it transmits. This ‘basic reproduction rate’ 
(R0) is the number of  secondary human infections arising from a single infected human, 
over the course of  a parasites developmental cycle [36, 37]. Vectorial capacity therefore 
describes the mosquito’s raw efficiency, while R0 describes the likelihood that Plasmodium 
will proliferate in a population. An R0 of  more than one indicates that a disease will remain 
or spread, as at least 1 secondary infection will result from each primary infection. Less 
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than 1, and a disease will decline until its elimination. In the recent outbreak in West Africa, 
the R0 of  Ebola-virus disease was estimated to lie between 1.51 and 2.53 [38]. Estimates 
for the R0 of  P. falciparum in Africa vary from <1 to more than 3000 [39]. This disparity 
is due in large part to the efficiency of  the malaria vector; in Tororo, Uganda, at the turn 
of  the century, individuals were observed being bitten by 160 A. gambiae s.s per night [40], 
providing numerous opportunities for transmission. The real multiplier though is the 
parasites behaviour within its hosts. The Ebola virus is spread from person to person by 
contact with infected bodily fluids. Severe symptoms develop rapidly and lead to the host’s 
death within days of  becoming infectious, creating a limited window for virus transmission. 
Left untreated, infective Plasmodium may circulate in semi-immune individuals for many 
months, and even after treatment infective parasites may remain viable for 6-8 weeks [41]. 
Given their short life span (2-6 weeks) infective mosquitoes are assumed to remain infective 
for life [42]. A single malaria infected individual may therefore seed hundreds of  mosquito 
infections, thousands if  the biting rate is as intense as it was in Tororo, each of  which could 
infect a new person at every feed until the end of  its life. Of  all the elements of  the malaria 
transmission cycle in the Ross-McDonald equation, reducing the number of  mosquitoes 
biting humans has the greatest impact on the parasites reproductive rate [39]. However, the 
chronicity of  mosquito and human infection is also hugely influential to the parasites ability 
to survive and reproduce, particularly in populations under intense malaria control.
Pathogenesis and the malaria life cycle
The Plasmodium life cycle is complex, passing through motile and immotile, sexual and 
asexual, and intra- and extracellular forms as it develops in humans and mosquitoes. The 
parasites genome is haploid for almost the whole cycle, except during stages that emerge in 
the mosquito after their transmission from capillaries in the skin. The parasites development 
in mosquitoes is complete once it reverts to haploidy by forming asexual sporozoites, which 
need to be present in the insect’s salivary glands to pass into the human blood supply when 
the mosquito feeds. Sporozoites develop inside oocysts bound to the mosquito’s gut wall, 
which become implanted shortly after the parasite is ingested (Figure 1).
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Figure 1. The Plasmodium life cycle (A. J. Knell, Malaria: A Publication of the Tropic Programme of the 
Wellcome Trust, 1991)
When sporozoites are fully formed and have enlarged the oocyst to breaking point (around 
10 days after the infective blood-meal), they rupture its walls and are carried in the 
mosquito’s haemolymph to the insect’s salivary glands, which they bind to and invade. 
When an infectious mosquito probes a human’s skin in search of  a blood-meal, it salivates 
and may egest sporozoites into the bite wound, most of  the time not directly penetrating 
a vessel but feeding on blood from lacerated capillaries that pools below the epidermis 
[43, 44]. Sporozoites deposited in the skin migrate through its tissues to enter the blood, 
where they are quickly carried to the sinusoid vessels supplying the liver [44, 45]. Here they 
interact with molecules produced by liver cells lining the vessel (hepatocytes and stellate 
cells) which bind and remove the parasite from circulation [46]. The parasites then enter the 
sinusoidal layer through Kupfer cells, cross the ‘space of  disse’ underlying the vessels walls, 
and begin their invasion of  the liver parenchyma [47]. After penetrating and migrating 
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through several hepatocytes, sporozoites are encapsulated in one to form a parasitophorous 
vacuole. Encapsulated sporozoites then break down and undergo shizogony, developing 
into thousands of  merozoites which are released back into the sinusoids (for P. falciparum 
around seven days after the initial infection) (Figure 2). 
 In the blood, P. falciparum merozoites quickly recognise, bind, and invade red-blood cells 
(RBCs). Within RBCs they form the characteristically ring shaped early trophozoite, and 
eventually mature into a multinucleated shizont (Figure 3). A small number of  shizonts 
become committed to sexual development, forming gametocytes to ensure transmission 
to the parasites definitive host [48]. The vast majority of  shizonts develop asexually, 
expanding within their human host to increase the transmission potential of  future parasite 
generations [49]. Asexually replicating shizonts each form 16-32 new merozoites, which 
burst from their first host cell around two days after its invasion to infect new healthy cells.
 The life cycle stages preceding the invasion of  RBC’s by merozoites (collectively, the 
pre-erythrocytic stages) are non-pathogenic. Malaria symptoms begin after the first waves 
of  cell rupture and invasion that occur during erythrocytic shizogony. Though differing 
with species and depending on the size of  the parasite inoculum and liver biomass, 
symptoms of  P. falciparum infection may begin 10 days or so after an infectious mosquitoes 
bite. Non-severe blood stage P. falciparum infection is characterised by a fever that cycles 
as parasites replicate in the blood, and other symptoms of  febrile illness like headache, 
dizziness, aches, pallor, and nausea. Anaemia begins when the rate of  erythrocyte invasion 
begins to exceed the rate at which new cells are formed, which can continue until so few 
healthy erythrocytes remain transfusion is required to prevent death. Continued infection 
compounds the declining cell count both by suppressing the production of  new RBCs, and 
stimulating responses that enhance the clearance of  healthy ones [50]. Left untreated, P. 
falciparum can replicate to the extent that more than 10% of  all a person’s RBCs may be 
simultaneously parasitized [51]. In real terms, this means that a 50kg child could host more 
than 19 billion infected RBCs. ‘Hyperparasitaemia’ of  this sort is extreme, but far more 
scant infections can cause debilitating disease and death, depending on the susceptibility 
of  the host. Symptoms of  severe malaria include pulmonary oedema, hyperpyrexia, renal 
failure, hypoglycaemia, and acidosis [52]. The most deadly effects of  P. falciparum infection 
are an artefact of  the parasites ability to bind to the walls of  small blood vessels in the brain 
and placenta, a process facilitated by its variant surface antigens (VSA). Though its precise 
pathology remains unclear, sequestration of  parasites in these organs leads to the occlusion 
of  micro-capillaries, leaving parts starved of  fresh blood [53]. Cerebral malaria may lead 
rapidly to coma and death, while placental malaria has often fatal consequences for first 
time mothers and their foetuses.
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Figure 2. Liver cell invasion and asexual development (A. J. Knell, Malaria: A Publication of the Tropic 
Programme of the Wellcome Trust, 1991)
Figure 3. Red blood cell invasion by merozoites (a), asexual development resulting in schizont 
formation and merozoite formation (b), and merozoite rupture and onward invasion (c) (A. J. Knell, 
Malaria: A Publication of the Tropic Programme of the Wellcome Trust, 1991)
Because its shizonts produce fewer merozoites, which are limited by their preference for 
newly formed RBC’s (reticulocytes), P. vivax infections tend to expand more slowly and to 
a lower overall density than P. falciparum [20]. Febrile illness associated with vivax malaria 
is severe and quick to take hold, and the parasites formation of  dormant hypnozoites in the 
liver can cause the disease to relapse for years after the inoculating infection [54]. However, 
because P. vivax has a lower multiplication rate (rarely resulting in severe anaemia), and 
because they cannot sequester in blood vessels, the disease is rarely fatal. In most cases, P. 
falciparum too does not cause severe disease. As demonstrated by the reproductive rate of  
the Ebola virus, dramatic clinical outcomes are a poor evolutionary strategy. The malaria 
parasite benefits from a longer period of  productivity within and transmission from its 
secondary host, which is facilitated by the partial immunity conferred by repeated parasite 
exposure.. Unlike many bacterial and viral diseases though, for which a single exposure 
can confer protection lasting many years, protective immunity to malaria builds slowly 
and can be lost rapidly [55]. Severe pathology in falciparum malaria is suffered mostly 
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by children, who lack immunity, and pregnant women, who are subject to the effects 
of  the parasites placental sequestration [52]. In the first 6-9 months of  life infants suffer 
relatively mild symptoms of  disease, but by their first birthday are generally fully vulnerable 
symptomatic infection. This pattern parallels the decay of  maternal antibodies transferred 
in utero, though it is unclear whether these actively protect infants from infection or if  they 
represent a biomarker for maternal exposure that masks other mechanisms of  protection 
[56-58]. Regardless, the first infections following this period of  protection are the most 
dangerous. Surviving children become resistant to severe malaria, but remain vulnerable 
to febrile illness. By late childhood, continuing or repeat infection builds from partial to 
clinical immunity, as immune cells become capable of  decreasing parasite replication in 
the blood and lessening symptom severity. Sterile protection against blood stage infection 
is rarely, if  ever observed in nature. Though parasite density and symptom severity may 
decrease throughout life to the point where infection becomes asymptomatic, there is no 
evidence of  acquired immunity that lessens the likelihood of  blood stage infection [59]. 
 The speed with which immunity develops changes from area to area in line with the 
intensity of  local transmission. In areas with intense transmission child mortality may be 
high, but clinical immunity in surviving children is likely to develop quickly in response to 
frequent immune exposure. In areas with little transmission or sporadic epidemics, these 
patterns may be less defined, with clinical immunity developing later in life, and older 
individuals suffering more severe symptoms because of  their low cumulative exposure [60]. 
In most settings, older children and adults exist in a state of  partial immunity, suffering 
‘uncomplicated’ infections and acting as a quiet reservoir of  transmission. It is essential 
here that symptom presentation is not interpreted as an indicator of  parasite density or 
infectivity; though immunity from febrile illness always necessitates some limitation of  
parasite growth, parasite density in asymptomatic patients may still be high. Asymptomatic 
infections are also not necessarily benign; infection in the absence of  febrile illness may 
have untold consequences on infant mortality and cognitive development, population 
productivity, and resistance to other diseases [61]. Transmission intensity and patterns of  
immunity and clinical presentation have an impact on the way infections and the infectious 
reservoir are identified.
Immunity and gametocytes
Immune responses to the malaria parasite may be targeted at any of  its developmental forms, 
and valuable findings have been made by observing the response to direct immunisation 
with various active and inactive forms of  the parasite. Exposure to attenuated sporozoites 
(that do not progress to liver stage infection) and live sporozoites (utilising drugs to supress 
the blood stages of  otherwise viable parasites) induces complete protection in humans 
and non-human animal models. This ‘sterile’ protection may act by targeting the exposed 
sporozoite during its travel to the liver, preventing invasion of  the livers cells, or directly 
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killing infected hepatocytes [62, 63]. In animal models sporozoites inoculated into the skin 
may be immobilised by sporozoite specific antibodies, including antibodies specific to the 
thick coat of  circumsporozoite protein (CSP) that protects the parasite and facilitates its 
traversal in both skin and liver [44]. Antibodies specific to sporozoite surface proteins are 
observed in individuals naturally exposed to the parasites, but their protective efficacy is 
unknown [64, 65]. Evidence from challenge studies indicates that the sterile protection 
induced by sporozoites is controlled after hepatocyte invasion by the activation of  both 
CD4+ and CD8+ T-cells [65-68]. However T-cell mediated killing has questionable 
relevance to the development of  natural immunity, having only been observed in response 
to unnaturally high exposure to sporozoites [68], or sporozoite antigen [69]. In endemic 
settings adults and children cleared of  all infection become re-infected at similar rates, 
indicating that natural immunity has limited control over the speed and success of  pre-
erythrocytic development [70, 71]. 
 Perhaps logically, given their relative biomass and longevity, natural immunity to 
malaria appears to be targeted to the parasites pathological blood stages. Before the end of  
the Second World War it was common to treat sufferers of  neurosyphilis with pyrotherapy, 
using malaria parasites as a treatment to induce fever and thus clear the bacterial infection. 
The parasites were incubated in long-term patients who were or became immune to malaria 
disease after repeated treatment [72]. In 1948, one such patient was exposed to the bites of  
2000 P. vivax infected mosquitoes, and remained free from blood stage parasites and disease 
despite developing liver stage infection [73, 74]. The hypothesis that natural immunity was 
focused on parasites replicating in the blood was confirmed in the 1960’s, when adults with 
clinical immunity were shown to remain asymptomatic after direct inoculation with blood 
stage parasites [75]. The dominant role of  antibody in this protection was shown after 
passively transferred IgG from immune adults reduced symptoms and parasite density in 
children suffering severe disease [76]. Anti-malarial antibodies have since been shown to 
prevent erythrocyte invasion by merozoites [77], activate complement protein fixation [78], 
stimulate neutrophil respiratory burst [79], opsonise infected cells for phagocytosis [80, 
81], reverse rosetting (clumping of  infected cells) [80] and prevent cells from binding to the 
endothelium of  the microvasculature [82, 83]. Antibodies specific to numerous parasite 
proteins have been linked with protection empirically or epidemiologically, including 
proteins involved in the parasites cell recognition and invasion machinery (Erythrocyte 
binding antigens; EBA [84], Reticulocyte binding homologue proteins; PfRH5 [84], Apical 
membrane antigen; AMA-1 & Rhoptry neck protein; RON2 [85], Merozoite surface 
protein; MSP-1 [78, 86, 87]), and proteins expressed on the erythrocyte surface (encoded 
by the var gene family, including Erythorcyte membrane protein 1; PfEMP-1 & var2csa 
[80, 82, 83]). However, none of  these responses has been linked unambiguously with the 
development of  natural immunity to blood stage infection [88]. Though there is mounting 
evidence that malaria infection may actively limit the effectiveness of  immune memory, the 
22
apparently ineffective development of  clinical immunity may also in part be explained by 
the complexity of  protein expression on the surface of  infected erythrocytes [55]. PfEMP-1 
is trafficked to ‘knob’ structures that develop on the erythrocyte surface after merozoite 
invasion, where it facilitates cell binding to ligands in the human microvasculature and thus 
prevents parasite clearance in the spleen. Individuals exposed to natural infection develop 
strong antibody responses to the protein, which have been linked with protection from 
disease [89-92]. However, as it is encoded by a transcriptionally regulated family of  60 var 
genes, each producing a distinct protein variant, the antibody response is only effective 
while all clonal parasites express a specific protein. Epigenetic mechanisms ensure that 
only one protein is produced at any time and facilitates spontaneous antigenic variation to 
ensure that novel variants become fixed in the parasite population in response to immune 
pressure [93, 94]. By cycling through the var gene repertoire the parasite ensures that it can 
survive for many generations, causing chronic disease and slowing the development of  
clinical immunity [95-97].
 The final stage exposed to the immune system within humans is the infective gametocyte. 
As the parasites entire reproductive potential depends on this small portion of  its total 
biomass, it is essential that gametocytes are able to avoid recognition and clearance. As 
for the VAR gene family, sexual commitment in shizonts is controlled epigenetically [93]. 
Sexual development is initiated by a signalling pathway during shizont development that 
releases the Apatella2-g (ap2-g) gene from transcriptional regulation, causing all the cells 
daughter merozoites to express the protein. When these invade new erythrocytes, instead 
of  proceeding through continued rounds of  asexual endomitotic replication, each produces 
a haploid gametocyte [98, 99]. Each sexually committed shizont produces daughter cells 
of  a single sex, and in natural infections the resulting gametocytes exist at a ratio of  
approximately 3-5 females to 1 male [100, 101]. P. falciparum gametocytes take 10-12 days 
to mature to a stage at which they are ready to infect mosquitoes. They do this in five stages, 
the first two of  which are morphologically indistinguishable from immature trophozoites. 
From stage III onwards the cell elongates to become the characteristically crescent shaped 
mature gametocyte (Figure 4).
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Figure 4. Female and male mature (Stage V) P. falciparum gametocytes (A. J. Knell, Malaria: A Publication 
of the Tropic Programme of the Wellcome Trust, 1991)
Unlike asexual parasites, gametocytes cannot bind to blood vessel walls because they 
appear to lack parasite-derived erythrocyte surface proteins. This is a double edged sword; 
the gametocyte remains immunologically silent, shielded within a relatively unchanged 
erythrocyte, but because they cannot sequester by binding to the microvasculature they 
risk splenic clearance. Instead, immature gametocytes sequester in the extravascular 
compartments of  the bone marrow and spleen [102-104]. Uninfected erythrocytes and 
immature gametocytes can pass into and out of  these areas, but gametocytes between stages 
II-IV appear to reduce the deformability of  their host cells to such a degree that they cannot 
escape to re-enter the circulation [105, 106]. Sequestration may therefore either be active, 
involving enhanced production of  gametocytes in these extravascular spaces, or passive; 
they may simply be retained [105]. There is also very recent evidence for the presence 
of  previously unidentified ligands on the early gametocyte surface, which may facilitate 
homing or binding to erythroblastic islands in the bone marrow parenchyma (Dantzler, in 
press). What is clear is that when gametocytes approach maturity, they once again become 
flexible, egressing the bone marrow into the blood, where they are once again vulnerable to 
immune recognition and clearance. Though there is a hypothesis that antibody responses 
to unknown proteins on the surface of  intact gametocytes may limit gametocyte density, 
the lack of  known parasite-derived surface antigens makes it unlikely that antibodies acting 
directly on gametocytes would have significant effect on their infectivity [107]. However, 
this is not to say that humans do not produce important antibody responses to gametocytes. 
Mature gametocytes express a raft of  unique proteins, as well as many RNA transcripts that 
are then subject to translational repression until the parasites development in mosquitoes 
[108, 109]. Though many proteins essential to parasites development in the mosquito are 
part of  the ‘repressome’, others are fully expressed by the gametocyte within humans, 
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so elicit antibodies when they break down and become exposed to immune cells in the 
blood. Antibodies produced against these proteins form the basis of  naturally acquired 
‘transmission reducing immunity’ (TRI), wherein antibodies from individuals exposed to 
malaria infection actively inhibit parasite development in mosquitoes [110, 111].
 Plasmodium transmission hinges on the successful development of  the parasites 
inside mosquitoes. Inside the mosquito gut, gametocytes become activated by mosquito 
compounds, and changes in temperature and pH, to undergo gametogenesis. Female 
gametocytes become spherical, and secrete proteins that enable them to emerge from their 
erythrocyte host cell [112, 113]. Male gametogenesis is more active. Male gametocytes 
undergo 3 rounds of  mitotic division to form 8 motile microgametes, which emerge from 
the erythrocyte in a process called exflagellation (Figure 5).This is why natural gametocyte 
sex ratios are female biased. The ideal strategy would be for the parasite to produce 8 
females for every male; enough to result in a gamete ratio of  1:1 [101, 114, 115]. Because 
gametocyte ratios vary based on the degree of  fertility competition with co-infecting 
strains [100] or red blood cell and gametocyte density [49], a lower female bias is generally 
observed, increasing the likelihood of  fertilisation at the expense of  its theoretical potential 
[49, 116].
 To enhance their chance of  locating a female macrogamete in the pre-digested blood 
meal, exflagellating male gametes bind neighbouring blood cells to form exflagellation 
centres. Proteins on the gamete surface facilitate the recognition and binding of  male 
gametes to the female, while secreted proteins enable their invasion and fertilisation [117]. 
Translationally repressed female gametocyte proteins are activated at this stage, enabling 
the resulting diploid zygote to form a motile ookinete in the gut lumen. The ookinete breaks 
through the peritrophic matrix that normally retains the particulate content of  a blood meal, 
and traverses the inner layers of  the gut epithelium to become embedded in its basal layer 
[42] (Figure 6). Here the parasite arrests, forming an oocyst which develops slowly and 
harbours the sporozoites that make the mosquito infective. In nature, mosquitoes usually 
harbour less than five oocysts, each of  which may contain several thousand sporozoites 
[118].
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Figure 5. Gametocyte activation in the mosquito midgut (a), gamete formation (b), fertilisation 
of macrogametes (female) by microgametes (male) (c), and subsequent life stages (right: zygote/
retort [top] and ookinete [bottom]) (A. J. Knell, Malaria: A Publication of the Tropic Programme of the 
Wellcome Trust, 1991)
Figure 6. Ookinete invasion of the mosquito midgut epithelium (a), oocyst formation and sporozoite 
budding (b), and oocyst rupture and sporozoite release into the mosquito haemolymph (A. J. Knell, 
Malaria: A Publication of the Tropic Programme of the Wellcome Trust, 1991)
The transition between life stages leading to oocyst formation occurs rapidly, with ookinete 
implantation occurring after 16-32 hours of  the blood meal in P. falciparum. Despite this 
speed, estimates of  the total population loss between the gamete and oocyst stages are 
as high as 99.4% [118]. This loss appears greatest before or during gamete fertilisation, 
though ookinetes may also fail to penetrate the midgut or be destroyed in the process, 
and successfully embedded ookinetes may also arrest in the midgut epithelium, and fail to 
develop into productive oocysts [118-121]. The vulnerability of  these exposed life stages 
to chance, to human and mosquito factors in the mosquito gut, and to their low and 
precipitously decreasing density make mosquito stage parasites an ideal target for malaria 
control; one in which relatively small disturbances may result in total reproductive failure.
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Elimination
The aim of  malaria control is to reduce mortality and morbidity caused by the disease. 
Our success in doing this since the turn of  the century is only apparent because it contrasts 
so starkly with the period before. The early 1990s saw an unprecedented public health 
crisis in Africa, with malaria outbreaks of  ‘epidemic proportions’ causing 300-500 million 
cases and 1.7-2.5 million deaths annually [122, 123]. Though political anergy and poor 
health infrastructure bear some responsibility, the crisis was catalysed by antimalarial 
drug resistance. Chloroquine had been the first-line antimalarial since the early 1950’s, 
and though resistance to the drug was observed as early as 1957 it remained effective in 
Africa until the late 1970’s [124, 125]. Sulphadoxine-pyrimethamine, a drug retracted 
decades previously due to the widespread emergence of  resistance, was reintroduced as 
an alternative in the 1990’s only to suffer the same fate within years [126, 127]. Hailed as 
the key to ‘averting a malaria disaster’, artemisinin derivatives became widely used for the 
treatment of  uncomplicated malaria in the early 2000s following mounting evidence of  their 
tolerability and efficacy in vivo [128]; one key study showed they cleared 10-100 times more 
blood stage parasites over a single asexual cycle than other antimalarials [129]. To avoid 
the fate of  previous treatments, the WHO advised against all artemisinin monotherapies 
in 2007, recommending that they be combined with slower acting partner drugs to avoid 
parasite recrudescence. In Ghana, Artemisinin combination therapies (ACTs) gave >97% 
clearance by four weeks after treatment while Sulphadoxine-pyrimethamine and chloroquine 
resulted in 60% and 25% clearance respectively [130]. ACTs have remained ‘first line’ 
in all malaria endemic areas, and their effectiveness is unchanged in most of  Africa. In 
South-east Asia though, widespread increases in parasite clearance time after treatment 
has marked the emergence of  artemisinin resistance [131]. Resistance is now known to be 
caused by mutations of  the parasite gene kelch13, and resistant strains associated with these 
mutations have spread throughout the mainland from Vietnam to northern Myanmar [132, 
133]. Thankfully the same mutations have yet to be observed in Africa, though increased 
clearance times have been reported in Kenya [134, 135]. As alternative drugs are still some 
distance from licencing and production at scale, resistance in Asia poses a major threat to 
malaria control globally. If  the spread of  these parasites continues unchecked, their eventual 
observation in Africa is inevitable. Containment of  resistant parasite strains is therefore of  
the upmost importance if  the recent successes of  malaria control are to be sustained, and 
local elimination of  (resistant) falciparum malaria may be the only viable solution. At the 
same time, declining cases and deaths have galvanised the public health community into a 
global call for the parasites eradication [136]. 
 Elimination of  any infectious disease is achieved when the number of  cases acquired 
in a defined area is reduced to zero. More formally, elimination status is granted after 
consolidation of  this transmission level for three years [137, 138]. Eradication is achieved 
when the disease agent is eliminated globally. The only infectious diseases to have been 
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eradicated by human efforts are the viral diseases smallpox and rinderpest, both of  which 
were eradicated with highly effective vaccines and rigorous surveillance [139, 140]. The only 
parasitic disease determined to be fully ‘eradicable’ is Dracunculiasis, for which individual 
cases are easily diagnosed, treated, and prevented from resulting in further transmission 
[141]. Malaria eradication is a far more complex prospect, particularly because it has failed 
before. In 1955 a global malaria eradication programme (GMEP) was initiated, imposing 
a rigid system of  indoor spraying with DDT, and treatment of  symptomatic cases with 
chloroquine [142]. By the late 1960’s, the WHO acknowledged the GMEP’s failure, and 
recommended a return to control rather than eradication. Though it suffered controversial 
social and operational problems, the GMEP’s inability to sustainably halt transmission 
has been blamed on its initial unwillingness to acknowledge that malaria transmission 
intensity varies with epidemiological and geographical context [6, 143]. In light of  the 
first GMEP’s failure, the prospect of  a renewed program of  malaria eradication has been 
regarded with understandable caution. Five countries have achieved elimination in recent 
years, all of  which are in the Eastern Mediterranean region and suffered low endemic 
transmission before pushing to eliminate [136]. Of  the 21 countries identified as being 
capable of  elimination by 2020, six are in the African region, and again all have stable 
low transmission. The heterogeneous nature of  malaria transmission, which is present at 
all levels of  endemicity but becomes more apparent as transmission is reduced, is now 
recognized as a major barrier to effective transmission reduction [144-147]. Another will 
be that the worst affected areas are some of  the least wealthy and politically stable; 35% of  
all deaths due to malaria occur in Nigeria and the Democratic Republic of  Congo [136]. 
In areas with moderate and high transmission intensity (most of  sub-Saharan Africa), 
traditional controls are unlikely prevent local transmission. Griffin et al. estimated that with 
80% coverage with long lasting insecticide treated nets (LLINs), treatment with ACTs, 
mass screening and treatment programs (MSAT), and an efficacious pre-erythrocytic 
malaria vaccine, areas with high level transmission would need additional tools or major 
social reform to bring parasite prevalence below 1% [148]. The call for malaria eradication 
has therefore been met not with a pre-defined program to achieve it, but with an agenda 
to focus research and development toward making elimination possible where it currently 
is not, so that eradication is put within reach. Much of  this hinges on shifting the malaria 
control paradigm from case prevention to transmission reduction. Though reduction of  
transmission is the natural result of  intensive control, it may be hastened by ensuring 
coverage of  those individuals who are most infectious to mosquitoes, or using tools 
specifically designed to reduce human-mosquito transmission.
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Measuring infectiousness
During the GMEP, Robert Muirhead-Thomson, an entomologist at the Liverpool school 
of  tropical medicine, observed that following extensive reductions in malaria transmission 
“the question of  bridging the gap between malaria control and malaria eradication may 
well depend on a more accurate appraisal of  the remaining source of  infection in the 
human population” [149]. In community surveys, around two thirds of  infections detected 
by microscopy are asymptomatic [150, 151], so would go untreated if  case detection 
was passive. Even if  surveillance were active, molecular diagnostics have revealed that 
a large proportion of  infections in endemic populations circulate at densities below the 
detection threshold of  microscopy or rapid diagnostic tests (~40 parasites per µl in rigorous 
assessments, but closer to 100/µl during standard surveillance). In low endemic settings, 
sub-microscopic infections may account for as much as 88% of  the infected population 
[152]. As gametocytes represent only 1-2% of  the total parasite biomass, the proportion 
of  the population that is hypothetically infectious is even more heavily underrepresented 
in standard surveillance [153]; an estimated 91.4% of  gametocyte infections are missed by 
microscopy [152]. Worryingly, mathematical models show that where controls are focused 
on standard case detection and control, a sub-microscopic parasite reservoir is sufficient to 
maintain transmission [154]. Because of  the frequency of  gametocyte infections, it makes 
sense that an ‘any is too many’ strategy is adopted, wherein parasite infection, symptomatic, 
gametocytaemic, or otherwise, is treated as potentially infectious [151, 155]. However, not 
all gametocytaemic individuals are likely to contribute equally to onward transmission.
 At the individual level, the density of  gametocytes in the blood that are detectable by 
microscopy is a poor predictor of  infectiousness to mosquitoes [156]. Gametocytes can 
be quantified with highly sensitive messenger RNA based assays, but so far these have not 
crystallised the relationship between their density and infectivity. Though high densities 
(>200 gametocytes per µl of  blood) are more likely to infect [157], various intrinsic 
parasite and human factors affect the chance of  establishment in the mosquito, with the 
result that many sub-microscopic gametocyte infections prove infectious, and some high 
density infections appear sterile [158-160]. Molecular gametocyte detection is currently 
based on the detection of  Pfs25 mRNA [161, 162]. Though abundant and highly specific 
to gametocytes, recent transcriptomic analyses show that Pfs25 is transcribed primarily 
by female gametocytes [163-165], so while useful for determining gametocyte presence, 
the most advanced gametocyte detection tools so far available are now known to provide 
inaccurate estimates of  total gametocyte density. 
 Several molecular markers for asexual and sexual stage parasites are in development, and 
have been used in concert to estimate the stage-specific composition of  natural infections 
[166]. Markers specific to male and female gametocytes [165], and to different stages of  
their development [106, 167] will bring us closer to developing RNA based assays capable 
of  accurately quantifying gametocytes and predicting their infectivity. Gametocytes only 
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recently released from sequestration are less infective than gametocytes that have had the 
time in circulation to produce sufficient quantities of  proteins and mRNAs that facilitate 
fertilization and establishment in the mosquito [168, 169]. PHISTa and PfGEXP5 have 
been identified as markers of  early gametocytes [166, 170], while PF14-0367 and Pfs25 are 
enriched in mid-stage and mature gametocytes respectively [166]. Separate male and female 
specific markers would enable to total gametocyte density to be quantified accurately, and 
provide estimates of  gametocyte sex ratio, which is critical to the likelihood of  successful 
fertilisation in the mosquito, and may be affected by total gametocyte density, by the 
duration and multiplicity of  infection, and by drugs with different levels of  activity against 
male and female gametocytes [116, 171, 172]. Sex specific gametocyte quantification is so 
far limited in sensitivity [165]. Different parasite strains may also be differently infectious, 
either producing more gametocytes or varying in their vulnerability to drugs or immune 
factors that might inhibit transmission [173]. 
 Human factors are also capable of  effectively sterilising viable gametocyte infections. 
Because gametocytes are hidden within the erythrocyte while circulating in the blood, 
human antibody responses to gametocyte proteins are more likely to affect the success of  
parasite development in mosquitoes than the number of  gametocytes in circulation [174]. 
Though there is evidence that naturally acquired TRI is short lived [175-177], develops in 
response to recent, high gametocyte exposure [110, 177], and is correlated with the presence 
of  antibodies specific to well characterised proteins involved in gamete fertilisation (Pfs230 
and Pfs48/45) [110, 111], our understanding of  the dynamics and causal mechanisms of  
TRI is poor. Transmission reducing immunity has been investigated by performing ELISA 
to detect antibodies specific to Pfs48/45 and Pfs230, but because these responses do not 
fully explain the occurrence of  TRI [156, 178], serological assessments cannot yet predict 
the effect of  immune factors on gametocyte infectiousness. 
 Because its effectors are so numerous, the only way of  comprehensively measuring 
infectivity is to feed mosquitoes on a potentially infectious individual’s blood and observe 
whether the insects become infected (in direct skin or membrane feeding assays; DSFA/
DMFA) [179, 180]. Xenodiagnoses of  this sort are extremely labour intensive, so can only 
realistically be considered an epidemiological tool, rather than one than might be used in 
standard surveillance. The presence of  TRI may be determined in the direct membrane feeding 
assay (DMFA) by reconstituting a potentially infectious person’s blood cells in serum of  
someone with no exposure to malaria [181], but this only adds to the complexity of  standard 
feeding assays. By purifying all antibodies from a blood sample, their effect on gametocytes 
grown in culture may also be tested in the standard membrane feeding assay (SMFA) [111, 
182]. Like the DMFA this assay is restrained by the skill and work load required to assess 
mosquito infection status, by manual dissection. So far these are the gold standard assays for 
predicting or measuring the infectiousness of  natural or cultured gametocytes.
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Mosquito feeding assays are rigorous and inclusive as a measure of  individual level 
infectivity. However, the infectious reservoir (the collective body of  individuals in a 
population capable of  infecting mosquitoes) is shaped by extrinsic factors that affect the 
likelihood of  infectious individuals actually infecting mosquitoes. Mosquitoes respond to 
infection by mounting an innate immune response, which varies in effectiveness in different 
mosquito-parasite species combinations [183], even between different members of  the A. 
gambiae subfamily [173, 184]. Human factors too may affect the shape of  the infectious 
reservoir, as individuals are likely to be differently exposed and attractive to mosquitoes, 
depending on their age and size [185], their protection from biting [186], their proximity 
to breeding sites and permissive mosquito species [187], and a range of  other factors. 
Understanding infectivity at a population level requires that extra-individual barriers to 
gametocyte transmission potential be considered.
Transmission reduction
Where their efficacy and population coverage are high, insecticide treated nets and effective 
schizonticidal drugs are capable of  effecting significant reductions in transmission [148, 
188, 189]. Improving our understanding of  who fuels transmission to mosquitoes may 
help facilitate this reduction, but in most areas with historically high intensity P. falciparum 
transmission, intensively applied conventional controls have proved unable to completely 
prevent transmission [190-192]. The diminishing returns of  increased net provision in areas 
of  high coverage [193], and the burgeoning importance of  outdoor biting mosquito species 
in maintaining residual malaria transmission [194] highlight the need for novel tools which 
directly combat human infectivity.
 Because of  their ability to immediately reduce human infectivity [195], and because 
they may be used to prevent the spread of  drug resistance [196], there is great interest 
in drugs that target mature gametocytes specifically. Artemisinins are active against stage 
I-III gametocytes, so they more rapidly decrease transmission potential than older more 
exclusively schizonticidal antimalarials [197-200]. Mature gametocytes appear robust 
to the effects of  standard artemisinin doses in vivo, so though they reduce infectivity 
compared to non-artemisinins, they do not completely prevent transmission [41]. Only 
the 8-aminoquinoline Primaquine, which has been used since the 1950’s for preventing 
P. vivax and P. ovale relapse due to its activity against liver hypnozoites [201], is currently 
licenced as a gametocytocide. At therapeutic doses primaquine is only active against the 
asexual liver and sexual blood stages of  P. falciparum [202, 203], so it has either been used 
as a prophylactic [204] or combined with a shizonticide as a single dose treatment for 
the reduction of  gametocyte transmission [205]. Opposition to the drugs more widespread 
use is largely based on its toxicity in individuals with glucose 6-dehydrogenase (G6PD) 
deficiency, a common x-linked trait that results in heightened risk of  acute haemolytic 
anaemia after treatment [206]. The severity of  primaquine toxicity in G6PD deficient 
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individuals is dependent on dosing; millions of  patients have received primaquine therapy 
for P. vivax and only 13 G6PD related deaths have occurred, all having received repeated 
high doses. Though incidences of  acute haemolysis have occurred in G6PD deficient males 
after a doses of  ~0.5 base/kg primaquine, no deaths have been associated with any single 
dose regimen [206]. As primaquine is rapidly metabolised and the half-life of  its metabolites 
is very short, a single dose of  0.75 mg base/kg was regarded as safe in G6PD deficient 
individuals for the prevention of  P. falciparum transmission until 2010, when use of  a lower 
dose of  0.25mg/kg was advised for use in areas aiming to eliminate, or areas at risk from 
artemisinin resistance [205, 206].
 The search for new gametocytocides is high on the research agenda for malaria 
elimination, and though there is some hope [207], the complexity of  screening drugs 
with outcomes manifest as reduced mosquito infection is a major stumbling block for the 
development of  transmission reducing drugs [208]. In vitro alternatives exist for assessing 
the viability of  cultured parasites after exposure to potential transmission reducing agents, 
but these only interrogate effects active on the gametocyte, which either kill or prevent 
them from activating to form gametes [209-212]. The same is true for vaccines designed 
to interrupt malaria transmission (VIMT). As with drugs, any vaccine that reduces liver 
or blood stage parasite reproduction may inhibit transmission to mosquitoes by limiting 
gametocyte production. Investment has so far largely focused on pre-erythrocytic and 
blood-stage vaccines, which afford both personal protection against disease and, if  potent 
enough, reduced infectivity. Though falling short of  the minimum requirements for 
protective efficacy and duration proposed by the WHO [213], the licencing of  the RTS,S 
vaccine in 2015 was a significant milestone in infectious disease control [214]. This said, 
reducing infectivity in enough individuals to cause community wide transmission reduction 
requires more stringent thresholds for vaccine efficacy. Sub-optimal pre-erythrocytic or 
blood stage vaccines may be complemented by VIMT [215] eliciting antibodies capable of  
neutralising parasite [215, 216] or mosquito [217, 218] proteins involved in the parasites 
sexual developmental pathway. 
 Antimalarial drugs can curb the long infectious period in infected individuals by 
abrogating asexual stage multiplication and preventing gametocyte production (all effective 
schizonticides) and specifically clearing mature gametocytes. However, the public health 
impact of  these measures will be largely determined by the proportion of  the total parasite 
reservoir that is successfully targeted, and the frequency and timing of  their application. 
Gametocytocidal drugs are generally discussed in the context of  mass administrations, which 
may have an important role in regional elimination [195]. Models suggest that the addition 
of  specifically gametocytocidal drugs may be less important during MDA than ensuring 
maximal coverage with effective schizonticides [219]. In areas where the effectiveness of  
current treatments is waning, gametocytocides are likely to have significant utility [196]. In 
the broader context of  transmission reduction though, a VIMT is highly desirable. A single 
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round of  vaccination with a VIMT that reduces infectiousness to zero for the length of  a 
transmission season, plus the time it takes for the human infectious reservoir to be cleared 
naturally, could effectively wipe-out the mosquito infectious reservoir and eliminate malaria. 
Coverage, immunogenicity, and longevity are the barriers to this ‘ideal public good’ [220], 
but even a partially effective vaccine overcomes many of  the disadvantages of  transmission 
blocking drugs, like sub-optimal treatment adherence, short half-life, long-term expense, and 
genetic effects on metabolism and safety [206, 221]. 
* * *
The chapters of  this thesis, Malaria: what affects who infects? are concerned with the 
measurement of  gametocyte infectivity, and with the evaluation of  interventions or intrinsic 
factors that affect individual infectivity and contribution to the population infectious 
reservoir. Understanding how the infectious reservoir changes as transmission decreases 
may enable tools to be targeted more effectively, by focusing on areas or populations in 
which transmission may be maintained and seeded from after intervention. Understanding 
and measuring individual level infectivity is essential for the development of  transmission 
reducing interventions, and their evaluation in endemic settings. 
Quantifying heterogeneity in parasite and mosquito exposure
Malaria transmission and clinical burden are highly heterogeneous at all levels of  endemicity 
[144-146]. One approach to improving the effectiveness of  interventions is to target them to 
individuals who are most regularly bitten and infected. Within a focus of  malaria transmission 
(an area around a mosquito breeding site where transmission is maintained throughout the 
year), some areas host greater than average transmission, resulting in high local infection 
rates and clinical incidence [144, 145]. These ‘hotspots’ may form because of  poor housing 
quality and proximity to breeding sites, among other social and geographical factors [222]. 
Their identification enables control targeting to maximize the impact of  interventions, but is 
also important because these may be the hardest populations in which to achieve and sustain 
elimination [39]. Hotspots may be detected by determining the spatial distribution of  current 
malaria infection and of  prior exposure at a population level, which represent biomarkers 
for malaria risk and potential infectivity [145]. Current infection is best determined using 
sensitive molecular diagnostics, while previous infection (and possibly current risk) can be 
interpreted from serologic assessments of  malaria-specific antibody titre. The distribution 
of  antibodies among individuals of  different age within populations provides a valuable 
indication of  change in transmission intensity over time [223]. At another level, exposure 
to mosquitoes may be measured to determine whether individuals in areas with a high risk 
of  infection are also likely to be bitten and contribute to the mosquito infectious reservoir. 
Previous studies indicate vector exposure may be determined serologically, by determining 
the presence of  antibodies to vector saliva [224-228]. 
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Understanding the human infectious reservoir for malaria
Whilst reliable measures to assess spatial variation in malaria infection, infection risk, 
and vector exposure support targeted interventions, the impact of  hotspot-targeting is 
not self-evident. A recent clinical trial examining the efficacy of  interventions targeted to 
serologically defined hot-spots of  malaria exposure concluded that the effects of  intensified 
vector and treatment based controls were only effective within intervention areas, and then 
only transiently, and did not influence transmission to a wider geographical area [229]. 
The trial illustrates our limited understanding of  the units of  malaria transmission in 
endemic settings, our failure to grasp how incident infections in naturally exposed humans 
and mosquitoes are related spatially and temporally, and what the unit of  targeting should 
be to effectively interrupt local transmission. Part of  the uncertainty lies in the fact that 
the distribution of  infectiousness does not necessarily correlate with the distribution of  
disease incidence or vector exposure. Improving our understanding of  the human infectious 
reservoir could make plain the failings of  current control deployment strategies for 
interrupting malaria transmission. It may be that effective transmission reduction requires 
more direct targeting of  the human infectious reservoir. Gametocyte prevalence and density 
are highest in infants and young children, decreasing with age as cumulative exposure and 
acquired immunity to the parasite builds [74, 230, 231]. Whilst this suggests that children 
may be the primary drivers of  transmission, the relationship between gametocyte densities 
and de facto contribution to transmission is obscured because children are generally well 
protected by nets during the evening, when mosquitoes are seeking blood meals, and may 
also be less attractive than adults. Though less objectively infective, adolescents and adults 
make up a larger proportion of  the population, may be more bitten more frequently, and 
so may contribute more to the infectious reservoir. These variations in immunity and 
mosquito exposure vary even between members of  the same house. It is important they are 
understood even if  transmission focused interventions are not targeted. 
Tools to assess infectivity and develop transmission-blocking 
interventions
From a public health perspective, the ultimate reason to understand the infectious reservoir is 
to target it and prevent onward transmission. Because conventional controls do not address 
the growing problems of  outdoor mosquito biting and residual malaria transmission [232], 
transmission-blocking drugs and vaccines are considered important components of  efforts 
to expedite elimination [233, 234]. Both the laboratory based development of  drugs and 
vaccines and the trial evaluation of  these interventions in the field require assays to measure 
transmission from humans to mosquitoes. In the lab SMFA can be employed to test the 
inhibitory effects of  drugs, or naturally acquired antibodies such as might be collected 
from pre- and post-vaccination sera during vaccine trials, on the infectiousness of  cultured 
gametocytes [208, 235]. Field based DMFA are more restricted to testing the infectivity of  
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naturally acquired gametocytes [181]. Both assays are expensive and logistically difficult, 
primarily because the readout, the quantity of  successfully established oocysts in the 
mosquito gut, normally requires pain staking dissection and microscopic examination of  
large numbers of  mosquitoes [236]. Where cultured gametocytes are used enhancements 
in scalability are made possible by changing the method of  quantifying mosquito infection 
intensity. Detecting a marker of  mosquito infection rather than counting oocysts could 
increase the assays scalability, and would have the additional benefit of  making its readout 
entirely objective. 
 Primaquine is the only currently available drug that actively sterilises P. falciparum 
infection, and despite an increasing number of  reports of  its safety and efficacy at single 
low dose in G6PD deficient individuals, concerns remain over its use in mass drug 
administrations (MDA) [206]. There is therefore a need to identify novel transmission 
blocking drugs. These should have a safety profile that permits their use in MDA, and 
ideally broad spectrum activity against asexual parasites and their gametocytes (for use in 
areas of  ACT resistance). Such assessments would benefit from increases to the SMFAs 
throughput and objectivity. 
 In the field, using transgenic parasites in feeding assays is impossible, but increases in 
throughput are still required for assessments during population level trials of  transmission 
reducing drugs and vaccines. If  mosquitoes with single oocysts are as capable as causing 
human infection as mosquitoes with multiple oocysts, then the quantity of  infection is 
less relevant and feeding assays made operationally attractive by replacing dissection with 
quicker methods of  detecting rather than quantifying mosquito infection.
Understanding and preventing malaria transmission in endemic areas
The DMFA is the gold standard measure of  human infectiousness, because its output 
(mosquito infection) is subject to all of  the intrinsic determinants of  gametocyte infectivity. 
Since the mid-20th century it has been established that some individuals do not infect 
mosquitoes, despite carrying many gametocytes [149, 160, 237]. In addition to their 
absolute quantity, and compounds or enzymes in the blood that may affect parasite 
survival, two key factors affect the likelihood of  gametocytes in human blood successfully 
infecting mosquitoes; gametocyte sex ratio, and transmission reducing immunity (TRI). 
The relationship between gametocyte density and infectivity generally appears non-linear, 
but previous assessments have either been based on estimates made by microscopy, or 
on molecular assessments which used sub-optimal female specific assays [157]. Accurate 
quantification of  male and female gametocytes separately would allow reliable assessment 
of  the relationship between total gametocyte density and gametocyte sex-ratio with 
infectivity. Such an assay would also allow investigation of  factors with putatively sex-
specific effects, such as the gametocytocidal drug primaquine [196].
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Naturally acquired transmission-reducing immunity
Though we have known of  the existence of  TRI for decades, and even induced it by 
inoculation with sexual stage parasites [233, 234] and recombinant gametocyte proteins 
[238-240], its mechanisms have remained unclear. Because we are unaware what antibody 
responses to malaria antigens are responsible for the phenomenon, investigation of  the 
impact of  TRI on natural malaria transmission has been very limited. At present, studies 
are restricted to determining the statistical associations of  infectivity and responses to 
gametocyte proteins known to induce TRI after immunisation (Pfs48/45 and Pfs230). The 
development of  the few transmission-blocking vaccines currently in development proceeded 
from the identification of  sexual stage antigens with essential roles in gamete fertilisation 
[235, 236], but antibody responses to other sexual stage proteins expressed by gametocytes 
are likely to contribute to transmission inhibition [178, 237].
 A better understanding of  the phenomenon of  naturally acquired TRI would provide 
insight into an essential component of  human infectivity, and possibly, new starting points 
for TBV development. 
Objectives
For the development of  transmission reducing drugs and vaccines, and translating their 
success from the laboratory to the field, measures of  Plasmodium’s infectivity to mosquitoes 
are essential. Malaria elimination, particularly local elimination in areas aiming to contain 
the spread of  artemisinin resistant parasite strains, requires rigorous surveillance of  the 
infectious reservoir and efficacious and operationally attractive approaches to clear this 
reservoir. The aim of  this thesis is to investigate the effectors of  human malaria infectiousness 
to inform the development and application of  transmission-reducing interventions. 
 In Chapter 2: Combined DNA extraction and antibody elution from filter papers 
for the assessment of malaria transmission intensity in epidemiological studies, we 
aim to develop and validate a tool for simultaneously assessing malaria prevalence and 
prior exposure during epidemiological studies, and population surveillance. This could 
have utility for intervention targeting, either to individuals with current infection, or to 
individuals within foci of  high malaria risk. In Chapter 3: IgG responses to Anopheles 
gambiae salivary antigen gSG6 detect variation in exposure to malaria vectors and 
disease risk, we aim to validate a serological assay detecting antibody responses to a 
recombinant Anopheles specific salivary protein, gSG6. We hope to show the assays utility 
for the measurement of  exposure to malaria vectors, and determine whether exposure to 
malaria vectors is associated with historical malaria incidence. This assay may have use in 
combination with population assessments of  malaria infectivity. In Chapter 4: Assessing 
the infectious reservoir of P. falciparum: Past and future, we review the available literature 
on the infectious reservoir, and highlight the importance of  direct assessments of  infectivity 
and their inherent weaknesses. We aim to stimulate discussion on the future role of  mosquito 
36
feeding assays in malaria surveillance, and to suggest methods for the improvement of  these 
techniques as measures of  the infectious reservoir. 
 In Chapter 5: A scalable assessment of Plasmodium falciparum transmission in 
the standard membrane-feeding assay, using transgenic parasites expressing Green 
fluorescent protein–Luciferase, and Chapter 6: A semi-automated luminescence 
based standard membrane-feeding assay identifies novel small molecules that inhibit 
transmission of malaria parasites by mosquitoes, we aim to develop a novel iteration of  
the standard membrane feeding assay (SMFA), for the laboratory assessment of  Plasmodium 
infectivity. Specifically, we aim to increase the throughput and objectivity of  the assay 
by using transgenic, luminescent parasite cultures, which should eliminate the need for 
mosquito dissection. Such assays may have utility in the development of  transmission-
reducing interventions prior to their application in the field. They may also have more 
direct benefits to the assessment of  infectivity of  endemic populations, by providing rapid 
assessments of  transmission-reducing immunity. In the field, increases in the throughput 
of  assessments of  infectivity can be achieved by similarly removing the need to dissect 
mosquitoes to assess their infection rate. In Chapter 7: The relevance and applicability 
of oocyst prevalence as a read-out for mosquito feeding assays, and Chapter 8: A 
comparison of Plasmodium falciparum circumsporozoite protein-based slot blot and 
ELISA immuno-assays for oocyst detection in mosquito homogenates, we aim to provide 
evidence that mosquito infection prevalence (determined at time points amenable to safe 
and rapid assessment) predicts eventual mosquito infectiousness. In so doing, we hope to 
open the way for rapid screening with mosquito feeding assays, which could ease the assays 
well known operational difficulties. Such improvements may support bringing successful 
transmission-reducing interventions to fruition in the field. 
 At the next level, if  new molecular and serological readouts can be shown to provide 
acceptable proxies for infectiousness, field based assessments of  malaria infectivity may 
be set aside altogether. Though such tools may be a long way from realisation, we aim to 
investigate key effectors of  malaria infectiousness; gametocyte density, gametocyte sex, 
and transmission-reducing immunity. In Chapter 9: Predicting mosquito infection from 
gametocyte density and sex-ratio, and Chapter 10: Gametocyte sex ratio and infectivity 
after dihydroartemisinin-piperaquine with primaquine: Results from two randomised, 
controlled trials, we aim to develop a new, sensitive, molecular assay of  gametocyte 
density, capable of  predicting the densities of  male and female gametocytes separately. 
We aim to utilise this assay to re-assess findings previously published on the relationship 
between total gametocyte density and infectivity with a new focus on sex-ratio and as the 
readout of  clinical trials with primaquine, a gametocytocidal drug thought to preferentially 
clear male gametocytes. Finally, with Chapter 11: Naturally acquired immunity to sexual 
stage P. falciparum parasites, and Chapter 12: Unravelling the immune signature of P. 
falciparum transmission blocking immunity, we aim to discuss and investigate the impact 
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of  transmission-reducing immunity on malaria infectivity. We aim to clarify the role of  
naturally acquired antibodies to proteins known to induce TRI after immunisation as 
recombinant proteins, and to uncover additional biomarkers of  TRI if  these exist. We aim 
to study the association of  antibody responses to these known and unknown proteins with 
infectivity in field assessments of  malaria infectivity, bridging the gap between lab and field 
based assessments of  the impact of  TRI on malaria transmission.
All figures have been reproduced with the permission of  the publisher from A. J. Knells “Malaria: 
A Publication of  the Tropic Programme of  the Wellcome Trust”, ISBN: 9780198547426, Published 
by Oxford University Press, Oxford, 1991.
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231. Ouédraogo, A.L., et al., The plasticity of  Plasmodium falciparum gametocytaemia in relation to age in 
Burkina Faso. Malaria Journal, 2010. 9(1): p. 281.
232. Govella, N.J. and H. Ferguson, Why use of  interventions targeting outdoor biting mosquitoe s will be 
necessary to achieve malaria elimination. Global change and human vulnerability to vector-borne 
diseases, 2012: p. 70.
233. The malERA Consultative Group on Vaccines, A Research Agenda for Malaria Eradication: Vaccines. 
PLoS Med, 2011. 8(1): p. e1000398.
48
234. The malERA Consultative Group on Drugs, A Research Agenda for Malaria Eradication: Drugs. PLoS 
Med, 2011. 8(1): p. e1000402.
235. Long, C.A. and F. Zavala, Malaria vaccines and human immune responses. Current Opinion in 
Microbiology, 2016. 32: p. 96-102.
236. Churcher, T.S., et al., Measuring the blockade of  malaria transmission – An analysis of  the Standard 
Membrane Feeding Assay. International Journal for Parasitology, 2012. 42(11): p. 1037-1044.
237. Muirhead-Thomson, R.C., Factors determining the true reservoir of  infection of  Plasmodium falciparum and 
Wuchereria bancrofti in a West African village. Transactions of  the Royal Society of  Tropical Medicine 
and Hygiene, 1954. 48(3): p. 208-225.
238. Singh, S.K., et al., A Plasmodium falciparum 48/45 single epitope R0.6C subunit protein elicits high levels of  
transmission blocking antibodies. Vaccine, 2015. 33(16): p. 1981-1986.
239. Farrance, C.E., et al., A Plant-Produced Pfs230 Vaccine Candidate Blocks Transmission of  Plasmodium 
falciparum. Clinical and Vaccine Immunology, 2011. 18(8): p. 1351-1357.
240. Outchkourov, N.S., et al., Correctly folded Pfs48/45 protein of  Plasmodium falciparum elicits malaria 
transmission-blocking immunity in mice. Proceedings of  the National Academy of  Sciences, 2008. 
105(11): p. 4301-4305.
49
1
Introduction
50
TWO
51
2
Chapter 2
Combined DNA extraction and antibody elution from 
filter papers for the assessment of malaria transmission 
intensity in epidemiological studies
Amrish Baidjoe1*, Will Stone1*, Ivo Ploemen1, Shehu Shagari2, Lynn Grignard4, 
Victor Osoti2, Euniah Makori2, Jennifer Stevenson3, Simon Kariuki2, Colin Sutherland4, 
Robert Sauerwein1, Jonathan Cox3, Chris Drakeley4, Teun Bousema1,4
1 Radboud Institute for Health Sciences, Radboud university medical center, PO Box 9101, Nijmegen, 
6500 HB, the Netherlands; 2 Department of  Immunology and Infection, London School of  Hygiene 
and Tropical Medicine, Keppel Street, London, WC1E 7HT, United Kingdom; 3 Antigen Discovery 
Inc., Irvine, California 92618, USA
* Contributed equally
Malaria Journal. 2013;12(1):272
TWO
52
Abstract
Background
Informing and evaluating malaria control efforts relies on knowledge of  local transmission 
dynamics. Serological and molecular tools have demonstrated great sensitivity to quantify 
transmission intensity in low endemic settings where the sensitivity of  traditional methods is 
limited. Filter paper blood spots are commonly used a source of  both DNA and antibodies. 
To enhance the operational practicability of  malaria surveys, a method is presented for 
combined DNA extraction and antibody elution. 
Methods
Filter paper blood spots were collected as part of  a large cross-sectional survey in the Kenyan 
highlands. DNA was extracted using a saponin/chelex method. The eluate of  the first wash 
during the DNA extraction process was used for antibody detection and compared with 
previously validated antibody elution procedures. Antibody elution efficiency was assessed by 
total IgG ELISA for malaria antigens apical membrane antigen-1 (AMA-1) and merozoite-
surface protein-1 (MSP-142). The sensitivity of  nested 18S rRNA and cytochrome b PCR 
assays and the impact of  doubling filter paper material for PCR sensitivity were determined. 
The distribution of  cell material and antibodies throughout filter paper blood spots were 
examined using luminescent and fluorescent reporter assays.
Results
Antibody levels measured after the combined antibody/DNA extraction technique were 
strongly correlated to those measured after standard antibody elution (p <0.0001). Antibody 
levels for both AMA-1 and MSP-142 were generally slightly lower (11.3-21.4 %) but age-
seroprevalence patterns were indistinguishable. The proportion of  parasite positive samples 
ranged from 12.9 % to 19.2 % in the different PCR assays. Despite strong agreement between 
outcomes of  different PCR assays, none of  the assays detected all parasite-positive individuals. 
For all assays doubling filter paper material for DNA extraction increased sensitivity. The 
concentration of  cell and antibody material was not homogenously distributed throughout 
blood spots.
Conclusion
Combined DNA extraction and antibody elution is an operationally attractive approach for 
high throughput assessment of  cumulative malaria exposure and current infection prevalence 
in endemic settings. Estimates of  antibody prevalence are unaffected by the combined 
extraction and elution procedure. The choice of  target gene and the amount and source of  
filter paper material for DNA extraction can have a marked impact on PCR sensitivity. 
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Background
To effectively implement and evaluate malaria control efforts a detailed knowledge is 
required of  Plasmodium carriage and transmission within target populations. Transmission 
intensity is traditionally assessed using mosquito trapping techniques to determine exposure 
to infected Anopheles mosquitoes. In low endemic areas, where vector populations may be 
sparsely infected, small or heterogeneously distributed, trapping becomes operationally and 
technically unattractive [1-3]. A frequently used alternative is the prevalence of  malaria 
infection in human populations, which is typically assessed by light microscopy. However, 
the limited detection limit and operational constraints of  microscopical surveillance 
present a major barrier to its application in low endemic areas [4-8]. With patterns of  
reducing malaria transmission intensity in many African settings [9-14], it will become 
increasingly important to have sensitive alternatives for population level surveillance in 
areas approaching a phase of  elimination [7, 15]. 
 Serological and molecular tools have been proposed to be particularly useful for 
monitoring transmission intensity and determining parasitaemia among populations in 
areas of  low endemicity. Antibody responses to recombinant asexual malaria antigens are 
strongly associated with entomological measures of  transmission intensity and microscopical 
parasite prevalence [16], but at low endemicity have a greater discriminative power [3]. Low 
level transmission may be detectable in the absence of  microscopically detectable infection 
[17] and serological markers can detect spatial variation in transmission intensity [18] and 
the efficacy of  interventions [19].While serology can be used to detect spatial and temporal 
patterns in transmission intensity [20], antibody responses are long-lived and, unless 
sampling is restricted to very young age groups, additional tools are required to quantify 
on-going transmission. The polymerase chain reaction (PCR) is a highly sensitive method 
for detecting Plasmodium infection at all levels of  endemicity [21-23]. In a meta-analysis 
comprising 106 surveys, microscopy detected 54.1 % of  all PCR-detected infections; a 
figure that decreased to below 20 % in low endemic settings [24]. Sub-microscopic parasite 
carriage has been shown to contribute significantly to the malaria infectious reservoir [25, 
26] and is therefore of  relevance for inclusion in control programmes. Actively identifying 
infected individuals using PCR may, therefore, be critically important when attempting 
to interrupt malaria transmission [7, 27, 28]. While PCR is commonly used as gold 
standard for detecting all parasitaemic individuals, there is variation between different PCR 
approaches [29, 30] and DNA extraction from filter papers may vary in efficiency [30, 31]. 
 In the context of  malaria elimination, there is a need to optimize molecular and 
serological assays for rapid and simultaneous assessment of  the significant numbers of  
samples that will be generated by large scale, long term surveillance [32]. At present, DNA 
extraction and antibody elution are the most time consuming and laborious aspects of  
serological and molecular assessments. It would be operationally attractive to source DNA 
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and antibodies from the same blood spots, as this would allow serology and PCR to be 
conducted in unison, increasing throughput while decreasing costs. 
 Here, a simple method for concurrently extracting antibodies and DNA from filter paper 
blood spots is presented. Antibody responses to malaria antigens are assessed to compare the 
efficacy of  antibody elution. PCR assays using two different target genes are compared, andtwo 
sources of  variation in PCR outcome are explored: the distribution of  parasite material on 
filter papers and the amount of  filter paper material that is used for DNA extraction. 
Methods
Study area and subjects
Blood spot samples were collected as part of  a cross-sectional study in the Western Kenyan 
Highlands (latitude -0.470431°, longitude 34.842628°) in June 2011 that received ethics 
approval from Scientific Steering Committee (SSC), the Ethical Review Committee (ERC) 
of  the Kenya Medical Research Institute (KEMRI) Nairobi (proposal numbers SSC 2163, 
2181 and 1589), the London School of  Hygiene & Tropical Medicine ethics committee 
(#6111), and from Centers for Disease Control and Prevention (with exempt status) [33]. 
Blood derived from a finger prick was blotted onto Whatman no. 3 filter paper (Whatman, 
Maidstone, UK) and was dried overnight before storage with silica gel at -20 °C. Each 
filter paper contained three individual blood spots of  indeterminate volume. Filter papers 
were wetted through by blood spots completely, as described by Corran et al [34]. A subset 
of  240 randomly selected blood spots was selected for both PCR and enzyme-linked 
immunosorbent assay (ELISA). 
Standard antibody elution 
The full protocol of  the elution and extraction steps is provided in the supporting 
documentation (Additional file 1). Three filter paper discs of  2.5 mm in diameter were 
punched from the centre of  each dried blood spot. Filter paper discs were immediately 
placed into the wells of  replicate 2.0 ml 96 deep well plates (Axygen Biosciences, CA, 
USA), one containing individual discs, the other pairs of  discs. Each plate contained 80 
samples so that the sample number in each corresponded to that of  2 ELISA plates, leaving 
wells free for controls. For standard elution single filter papers were incubated in 1120 µl of  
a 0.5 % sodium azide/ PBS solution [34]. Plates were sealed and placed onto a plate shaker 
on their side, allowing the cut filter paper discs to move freely along the length of  their 
wells. After overnight incubation, the eluate was stored at -80 °C. The final serum dilution 
of  the eluate based on estimates of  the volume of  whole blood in a 2.5 mm filter paper disc 
was 1:400 [34]. 
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Combined antibody elution and DNA extraction
Filter paper discs were prepared and stored in deep well plates as for standard antibody 
elution. For combined DNA extraction and antibody elution (henceforth combined elution), 
1120 µl of  a 0.5 % saponin/PBS solution was added to each well and plates were incubated 
overnight as for standard elution. 200 µl of  the eluate, which contained all soluble elements 
including antibodies, was transferred to a new plate and stored at -80 °C until use in ELISA. 
To continue with DNA extraction, the remaining saponin solution was aspirated and 1 ml 
of  PBS washing solution was added to each well at 4 °C. Plates were horizontally incubated 
on a shaker for one hour as above, before PBS was aspirated and discarded. 150 µl of  a 6 % 
Chelex in DNase/ RNase free water solution was added to each sample. Plates were sealed 
using adhesive foil mats (Axygen Biosciences, CA, USA) and incubated in a water bath for 
3*10 minutes at 97 °C. Between 10 minute incubations plates were briefly centrifuged in 
order to relieve pressure and ensure optimal DNA elution. After the last incubation plates 
were spun down at maximum speed for 5 minutes to allow the Chelex to settle. 120 µl of  the 
DNA containing solution was taken and aliquoted into new plates. Samples were stored at 
-80 °C until further analyses. To exclude the risk of  cross-contamination during extraction 
materials were extensively tested using positive and negative controls (2.5 % Plasmodium 
DNA and blank wells respectively). No cross-contamination was observed during extraction.
AMA-1 and MSP-142 ELISA
IgG antibody responses against AMA-1 (BPRC, 0.3 µg/ml coating concentration) and 
MSP-142 (FVO, 0.2 µg/ml coating concentration) were detected as previously described 
[16, 35]. Test sera were analysed in duplicate at 1:1000 (MSP-142) or 1:2000 (AMA-1) in 
PBST/Marvel milk powder (Cadbury, UK). Blank wells and a serial dilution of  pooled 
hyper-immune sera were included in duplicate on each plate to correct for non-specific 
antibody reactivity and standardise responses for inter-plate variation. Seroprevalence 
of  IgG antibodies to both antigens was determined using a mixture model as described 
previously [16, 34]. The model was used on each population of  samples, giving four 
separate positivity thresholds (one each for AMA-1 standard elution, AMA-1 combined 
elution, MSP-142 standard elution, and MSP-142 combined elution). 
Parasite detection by PCR
Three nested PCR assays were evaluated; an 18S PCR targeting the small ribosomal subunit 
of  Plasmodium falciparum developed by Snounou et al [22] and two variations of  a more 
recent assay which targets the mitochondrial cytochrome b as described by Steenkeste et al. 
[36, 37]. Because of  inconsistent amplification of  amplicons generated by the nest 1 (N1) 
primers described by Steenkeste et al primers of  the N1 reaction were redesigned. The 18S 
PCR was performed according to the original protocol except that the quantity of  template 
used in the N1 reaction was increased from 1 µl to 5 µl. In every set of  PCR conditions 5 
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µL template was used in the N1 reaction and 1.5 µl of  product in the N2 reaction. For a 
more detailed overview of  primer sequences, product sized and PCR cycling conditions 
see Additional file 1 Pooled DNA extracts from P. falciparum NF54 cultured in Nijmegen, 
the Netherlands were run on every PCR plate as a positive control, alongside a negative 
water control. Positive control was diluted to the extent that both N1 and N2 fragments 
were sufficiently amplified so that both amplicons could be visualized on gel. N1 and N2 
products were mixed and 10 µl was visualized on a 0.8 % agarose gel by electrophoresis in 
0.5 x Tris-acetate-EDTA buffer (0.04 M Tris-acetate and 1 mM EDTA, pH 8.0). Each assay 
was assessed using single and double filter papers, creating a total of  6 PCR conditions for 
comparison.
Distribution of parasite material on filter papers
To visualize cell material in filter paper blood spots two C57BL/6 mice were infected 
as previously described with a transgenic Plasmodium berghei strain (PbGFP-Luccon) 
expressing a fusion protein of  GFP and Luciferase from the eef1a promoter [38, 39]. The 
original studies that were used as a source of  blood material were performed according to the 
regulations of  the Dutch “Animal On Experimentation act” and the European guidelines 
86/609/EEG; approval was obtained from the Radboud University Experimental Animal 
Ethical Committee (RUDEC 2009-019). 100 µl of  blood from the infected mice was 
collected in heparinised tubes and mixed with 3.2 µl of  highly concentrated (67 mg/ml) 
D-luciferin (Xenogen, CA, USA) dissolved in PBS [38]. 30 µl of  this mixture was pipetted 
onto Whatman no. 3 paper (Whatman, Maidstone, UK) in a manner closely approximating 
that of  blood spot collection in the field. Drops were first formed on the pipette tip before 
contact with the paper was made, and filter papers were wetted through completely. Blood 
spots were left to dry for 15 minutes before luminescent imaging was performed using a 
Lumina Caliper (PerkinElmer, MA, USA) (5 cm FOV, medium binning factor, 1 second 
exposure). This process was repeated for two blood spots. A blood spot without the addition 
of  D-luciferin was used as a negative control. 
Distribution of antibody material on filter papers
Batches of  100 µl whole human blood were mixed with fluorescent labeled anti- APC-Cy7-
anti-CD4 (Biolegend, CA, USA) and/or anti-human APC-IL-2. (eBioscience, CA, USA). 
Blood spot preparation and imaging was performed as in the cell distribution experiments.
Data analysis
Statistical analysis was conducted using STATA 12 (StataCorp., TX, USA) and GraphPad 
Prism 5.0 (GraphPad Software Inc., CA, USA). IgG responses between groups of  paired 
data were compared by Wilcoxon signed rank test. Seroprevalence comparisons were 
made using Chi-square test, with a test for trend in proportions. Associations between IgG 
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responses expressed as antibody titre were quantified by Spearman correlation coefficients, 
and differences between elution approaches tested by linear regression presenting 95% 
confidence intervals (CI). The level of  agreement, kappa value and sensitivity were assessed 
by comparing individual PCR conditions with ‘true positivity’ that was defined as positivity 
in any one of  the PCR assay variants. The difference in the proportion of  positive samples 
between PCR conditions was tested by McNemar’s chi-square for paired data. To minimize 
the influence of  possible false positive PCR results on sensitivity estimates, calculations 
were repeated after ‘true positivity’ was defined as a positive PCR in at least two of  the 
PCR conditions. For the cell/antibody distribution experiments Living image 3.2 was used 
(PerkinElmer, MA, USA). To map the relative fluorescence/intensity in different areas of  
the blood spot they were overlaid with grids containing cells of  2.5 mm2. Grids extended 
to the spots edges, and cells were excluded from analysis if  their area was not entirely filled 
with dried blood. For comparison between cells, fluorescence and luminescence values 
were calculated as a proportion of  the highest cell value.
Results
Antibody responses
Antibodies were eluted from 236 filter papers by both the standard elution procedure and the 
combined elution procedure. For both AMA-1 and MSP-142, a strong positive correlation 
was observed between the IgG responses of  filter paper blood samples eluted by standard 
and combined methods (Figure 1). While strongly correlated, there was a tendency toward 
higher antibody responses when samples were eluted using the standard methodology for 
both antigens (p=<0.0001). For antibody level (optical density), responses were on average 
11.3% higher for AMA-1, and 21.4% higher for MSP-142 when using standard rather than 
combined elution. Linear regression analysis showed that for AMA-1 an increase of  titre 
1 using combined elution was associated with an increase of  titre 1.773 (95 % CI 1.712-
1.834; p<0.0001) using standard elution. For MSP-142 an increase of  titre 1 using combined 
elution was associated with an increase of  titre 1.811 (95 % CI 1.647-1.975, p<0.0001) using 
standard elution. For use as marker of  exposure, antibody responses against AMA-1 and 
MSP-142 are commonly combined to give a prevalence of  any anti-P. falciparum antibodies 
[17, 18, 20]. Between standard and combined elution methods seroprevalence of  antibody 
responses to AMA-1 and MSP-142 did not differ significantly (p >0.8), and for both methods 
showed a strong age-dependent increase (Figure 2; p <0.0001). Within age-groups, antibody 
seroprevalence did not differ significantly between elution methods (p >0.5). 
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Figure 1. Antibody level from standard and dual filter paper blood spot elution methods for 
AMA-1 and MSP-142. A. Scatter plot showing anti-AMA-1 IgG level detected in 236 individuals by 
standard (x-axis) and combined (y-axis) elution of filter paper blood spots. R2 (linear regression) = 
0.93 ( p=<0.0001). B. Scatter plot showing anti-MSP-142 IgG level detected in 236 individuals using 
standard (x-axis) and combined (y-axis) elution of filter paper blood spots. R2 (linear regression) 0.671 
(p=<0.0001).
Figure 2. Seroprevalence of anti-AMA-1 or MSP-142 IgG responses by filter paper elution method 
and age. Error bars indicate 95 % confidence intervals (CI). Sample sizes for the age groups were 53 (< 5 
years), 38 (6-10 years), 43 (11-15 years), 36 (16-25 years), and 67 (>25 years).
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Table 1. Agreement between 18s, modified cytochrome b and original cytochrome PCR assays
PCR Assay Filter paper 
number
Positivity,
% (n/N)
Agreement, % Kappa Sensitivity, 
% (95% CI)
18S rRNA
Single 12.9 (31/240) 90.0 0.666 56.4 (42.3 - 69.7)
Double 16.7 (40/240) 93.8 0.804 72.7 (59.0 - 83.9)
Modified 
Cytochrome B
Single 15.4 (37/240) 92.5 0.760 67.3 (53.3 - 79.3)
Double 18.3 (44/240) 95.4 0.861 80.0 (67.0 - 89.6)
Original 
Cytochrome B
Single 17.9 (43/240) 95.0 0.847 78.2 (65.0 - 88.2)
Double 19.2 (46/240) 96.3 0.887 83.6 (71.2 - 92.2)
The agreement, kappa value and sensitivity were calculated by comparing individual PCR conditions 
with ‘true positivity’ that was defined as positivity in any one of the PCR assay variants. The abbreviation 
n/N indicates PCR positive individuals (n) as a proportion of the total sample size (N).
Parasite prevalence by PCR
Parasite prevalence by PCR differed between different methodologies and ranged from 12.9 
% (31/240) when the 18s rRNA-based PCR was used with single filter paper discs to 19.2 
% (46/240) when the original cytochrome b based PCR was used with two filter paper 
discs (Table 1). The level of  agreement between these two estimates, representing the two 
extremes of  parasite prevalence, was high (90.4 %, kappa 0.65) but the cytochrome b PCR 
with two filter paper discs resulted in significantly more positive results compared to the 18s 
rRNA based PCR with single filter paper discs (p=0.002). When true positivity was defined 
as a sample being positive in any one of  the assays, the standard cytochrome b assay using 
DNA from two filter paper discs showed the highest sensitivity (83.6 % C.I. 71.2-92.2 %). 
Defining true positivity as a positive signal in at least two of  the PCR assays did not change 
the estimates of  sensitivity and kappa considerably (see Additional file 2). 
 Doubling filter paper material for DNA extraction increased the sensitivity of  PCR assays 
by 5.4-16.3 %. When pairs of  results from the same PCR assay but using DNA template from 
single or double filters were compared (n=720 pairs), the latter resulted in significantly more 
parasite positive results (p=0.013). 130 of  the PCRs performed on DNA from double filter 
paper punches were PCR positive, compared to 111 of  the PCRs performed on DNA from 
Table 2. Consistency of outcomes in different PCR assays in relation to the amount of filter paper 
material used for extraction
Filter paper 
number
Never 
positive (%)
Positive in 1/3 
PCR assays (%)
Positive in 2/3 
PCR assays (%)
Positive in 3/3 
PCR assays (%)
Single 80.8 (194/240) 2.9 (7/240) 5.4 (13/240) 10.8 (26/240)
Double 79.6 (191/240) 1.3 (3/240) 4.6 (11/240) 14.6 (35/240)
The proportion (n/N) of positive PCR assays when aliquots of the same extracted material was used in 
three different PCR assays.
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single filter paper punches. Surprisingly, 18.0 % (20/111) of  the samples that were positive in 
a PCR using template from a single filter punch were negative in the PCR performed when 
two punches were taken from the same filter paper.
 Doubling filter paper material also appeared to increase the consistency of  PCR outcomes 
on the same DNA material, albeit not statistically significant. When the 18s rRNA-based PCR 
and both cytochrome b based PCRs were performed on material from the same extraction, 
inconsistent results (i.e. one or two but not all three PCR assays giving amplification) were 
observed for 8.3% (20/240) of  the samples when material from single filter paper punches 
was used compared to 5.9% (14/240) of  samples when filter paper material was doubled 
(Table 2, p=0.36).
Distribution of parasite material on blood spots 
Luminescence produced by GFP expression in Pb-GFPluccon infected blood samples was 
previously shown to correlate strongly with parasitaemia [40]. Here, the distribution of  DNA on 
filter paper was assessed by measuring the luminescent intensity in dried blood spots from mice 
infected with Pb-GFPluccon [41]. Cell by cell luminescence analysis of  the grid overlaying the 
blood spot was used to describe heterogeneity in parasite material in different parts of  the blood 
spot. Both blood spots tested showed a considerable degree of  heterogeneity in the distribution 
of  parasite material (Figure 3). In the two separate experiments, 25 % and 64 % of the grid 
cells contained less than 85 % of the parasite material of  the grid cell with the highest quantity. 
Parasite material seemed less concentrated towards the extreme edges of  the blood spot; the grid 
cell with the lowest parasite quantity contained 70% of the maximum value (Figure 3).
Distribution of antibody material on blood spots 
The distribution of  antibodies on filter paper was evaluated by the adding two marker molecules 
which have approximately the same molecular weight of  human IgG and have no detectable 
interaction with other components in human blood. Analysis of  fluorescence intensity based on 
the overlaying grid showed that also antibodies were heterogeneously distributed throughout 
the blood spot (Figure 3). In the two separate experiments, 65 % of  the grid cells contained 
less than 85 % of  the parasite material of  the grid cell with the highest quantity. Contrary to 
the observations on parasite material, there was no evident pattern in antibody concentration 
on the blood spot and concentrations of  antibodies did not appear to be higher in the middle 
of  the spot (Figure 3). The grid cell with the lowest antibody concentration contained 67% of  
the maximum value. 
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Figure 3: DNA/Cell and antibody distribution on filter paper. A. Figure 3: DNA/Cell and antibody 
distribution on filter paper. A. Photograph of one of the two blood spots analysed for cell material 
distribution, in which luminescence intensity is proportional to the density of cell material. 
Luminescence intensity values in the cells of the overlying grid are calculated as a proportion of the 
highest cell value, and are presented in the adjacent grid schema. B. Photograph of one of the two 
blood spots analysed for antibody material distribution, in which fluorescence intensity is proportional 
to the density of antibodies. Fluorescence intensity values are calculated and presented as in Figure 3A.
Discussion
The methodology described in this report offers a cost-efficient high-throughput approach 
to preparing large numbers of  filter paper samples for the assessment of  cumulative malaria 
exposure and current infection status. Used in concert, serological and molecular assays can 
provide detailed insight into the transmission dynamics of  Plasmodium.
 The utility of  serological assessments in malaria surveillance has been evidenced by 
numerous studies of  the antibody responses of  endemic populations to recombinant 
Plasmodium [42] and Anopheles [43-45] antigens. Recently the importance of  molecular tools 
in malaria surveillance has been emphasised, as it has become apparent that the extent 
and relevance of  sub-microscopic malaria infections in low endemic areas may be much 
greater than previously assumed [6, 24]. As the number of  areas making efforts to reduce or 
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interrupt native malaria transmission grows so will the importance of  sensitively detecting 
malaria exposure [7, 32, 46]. As such, the development of  strategies to ease sample collection 
and processing during wide-scale population level surveillance is both timely and apposite 
to the wider malaria eradication agenda. The use of  filter papers for blood collection and 
their subsequent storage and processing for sero-epidemiological analyses was discussed in 
depth by Corran et al. [34]. Since this time many studies have benefitted from the use of  
filter paper blood spots as a source of  serum antibodies to reveal age-dependent [20], spatial 
[17-19] and temporal [47] patterns in cumulative malaria exposure. In the current study 
antibody levels (OD) from the standard elution methodology and the combined elution 
methodology (in which a portion of  the filter paper eluate undergoes onward processing for 
DNA extraction) show a strong and highly significant correlation. Though the relationship 
between absolute antibody titre in paired measures was strongly related, higher antibody 
levels were generally observed when blood spots underwent standard elution procedures. 
The reason for this is unknown and may reflect differences in the relative concentration of  
detergent. The lower antibody yield in the combined method warns against using the two 
approaches simultaneously; quantitative outcomes of  individual samples cannot be directly 
compared when different elution methods have been used. In epidemiological studies it is 
more common to analyse variation in malaria exposure using measures of  (age-dependent) 
antibody seroprevalence [19, 20, 48]. In the current study, seroprevalence did not differ 
significantly between the two elution methods, and both methods showed the same age-
dependent acquisition of  antibody responses. This indicates that combining antibody 
elution with DNA extraction is an operationally attractive alternative to the standard 
method of  antibody elution that can reliably be used to compare antibody responses 
between populations of  blood donors. 
 The elution of  antibodies during the process of  DNA extraction adds an advantage to 
the chelex/saponin extraction method, which is probably the most widely used extraction 
method in epidemiological malaria studies. This extraction method has repeatedly been 
shown to give comparable results when compared to commercial extraction kits [49, 
50]; although in case of  older or incorrectly dried and stored filter papers commercial 
kits may be recommended [31]. Because of  its evident superior sensitivity compared to 
microscopy [6, 24], PCR may be considered to be the gold standard for the detection of  
malaria infections in epidemiological studies. The current study highlights three relevant 
caveats to this assumption. Firstly, different PCRs differ in their sensitivity to detect malaria 
parasite. Although a recent meta-analysis found no differences in sensitivity compared to 
microscopy for different nested PCR assays [24], the current study presents evidence for 
a higher sensitivity of  PCR based on the cytochrome b target gene compared to the most 
widely used 18s rRNA target gene [31, 51]. This may be due to better conservation of  
mitochondrial material [52]. The current study shows no advantage of  the newly designed 
primers for the cytochrome b gene in overcoming the anecdotal problems of  inconsistency 
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of  PCR results with the original protocol. The shorter N1 primers amplify the same area , 
may give more consistent results (data not shown) and may increase primer stability during 
freeze/thawing cycles but did not lead to improved sensitivity for the 240 samples tested in 
the current study. 
 Secondly, the current study presents evidence that increasing the amount of  filter paper 
material for DNA extraction results in an increased sensitivity. Although this finding is 
intuitively correct, its actual relevance for determining parasite prevalence in field studies 
has not been described in detail before. One could argue that a single copy of  template 
material may result in successful amplification and therefore only infections with densities 
close to the threshold density for detection by PCR would give discordant PCR results. 
The current findings suggest that this is frequently the case and that doubling filter paper 
material can lead to parasite prevalence estimates that are up to 3.8 % higher. 
 Thirdly, the results illustrate the stochastic nature of  PCR. Although the agreement 
between PCR outcomes was very high, agreement was never perfect. Discordant PCR 
results were common, especially if  single filter paper punches were used. Importantly, 
some PCRs performed on single filter paper punches detected parasites while the same 
PCR on double filter paper punches did not. This serves as a word of  warning against 
assuming 100 % sensitivity of  PCR. It has been previously acknowledged that PCR assays 
may fail to detect all circulating parasite clones [53, 54], the current study indicates that this 
imperfection of  PCR assays may also affect parasite prevalence estimates. The exploratory 
experiments described in this study on the distribution of  parasite material on filter papers 
may be relevant in this respect: the amount of  parasite material can differ by more than 15% 
between different punches from the same bloodspot despite the blood completely wetting 
the paper. 
Conclusion
When the combined DNA extraction-serum elution methodology is used, robust PCR 
and ELISA results can be obtained. The combined approach can significantly reduce 
the workload in large-scale epidemiological studies and allow efficient use of  blood spot 
material for molecular and immunological assays. The efficient use of  blood spot material 
may allow researchers to increase the amount of  filter paper material that is used for this 
combined extraction. This will increase PCR sensitivity and may increase robustness of  
parasite prevalence estimates. 
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Abstract
Assessment of  exposure to malaria vectors is important to our understanding of  spatial 
and temporal variations in disease transmission and facilitates the targeting and evaluation 
of  control efforts. Recently, an immunogenic Anopheles gambiae salivary protein (gSG6) 
was identified and proposed as the basis of  an immuno-assay determining exposure to 
Afrotropical malaria vectors. In the present study, IgG responses to gSG6 and 6 malaria 
antigens (CSP, AMA-1, MSP-1, MSP-3, GLURP R1, and GLURP R2) were compared to 
Anopheles exposure and malaria incidence in a cohort of  children from Korogwe district, 
Tanzania; an area of  moderate and heterogeneous malaria transmission. Anti-gSG6 
responses above the threshold for seropositivity were detected in 15% (96/636) of  the 
children, and were positively associated with geographical variations in Anopheles exposure 
(OR 1.25, CI 1.01–1.54, p=0.04). Additionally, IgG responses to gSG6 in individual 
children showed a strong positive association with household level mosquito exposure. IgG 
levels for all antigens except AMA-1 were associated with the frequency of  malaria episodes 
following sampling. gSG6 seropositivity was strongly positively associated with subsequent 
malaria incidence (test for trend p=0.004), comparable to malaria antigens MSP-1 and 
GLURP R2. Our results show that the gSG6 assay is sensitive to micro-epidemiological 
variations in exposure to Anopheles mosquitoes, and provide a correlate of  malaria risk 
that is unrelated to immune protection. While the technique requires further evaluation in 
a range of  malaria endemic settings, our findings suggest that the gSG6 assay may have a 
role in the evaluation and planning of  targeted and preventative anti-malaria interventions.
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Introduction
Heterogeneity in malaria exposure is present at all levels of  endemicity [1] but is most 
readily observed in areas of  low transmission and following periods of  extensive control 
[1-3]. Recent evidence of  decreasing malaria incidence [2,4], has fuelled calls for malaria 
elimination from the world’s public health, political and philanthropic authorities [5,6]. As 
a result the interest in malaria heterogeneity and its potential effect on malaria control has 
increased [2,3,7]. Hotspots of  higher malaria transmission are likely to hamper malaria 
elimination efforts, as residual foci of  persistent malaria infection may seed transmission to 
the wider community [8-10]. 
 Although not all factors that affect malaria heterogeneity are fully understood, variation 
in the exposure to malaria vectors is likely to be of  key importance [3,11-13]. In sub-
Saharan Africa, the transmission of  Plasmodium falciparum is maintained by three key 
mosquito species; Anopheles gambiae, An. arabiensis and An. funestus [14]. Mosquito exposure 
is typically assessed as a component of  the entomological inoculation rate (EIR), which 
is defined as the number of  infectious Anopheles bites per person per unit time (ib/p/yr) 
[15,16]. Despite its value in malaria research, a direct assessment of  EIR to determine 
small-scale variation in malaria exposure is operationally unattractive at low levels of  
transmission (EIR<10 ib/p/yr) [17-19]. The development of  accurate and sensitive tools 
for identifying micro-epidemiological variations in vector exposure and malaria risk 
is important in assessing the efficiency of  control efforts and focusing interventions to 
those areas or populations that are most affected by malaria. Serological assessments of  
malaria exposure are receiving increasing interest in this respect and have been used for 
quantifying malaria transmission intensity [20] and its temporal [21] and spatial variation 
[11,22,23]. Recently, serological markers of  malaria exposure were also used to quantify 
heterogeneity in the efficacy of  malaria interventions [24]. Recombinant malaria blood 
stage antigens have been most widely used for these purposes [25], while responses to the 
infective sporozoite specific circum-sporozoite protein (CSP) are currently viewed as the 
best available serological tool to detect exposure to infectious mosquito bites [18,26-28]. 
A similar tool to identify spatial patterns of  cumulative exposure to Anopheles biting could 
be integral to the detection of  malaria hotspots and play a role in forecasting the risk of  
malaria epidemics or the dynamics of  malaria resurgence in areas where parasite carriage 
in human populations has decreased but exposure to malaria vectors persists [29]. 
 Our understanding of  the human immune response to mosquito saliva has until recently 
been largely restricted to culicine mosquitoes and the clinical consequences of  allergy 
[30-32]. Humoral responses to the saliva of  various disease vectors have been exploited 
epidemiologically, revealing significant correlation with disease seropositivity and vector 
exposure. Such assays have now been described for Ixodes ticks [33,34], triatomine bugs 
[35], Glossina tsetse flies [36] and Lutzomyia and Phlebotomus sand flies [37,38]. Recently, 
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transcriptome analysis of  the salivary glands of  A. gambiae females identified over 70 
putative secreted salivary proteins [39-41]. A small (~10kb) immunogenic protein, gambiae 
salivary gland protein 6 (gSG6), that is well conserved in the three major Afrotropical 
malaria vectors (A. gambiae, An. arabiensis and An. funestus) and restricted to anopheline 
mosquitoes [42], has been identified as a suitable candidate for a bioassay of  Anopheles 
exposure [43,44]. Antibody responses to a gSG6 peptide (gSG6-P1) described Anopheles 
exposure in areas of  low vector density [45] and in response to vector control programs 
[46] with some success, and were recently shown to reflect Anopheles heterogeneity at 
the district level in Dakar, Senegal [47]. Recombinant full length gSG6 has also shown 
strong immunogenicity among rural populations in Burkina Faso, which appears to be 
sufficiently short lived to correlate with seasonal changes in Anopheles abundance [43,48].
The relationship between malaria case incidence and anti-gSG6 response has not been 
studied, despite early indications that humoral responses to Anopheles whole saliva were 
positively associated with malaria infection [49].
 Using a subset of  samples collected during a large study of  intermittent presumptive 
treatment among infants (IPTi) [50], along with entomological data from an intensive 
survey in the same area [11], we present the first evaluation of  IgG antibody responses 
to the recombinant gSG6 salivary antigen for describing spatial heterogeneity in vector 
exposure between and within geographically defined subvillages in an area of  moderate and 
heterogeneous malaria exposure in northern Tanzania. At the individual level, we determine 
the association of  gSG6 reactivity with household Anopheles exposure and subsequent 
malaria incidence. In addition, we determined reactivity against a selection of  malaria 
antigens that have been more commonly used in epidemiological studies, namely CSP and 
four blood stage proteins, AMA-1, MSP-1, MSP-3, and glutamate-rich protein (GLURP).
Methods
Ethics statement
Witnessed written consent was provided by the caregivers of  all children involved in 
serological sampling, and by heads of  households for participation in the entomological 
survey. Ethical approval was granted by the review board of  the National Institute for 
Medical Research of  Tanzania, and the London School of  Hygiene and Tropical Medicine 
ethics committee.
Study area and subjects
Plasma samples were collected from children recruited over 18 months, as part of  a longer 
term study (2004-2008) carried out in the district of  Korogwe, Northern Tanzania, an area 
of  moderate malaria endemicity. Korogwe district is situated ~600m above sea level, and 
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has a seasonal pattern of  rainfall (800-1400mm/year) [50]. Malaria transmission in the 
Korogwe region has declined in recent years [51], such that an EIR of  1-14 ib/p/yr was 
estimated in 2007 [21]. The original study investigated the relative impacts of  different drug 
regimens for intermittent presumptive treatment (IPTi) among a total of  1280 infants [50]. 
Entomological data collection
In the final year of  the IPTi study a randomly selected subset of  600 children were enrolled 
in a detailed entomological survey, aiming to describe spatial patterns of  malaria incidence 
in relation to mosquito exposure [11]. In the room of  each selected child, mosquitoes were 
sampled with miniature CDC light traps (Model 512; John W. Hock Company, Gainesville, 
Florida) for one night at the end of  the wet season (May), again at the beginning (July) and 
finally the end (September) of  the dry season in 2008. Mosquito exposure at the household 
level was highly correlated between all surveys (correlation coefficient: May/July=0.462, 
May/September=0.497, July/September=0.444; p<0.0001). Mosquito data from first of  
the three sampling points, during the peak transmission season when Anopheles abundance 
was highest, was therefore deemed adequate in displaying variation in exposure. Of  the 
total Anopheles females caught during sampling, A. gambiae s.l. made up 80.3%, An. funestus 
18.6% and other anophelines 1%.
Clinical data and plasma samples
Malaria incidence was assessed by passive monitoring for signs of  illness throughout the 
22 months following recruitment, during which time free access to clinical treatment was 
provided [50]. The average age at recruitment was 9.4 weeks (range 8–17 weeks) and infants 
were recruited at different times of  the year, i.e. at different time-points in the transmission 
season. Plasma samples used in the current study were taken at 9 months of  age when 
infants were presented at clinics as part of  the Expanded Program on Immunisation (EPI). 
Blood samples were collected by finger prick and after plasma separation samples were 
stored at -20°C until processing. In our analyses, we included malaria incidence in the 
period between serum collection at 9 months of  age and the end of  follow-up. This gave 
an effective follow up period of  approximately 15 months and ensured that the follow-up 
period included one or more peak malaria transmission seasons for each child. The current 
analyses are an ancillary study and many of  the blood samples had been used previously for 
other IPTi specific investigations. As a result of  this non-systematic exhaustion of  samples, 
sera were available for a subset of  636/1280 children for gSG6 ELISA; 247/636 children 
from this subset were involved in the household level entomological survey. 
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gSG6 ELISA
ELISA was performed as previously described with few modifications [43,48]. Briefly, 
Maxisorp 96-well plates (Nunc M9410) were coated with gSG6 at 5ug/ml. Test and negative 
control serum were analysed in duplicate at 1:100 in phosphate buffered saline with 0.05% 
Tween 20 (PBST)/1% skimmed milk powder (Marvel, UK). On every plate blank wells 
(PBST/Marvel) were included to correct sample ODs for background antibody reactivity, 
and positive control sera (1:40 in PBST/Marvel) were analysed to allow standardisation of  
OD values for day-to-day and inter-plate variation. Positive control sera was provided, with 
consent, by an employee of  the London School of  Hygiene and Tropical medicine who was 
exposed weekly to the bites of  approximately 50-100 laboratory bred A. gambiae s.s (Kisumu 
strain) during colony feeding.
 Sera from 39 Europeans with no recent history of  travel to malaria endemic countries were 
used as negative controls for calculation of  IgG seroprevalence. Cut off  for seropositivity 
among samples was determined as the mean OD of  the unexposed sera plus 3 standard 
deviations. 
P. falciparum ELISA and Luminex assays
For this analysis, IgG antibody responses were chosen in preference to IgM for their high 
antigen specificity. IgG antibody responses against CSP (Gennova, 0.009µg/ml), AMA-
1 (BPRC, 0.3µg/ml) and MSP-119 (CTK Biotech, 0.2µg/ml) were detected as previously 
described [20,27]. Test sera were analysed in duplicate at 1:200 (CSP), 1:1000 (MSP-119) or 
1:2000 (AMA-1) in PBST/Marvel. Blank wells, positive control sera from a hyper-endemic 
region in the Gambia [20], and a serial dilution of  pooled hyper-immune sera were included 
in duplicate on each plate to correct for non-specific reactivity and allow standardisation of  
inter-plate variation. Seroprevalence of  IgG antibodies to these non-salivary antigens was 
calculated using a mixture model as described previously [20,52].
 Recombinant proteins corresponding to the R1, R2 (Central repeat and C-terminal repeat 
regions of  GLURP), and the C-terminal region of  MSP-3 [53] were covalently coupled to 
carboxylated luminex microspheres according to the manufacturer’s protocol and tested 
as previously described [54]. Cut-off  for positivity was calculated as the mean reactivity in 
malaria non-exposed European individuals plus 2 standard deviations. 
Data analysis
To examine the relationship between patterns of  gSG6 reactivity and small scale spatial 
variation in Anopheles exposure, antibody responses were described at the level of  
subvillages, which are defined by their geographical location (figure 1) [11]. The average 
(arithmetic mean) mosquito exposure for each village was used for ranking villages from 
low to high mosquito exposure; this rank was related to antibody prevalence and mean 
log 10 adjusted antibody level per subvillage. This enabled analyses relating to geographic 
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variations in Anopheles abundance for all individuals, irrespective of  their involvement in 
the entomological survey (figure 2). 
 For infants for whom both household mosquito data and plasma samples were available, 
it was possible to investigate associations between Anopheles exposure and antibody 
reactivity against salivary and malaria antigens at an individual level. For this purpose, 
households were analysed in quintiles of  Anopheles exposure (table 1). 
Figure 1. Map of Tanzania showing the north-eastern provinces, and the location of Korogwe 
district. Sampling in Korogwe district was conducted in 5 areas, which are marked on the map: 
Korogwe, Majengo, Magasin, Mnyuzi, and Mandera. Within these areas, our study population were 
resident in 15 subvillages. Korogwe consisted of the following subvillages: Kwasemangube (KS), 
Lwengera (LW) Msambazi (MS) and Masuguru (MU). Majengo consisted of the following subvillages: 
Kilole (KI), Majengo (MJ) and Manundu (MA). Magasin consisted of the following subvillages: Kwagunda 
(KW) and Maguga (MG). Mnyuzi consisted of the following subvillages: Gereza (GE), Lusanga (LU), 
Mkwakwani (MK), Mnyuzi (MY) and Shambakapori (SH). Mandera (MD) was an isolated subvillage.
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Figure 2. Mean household Anopheles female count during peak transmission (May) in different 
subvillages. Numbers of households sampled for each subvillage, in order of Anopheles exposure, 
were as follows: MY=45, MS=23, MA=26, MU=21, MJ=29, KS=24, LW=65, LU=61, MD=45, MK=14, 
KW=99, SH=13, GE=47, KI=30, MG=91.
Table 1. Households grouped into quintiles according to their relative exposure to Anopheles 
females during the wet season entomological survey (May). 
Quintile Households
Female Anopheles per household
Mean Range
1 64 0 0
2 44 1.59 1-2
3 45 4.11 3-5
4 45 11.71 6-17
5 49 43.37 17-119
Table 2. Seroprevalence and IgG antibody levels among seropositive children to A. gambiae 
gSG6, and P. falciparum CSP, AMA-1, MSP-1, MSP-3, GLURP R1 and GLURP R2. 
gSG6 CSP AMA-1 MSP-1 MSP-3 GLURP R1 GLURP R2
Antibody prevalence 
% (n/N)
15 
(96/636)
21 
(121/575)
2 
(9/540)
10 
(52/540)
10
(54/566)
3
(16/566)
12
(67/566)
Median OD 
(IQR)*
0.29
(0.21-0.58)
0.46 
(0.38-0.74)
0.09 
(0.07-0.11)
0.21
(0.11-0.33)
- - -
OD optical density
IQR inter-quartile range (25th and 75th percentiles)
n/N proportion of seropositive individuals/total sample size
*  seropositive individuals only
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Statistical analysis was conducted in STATA (Version 10, STATA statistical software 
StataCorp) and GraphPad Prism (Version 5.0, GraphPad Software Inc., La Jolla, CA) 
software packages. IgG responses to salivary or malaria antigens between two independent 
groups were compared by Wilcoxon rank-sum tests (Mann-Whitney U test), with Bonferroni 
correction for multiple comparisons between subgroups. Comparisons of  multiple groups 
were carried out by Kruskal-Wallis test. Seroprevalence comparisons were made using Chi-
square test, with a test for trend in proportions. Correlations between IgG and malaria or 
entomological measures were made using Spearman correlation or with linear regression 
analysis after log10-transformation of  OD data. IPTi treatment arm was included in our 
analyses as potential confounder. As a small number of  sample ODs were lower than their 
ELISA plate blank value, some normalised ODs had negative values and an arbitrary positive 
value (+1) was therefore added to all ODs before transformation. 
Results
Small scale spatial variation in Anopheles exposure and anti-gSG6 
responses
The recombinant gSG6 protein elicited significant anti-gSG6 IgG responses in children 
from Korogwe district (mean OD 0.109, maximum OD 2.014). European sera were 
used as negative controls for exposure to Anopheles mosquitoes, the responses of  which 
were pooled to determine a cut-off  for seroprevalence at OD 0.167 (table 2). Mean OD 
among antibody negative children from Korogwe was 0.052, and ranged from 0.001-0.166 
(standard deviation 0.040). IPTi treatment arm was not associated with gSG6 antibody 
prevalence (p=0.23) or density (p=0.38) and did not show any evident association with any 
of  the other antigens tested, nor was it found to be a confounder in any of  the associations 
presented below (data not shown).
When mean mosquito exposure was plotted against log 10 adjusted anti-gSG6 IgG level 
for each of  the 15 subvillages, a significant positive association was observed between 
mean mosquito exposure and antibody reactivity (figure 3). Similarly, despite significant 
variability in gSG6 response between subvillages, there was a significant positive association 
between mean mosquito exposure per subvillage and anti-gSG6 IgG seropositivity, wherein 
an average increased exposure of  10 mosquitoes was associated with a 25% increase in 
antibody positivity (odds ratio [OR] 1.25, CI 1.01–1.54, p=0.04).
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Figure 3. Mean anti-gSG6 IgG level per subvillage, plotted against increasing mosquito 
exposure per subvillage. Anti-gSG6 IgG levels are given as the log-10 adjusted mean anti-gSG6 OD 
per subvillage. Mosquito exposure is given as the ascending and sequential mean Anopheles female 
count for each of 15 subvillages (x-axis), as in figure 2. The trend-line from the linear regression is 
shown as a dashed line (r2=0.436, p=0.007). 
Household level mosquito exposure and anti-gSG6 response
Information on household-level mosquito exposure was available for the households of  
247 children. At the level of  individual households, exposure to Anopheles females showed 
a significant positive correlation with anti-gSG6 IgG level (correlation coefficient 0.188, 
p=0.003) but not with levels of  anti-CSP IgG (correlation coefficient 0.036, p=0.59). When 
households were grouped into quintiles according to their relative exposure to Anopheles 
(table 1), there was a statistically significant positive association between Anopheles exposure 
in quintiles and anti-gSG6 IgG levels (p=0.001) and prevalence (test for trend in proportions, 
p=0.001) (figure 4). There was no evident association between individual Anopheles exposure 
in quintiles and individual CSP antibody level (p=0.544) or prevalence (test for trend in 
proportions p=0.422). Similarly, no significant associations were observed between Anopheles 
exposure in quintiles and individual responses to any blood stage antigen, save MSP-3 for 
which there was a significant positive association with antibody level (p=0.017).
Malaria incidence and anti-gSG6 and anti-malaria responses
Antibody levels were positively associated with the frequency of  malaria episodes recorded 
after serum collection for all antigens except AMA-1 (gSG6 correlation coefficient 0.240, 
p<0.0001 (figure 5A); CSP correlation coefficient 0.183, p=0.004; MSP -1 correlation 
coefficient 0.256, p<0.0001; MSP-3 correlation coefficient 0.141, p=0.0008; GLURP R1 
correlation coefficient 0.126, p=0.003; GLURP R2 correlation coefficient 0.101, p=0.017 
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[data not shown]). The prevalence of  IgG responses varied significantly with grouped 
malaria incidence for gSG6 (p<0.0001), AMA-1 (p=0.004), MSP-1 (p<0.0001) and GLURP 
R2 (p=<0.001). No significant variation in seroprevalence of  antibodies to CSP, MSP-3 
and GLURP R1 was present between groups of  malaria incidence (figure 5B). A strong 
positive association was observed between grouped malaria incidence and the prevalence 
of  antibody responses against gSG6, MSP-1 and GLURP R2, while this relationship was 
present but only marginally significant for MSP-3 (figure 5B).
Figure 4. IgG responses to gSG6 and P. falciparum antigens, grouped into quintiles of household 
Anopheles exposure. A. Box plots showing anti-gSG6 IgG level between groups sorted according 
to Anopheles exposure in quintiles. Boxes show the median and 25th/75th percentiles, whiskers show 
the 5th/95th percentiles, and outliers are represented by dots. Where outliers were excluded from the 
graph but not analysis they are marked with a + and included in parentheses. P values for pairwise 
comparisons were determined by Mann-Whitney test with Bonferroni correction (*), and for all groups 
by Kruskal-Wallis test (**). B. Seroprevalence of anti-gSG6 and anti-P. falciparum IgG antibodies plotted 
against Anopheles exposure in quintiles. Error bars indicate 95% confidence intervals (CI). P values were 
determined by a test for trend in proportions (***).
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Figure 5. IgG responses to gSG6 and P. falciparum antigens, plotted against malaria incidence 
after serum collection. Malaria incidence is grouped into 0 episodes, 1-2 episodes or >3 episodes. 
A. Box plots showing anti-gSG6 IgG level between groups sorted according to malaria incidence 
subsequent to serological sampling. Boxes, whiskers and P values are as in figure 4. n=269. B. 
Seroprevalence of anti-gSG6 and anti-P. falciparum IgG antibodies plotted against grouped malaria 
incidence. Sample sizes vary by antigen according to the available serological methodology; CSP 
n=246, AMA-1 n=227, MSP-1 n=227, MSP-3 n=566, GLURP R1 n=566, GLURP R2 n=566. P values were 
determined by a test for trend in proportions (***). Error bars denote 95% CI.
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Discussion
In the present study we show that the antibody responses of  young children to the 
recombinant A. gambiae salivary protein, gSG6, reflect small scale spatial variation in 
malaria transmission, and are strongly associated with malaria risk in an area of  moderate 
transmission intensity in northern Tanzania where A. gambiae and An. funestus are the main 
malaria vectors. 
 Reactivity to both the peptide and recombinant forms of  the anopheline gSG6 protein 
has previously been associated with seasonal or regional patterns in mosquito exposure 
[45-48,55]. The current study is the first to describe antibody responses to the recombinant 
gSG6 protein in relation to village of  residence, and individual level mosquito exposure 
and malaria incidence. For this, we utilised a detailed entomological dataset from Korogwe 
district, Tanzania, that revealed significant heterogeneity in Anopheles abundance between 
and within villages [11]. Despite generally low reactivity among our infant study population, 
anti-gSG6 IgG level and prevalence effectively described varying levels of  exposure to 
Anopheles between subvillages, corroborating recent findings from Senegal where gSG6-P1 
responses reflected spatial variation in Anopheles exposure between districts in urban Dakar 
[47]. The first studies to assess IgG responses to recombinant gSG6 were carried out in 
two rural villages in Burkina Faso, and revealed >50% seroprevalence in children during 
the peak transmission season [48]. The lower responses observed in this study confirm the 
lower transmission intensity in the current study area. 
 At the level of  subvillages, anti-gSG6 antibody responses closely followed patterns in 
malaria incidence and community-level antibody responses to malaria-specific antigens AMA-
1 and MSP-119 [11]. This broad agreement in estimates of  malaria incidence and Anopheles 
and malaria-specific antibody responses at subvillage level is unsurprising [45,48,49,55]. 
Patterns may diverge when assessed at an individual level, as Anopheles abundance and biting 
behaviour may be unevenly distributed between households [12,21,56] and intense mosquito 
exposure may not necessarily mean a high malaria exposure if  anophelines are not infected. 
This commonly happens at the start of  the wet season when mosquitoes have just emerged 
and are unlikely to have completed a sporogonic cycle [57], but mosquito sporozoite rates 
may also show spatial variation [11]. Associations between mosquito exposure, malaria 
incidence and immune responses are further complicated by the fact that individuals 
with the highest malaria exposure will acquire protective immunity most rapidly and may 
experience lower malaria incidence in some settings [58,59]. In general, it is complex to 
disentangle markers of  exposure from markers of  protection when analysing malaria blood 
stage antigens. Recent studies highlight the importance of  considering malaria heterogeneity 
when determining the protective effect of  antibody responses on clinical malaria. Initially, 
counterintuitive observations that higher blood stage immune responses were associated 
with increased malaria incidence [60,61], were explained by adjusting for heterogeneity in 
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malaria exposure and excluding non-parasitaemic individuals. This revealed a protective 
effect among immune responders, reflecting either true or surrogate humoral immune 
mediation [60]. This methodological challenge, first described by Bejon and colleagues 
[62,63], has highlighted the need for markers that capture heterogeneity in malaria exposure 
but are not associated with clinical protection [58,60,61]. Markers of  mosquito exposure, as 
described in this manuscript, may play this role by identifying those individuals most at risk 
of  malaria.
 No clear associations were apparent between Anopheles exposure at an individual level 
and antibody responses to any of  the malaria-specific antigens (CSP, AMA-1, MSP-1, 
MSP-3, GLURP R1, GLURP R2). Anti-CSP reactivity might be expected to correlate with 
exposure to infected mosquito bites and therefore perhaps also with overall mosquito biting, 
but in our analysis did not. This may be a consequence of  the relatively small sample size, 
and low EIR [11,21]; in moderate to low endemic areas the proportion of  infected vectors is 
frequently lower than 1% [15,64,65]. Contrary to this, individual-level anti-gSG6 responses 
were strongly associated with household Anopheles exposure. Interestingly, mosquito 
exposure was assessed towards the end of  the study, starting approximately 15 months after 
the serum sample that was used for serology was collected. This suggests that heterogeneity 
in mosquito exposure is consistent over time in our study area, supporting the hypothesis of  
stable hotspots of  malaria transmission [10,22]. 
 We previously showed that antibody responses to blood stage malaria antigens determined 
in clinic attendees reliably predicted spatial patterns in malaria incidence in a cohort of  
children living in the same area [11]. We here extended these analyses and showed that 
an individual’s antibody responses to MSP-1, MSP-3 and GLURP-R2 are all positively 
associated with subsequent malaria incidence. The selection of  malaria antigens we used in 
this study was not intended to be exhaustive, nor did we aim to identify the malaria antigen 
with the highest discriminative power to detect variation in malaria exposure. We chose 4 
malaria antigens to put our findings with gSG6 in an epidemiological context. Our findings 
are consistent with previous reports from areas of  heterogeneous exposure where malaria 
specific antibody responses as markers of  past exposure predict future exposure [60,61]. 
Strikingly, in our analyses anti-gSG6 responses also provided a strong association with 
malaria incidence, indicating that malaria heterogeneity is associated with heterogeneous 
biting behaviour [12]. Unlike responses to transmission and blood stage malaria antigens 
[65,66] responses to gSG6 confer no protection to malaria, thus avoiding any confounding 
associations with immunity and malaria incidence. In such a way, the gSG6 assay may 
provide a useful marker for exposure to malaria for use in clinical studies [58].
 Though the sampling framework of  the current study was not designed to evaluate the 
temporal dynamics of  the anti-gSG6 response, there are indications that, as with responses 
to the salivary proteins of  other haematophagous arthropods, it elicits short lived antibody 
responses, reflecting only recent Anopheles exposure [45,46,48]. As blood-feeding is 
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transitory, and saliva is only released into the skin during probing with the majority likely 
to be re-ingested with the blood meal, this limits the development of  a humoral immune 
response to mosquito saliva [67-69]. This short exposure to antigen explains the low anti-
gSG6 responses observed among children from Korogwe. These low level responses highlight 
inherent problems in assessing exposure using an arbitrarily defined cut off  for seropositive 
individuals. Identifying individuals never exposed to malaria is relatively straightforward 
but the same cannot be said for individuals never exposed to Anopheles, a genus which has 
a very wide geographical distribution. The nature of  mosquito feeding, with the strength 
of  the correlations observed in our analyses between spatial and individual level mosquito 
exposure and antibody OD, supports the use of  antibody level rather than seroprevalence 
as a finer tool for assessment of  Anopheles exposure intensity. 
Conclusions
This is the first report that antibody responses to the recombinant A. gambiae salivary protein 
gSG6 in children can reflect small-scale spatial variation in exposure to anophelines at 
village and household level. Importantly, our analysis also provides the first evidence for a 
reliable association between malaria incidence and anti-gSG6 response; a relationship only 
previously observed using whole A. gambiae saliva [44]. Caution is required in extrapolating 
findings from this study to other age groups because our analyses were restricted to plasma 
samples from children aged 9 months and a role of  maternal transfer of  IgG during 
breastfeeding can therefore not be excluded. This limitation of  the current study does 
not alter our conclusions that these antibody responses are suitable markers of  micro-
epidemiological differences in Anopheles exposure. Potential uses for this assay include 
establishing Anopheles biting exposure to include indoor and outdoor biting, controlling 
for exposure in highly heterogeneous settings, and as a measure of  receptivity to inform 
programs that are moving toward elimination where there is a high risk for re-introduction. 
However, its utility in low endemic and pre-elimination settings first needs to be assessed 
[8]. To this end, it will be important to establish the assays suitability for use with scalable 
antibody sources such as dried filter paper blood-spots. The identification and analysis 
of  other salivary proteins may also help increase the sensitivity of  the approach in such 
settings [70]. 
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Abstract
Renewed interest in malaria eradication has placed greater emphasis on the development 
of  tools to interrupt Plasmodium transmission, such as transmission-blocking vaccines. 
However, effective deployment of  such tools is likely to depend on improving our under-
standing of  which individuals transmit infections to mosquitoes. To date, only a handful of  
studies have directly determined the infectiousness of  individuals in endemic populations. 
Here we review these studies and their relative merits. We also highlight factors influencing 
transmission potential that are not normally considered: the duration of  human 
infectiousness, frequency of  sampling by mosquitoes, and variation in vector competence 
among different mosquito populations. We argue that more comprehensive xenodiagnostic 
assessments of  infectivity are necessary to accurately quantify the infectious reservoir and 
better target interventions.
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Glossary 
Endophilic: arthropod behaviour describing a preference for resting indoors after blood feeding. 
Exophagic: arthropod behaviour describing a preference for blood feeding outdoors. 
Exophilic: arthropod behaviour describing a preference for resting outdoors after blood feeding.
Gametocyte: the sexual stages of  the malaria parasite capable of  reproduction in the mosquito. 
Female and male gametocytes circulate in the human peripheral blood, where they may be 
ingested by blood-feeding Anopheles mosquitoes and begin sexual development. 
Mosquito feeding assay: xenodiagnostic assays developed to determine the infectiousness of  
Plasmodium gametocytes to Anopheles mosquitoes. Mosquito feeding assay may refer to skin 
feeding assays, in which mosquitoes are allowed to feed directly on a subject’s skin, to direct 
membrane feeding assays, in which mosquitoes feed on venous blood from a subject maintained 
at body temperature in a membrane feeding device, or to standard membrane feeding assays, in 
which mosquitoes feed on cultured gametocytes in a membrane-based feeder system. 
Perennial transmission: malaria transmission may be described as perennial where 
environmental and climatic conditions allow parasite transmission throughout the year. 
Seasonal transmission: malaria transmission may be described as seasonal where mosquito 
biting and thus transmission are clustered temporally, generally occurring following predictable 
periods of  rain and subsequently decreasing in periods of  drought. 
Transmission-blocking immunity: the development of  humoral immunity to antigens present 
during gametocyte development. Antibodies specific to gametocyte antigens may be ingested 
along with mature gametocytes during blood feeding. If  these antibodies target proteins 
essential for parasite development (e.g., Pfs48/45, Pfs230) and are sufficiently abundant, 
antibody interaction can prevent parasite development and transmission potential is reduced 
or entirely blocked. There is a growing body of  evidence for the development of  transmission-
blocking immunity in individuals naturally exposed to malaria infection. 
Xenodiagnosis: in this context, is a method to determine the infectiousness of  a potentially 
parasitized host (i.e., malaria-infected humans) by allowing vectors (i.e., mosquitoes) to feed on 
the subject. Infectiousness is assessed by the infection status of  the vector (i.e., mosquito) after 
a suitable period of  parasite development.
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Reducing transmission of malaria: the future of elimination 
programs 
The burden of  malaria has declined in many endemic settings in Africa and elsewhere 
[1]. Local malaria elimination is considered achievable with current control approaches in 
some of  these areas when transmission intensity is low and reintroduction unlikely [2, 3]. 
However, in most endemic areas operational and technical limitations are likely to hinder 
the complete interruption of  transmission [4, 5]. New or renewed tools aimed specifically 
at interrupting the spread of  Plasmodium species from human to mosquito may therefore be 
critical for future elimination programs [6, 7], especially if  transmission efficiency increases 
as parasite prevalence goes down [8]. Un-like traditional control strategies, which aim to 
reduce severe morbidity in vulnerable populations, the effective-ness of  transmission-
reducing interventions (TRIs) hinges on their coverage of  individuals responsible for 
transmission to mosquitoes regardless of  their symptomatic status [9]. Despite the central 
importance of  human infectivity for TRI [10], there have been few direct assessments of  this. 
Here we discuss previous studies that aimed to directly assess infectivity at the population 
level, examine factors necessary to link these controlled transmission experiments with 
transmission in nature, and advocate the next steps that will provide the key information 
necessary to better target the human infectious reservoir for malaria. 
Quantifying the human infectious reservoir of malaria (1957–2014) 
In infected humans, the life cycle of  a small portion of  the total malaria parasite population 
culminates the differentiation and maturation into gametocytes (see Glossary). When an 
anopheline mosquito feeds on blood containing mature gametocytes some may be ingested, 
which then fuse and undergo sporogonic development making the insect infectious to 
humans. The human component of  the infectious reservoir is the proportion of  a population 
that is capable of  infecting mosquitoes [11].
 In community surveys, data from microscopy typically show that children and infants 
harbour Plasmodium gametocytes more commonly and in greater numbers than older age 
groups [12]. Such observations have long galvanized belief  among the scientific community 
that young individuals represent the main source of  infection for mosquitoes [12]. However, 
in the late 1940s and early 1950s xenodiagnostic assessments revealed that the presence of  
gametocytes in blood films was not a prerequisite for onward transmission [12–15]. The first 
population-based assessment of  human infectivity to mosquitoes was conducted in rural 
Liberia, where individuals living in an endemic region were recruited for mosquito feeding 
experiments regardless of  their parasite status [16]. While this study found that young 
children were much more infectious to mosquitoes, it also showed that, when estimates 
were adjusted for the demographic composition of  the population, all age groups were 
relevant contributors to malaria transmission (Box 1). In nearly 60 years since this study, 
a handful of  similar surveys have been reported (Tables 1 and 2). In general, these studies 
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show that while young children are consistently more likely to be infectious per se [17, 18], 
the contribution of  older age groups is by no means negligible; in previous xenodiagnostic 
surveys that were able to sample individuals of  all ages, individuals >15 years old constituted 
between 21.9% and 40.7% of  the total infectious reservoir [16–19]. Several studies have 
assessed human–mosquito transmission using entomological parameters [20]. However, 
these studies provide only broad population estimates of  infectiousness and they are neither 
able to describe the distribution of  the reservoir among different members of  the population 
nor allow an examination of  the role of  parasite density and infection dynamics. 
Box 1. Demography and the malaria infectious reservoir 
In previous surveys, the ‘bottom-heavy’ age structure typical of malaria endemic regions has acted 
to boost the contribution of more infectious children to the total malaria infectious reservoir, while 
less infectious adults, representing approximately half of most populations, generally contributed 
to a lesser extent. Recent demographic estimations show that Sub-Saharan African populations 
are still disproportionately young: approximately 17% and 27% of the population are aged 0–4 
and 5–14 years, respectively (http:// esa.un.org/wpp/). The influence of demography on patterns of 
transmission needs to be considered in light of the numerous other factors affecting the likelihood 
of infectious individuals contributing to mosquito infections. Although infants and children are 
over-represented in endemic areas they may be the age group least available and, perhaps, least 
attractive to mosquitoes (see ‘Determinants of human transmission potential: the need for data’). 
Conversely, older children and adolescents may represent a privileged group for human–mosquito 
transmission; individuals in this age group possess moderate gametocyte densities (approximately 
double the infectivity of individuals >15 years), lack the severe symptoms that prompt treatment, 
and appear comparatively vulnerable to mosquito biting (see Figure 1 in main text). Women in 
pregnancy have been observed to attract more than twice as many anophelines as non-pregnant 
women over short distances [21]. However, such observations must be weighed against behavioural 
and demographic parameters unique to this group. Census and fertility rate data show that 
pregnant women comprise a small proportion of African populations. In Zambia, 8.7% of women 
of child-bearing age were pregnant at any one time in 2013, which equates to 2–2.5% of the entire 
population (http://www. dhsprogram.com/pubs/pdf/FR304/FR304.pdf ). Pregnant women are 
also preferentially targeted by net and drug treatment campaigns, so the high attractiveness to 
mosquitoes of this small proportion of the population may be balanced by interventions.
Ultimately, determining the infectiousness of  different age groups relative to their 
representation in the population is just one necessary step in characterizing the infectious 
reservoir. Contribution to transmission is influenced not only by intrinsic parasite and 
human determinants of  infectivity, reflected in the outcome of  mosquito feeding assays, 
but also by various additional factors that make the capacity to infect mosquitoes in 
controlled experiments distinct from the probability of  onward transmission in nature (e.g., 
human exposure to mosquito biting) (Figure 1). These factors are not commonly taken into 
account and are not uniform across time or space or between individuals of  different ages. 
To more accurately reflect transmission in its epidemiological context, these elements need 
to be considered and incorporated into future assessments. 
95
The infectious reservoir of falciparum malaria
4
Ta
b
le
 2
. S
u
m
m
ar
y 
o
f s
tu
d
ie
s 
as
se
ss
in
g
 t
h
e 
m
al
ar
ia
 in
fe
ct
io
u
s 
re
se
rv
o
ir
 t
h
at
 r
ec
ru
it
ed
 o
n
ly
 g
am
et
o
cy
te
-p
o
si
ti
ve
 in
d
iv
id
u
al
s 
fo
r 
fe
ed
in
g
 a
ss
ay
s 
a
St
ud
y 
lo
ca
ti
on
Lo
ca
l 
tr
an
sm
iss
io
n 
se
tti
ng
Fe
ed
in
g 
m
et
ho
d
As
sa
y
en
dp
oi
nt
b
Sp
ec
ie
s
Pr
ev
al
en
ce
 o
f 
in
fe
cti
ou
sn
es
s 
(%
)c
Pr
op
or
ti
on
al
 c
on
tr
ib
uti
on
 t
o 
re
se
rv
oi
r 
(%
)d
M
os
qu
ito
 
in
fe
cti
on
 
pr
ob
ab
ili
ty
e
R
ef
er
en
ce
1 
- 4
5 
- 9
10
 - 
19
≥2
0
Th
e 
G
am
bi
a
In
te
ns
e 
se
as
on
al
M
em
br
an
e
O
oc
ys
ts
A.
 g
am
bi
ae
5.
6
17
.5
21
.7
22
.2
37
.9
0.
01
5
(1
1)
Ta
nz
an
ia
In
te
ns
e 
pe
re
nn
ia
l
M
em
br
an
e
O
oc
ys
ts
A.
 g
am
bi
ae
 s.
l.
3.
2
28
.4
23
.1
14
.2
34
.0
0.
00
7
(1
1)
Pa
pu
a 
N
ew
 
G
ui
ne
af
M
od
er
at
e 
pe
re
nn
ia
l
D
ir
ec
t 
&
 
M
em
br
an
e
O
oc
ys
ts
A
n.
 fa
ra
uti
 
3.
6 
(1
.4
)
48
.0
12
.4
24
.0
15
.5
0.
01
2 
(0
.0
04
)
(1
9)
a  O
n
ly
 s
tu
d
ie
s 
th
at
 h
av
e 
u
ti
liz
ed
 d
em
o
g
ra
p
h
ic
 a
n
d
 m
o
sq
u
it
o
 fe
ed
in
g
 d
at
a 
to
 c
h
ar
ac
te
ri
ze
 th
e 
h
u
m
an
 in
fe
ct
io
u
s 
re
se
rv
o
ir
 o
f P
la
sm
od
iu
m
 in
 e
n
d
em
ic
 p
o
p
u
la
ti
o
n
s 
ar
e 
in
cl
u
d
ed
. A
ll 
st
u
d
ie
s 
w
er
e 
co
n
d
u
ct
ed
 in
 a
re
as
 w
h
er
e 
Pl
as
m
od
iu
m
 fa
lc
ip
ar
um
 a
n
d
 n
o
n
-f
al
ci
pa
ru
m
 s
p
ec
ie
s 
co
ci
rc
u
la
te
, s
o
 t
h
e 
o
u
tc
o
m
e 
o
f 
fe
ed
in
g
 a
ss
ay
s 
ca
n
n
o
t 
b
e 
at
tr
ib
u
te
d
 u
n
am
b
ig
u
o
u
sl
y 
to
 fa
lc
ip
ar
um
 m
al
ar
ia
. 
b
 A
ss
ay
 e
n
d
 p
o
in
t 
w
as
 o
o
cy
st
s 
co
u
n
te
d
 o
n
 t
h
e 
m
o
sq
u
it
o
 m
id
g
u
t 
b
y 
m
ic
ro
sc
o
p
y.
 
c  P
re
va
le
n
ce
 o
f i
n
fe
ct
io
u
sn
es
s 
w
as
 c
al
cu
la
te
d
 a
s 
th
e 
co
m
b
in
ed
 p
re
va
le
n
ce
 o
f i
n
d
iv
id
u
al
s 
in
fe
ct
io
u
s 
to
 ≥
1 
m
o
sq
u
it
o
 in
 e
ac
h
 a
g
e 
ca
te
g
o
ry
, a
d
ju
st
ed
 fo
r t
h
e 
p
ro
p
o
rt
io
n
 
o
f t
h
e 
to
ta
l p
o
p
u
la
ti
o
n
 c
o
n
st
it
u
te
d
 b
y 
th
e 
ag
e 
g
ro
u
p
s.
 
d
 P
ro
p
o
rt
io
n
al
 c
o
n
tr
ib
u
ti
o
n
 t
o
 t
h
e 
re
se
rv
o
ir
 r
ep
re
se
n
ts
 t
h
e 
p
ro
p
o
rt
io
n
al
 c
o
n
tr
ib
u
ti
o
n
s 
o
f 
th
re
e 
o
r 
fo
u
r 
ag
e 
g
ro
u
p
s 
to
 t
h
e 
p
o
p
u
la
ti
o
n
-a
d
ju
st
ed
 r
es
er
vo
ir,
 w
it
h
 a
g
e 
g
ro
u
p
in
g
s 
co
m
b
in
ed
 w
h
er
e 
th
e 
d
at
a 
in
 t
h
e 
o
ri
g
in
al
 p
u
b
lic
at
io
n
 a
llo
w
ed
. 
e 
M
o
sq
u
it
o
 in
fe
ct
io
n
 p
ro
b
ab
ili
ty
 c
o
rr
es
p
o
n
d
s 
to
 t
h
e 
p
ro
b
ab
ili
ty
 t
h
at
 a
 m
o
sq
u
it
o
 b
it
in
g
 a
 r
an
d
o
m
 in
d
iv
id
u
al
 in
 a
 p
o
p
u
la
ti
o
n
 w
ill
 d
ev
el
o
p
 in
fe
ct
io
n
. T
h
is
 m
ea
su
re
 
is
 p
re
se
n
te
d
 a
s 
in
 t
h
e 
p
u
b
lis
h
ed
 d
at
a 
o
r 
w
as
 c
al
cu
la
te
d
 b
y 
co
m
b
in
in
g
 d
em
o
g
ra
p
h
ic
 d
at
a,
 a
g
e-
sp
ec
ifi
c 
p
re
va
le
n
ce
 o
f 
in
fe
ct
io
u
sn
es
s,
 a
n
d
 a
g
e-
sp
ec
ifi
c 
m
o
sq
u
it
o
 
in
fe
ct
io
n
 r
at
es
 d
u
ri
n
g
 in
fe
ct
iv
e 
m
em
b
ra
n
e 
fe
ed
in
g
 e
xp
er
im
en
ts
. 
f F
o
r 
th
is
 s
tu
d
y,
 a
ll 
sp
ec
ie
s 
an
d
 P
. f
al
ci
pa
ru
m
-s
p
ec
ifi
c 
(w
it
h
in
 p
ar
en
th
es
is
) e
st
im
at
es
 a
re
 p
re
se
n
te
d
.
96
97
The infectious reservoir of falciparum malaria
4
Figure 1. Age contributions to the infectious reservoir. (A) Individuals in the figure are represented by 
circles in three age groups: <5, 5–15, and >15 years. The abundance of individuals in each group reflects 
a simplified population age structure in Sub-Saharan Africa as described in Box 1 and in the studies 
detailed in Tables 1 and 2 (<5 = 15%, 5–15 = 30%, >15 = 55%) (http://esa.un.org/wpp/). (B) Speckling 
within circles represents the presence of Plasmodium falciparum gametocytes detectable using 
quantitative nucleic acid sequence-based amplification (QT-NASBA); age-specific prevalences presented 
here were taken from an area of intense seasonal transmission [87]. (C) Solid filled circles represent 
who might infect mosquitoes in a mosquito feeding assay. Some (or most) gametocytemic individuals 
may not be infectious for various reasons, including gametocyte density, maturity, recent treatment, 
and transmission-blocking immunity. Infectiousness prevalence for the three age groups (<5 = 25%, 
5–15 = 13%, >15 = 7%) is based on surveys described in Table 1 [16–18]. Pie Chart 1 demonstrates the 
proportional contribution of each age group to the total population infectious reservoir. Demographic 
adjustment is unnecessary as this example directly represents the age composition of a typical 
population. Of the theoretical total infectious population [9.8% (5/51 individuals)], individuals in the 
age groups <5, 5–15, and >15 years account for 40%, 40%, and 20% of the reservoir, respectively. (D) 
Equally exposed individuals of different ages are differently attractive to mosquito biting, partly due to 
differences in body surface area. To reflect this, individual circles are given a surface area proportional 
to the average body surface area of individuals in the three age groups (<5 = 0.4 m2, 5–15 = 1.2 m2,  
>15 = 1.6 m2; ratio of surface area 1:3:4) using data from Port et al. showing that body surface 
area correlated positively with mosquito biting rate [45]). Pie Chart 2 illustrates the potential 
effect of increased mosquito sampling due to body surface area in each age group on the 
infectious reservoir. Finally, to account for some of the age-related differences in exposure 
intensity, the percentage bed net use recorded in individuals from Western Kenya (coverage:  
<5 = 42%, 6–17 = 26%, >17 = 57.7%; ratio of exposure 1:1.2:0.7) was used to further adjust the surface 
area weighted contributions to the infectious reservoir (pie Chart 3) [88].
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Figure 2. Cross-sectional surveys and infectious reservoir dynamics. Data represent hypothetical 
annual transmission measures in two different endemic settings of seasonal and perennial malaria 
transmission. The broken line corresponds to the timing of cross-sectional xenodiagnostic surveys. 
The population plots underneath the main charts reflect hypothetical population-level infectiousness, 
as would be measured in direct assessments of the reservoir. Individuals in the plots are represented 
by circles in three age groups: <5, 5–15, and >15 years. The abundance of individuals in each group 
reflects a simplified population age structure in Sub-Saharan Africa, as described in Box 1 and in the 
studies detailed in Tables 1 and 2 (<5 = 15%, 5–15 = 30%, >15 = 55%) (http://esa.un.org/wpp/). Speckling 
within circles represents the presence of Plasmodium falciparum gametocytes; age-specific prevalence 
is hypothetical. Solid filled circles represent who might infect mosquitoes in a mosquito feeding assay; 
infectiousness prevalence for the three age groups is hypothetical. To reflect differences in body size 
and potentially attractiveness to mosquitoes, individual circles are given a surface area proportional 
to the average body surface area of individuals in the three age groups (<5 = 0.4 m2, 5–15 = 1.2 m2,  
>15 = 1.6 m2; ratio of surface area 1:3:4) using data from Port et al. showing that body surface area 
correlated positively with mosquito biting rate [45]. The combined surface area of individuals in the 
plots can be interpreted broadly as the contribution each group makes to the total infectious reservoir. 
Combined, the figure illustrates that the total infectious reservoir and the proportional contribution 
of differently aged individuals are likely to vary, potentially significantly, over time in response to the 
dynamicity of numerous factors. Although variations in transmission potential would probably be 
clearest between surveys where transmission is seasonal, age-specific contributions may vary with time 
in areas where transmission is intense and perennial.
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Determinants of human transmission potential: the need for data 
Duration and dynamics of infectivity 
The likelihood of  transmission to Anopheles mosquitoes is determined primarily by gametocyte 
density, fitness, and circulation time. The nonlinear relationship between gametocyte density 
and mosquito infection risk has been described several times [21–23]. Yet, because of  the 
relatively high proportion of  low-density parasitemias and gametocytemias in natural 
infections, there is increasing focus on how important these often subpatent infections are for 
the maintenance of  transmission [24, 25]. While the limited sensitivity of  microscopy to detect 
gametocytes is well established [21], many claims of  submicroscopic gametocyte densities 
contributing to transmission are based on microscopy-positive asexual parasite carriers with 
ac-companying submicroscopic gametocyte densities. This is an important difference when 
considering how current diagnostics may capture the human infectious reservoir [26, 27]; 
infections with submicroscopic gametocytes that accompany patent asexual parasites are 
detectable by conventional diagnostics while infections with no microscopically detectable 
parasite stages require more sensitive diagnostics [28]. 
 Because of  their cross-sectional nature, previous xenodiagnostic surveys have not formally 
examined the duration of  infectiousness, another key factor influencing transmission 
potential. Data from malaria therapy studies suggest that the infectiousness of  an individual 
infection can last for many months [29]. However, it is difficult to extrapolate the observations 
from a limited age range of  malaria-naive individuals to endemic populations. Broadly, 
in endemic settings children (possessing limited immunity) are likely to have more acute, 
higher-density infections that often require treatment [30]. This may result in cross-sectional 
surveys missing recently treated infections and identifying only a limited number of  highly 
infectious children without recent treatment. Conversely, adults and older children (often 
semi-immune, and presenting few clinical symptoms) would have longer, chronic infections, 
which could result in longer infectious periods, balanced by lower infectivity at individual 
time points [31]. These patterns of  infection are likely to differ with transmission intensity. 
In areas of  intense malaria transmission, children may have repeated malaria infections with 
relatively high gametocyte densities and a high likelihood of  malaria transmission (Figure 
2). In areas with lower transmission, including areas that have reduced transmission in the 
context of  an elimination program, infection duration is likely to have a more significant 
influence on the infectious reservoir. At present only one study has directly assessed 
population-level infectiousness in an area of  low malaria transmission [32]. Because of  
the utility of  these data to control and elimination programs, further studies assessing the 
infectious reservoir in areas of  low transmission would be advantageous. 
 In an individual infection, infectiousness per gametocyte may be higher at the beginning 
of  an infection than at the end because of  changes in parasite competency [33], sex ratio 
[34, 35], and, possibly, the development of  sexual stage immune responses [36–38]. 
Transmission-blocking immunity is boosted by recent exposure to gametocytes [37] and 
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may reduce infectiousness during the course of  infections that last several weeks or months. 
Superinfecting clones influence parasite growth dynamics, including total gametocyte 
biomass [39], and multiplicity of  infection could in itself  be a determinant of  transmissibility 
[40]. This combination of  factors might also indicate that the infectiousness of  one infection 
may not reflect the infectiousness of  subsequent infections (when multiplicity of  infection 
and transmission-blocking immunity may differ), suggesting greater complexity than that 
estimated from a single time point during the transmission season. 
Mosquito exposure
Artificial feeding experiments in xenodiagnostic surveys have tended to use fixed numbers 
of  mosquitoes, improving the precision of  estimates of  infectiousness by maximizing 
mosquito sample sizes. However, in any endemic area mosquito biting rates of  humans 
vary considerably. As an example, a recent study in Uganda found that biting rates varied 
from 270 to 7399 bites/year between study sites, with each site showing distinct seasonal 
fluctuations [41]. The transmission potential of  infectious individuals will be determined 
by the rate at which they are sampled by local mosquitoes and the competence of  these 
vectors. Where vector densities and survival rates are low, the number of  mosquitoes 
that become infected and subsequently transmit their infections will be very low even if  
there are infectious individuals in the human population. Although essential to accurately 
characterize individual-specific contributions to transmission, these entomological 
parameters have never been measured in conjunction with xenodiagnostic surveys. 
Attractiveness to mosquitoes 
In the early 1950s, Muirhead-Thomson observed that Jamaican adults attracted more 
Anopheles mosquitoes than equally exposed children [42]. The conclusions of  this study 
are supported by later reports in which wild Anopheles were allowed to feed on unprotected 
humans under observation [43, 44] or ABO blood typing allowed the identification of  
blood-meal origin [45], although some studies show more random biting selection [46]. 
Carnevale et al. near Brazzaville in the Republic of  Congo described the biting behaviours of  
approximately 6500 mosquitoes on 24 individuals of  all ages [43]. Anopheles biting increased 
with age, with individuals >20 years old being bitten three times more than <2-year-olds. 
Port et al. were able to ascribe this age-related biting pattern to increased body weight and 
surface area [45]. In addition to increased surface area, body temperature and chemical cues 
change with age and physiological maturity and may be associated with attractiveness [47–
49]. This might also help explain why pregnant women are thought to be more attractive to 
mosquitoes than non-pregnant women [50]. Muirhead-Thomson also observed that infants 
reacted more actively in sleep to the probing of  mosquitoes than adults and that mosquitoes 
were less likely to feed on infants even after alighting on their skin [42]. Data are less robust 
on the influence of  Plasmodium infection on mosquito attractive-ness. Reports from animal 
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models and studies on a small number of  humans infected with P. falciparum suggest that 
the presence of  gametocytes may increase attractive-ness to anopheline mosquitoes [51, 
52], possibly due to the production of  attractive volatiles [53]. It is unclear whether the 
small biomass of  gametocytes could have specific systemic effects that would increase the 
attractiveness of  children (harbouring higher gametocyte densities) and whether this might 
counteract the reduced attraction associated with their smaller surface area. 
Availability to mosquitoes 
However attractive and infectious individuals are, they must be available to mosquitoes for 
feeding and subsequent transmission to occur. This availability is shaped primarily by human 
social and behavioural practices, including use of  mosquito nets and sleeping patterns. 
 Age-specific net use depends on the setting and extent of  ownership, but in areas with 
good coverage appears highest among young children (<5 years) and lowest among older 
children and adolescents (5–15 years) [54–57]. In addition to bed nets’ community-wide 
effect on transmission, they may also reduce an individual’s chance of  infecting mosquitoes 
and divert vectors to other blood-meal sources. In The Gambia, the introduction of  
insecticide-treated nets (ITNs) protected children against malaria and diverted mosquito 
bites to other hosts (animals or adults) [58]. Net distribution has also been linked to changes 
in vector behaviour and species composition; Anopheles gambiae and Anopheles funestus have 
shown signs of  responsive exophagy [59] and there are observations that peak biting in 
these species may shift to the early evening and morning [60, 61]. Net-related reductions 
in A. gambiae s.s. populations have also been linked to increasingly dominant roles for A. 
funestus [62] and Anopheles arabiensis [63]. 
 These elements, together with sleeping times and time spent indoors or outdoors at night, 
determine availability to different mosquito populations. Children might be expected to 
sleep earlier than adults, but the protection afforded by long periods of  time under bed nets 
depends on when local vectors are most active. Data on time spent indoors, time spent under 
nets, and the biting activity of  local vectors can be combined to determine the true protective 
efficacy of  bed nets by age [64]. This is an informative composite measure that could be used 
to estimate age-specific patterns of  mosquito exposure. 
 Effectively delineating the interaction of  mosquito exposure and subsequent malaria 
transmission is difficult. Individuals identified as infectious in xenodiagnostic surveys must 
have been exposed to malaria vectors at some stage, but heterogeneity in attractiveness 
and the degree of  exposure should still significantly influence their relative contribution 
to the infectious reservoir. Surveys quantifying mosquito exposure and infectiousness in 
the same population could provide more realistic estimates of  age-specific contributions 
to transmission. 
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Heterogeneous mosquito populations
Although several vector species might contribute to local transmission in endemic areas, most 
xenodiagnostic surveys have been performed using A. gambiae s.s. (Tables 1 and 2), most of  
which were colony reared. Evidence is limited on whether infectiousness to A. gambiae during 
membrane or skin feeding assays corresponds to infectivity to other vector species. Two major 
malaria vectors, A. funestus and A. arabiensis, are distributed throughout Sub-Saharan Africa, 
often coexisting with A. gambiae s.s. [65]. The highly anthropophilic biting preferences of  A. 
funestus [66] and its high longevity [67] and sporozoite rate [62, 68] (higher than A. gambiae 
in some endemic areas) indicate that a non-negligible part of  malaria transmission might 
be sustained by this vector where it is present. Conversely, A. arabiensis is considered more 
exophilic and exophagic; in Burkina Faso, A. arabiensis was as susceptible to infection as A. 
gambiae s.s. in feeding assays [69], while in Senegal lower infection rates were observed in 
membrane feeding assays with A. arabiensis compared with A. gambiae s.s. [70]. The recent 
description of  cryptic malaria vectors [71, 72] and conflicting results on the differential 
susceptibility of  A. gambiae s.s. and Anopheles coluzzi [69, 70] (previously the molecular forms 
S and M of  A. gambiae, respectively [73]), further illustrate the need to quantify transmission 
efficiency against the background of  diverse vector populations. 
Considerations for future studies 
To more rigorously assess the human infectious reservoir using direct xenodiagnostic 
surveys, several methodological issues require consideration. In this section, we suggest 
suitable inclusion criteria and methods for measuring or predicting individual-level 
mosquito exposure. Other important factors that are discussed include the type of  feeding 
assay, measures of  infectiousness, and general study design. 
Inclusion criteria for direct assessments of the infectious reservoir
There is abundant evidence that microscopy is insufficiently sensitive to detect low densities 
of  asexual parasites and gametocytes [15, 19, 74–78]. Studies including only individuals 
with patent gametocytes [11, 19, 79] are likely to have underestimated the proportion of  
populations capable of  infecting mosquitoes, and biased measures of  mosquito infection 
probability (Table 2). Since low-density gametocyte carriage is prevalent in many endemic 
areas [25] and may represent a major source of  secondary mosquito infections [22, 80, 81], 
studies aiming to characterize the human infectious reservoir should not have gametocyte 
positivity by microscopy as an inclusion criterion. 
Defining infectiousness at the population level 
The simplest method for quantifying the infectious reservoir combines the prevalence of  
people in different age groups infecting at least one mosquito and the proportion of  those 
groups in the total population [16, 77]. Alternatively, population-level infectiousness may 
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be presented as mosquito infection probability (K), the likelihood of  a mosquito becoming 
infected after feeding on any member of  the population, calculated as the age-adjusted 
mosquito infection rate. Although the former metric has value for efforts that aim to 
identify or target all individuals who contribute to onward malaria transmission, the latter 
(mosquito infection probability) makes estimates more comparable between studies where 
the number of  mosquitoes used in feeding assays may differ widely [18, 19] and captures 
variations in infectiousness intensity in different age groups that may not be apparent when 
reporting only infectiousness prevalence. 
Assay methodology
There are two types of  mosquito infection assay that have been used in previous surveys: 
direct skin feeding and membrane feeding assays (Tables 1 and 2). Direct feeds better reflect 
natural infection and avoid some of  the technical challenges that limit the wide-scale use of  
mem-brane feeding assays (e.g., adapting mosquito colonies to membrane feeding, preventing 
gametocyte activation be-tween bleeding and feeding, a potential effect of  anticoagulants) 
[82, 83]. Although their use is currently hindered by ethical concerns that have precluded 
their use in repeated assessments of  mosquito infection from young children [82], further 
direct comparisons of  xenodiagnostic surveys using skin and membrane feeding experiments 
would be highly valuable to parameterize the extent to which the latter reflect the natural 
situation. Unless direct skin feeding is acceptable in all age groups and with sufficient 
mosquito numbers to allow precise estimates of  infection, studies aiming to characterize the 
full infectious reservoir in endemic populations should do so using direct membrane feeding 
assays using locally relevant malaria vectors. 
 Whether feeding assays measure infection by detection of  oocysts in the mosquito gut 
or sporozoites in the salivary glands (Tables 1 and 2) should make little difference to the 
comparability of  future studies, as even in low-intensity infections (such as those occurring 
commonly in nature) there is a close correlation between oocyst prevalence and the prevalence 
of  subsequent salivary gland infection [84]. Salivary gland dissections are technically even 
more demanding than midgut dissections, will result in higher mosquito mortality between 
the day of  feeding and the day sporozoites are first detectable, and impose additional 
safety measures for insectaries that need to be equipped for holding mosquitoes that form a 
biohazard to insectary personnel. We therefore suggest that detection of  Plasmodium oocysts 
is the most viable measure of  mosquito infection. 
Measuring mosquito exposure
As outlined above, the number of  mosquito bites an individual receives is influenced by 
their physical characteristics and behaviour [42, 45]. There is also spatial heterogeneity in 
exposure, with individuals living in households with higher vector densities (e.g., houses 
nearer to breeding sites) receiving more bites and having greater risk of  disease than those 
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in households where vector density is lower [85]. Infectious reservoir assessments should 
ideally use a direct approach to quantify mosquito biting rates, simultaneously accounting for 
the availability and attractiveness of  human hosts to mosquitoes: collection of  mosquitoes 
from households and identification of  blood-meal sources by DNA fingerprinting would 
provide reliable estimates of  true exposure to mosquito bites. A recent study in Peru used this 
approach to show that adults were more often bitten by Aedes aegypti mosquitoes compared 
with children living in the same houses [86]. We suggest that in areas where transmission 
is dominated by indoor-biting mosquitoes, the rate of  secondary mosquito infections 
could be calculated by multiplying individual-specific mosquito biting rates (determined 
experimentally using the above methods) by infectiousness (the probability that a mosquito 
develops infection after feeding, determined with mosquito feeding assays). This measure 
would be informative as it accounts for all major factors influencing transmission potential. 
An obvious problem with this approach is that only endophilic mosquitoes are sampled and 
there are currently no standardized sampling strategies for outdoor-biting vectors. 
 Where direct assessments are operationally impossible, or made unreliable by vector 
behaviour, we suggest that daily mosquito biting rates could be estimated for each study 
subject by collating mosquito (e.g., abundance, estimated indoor and outdoor biting rate), 
demographic (e.g., age, body surface area and attractiveness, house-hold conditions, distance 
to breeding sites, number of  people living in the same house/room) and behavioural (e.g., 
sleeping times, net use) data, so that a rate of  secondary mosquito infections could be 
broadly estimated by combination with experimentally determined infectiousness. Figure 1 
is a simplified and hypothetical re-presentation of  the potential influence of  some of  these 
factors on the contribution of  different age groups to the infectious reservoir.
Longitudinal studies with mosquito exposure estimation
Longitudinal studies with frequent follow-up would be valuable not only to estimate the 
duration of  infectiousness in different age groups but also to assess whether some individuals 
or groups of  individuals are infectious through-out a transmission season. This approach 
would help determine whether transmissibility is associated with clusters of  higher malaria 
infection incidence; that is, where mosquito-to-human transmission is high. The more complete 
interpretation of  such assessments could be made with concurrent mosquito biting rates. 
Concluding remarks
We acknowledge that there are several malaria-endemic settings in which progress toward 
elimination has been made in the absence of  detailed local knowledge of  the infectious 
reservoir. However, malaria remains a threat in many countries, particularly in Africa, and 
resurgence due to natural receptivity for transmission and drug and insecticide resistance 
means that a better understanding of  who within a community infects mosquitoes can only 
benefit malaria control. 
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The complexity of  factors influencing malaria transmission means that studies aiming to 
fully understand how this occurs are challenging. Previous xenodiagnostic surveys provided 
valuable insights into the epidemiology of  malaria transmission, but these studies need to 
be extended to simultaneously evaluate additional key factors. Moreover, the longitudinal 
nature of  infectiousness during natural malaria infections needs to be considered in future 
studies, as this will influence the contribution of  different age groups to transmission. 
 While human and parasite factors, including the intensity and duration of  gametocytemia, 
affect infectiousness at the individual level, entomological factors dictate the transmission 
potential of  each individual and the infectious reservoir as whole. Therefore, mosquito 
exposure assessments need to be an integral part of  xenodiagnostic surveys if  we are to 
effectively target the reservoir of  infection (Box 2). 
Box 2. Outstanding questions
If and how does human population infectiousness to mosquitoes differ in areas of low malaria 
transmission? 
Are traditionally low endemic settings different from those under epidemiological transition (i.e. 
settings moving from moderate to low transmission as a result of heightened control activities)?
What is the duration of infectiousness of individuals to mosquitoes?
Are certain people infectious for longer periods and, if so, what are their characteristics?
How do fluctuations in mosquito densities and feeding rates affect the transmission potential of 
infectious humans?
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Abstract
Background
The development of  drugs and vaccines to reduce malaria transmission is an important 
part of  eradication plans. The transmission reducing activity (TRA) of  these agents is 
currently determined in the standard membrane feeding assay (SMFA) based on subjective 
microscopical read-outs and with limitations in up-scaling and throughput.
Methods
Utilising a Plasmodium falciparum strain expressing the firefly luciferase protein, we present 
a luminescence based approach to SMFA evaluation that eliminates the requirement 
for mosquito dissections in favour of  a simple approach where whole mosquitoes are 
homogenised and examined directly for luciferase activity. 
Results
Analysis of  6860 Anopheles stephensi mosquitoes across 68 experimental feeds shows 
that the luminescence assay was as sensitive as microscopy for infection detection. The 
mean luminescence intensity of  individual and pooled mosquitoes accurately quantifies 
mean oocyst intensity and generates comparable TRA estimates. The luminescence assay 
presented here could increase SMFA throughput so that 10-30 experimental feeds could be 
evaluated in a single 96-well plate.
Conclusions
This new method of  assessing Plasmodium infection and transmission intensity could 
expedite the screening of  novel drug compounds, vaccine candidates and sera from 
malaria exposed individuals for TRA. Luminescence-based estimates of  oocyst intensity in 
individual mosquitoes should be interpreted with caution.
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Introduction
With an estimated 627,000 deaths and approximately 207 million clinical cases annually, 
Plasmodium falciparum malaria remains the world’s most devastating parasitic disease [1]. 
In recent years, large-scale distribution of  highly effective artemisinin-based combination 
therapies and long-lasting insecticide-treated nets have contributed to a reduction in the 
burden of  malaria in many endemic settings. Despite these positive trends, in the majority 
of  areas where malaria is currently endemic, malaria elimination is unlikely to be achieved 
using only the available tools [2]. The development of  drugs and vaccines with transmission 
reducing activity (TRA) has therefore become central to plans to eradicate the disease [3, 4]. 
 The efficacy of  agents with putative effects on Plasmodium transmission is determined 
under laboratory conditions, using the biological standard membrane feeding assay (SMFA). 
Mosquitoes are fed on blood containing cultured Plasmodium gametocytes, and the effect 
of  components added to this surrogate blood-meal is determined around a week later by 
assessing the prevalence and intensity of  established parasites in a sample of  mosquitoes. 
Infection status is determined by the observation and quantification of  Plasmodium oocysts 
on the dissected mosquito midgut. The TRA is defined as the percentage reduction in mean 
oocyst intensity between test and control mosquitoes [5, 6]. 
 Although the SMFA is a powerful bio-assay, the technique’s reliance on manual 
mosquito dissection and screening of  individual mosquito midguts by microscopy makes 
its evaluation slow and laborious, and its interpretation inherently subjective [7, 8]. 
Recent studies have quantified the impact of  the number of  mosquito observations on the 
precision and variance of  TRA estimates [5, 9], further highlighting the need for SMFA 
improvements that might facilitate the efficient and accurate evaluation of  large numbers of  
mosquitoes. The use of  green fluorescent protein (GFP)-expressing Plasmodium berghei has 
been reported as a first attempt to make the SMFA more scalable using a semiautomated 
oocyst counting approach after the manual dissection and mounting of  mosquito midguts 
[7, 10, 11]. 
 Here, using transgenic P. falciparum expressing the firefly luciferase protein [12], we 
present a luminescence based SMFA that eliminates the need for mosquito dissections. 
Our results from 68 separate experimental mosquito feeds (comprising data from 6860 
mosquitoes), indicate that the luminescence assay performed on whole homogenised 
mosquitoes is equally or more sensitive than microscopy for infection detection, and that 
the mean luminescence intensity of  groups of  individual or pooled mosquitoes correlates 
closely with mean oocyst intensity in separate groups of  mosquitoes from the same 
experimental feeds.. Although the luciferase assay may have limitations in accurately 
quantifying oocyst densities in individual mosquitoes, we propose that the luciferase-based 
SMFA can replace microscopy as a more efficient and objective screening technique for 
Plasmodium TRA. 
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P. falciparum (NF54HT-GFP-luc) culture
Transgenic P. falciparum gametocytes (NF54HT-GFP-luc) [12] expressing a fusion of  GFP 
and firefly luciferase protein (14 day culture; 0.3-0.5% gametocytes and 2% haematocrit) 
were obtained from an automated tipper system and prepared with packed red blood cells 
as previously described [12-14]. The NF54HT-GFP-luc parasite line is available upon 
request and has been deposited at the Malaria Research and Reference Reagent Resource 
Center (MR4). 
Mosquito breeding and feeding
Anopheles stephensi mosquitoes (Sind-Kasur Nijmegen strain) [15] were reared at 30°C 
and 70-80% humidity, while exposed to a 12/12-hour day/night cycle. Mosquitoes aged 
3-5 days were fed on a glass membrane midi-feeder system containing 1.2 mL of  the P. 
falciparum culture/reagent mix [13, 14]. Unfed and partially fed mosquitoes were removed 
after feeding and blood fed females were maintained at 26°C and 70-80% humidity. 
 Sixty-eight separate experimental mosquito feeds with A. stephensi (hereafter, ‘feeds’) were 
performed in 10 sets of  experiments. Of  these 68 feeds, 63 were performed as assessments of  
TRA using test or control agents; the remaining 5 were performed for assay optimisation of  
the luminescence assay (full details of  all experiments and sample sizes in Supplementary 
Table 1). Two transmission reducing agents were used for assessments of  TRA: (1) rat 
monoclonal antibody (mAb) 85RF45.1, specific to the Plasmodium protein Pfs48/45, a 
protein present on the surface of  gametocytes that is necessary for zygote formation in 
the mosquito [16, 17]; and (2) human serum immunoglobulin G (IgG) purified from the 
blood of  a European expatriate with well-documented TRA [6, 18]. 85RF45.1 mAb was 
diluted into human serum, added to the gametocyte/red blood cell culture mix (1.2 mL 
total), and provided to mosquitoes at 2.5 µg/mL (nine feeds), 1.25 µg/mL (3 feeds), 0.63 
µg/mL (9 feeds), 0.31 µg/mL (2 feeds) and 0.16 µg/mL (2 feeds). Human serum was used 
as a control for TRA assessments in all 85RF45.1 mAb experiments (12 feeds). Subsidiary 
isotypic controls (non-transmission effective mAb specific to the Plasmodium Glutamate 
rich protein, GLURP) were also tested (3 feeds). Serum IgG was diluted into human serum 
and added to the gametocyte/red blood cell culture mix (1.2mL total) at 9 fold (3 feeds), 
27 fold (3 feeds), 81 fold (3 feeds), 243 fold (3 feeds) and 749 fold (3 feeds) dilutions from a 
stock concentration of  9.8 mg/mL. Human serum was used as a control in all serum IgG 
experiments (5 feeds). Subsidiary isotypic controls (a 9-fold dilution of  non-transmission 
effective IgG from native Dutch donors) were also tested (3 feeds). In all serum IgG 
feeds 125 µL of  active complement from human sera (Sanquin Blood Supply, Nijmegen, 
Netherlands) was included in the culture mix. No significant differences were observed 
between isotypic and human serum controls, and TRA calculations based on either control 
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were highly correlated for all methods (Supplementary Figure 1); human serum control 
was used as the primary control as it was available for all experiments. All SMFAs were 
blinded for evaluation and analysis. 
 In a direct comparison of  infection rates in A. stephensi and Anopheles gambiae, we 
observed no oocysts and no mosquitoes with luminescence above the positivity threshold in 
A. gambiae, confirming the role of  Pf47 (disrupted during insertion of  the GFP-Luciferase 
construct in NF54HT-GFP-Luc) in P. falciparum immune evasion [19] (Supplementary 
Table 1). 
Microscopy and luminescence based SMFA evaluation
Individual mosquitoes were analysed separately for microscopy-based (n=30-58) and 
luminescence-based assessments (n=30-50) from every feed. Alongside individual 
mosquitoes, 3 separate groups of  5 and 10 mosquitoes were taken for processing as pools in 
the luminescence assay. If  fewer than 3 pools of  5 or 10 mosquitoes were available because 
of  mosquito mortality, pool-based analysis was not conducted. In total, 3 pools of  5 and 10 
mosquitoes were taken from 62 and 57 feeds respectively.
 For standard microscopy, live mosquitoes were collected on day 7 after infection, and 
midgut dissections were carried out in 1% mercurochrome solution by expert microscopists. 
 All luminescence assays used to assess the association of  luminescence- and microscopy- 
based measures of  infection and TRA were conducted on day 8 after infection (Figure 1A). Day 
9 after infection was equally or more suitable for luminescence assays but was not chosen 
in the current study for logistical reasons. Full protocols for the luminescence assay are in 
the Supplementary Materials. Briefly, for the individual mosquito assay, live immobilised 
mosquitoes were homogenised for 5 seconds using re-usable plastic pestles and a hand 
held pestle rotator (Argos Technologies, Elgin, IL) in micro-centrifuge tubes containing 
48 µL of  a phosphate buffered saline (PBS, 1%, pH 7.2), 1% EDTA, 1% protease inhibitor 
cocktail solution (Protease Inhibitor Cocktail Kit [78410], Thermo Scientific, Waltham, 
MA). Individual mosquito homogenates (48 µL) were pulsed in a micro centrifuge and 
stored at 4°C before being mixed, pipetted into 96 well plates (uClear black plates [655090], 
Greiner BioOne, Frickenhausen, Germany) with 12 µL of  lysis buffer (Luciferase assay 
system [E1501], Promega, Madison, WI), and left for 30 minutes at room temperature. 
After 30 minutes 60 µL of  luciferase substrate was added to all wells, plates were shaken for 
five seconds, and bioluminescence (measured as relative light units [RLU; i.e, counts per 
second]) was measured using a multipurpose plate reader (Synergy 2, Biotek UK) for each 
well (1 second, top-down read). 
 For pooled mosquito luminescence assays, groups of  5 or 10 mosquitoes were 
homogenised as described but for 10 or 15 seconds, respectively, in 100 µL of  the same 
PBS/Protease inhibitor mix. The volume of  the homogenate was then increased to a level 
equal to 48 µL per mosquito (i.e., pools of  5 mosquitoes had a final volume of  240 µL, 
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and pools of  10 mosquitoes had a final volume of  480 µL). All pooled homogenates were 
mixed, and three 48 µL samples were tested by the luminescence assay as described above. 
The luminescence intensity of  a pool of  mosquitoes was determined by taking the mean 
of  3 separate assays sampled from the same mixed homogenate. The mean pool-associated 
luminescence intensity for experimental feeds was calculated as the mean value for 3 
separately processed pools (yielding nine total assays per feed for a specific pool size). 
 Uninfected negative control mosquitoes were processed in all experimental runs 
(n = 23-53) for the calculation of  luminescence based infection prevalence. Cut-offs were 
determined arbitrarily as the mean luminescence intensity of  uninfected controls plus 5 
SDs (Supplementary materials). The mean luminescence intensity of  uninfected control 
mosquitoes was 2.5 RLU (range, 0-7 RLU), which gave thresholds for NF54HT-GFP-luc 
infection for the 10 different experiments of  5.7-10.1 RLU. Grouping all the uninfected 
controls from the ten experiments together gave a cut-off  of  9 RLU. As infection prevalence 
was identical when using either the experiment specific or overall cut-off, the single cut off  
of  9 RLU was used for ease of  analysis.
Data analysis
Statistical analyses were conducted by comparing separate groups of  mosquitoes sampled 
from the same feeds. Comparisons between oocyst- and luminescence-based measures 
of  mosquito infection prevalence were made with Chi-squared tests with Bonferonni 
correction. Associations between oocyst and luminescence intensity were quantified with 
linear regression, and differences between different luminescence-based assay outcomes 
were determined by Wilcoxon sign rank tests. 95% confidence intervals (CIs) around mean 
luminescence and oocyst intensity data were calculated by bootstrapping (1000 repetitions). 
 Luminescence- and microscopy-based TRA estimates from individual mosquitoes were 
made using generalised linear mixed models (GLMMs) with zero-inflated negative binomial 
error structure [5, 20]. The association of  prevalence and TRA estimates made by separate 
methods was assessed with linear regression, with R2 calculated against a perfect linear 
trend (x=y). As only 3 groups of  mosquitoes were taken from each feed for pool based 
assessments, TRA estimates from pools of  mosquitoes were calculated as the percentage 
reduction in mean luminescence intensity between test and control pools (Supplementary 
Materials), with 95% CIs around these estimates calculated by bootstrapping (1000 
repetitions). TRA estimates less than 0% where converted to 0% for all figures.
 For the analysis of  TRA according to antibody dilution, a 4-parameter non-linear 
regression analysis was performed (Supplementary Materials). Statistical analysis was 
conducted using R (Foundation for Statistical Computing, Vienna, Austria), STATA 12 
(StataCorp., TX, USA) and GraphPad Prism 5.0 (GraphPad Software Inc., CA, USA).
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Results
Luminescence assays were conducted on day 8 after infection when the luciferase 
signal allowed better differentiation of  positive and negative mosquitoes than on day 
7 after infection (Figure 1A), plausibly as a consequence of  sporozoite/luciferase 
proliferation in infected mosquitoes [8]. Figure 1B shows that the overall distribution 
of  oocyst and luminescence intensities from individual mosquitoes are indistinguishable 
[12]. Overall, averaged measures of  infection intensity were taken from a total of  2079 
mosquitoes dissected for oocyst detection, 2141 mosquitoes processed individually 
in the luminescence assay, and 2640 mosquitoes assayed in pools of  5 (n = 930) or 10 
(n = 1710). Mean oocyst intensity in control infections ranged from 1.7 to 47.8, and mean 
luminescence intensity in control infections ranged from 40.7 to 3263.9 RLU. Direct 
comparisons between oocyst counts and luminescence intensity from the same mosquito 
midguts were reported in Vaughan et al. [12]. In a small experiment, we determined oocyst 
counts by microscopy before removing and homogenising the examined guts with the 
carcass of  an uninfected mosquito. Five mosquitoes with oocysts counts of  1, 8, 13 15 and 
33 gave RLUs of  38, 522, 579, 737 and 1696, respectively.
Microscopy and luminescence based estimates of infection prevalence
Microscopy- and luminescence-based mosquito infection prevalence estimates were 64.9% 
(1350/2079) and 67.7% (1449/2141), respectively. The median luminescence intensity of  
negative test mosquitoes (692/2141) was 2 RLU (interquartile range [IQR], 2-4 RLU; range 
0-8 RLU). As 14.1% of  microscopically examined mosquitoes (190/1350) had single oocyst 
infections, and 43.2% of  infections (583/1350) had 1-5 oocysts, the close association between 
oocyst- and luminescence-based prevalence estimates for all separate feeds (Figure 1C) 
strongly indicates that the luminescence assay consistently discriminated between infected 
and uninfected mosquitoes at all levels of  infection intensity. Changing the luminescence 
based cut-off  from the negative control mean plus 5 SDs to 3 or 10 SDs had limited impact 
and altered prevalence estimates to 68.8% (1474/2141) and 66% (1414/2141), respectively. 
Differences between luminescence- and oocyst-based prevalence estimates were non-
significant for all feeds (Figure 1C). 
Microscopy and luminescence based estimates of infection intensity
The luminescence assay accurately predicts mean oocyst intensity, despite the inherent 
variability in oocyst counts between separate mosquito samples from the same feeds 
[5, 21] (Figure 1D). The mean luminescence intensity of  pools of  5 and 10 mosquitoes 
from the same feeds were also strongly associated with mean oocyst intensity 
(Figure 1E). Although the mean luminescence intensity of  pooled mosquitoes was generally 
somewhat lower than that for individual mosquitoes (Figure 1F), paired luminescence 
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values for separate feeds were not significantly different between pooled and individual 
mosquitoes. The mean luminescence intensity of  all individually assayed mosquitoes was 
470.4 RLU, while those of  all pools of  5 and 10 mosquitoes were 472.5 RLU and 462.8 
RLU, respectively. 
 Variation in luminescence intensity between repeat measures from the same pools (i.e., 
the intrapool variation) was low, and although sampling error might be expected to have had 
a major impact on interpool luminescence variation (each of  the 3 pools taken from each 
feed represented the average luminescence intensity of  five or ten mosquitoes, rather than 
the standard 30 mosquitoes) interpool variation was also modest, with no clear association 
with mean oocyst intensity (Supplementary Figure 2).
Assessments of TRA 
TRA estimates based on oocyst counts and luminescence measures were highly related 
(Figure 2A). Deviations from this linear trend were more apparent when both methods 
estimated TRA at <60%, as reflected by the size of  the CIs. 
 A stochastic element in measuring TRA is well appreciated [5, 6, 22] and a cut-off  
for reproducible TRA results of  >80% is commonly used [6, 23]. Where TRA ≥80% was 
measured by either method the mean difference between luminescence and microscopy 
based TRA estimates was 4.0%, and CIs were equally precise for both methods. Across the 
range of  TRAs, CIs were generally wider for luminescence (mean interval, 20.4 percentage 
points) than for microscopy (mean interval, 15.0 percentage points). TRA estimates 
based on the luminescence assay for pooled mosquitoes were similarly representative of  
microscopy-based estimates (Figure 2B). When test agents caused a TRA ≥80%, the mean 
difference between microscopy- and pool-based TRA estimates was 3.6% and 3.0% for 
pools of  5 and 10, respectively. Supplementary figure 2A shows the results of  all pool-
based TRA estimates relative to microscopy values if  only single pools are used in their 
calculation (instead of  all 3).
 In our large set of  blinded experiments, we determined the TRA of  different blocking 
and non-blocking concentrations of  85RF45.1 mAb and serum IgG. TRA was calculated 
using microscopy and luminescence of  individual mosquitoes and pools of  mosquitoes. We 
observed excellent agreement between TRA estimates (figures 2C and 2D), with only one 
of  the weakest dilutions of  serum IgG luminescence giving non-significantly higher TRA 
estimates derived from pools of  5 mosquitoes. 
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Figure 2. Microscopy- and luminescence-based assessments of the transmission-reducing 
activity (TRA) of transmission effective mAb (Pfs45.1), and serum immunoglobulin G (IgG). 
All TRA calculations were made using human serum controls (Supplementary Figure 1) A. TRA 
calculated separately, using mean oocyst intensity and mean luminescence intensity from individual 
mosquitoes from all feeds in which a transmission-reducing agent was used (n=46). R2 was calculated 
based on deviation from a perfect linear association (i.e. x=y). The mean widths of the 95% CIs in which 
either estimate was ≥80% was 3.86 percentage points and 3.61 percentage points for luminescence 
and microscopy, respectively. B. TRA calculated separately using mean oocyst intensity and mean 
luminescence intensity from pools of 5 (print = light grey, online = blue) and 10 (print = dark grey, 
online = red) mosquitoes from all feeds for which a transmission-reducing agent was used and from 
which the minimum number of pools were analysed (pools of 5, n=33; pools of 10, n=38). R2 was 
calculated based on deviation from a perfect linear association (i.e. x=y). For data presentation, 1% TRA 
was added on the x-axis to all points of pools of 10 mosquitoes to distinguish between CIs from pools of 
5 mosquitoes. C. Non-linear regression of TRA assessments from all luminescence and oocyst intensity 
data from feeds with Pfs45.1 mAb. (R2: microscopy, 0.99; luminescence for individual mosquitoes, 
0.99; luminescence for pools of 5, 0.94; luminescence for pools of 10, 0.93). D. Nonlinear regression 
of TRA assessments from all luminescence and oocyst intensity data from feeds with transmission-
effective serum IgG from a Dutch ex-patriate donor (R2: microscopy, 1.0; luminescence for individual 
mosquitoes, 1.0; luminescence pools of 5, 0.92; luminescence pools of 10, 0.83).
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Discussion
Our primary finding is that luciferase-expressing P. falciparum strains can be used effectively 
in the SMFA to provide an objective, scalable, and accurate measure of  infection intensity 
in groups of  individual and pooled mosquitoes. The luminescence assay discriminated 
accurately between infected and uninfected mosquitoes. The mean luminescence intensity 
of  individual and pooled undissected mosquitoes correlated strongly with mean oocyst 
intensity in the same feeds, and the strength of  this relationship was reflected in the close 
association of  TRA estimates made by both methods. 
 Precise estimates of  TRA depend on experiment replication and an adequate number 
of  mosquito observations [5, 6]. These requirements are often not met in the SMFA as 
it is routinely conducted; improvements in throughput and readout are needed to allow 
more-robust and more-scalable assessments of  TRA. We present the first approach that 
eliminates the requirement for mosquito dissections and allows groups of  individual 
or pooled mosquitoes to be examined for the average intensity of  infection. Previous 
attempts to increase SMFA efficiency continued to rely on manual mosquito dissection 
and semiautomated oocyst visualisation, with modest impact on SMFA throughput [7, 
8]. Accepting the loss of  information at the individual mosquito level, we show that the 
averaged luminescence of  groups or pools of  mosquitoes provides an accurate proxy for 
mean infection intensity. The most scalable approach presented in the current study was the 
screening of  pools of  mosquitoes. Although luminescence intensity was generally slightly 
lower for pools than for individual mosquitoes, possibly because of  the slightly longer 
homogenisation required during pool processing, luminescence intensity was similarly 
predictive of  oocyst intensity for all methods. When examining 3 pools from each feed 
and assaying each pool in triplicate, 10 feeds can be evaluated simultaneously on a single 
assay plate. We observed concordant results if  single pools of  mosquitoes were examined, 
indicating that mosquito homogenisation can be made more scalable if  fewer pools are 
examined per feed. Further improvements in throughput and in the standardisation 
of  mosquito processing might be achieved if  pools are homogenised using plate-based 
bead beating (Supplementary Materials); this technique might also be used to scale-up 
individual mosquito processing if  details of  infection prevalence are desirable. Other clear 
benefits of  luminescence-based outcomes are that they are recorded objectively and stored 
automatically. With the combined advantages of  the luminescence assay we estimate a five 
to ten fold increase in our SMFA throughput capacity (Supplementary Materials).
 The luciferase assay can detect increases in oocyst size and maturation, as indicated by 
the higher luminescence intensity on days 8 and 9 after infection, compared with that on 
day 7. Inevitable variations in the productivity of  concomitant oocysts limit our ability to 
accurately interpret oocyst number from an indirect measure of  luminescence intensity 
for individual mosquitoes, which is likely only possible using visualisation techniques [7]. 
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However, we find no evidence that these variations affect luciferase-based TRA estimates, 
which consistently mirror those based on microscopical read-outs. Because size differences 
are more likely in high-intensity infections, where nutrient and space competition may be 
more pronounced, very high control oocyst intensities may need to be avoided to ensure an 
accurate correlation between mean luminescence and oocyst intensity. It could be argued, 
though, that because luciferase production reflects sporozoite proliferation more directly, 
luminescence intensity may provide a less abstract measure of  TRA than oocyst intensity. 
The disadvantages of  the traditional SMFA in this respect have been discussed previously 
[5, 8]. Luminescence-based outcomes are particularly suitable for studies where changes in 
oocyst size or maturation and not solely their presence are of  interest [8] and for assessments 
of  other aspects of  sporogonic development, such as haemolymph or salivary gland infection, 
where parasite loss during standard investigations is a concern. 
 In the conventional SMFA with microscopy-based readouts the threshold for transmission 
blockage is commonly set at 80% transmission reduction [23], not because vaccines or 
drugs with lower levels of  TRA may not be of  value [24] but because there is considerable 
variation in estimates of  low level TRA, and only high level transmission reduction can 
be reproducibly measured [6, 22]. As anticipated, in our experiments, CIs were narrowest 
and agreement between luminescence- and microscopy-based estimates were greatest 
in the transmission blocking range. Estimating lower levels of  the TRA requires a larger 
number of  mosquito observations, ideally collected through a study in which the activity of  
compounds or test sera is assessed against a range of  control oocyst densities[5]. Because 
of  its scalability and strong association with oocyst prevalence and intensity, the proposed 
luminescence assay can facilitate these repeated assessments of  large mosquito numbers 
that may be operationally unattractive when relying on microscopy. Despite the value of  
our approach, there are experiments where microscopy remain of  indisputable value. These 
include experiments with A. gambiae mosquitoes, where the use of  the NF54HT GFP-Luc 
parasite line is precluded, and investigations where oocyst enumeration is of  specific interest.
 A high-throughput, semiautomated SMFA could significantly increase the efficiency 
of  screening drugs and vaccines with potential effects on Plasmodium transmission, which 
have taken a central role in plans to achieve malaria eradication. The results of  the current 
study represent a scalable alternative to traditional SMFA techniques that may also increase 
the operational feasibility of  population-level trials with transmission-blocking vaccines, 
by complementing direct-feeding assessments with scalable assessments of  transmission 
blocking immunity [25]. 
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Selected supplementary material
Supplementary Tables 1 A. Experiments performed for the primary analyses of  luciferase 
and oocyst based measures of  NF54HT-GFP-Luc infection and TRA. B. Experiments to 
determine the permissiveness of  A. stephensi and A. gambiae to NF54HT-GFP-Luc. Three 
small experiments were conducted to confirm the role of  Pf47 in Plasmodium immune 
evasion during A. gambiae infection. A. stephensi and A. gambiae mosquitoes were infected 
with three gametocyte cultures, and 30 mosquitoes from each of  these feeds were assayed 
individually for oocyst and luminescence intensity. Whilst notable, there are at present no 
indications of  vector specific transmission reducing effects of  malaria drugs or vaccines, 
suggesting that the proposed SMFA, though restricted to A. stephensi, would have broad 
utility. C. Preliminary experiments to determine the effect of  bead beating for mosquito 
homogenization on luminescence intensity. Four pools of  ten mosquitoes from separate 
experiments processed using standard methods and plate-based bead beating to determine 
the effect on luminescence intensity of  high-throughput mosquito pool grinding. Standard 
homogenisation was for 15 seconds with a hand-held pestle rotator. The impact of  bead 
beating was determined by subjecting the same standard homogenate to an additional 10 
second high-intensity homogenisation with zirconia beads in deep-well plates, as described 
in the full protocol.
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Figure S1 TRA estimates made using human serum and isotypic controls. X-axis = TRA calculated 
using human serum controls. Y-axis = TRA calculated using IgG or MAb isotypic controls. TRA was 
calculable using isotypic controls for 28 of the 46 experiments in which any transmission reducing 
agent was applied.
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Abstract
In pre-clinical development, the efficacy of  agents with putative effects on Plasmodium 
transmission is determined using the standard membrane feeding assay (SMFA). Because 
the end-point of  the SMFA is normally the enumeration of  oocysts on the mosquito midgut, 
the assays reliance on mosquito dissections and microscopy makes it slow, labour intensive, 
and subjective. Below, we describe a novel method of  assessing the transmission of  a 
Plasmodium falciparum strain expressing the firefly luciferase protein in the SMFA. The use 
of  a transgenic parasite strain allows for the elimination of  mosquito dissections in favour 
of  a simple approach where whole mosquitoes are homogenised and examined directly for 
luciferase activity. Measuring the mean luminescence intensity of  groups of  individual or 
pooled mosquitoes provides comparable estimates of  transmission reducing activity at 5-10 
fold the throughput capacity of  the standard microscopy based SMFA. This high efficiency 
protocol may be of  interest to groups screening novel drug compounds, vaccine candidates, 
or sera from malaria exposed individuals for transmission reducing activity (TRA).
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Introduction
Interventions that reduce the likelihood of  humans with infectious malaria parasites seeding 
secondary mosquito infections are valuable components of  malaria elimination campaigns 
[1, 2]. All drugs or vaccines that affect the asexual reproduction of  Plasmodium life stages 
supress transmission by limiting the number of  parasites that develop into gametocytes; the 
life stages responsible for transmission from humans. In addition, drugs and vaccines can 
also specifically target mature transmission stages, gametocytes, or their transmissibility to 
mosquitoes. Only a limited number of  antimalarial drugs have activity against gametocytes; 
these drugs include artemisinin derivatives [3], 8-aminoquinolines [4], and methylene blue 
[5]. With the renewed interest in malaria elimination, testing the activity of  novel candidate 
drugs on gametocytes and their transmissibility is now widely advocated [6-9].
 The development of  transmission blocking vaccines (TBVs) is supported by the 
identification of  immune markers of  transmission reducing activity (TRA) among naturally 
exposed populations [10-15]. Antibodies to a handful of  antigens expressed during the 
parasites sporogonic cycle in the mosquito have been shown to be able to interrupt this 
development to prevent mosquito infectivity [16], although it is evident that the full immune 
profile of  naturally acquired transmission-reducing immunity remains to be explored.
 The effect of  any agent on Plasmodium transmission is determined by performing the 
standard membrane feeding assay (SMFA), in which mosquitoes are fed the putative 
transmission blocking agent along with a mixture of  cultured Plasmodium gametocytes and 
blood. The outcome of  the assay is the prevalence and intensity of  parasites achieving 
successful sporogony in a sample of  mosquitoes, which is determined by the quantification 
of  Plasmodium oocysts on the dissected mosquito midgut. TRA is generally defined as the 
percentage reduction in mean oocyst intensity between test and control mosquitoes [17, 
18]. Because the assay involves manually dissecting individual mosquitoes, and because of  
the requirement for large sample sizes to ensure precision in TRA estimates [17, 19], the 
SMFA in its current form is limited by labour intensiveness and subjectivity [20, 21].
 Transgenic P. berghei variants (PbGFPCON) have been used previously to increase the 
scalability of  the SMFA. Though excellent correlations are described between in silico 
fluorescence based and manual oocyst counts [20, 22, 23], the technique requires all mosquito 
mid guts to be dissected and mounted prior to counting, so remains limited in scalability. 
Recently, a strain of  Plasmodium falciparum expressing a fusion of  the Green Fluorescent 
(GFP) and firefly Luciferase proteins, NF54HT-GFP-luc, was produced by Vaughan et 
al. [24]. This strain can be cultured in similar conditions and shows comparable growth 
patterns to the standard P. falciparum NF54 parasite strain. Importantly, NF54HT-GFP-
luc was shown to express luciferase throughout the parasites life cycle, including all stages 
of  the parasites sexual development in the mosquito [24]. Here, using cultured NF54HT-
GFP-luc gametocytes, we present a luminescence based approach to SMFA evaluation 
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that eliminates the need for mosquito dissections. Our previous assessments indicate that 
the luminescence assay performed on whole homogenised mosquitoes is equally or more 
sensitive than microscopy for infection detection, and that the mean luminescence intensity 
of  groups of  individual or pooled mosquitoes correlates closely with mean oocyst intensity 
in the same mosquito groups [25]. Variable productivity between concomitant oocysts [26, 
27] limits the degree to which we can interpret actual oocyst number from luminescence 
intensity for individual mosquitoes. Therefore, for experiments requiring precise oocyst 
numbers, visualisation and counting are still essential [20]. However, we suggest that 
because luciferase production reflects sporozoite proliferation more directly, luminescence 
intensity may provide a less abstract measure of  TRA than oocyst intensity. Certainly, the 
assay is particularly suitable for studies where changes in oocyst size or maturation and not 
solely their presence are of  interest [21]. 
 The procedures involved in the SMFA have been described in detail elsewhere [28, 
29]. It is not our intention to describe the already standardised methods of  gametocyte 
culture, mosquito husbandry, and mosquito infection, but to provide a scalable alternative 
to microscopy for the determination of  infection prevalence and TRA. Below, we provide 
a short summary of  the methods involved in each step of  the SMFA, with notes on details 
particularly relevant to our evaluation methodology. 
Experimental design
Our method involves assaying the luminescence intensity of  homogenised individual or 
pooled mosquitoes, and utilising this measure of  luciferase activity as a proxy for mosquito 
infection intensity. Section 3.3 of  the methods describes how infection prevalence in 
groups of  individual mosquitoes is determined using a cut-off  based on the luminescence 
intensity of  uninfected control mosquitoes. For the calculation of  TRA, it is necessary to 
conduct separate mosquito feeds using the same gametocyte culture but with the addition 
of  a neutral control (non-transmission blocking, and preferably isotypic). TRA may be 
calculated as the percentage reduction in mean luminescence intensity between each group 
of  test mosquitoes and the control (Equation 1). This method, transplanting mean oocyst 
intensity with luminescence intensity, is the most commonly used method of  assessing 
the SMFA. Alternatively, when using individual mosquitoes, TRA may also be calculated 
from luminescence or oocyst outcomes using generalised linear mixed models (GLMMs). 
GLMMs incorporate the distribution of  oocyst/luminescence counts from individual 
mosquitoes allowing for more robust analyses of  TRA, and limiting the sample size 
necessary for achieving adequate statistical power [17]. Such analysis is not possible using 
the pooled mosquito assay, as only 2/3 observations will be recorded per cage.
139
Luminescent P. falciparum in the SMFA
5b
Equation 1.
A. Oocyst intensity based TRA
B. Luminescence intensity based TRA
With both the individual and pooled assay, the same numbers of  mosquitoes should be 
sampled per cage as would be acceptable with oocyst detection (generally 25-50), however 
the increased scalability of  the pooled method makes the evaluation of  greater numbers of  
mosquitoes very feasible. 
Gametocyte culture
The NF54HT-GFP-luc parasite line is available upon request, and has been deposited at 
the Malaria Research and Reference Reagent Resource Center (MR4). Because parasite 
transfection was based on single strand cross-over of  the pEFGFP–luc plasmid, NF54HT-
GFP-luc requires exposure to the selective agent WR99210 during culture to avoid reversion 
to wild type. Except for the addition of  this selective agent, gametocyte culture for NF54HT-
GFP-luc is no different than for the standard NF54 P. falciparum parasite line: Transgenic 
P. falciparum gametocytes (NF54HT-GFP-luc) (14 day culture, 0.3-0.5% gametocytes, 2% 
haematocrit) should ideally be obtained from an automated tipper system and prepared 
with packed red blood cells as previously described [24, 28, 29]. 
Mosquito husbandry and the SMFA
Though the insertion of  the GFP-Luciferase construct into the Pf47 gene locus of  NF54HT-
GFP-luc was conducted under the assertion that the Pf47 protein was ‘dispensable’, 
gene knockouts have since proven that the locus is essential for evasion of  the mosquito 
immune system in Anopheles gambiae, but not in A. stephensi which lacks functional thioester 
containing protein 1 (TEP1) mediated immune mechanisms [30]. The NF54HT-GFP-luc P. 
falciparum strain is therefore restricted to experiments with A. stephensi. Though A. gambiae 
is the dominant vector for P. falciparum in Africa, the SMFA for P. falciparum transmission is 
generally conducted using the A. stephensi vector system, which is easier to breed and more 
permissive to infection.
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For the SMFA, Anopheles stephensi should be reared as standard (30°C and 70-80% humidity, 
exposed to a 12/12 hour day/night cycle). 3-5 day old mosquitoes should be fed on a glass 
membrane midi-feeder system containing 1.2 ml of  the P. falciparum culture/reagent mix 
[28, 29]. Unfed and partially fed mosquitoes should be removed after feeding, and blood 
fed females should then be maintained at 26°C and 70-80% humidity. In each experiment, 
additional uninfected mosquitoes need to be assayed for the determination of  infection 
positivity in test mosquitoes.
Infection detection and quantification using bioluminescence
Though oocyst detection by microscopy is possible from day 6 after initial infection [31] we 
advise waiting longer before conducting the luminescence assay to ensure optimal oocyst 
productivity. Luminescence intensity and the distinction between positive and negative 
mosquitoes increases from day 7 onwards [25]. Though oocyst productivity increases 
until their rupture at around day 10 post-infection (PI), thereafter becoming unpredictable 
due to sporozoite loss during hemolymph traversal, because of  the increasing chance of  
mosquitoes becoming infectious to humans we suggest that day 9 PI is probably optimal 
for luminescence assessments. We suggest that the luminescence assay time point should 
generally be weighed on the aims of  the study, but that day 7 PI is perhaps too early to 
sufficiently differentiate positive and negative mosquitoes.
 Two variations on our standard method of  luminescence based evaluation of  mosquito 
infection are presented. These are as follows:
 Individual mosquito assessments (subheadings 3.2 and 3.3): Individual mosquitoes are 
homogenised and assayed, allowing for the determination of  infection prevalence. The 
mean luminescence intensity of  all mosquitoes in a sample is used as a proxy for mean 
oocyst intensity in the calculation of  TRA. Though more objective, the speed of  such 
assessments is not much in excess of  microscopic oocyst detection.
 Pooled mosquito assessments (subheadings 3.3 and 3.4): For increased scalability, pools of  
mosquitoes may be homogenised and assayed together. The mean luminescence intensity 
of  a pre-determined number of  repeat pools from each experimental group of  mosquitoes 
is used for the calculation of  TRA. Estimates of  infection prevalence are not possible when 
pooling, but the scalability of  the TRA assessments is increased 5-10 fold, depending on 
chosen sample numbers. Details of  the timing of  the pooled assay, with comparison to 
microscopy, are provided in the supplementary information of  Stone et al. 2014 [25]. For 
each experimental feed, we find that the mean luminescence intensity of  3 pools of  5 or 
10 is strongly correlated with mean luminescence intensity determined in the individual 
mosquito assay (subheading 3.2) when these are carried out on separate mosquito samples 
from the same feeds. We also find that these measures provide TRA estimates that correlate 
strongly with TRA estimates made using standard oocyst counts.
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Materials
Luminescence based SMFA evaluation
1.  CO2 source for mosquito sedation
2.  Netted cages for mosquito collection
3.  Auto-clavable pestles (Argos Technologies, Elgin, IL)
4.  Handheld pestle rotator (Argos Technologies, Elgin, IL)
5.  1.5ml conical bottom microcentrifuge tubes
6.  Grinding buffer: Phosphate buffered saline (PBS) pH 7.2, containing 1% EDTA, 1% 
Protease inhibitor cocktail solution (Protease Inhibitor Cocktail Kit [78410], Thermo 
Scientific, Waltham, MA)
7.  200 µl pipette tips
8.  Tube racks
9.  Ice trays
10. Microcentrifuge
11. 96 well clear bottomed plates (uClear black plates [655090], Greiner BioOne, 
Frickenhausen, Germany)
12. Plate rocker
13. Luciferase assay buffer (Luciferase assay system [E152A], Promega, Madison, WI)
14. Luciferase assay substrate (Luciferase assay system [E151A], Promega, Madison, WI)
15. Multi-purpose plate reader (Synergy 2, BioTek, Winooski, VT)
Methods
Preparation of reagents
1.  Prepare fresh mosquito grinding buffer. Dispose of  if  unused after 24 hours.
2.   Remove luciferase assay buffer from storage at -20°C, and allow to thaw to room 
temperature.
Determining infection prevalence and intensity in groups of individual 
mosquitoes
1.  Prepare assay plate plans, including space for blank wells (assay substrates only) 
and negative controls on each plate. In each experimental run, at least the same 
number of  uninfected negative control mosquitoes should be processed as for a single 
infectious feed (i.e. if  30 mosquitoes are processed from each infectious feed, at least 
30 uninfected mosquitoes should be processed as negative controls, and assayed on 
the same plates. Because individual mosquito assays require numerous assay plates, 
uninfected controls should be spread out so that some are assayed on every plate).
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2.  Aliquot 48 µl of  mosquito grinding buffer into microcentrifuge tubes (one tube per 
mosquito). Place tubes in racks (see Note 1), and store until ready for use at 4°C.
3.  Aliquot 12 µl of  luciferase assay buffer into all assay plate wells according to plate plans. 
Store covered at room temperature (see Note 2).
4.  Remove required number of  mosquitoes from primary feeding cage into a smaller netted 
container.
5.  Remove microcentrifuge tubes from the fridge into an ice-tray, and move the tray next to 
the mosquito cage on the bench-top.
6.  Immobilize mosquitoes with CO2.
7.  Remove mosquitoes one by one into microcentrifuge tubes. As soon as a mosquito is 
placed in a tube, place a pestle on top, with enough pressure to ensure that the mosquito 
is submerged and killed (see Note 3).
8.  Attach a hand-held pestle rotator to the pestle, and homogenise the mosquito for 
approximately 5 seconds (see Note 4). Spin pestle at top of  microcentrifuge tube to 
remove excess homogenate (see Note 5). After homogenisation, remove pestle to a 
container for washing and autoclaving to allow re-use.
9.  Repeat for all mosquitoes (see note 6).
10. Pulse mosquito homogenates in a microcentrifuge for 15 seconds to remove residual 
homogenate from tube walls, and store in racks at 4°C.
11. Remove homogenates from 4°C, and using modified 200 µl pipette tips (see Note 7) mix 
and aliquot all mosquito homogenates separately from tubes into assay plate wells. 1-2 ml 
residual homogenate in the microcentrifuge tube is inevitable, but unavoidable (see Note 
5). When entire assay plate is filled according to plate plan, cover and agitate gently on a 
rocker at room temperature for 30-45 minutes.
12. During the first plates incubation with luciferase assay buffer, reconstitute luciferase 
substrate according to the number of  mosquitoes under analysis (60 µl per mosquito), 
and leave to equilibrate at room temperature in darkness (see Note 8). Additionally, 
ensure that the plate reader is on and warmed up, with settings appropriate for the 
luminescence assay (all wavelengths, 1 second measurement per well is sufficient). 
13. With a multichannel pipette, add 60 µl luciferase substrate to every well (see 
Note 9). Place plate into plate reader immediately, shake for 5 seconds to mix 
(manually, if  the machine is not capable of  doing so during its program), and assay 
for luminescence intensity.
Data processing
1.  Name and store files with reference to assay date and plate plans.
2.  Transfer all raw data (from an entire experiment) into a combined spread sheet, and 
calculate summary statistics, including mean blank well luminescence (from every 
plate). From each plate, the mean blank well value should be subtracted from all 
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test well values (including uninfected mosquito controls) to correct for background 
luminescence. 
3.  A cut-off  for infection positivity can be determined as the mean luminescence 
intensity of  the corrected luminescence values for the uninfected controls (from every 
plate combined) plus five standard deviations (see Note 10). 
Determining infection intensity in groups of pooled mosquitoes
1.  Prepare assay plate plans, including space for blank wells (assay substrates only) and 
negative control pools on each plate. Pool size and number should be decided in advance 
of  all experiments. Here, we describe the preparation of  3 pools of  10 mosquitoes. In 
previous publications we have shown that 3 pools of  5 or 10 mosquitoes give similar 
results (see Introduction section 1.4). In each experimental run, we suggest that at 
least the same number of  uninfected negative control mosquitoes should be processed 
as for a single infectious feed (i.e. if  3 pools of  10 are processed from each feed, 
3 pools of  10 uninfected mosquitoes should be processed as negative controls, and 
assayed on the same plates).
2.  Aliquot 100 µl of  mosquito grinding buffer into microcentrifuge tubes (one tube per 
pool). Place tubes in racks (see Note 1), and store until ready for use at 4°C.
3.  Aliquot 12 µl of  luciferase assay buffer into all assay plate wells according to plate 
plans. Store covered at room temperature (see Note 2).
4.  Remove required number of  mosquitoes from primary feeding cage into a smaller 
netted container.
5.  Remove microcentrifuge tubes from the fridge into an ice-tray, and move the tray next 
to the mosquito cage on the bench-top.
6.  Immobilise mosquitoes with CO2.
7.  Remove mosquitoes one by one into a microcentrifuge tube. As soon as 10 mosquitoes 
are placed in a tube, place a pestle on top, with enough pressure to ensure that all 
mosquitoes are killed (see Note 3).
8.  Attach a hand-held pestle rotator the pestle, and homogenise the mosquitoes for 
approximately 10-15 seconds (see Note 4). Spin pestle at top of  microcentrifuge tube 
to remove excess homogenate (see Note 5). After homogenisation, remove pestle to a 
container for washing and autoclaving to allow re-use.
9.  Repeat for all mosquito pools (see note 6).
10. Total volume of  mosquito grinding buffer per mosquito should be kept at 48 µl, as 
for the individual mosquito assay. After homogenisation, for pools of  10 mosquitoes, 
add additional mosquito grinding buffer to a total volume of  480 µl (380ul additional 
buffer). For pools of  5 mosquitoes, add additional mosquito grinding buffer to a total 
volume of  240 µl (140 µl additional buffer).
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11. Pulse mosquito homogenates in a micro-centrifuge for 15 seconds to remove residual 
homogenate from tube walls, and store in racks at 4°C.
12. Remove homogenates from 4°C, and using modified 200 µl pipette tips (see Note 7) 
mix and aliquot at least 3 samples of  48 µl from each pooled homogenate into assay 
plate wells (see Note 5). When entire assay plate is filled according to plate plan, cover 
and agitate gently on a rocker at room temperature for 30-45 minutes.
13.  During the first plates incubation with luciferase assay buffer, reconstitute luciferase 
substrate according to the number of  mosquitoes under analysis (60 µl per mosquito), 
and leave to equilibrate with room temperature in darkness (see Note 8). Additionally, 
ensure that the plate reader is on and warmed up, with settings appropriate for the 
luminescence assay. Settings are as follows:
14. During the first plate’s incubation with luciferase assay buffer, ensure that the plate 
reader is on and warmed up. Ensure that settings are appropriate for the luminescence 
assay (all wavelengths, 1 second measurement per well is sufficient).
15. With a multichannel pipette, add 60 µl luciferase substrate to every well (see Note 9). 
Place plate into plate reader immediately, shake for 5 seconds to mix (manually, the 
machine is not capable of  doing so during its program), and assay for luminescence 
intensity.
Notes
1.  When handling very large numbers of  mosquitoes, it is easiest after addition of  
grinding buffer to microcentrifuge tubes to leave them open at 4°C. It is therefore 
important that they be undisturbed, to minimise the risk of  contamination.
2.  Luciferase assay buffer is stored at -20°C, and though it does not freeze at this 
temperature it is very viscous, remaining so until fully equilibrated at room 
temperature. Because of  its viscosity, special care should be taken to ensure accuracy 
with pipetting. Multi-channel pipettes are useful here, but wastage in reservoirs is 
significant.
3.  If  homogenising all mosquitoes from a cage at once, we find it easiest to remove all 
mosquitoes to their tubes, placing a pestle into each tube in turn to immediately to 
kill the mosquito. Homogenisation can then be initiated at the convenience of  the 
technician. This also avoids time wastage due to CO2 immobilisation, which requires 
repetition every few minutes.
4.  Manual homogenisation is not truly standardisable, however, it quickly becomes 
apparent how long it takes for a mosquito to become homogenised. We find that 
5 seconds is long enough to ensure an even mixture when homogenising single 
mosquitoes, with no large body parts remaining intact. Mosquitoes differ in size, 
so this may differ by 1 or 2 seconds either way. Some flexibility should be allowed 
here, but it is important that mosquitoes are not homogenised excessively. We 
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have conducted studies using automated bead beating devices that show that high 
temperature/friction has a limiting effect on luciferase activity, which is why we 
advise caution.
5.  For mosquito pools, longer homogenisation is necessary to achieve the same 
consistency. For pools of  5 we advise approximately 10 seconds homogenisation, 
while for pools of  10 mosquitoes, 15 seconds is adequate.
6.  An additional consideration for the homogenisation process is loss of  material on 
the pestle. After homogenising the mosquito, we spin the pestle in the empty upper 
half  of  the microcentrifuge tube to remove residual homogenate. We find that if  any 
debris does remain on the pestle, this tends to be the harder and larger portions of  
the mosquito carcass (i.e. parts of  leg). Though this, and the process of  pipetting 
homogenates from tubes to assay wells, mean that a small amount of  homogenate 
may not be assayed, our results on the sensitivity of  this assay for the detection of  low 
intensity infections (see Methods 3.3) indicate that this has no detrimental effect.
7.  As only a portion (3 aliquots) of  each pool is assayed, homogenate loss is not an issue for 
pooled mosquitoes, so no additional measures need to be taken after homogenisation. 
However, if  the entire homogenate is required, the pestle may be rinsed into the same 
microcentrifuge tube while making the homogenate up to volume (48 µl grinding buffer 
per mosquito). For pools of  5 mosquitoes pestles can be rinsed with 140 µl of  additional 
buffer, and for pools of  10 pestles can be rinsed with 380 µl. Our previous results indicate 
that there is remarkable consistency in luminescence read-outs between separate aliquots 
from the same mosquito pools [25].
8.  As discussed in Note 1, and Introduction 1.4, the individual luminescence assay 
in the form described here does not represent a major increase in throughput over 
mosquito dissections. To increase scalability (for example if  assessing enough 
mosquitoes to require 2 or more assay plates) it is generally useful if  two technicians 
are available. After homogenisation of  enough mosquitoes to fill one assay plate, a 
second technician can then immediately prepare these homogenates for lysis, whilst 
the remaining cages of  mosquitoes are homogenised. 
9.  However, this is not essential, as the protease inhibitors in the grinding buffer are 
stable at room temperature for 24 hours. By ensuring that mosquitoes are stored at 
4°C after homogenisation, a single technician could perform homogenisation and the 
assay sequentially, over a suitable timeframe.
10. Because homogenates contain mosquito debris, pipetting using standard tips is not 
efficient (blockage is common, and leads to wastage of  the homogenate, and time). 
Before beginning the assay, whenever convenient, we find it useful to cut the first half  
centimetre off  a group of  200 pipette tips, to widen the opening and allow unimpeded 
transfer of  mosquito homogenates.
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11. Another option would be to spin down the mosquito homogenates to form a pellet, 
then remove only the supernatant using standard pipette tips to the assay plate. We 
find this works equally well, but in the interests of  time and standardisation have 
more often chosen to use the whole mixed homogenate. 
12. Luciferase substrate should be kept in total darkness except during pipetting, and 
should ideally be used on the day of  reconstitution (though freezing once for re-use 
is acceptable).
13. Because of  the time sensitive reaction of  the Luciferase enzyme once in contact 
with substrate, a multichannel pipette is essential here. Pipetting should be left until 
immediately prior to measurement. With a 1 second read per well, the time between 
substrate addition and assaying all wells in a 96 well plate should be just over 2 
minutes. This is well within the stability range of  the substrate we advise use of  here. 
Other luciferase assay systems may have longer stability.
14. Previous results indicate that infection detection using individual mosquitoes is 
exceptionally robust at all levels of  infection intensity. In experiments where almost 
half  of  all oocyst positive mosquitoes were in the 1-5 oocyst range (n=1350), 
prevalence estimates made by microscopy and luminescence assay from separate 
mosquito samples were very similar (64.9% and 67.7% respectively), and adjustment 
of  the luminescence based positivity threshold between the mean plus 3 – 10 SD had 
little impact on these prevalence estimates (66-68.8%) [25].
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Abstract
Current first-line treatments for uncomplicated falciparum malaria rapidly clear the asexual 
stages of  the parasite, but do not fully prevent parasite transmission by mosquitoes. The 
standard membrane feeding assay (SMFA) is the biological gold standard assessment of  
transmission reducing activity (TRA), but its throughput is limited by the need to determine 
mosquito infection status by dissection and microscopy. Here we present a novel dissection-
free luminescence based SMFA format using a transgenic Plasmodium falciparum reporter 
parasite without resistance to known antimalarials and therefore unrestricted in its utility 
in compound screening. Analyses of  sixty-five compounds from the Medicines for Malaria 
Venture validation and malaria boxes identified 37 compounds with high levels of  TRA 
(>80%); different assay modes allowed discrimination between gametocytocidal and 
downstream modes of  action. Comparison of  SMFA data to published assay formats for 
predicting parasite infectivity indicated that individual in vitro screens show substantial 
numbers of  false negatives. These results highlight the importance of  the SMFA in the 
screening pipeline for transmission reducing compounds and present a rapid and objective 
method. In addition we present sixteen diverse chemical scaffolds from the malaria box that 
may serve as a starting point for further discovery and development of  malaria transmission 
blocking drugs.
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Introduction
The introduction of  Artemisinin combination therapy (ACT) as the first line treatment 
for malaria has contributed substantially to recent declines in child mortality across Africa 
[1, 2]. ACT rapidly clear the Plasmodium life stages responsible for clinical disease, but have 
only limited effect against mature gametocytes, the stage transmitted to mosquitoes [3]. 
Though immature gametocytes may be cleared shortly after their production [4] resulting 
in reduced gametocyte burden and transmission potential [5], current dosing regimens of  
ACT do not radically clear mature transmission stages and do not prevent transmission 
shortly after treatment [6]. Expanding efforts to achieve local malaria elimination and 
contain transmission in areas of  emerging ACT resistance have stimulated interest in 
combining standard treatment with compounds active against mature gametocytes [7] and 
have highlighted the need to screen new antimalarial drug candidates for their transmission 
reducing activity (TRA). 
 Currently the only available drug that radically prevents malaria transmission is 
primaquine [8], but its wide-scale deployment is hampered by issues of  safety and dosing 
[9, 10]. Though the results of  numerous ongoing trials give reason to expect wider scale 
use of  single-low dose primaquine for reducing P. falciparum transmission, there is growing 
interest in identifying novel transmission reducing compounds [7].
 For screening new compounds, several assays determining gametocyte viability activity 
have been developed. These have been based on the expression of  metabolic markers or 
reporter genes, or more recently on gametocyte activation in vitro measured by the presence 
of  female and male gametes [11-13]. Such assays are, however, not always predictive of  
blocking transmission of  the parasite to the mosquito, and agents with putative TRA 
are best tested in the standard membrane feeding assay (SMFA). In the SMFA cultured 
gametocytes are mixed with blood and test compounds, and this mix is fed to laboratory 
reared mosquitoes to determine the effect of  the compound on the parasites establishment 
in the mosquito. As the outcome of  the SMFA is mosquito infection and the timing and 
duration of  compound exposure is controlled, the assay is easily adapted to assess effects 
active at any stage of  parasite development – from gametocyte inhibition, to inhibition 
of  sporogony [13, 14]. The SMFA has numerous pitfalls though, first among these being 
the need to dissect mosquitoes and count oocysts on the mosquito midgut by microscopy; 
a labour intensive and subjective task, which imposes significant limits on the assays 
scalability. We previously described the use of  a parasite line expressing a fusion of  the 
green fluorescent and firefly luciferase proteins (NF54HT-GFP-Luc) in a new SMFA format 
based on the measurement of  luciferase activity in groups of  homogenised individual or 
pooled mosquitoes [15]. Although very effective, this strain may be sub-optimal for drug 
screening; introduction of  the human dihydrofolate reductase (hDHFR) selection marker 
during integration of  the GFP-Luc expression cassette renders it resistant to antifolates 
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[16] and makes it necessary to maintain exposure to antifolate compound WR99210 during 
parasite culture to prevent reversion to wild-type (WT), possibly modifying its response 
to other inhibitors by affecting parasite metabolism. Here we report the development 
of  a parasite line that constitutively expresses GFP-Luc and is free of  limiting selection 
markers, for use in an efficient, dissection-free SMFA screen. Our approach used frozen 
mosquitoes and machine homogenisation in a 96-well format to improve the efficiency of  
indiscriminate drug screening. After validation and comparison of  luciferase expression 
with microscopy based oocyst counts we used our luminescent SMFA to screen 47 
marketed and experimental antimalarials and compared the results with data from the 
gametocytocidal lactate dehydrogenase (pLDH) activity assay and Pfs25 AlphaLISA 
assay. Furthermore, the luciferase screen was used to evaluate the TRA of  18 compounds 
selected from the Medicines for Malaria Venture (MMV) malaria box specifically for their 
potential activity as gametocytocidals. In this final screen, gametocytocidal or permanent 
inhibitory activity was confirmed by incubating gametocytes with compounds before 
‘washing out’ the compound prior to mosquito feeding, while specific activity against the 
parasite stages emerging in the mosquito gut was confirmed by adding compounds to the 
gametocyte culture immediately prior to mosquito feeding. These assays identified novel 
transmission blocking small molecules and provide new insight into the predictive value 
of  in vitro metabolic and gamete formation inhibition assays, showing they can miss potent 
compounds, and highlighting the advantages of  the gold-standard SMFA for screening 
transmission blocking compounds. Importantly, our more scalable luciferase based read-
out increases throughput of  the assay and makes compound screening with the SMFA less 
resource intensive than when performed with microscopy.
Results
Generation of a GFP-Luc expressing parasite line free of selection 
markers
To allow unrestrained evaluation of  new compounds we developed a new parasite line, free 
of  drug selection markers (full title: NF54-∆Pf47-5’hsp70-GFP-Luc; hereafter: NF54-HGL), 
that stably expresses a GFP-Luciferase fusion protein under control of  the constitutive P. 
falciparum hsp70 promoter (Figure 1 A-B). 
 To confirm the proposed effect of  removal of  the hDHFR selection marker on antifolate 
sensitivity, we compared sensitivity of  wildtype NF54, intermediate clone NF54-HGL-
hDHFR (created prior to FLP recombinase-mediated excision of  the hDHFR maker) 
and NF54-HGL asexual blood stage parasites to dihydroartemisinin (DHA), chloroquine, 
and two antifolate drugs: WR99210 and Pyrimethamine. The half  maximal inhibitory 
concentration (IC50) for DHA and chloroquine are comparable for all three parasite lines. 
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As predicted, presence of  the hDHFR selection marker in NF54-HGL-hDHFR renders this 
parasite resistant to WR99210 and Pyrimethamine. Excision of  the hDHFR open reading 
frame effectively restores sensitivity to these antifolates for NF54-HGL (Figure 1 D-G). 
Since pLDH is a stable enzyme and antifolates have relatively slow parasite killing kinetics, 
the inhibition by WR99210 and pyrimethamine did not reach 100% within the timeframe 
of  the assay [17].
Assessment of GFP-Luc expression
Analyses of  luminescence signals confirmed expression of  the GFP-Luc protein in asexual 
blood stage parasites (Figure 1 C). In line with previous reports on different expression 
levels in the various life cycle stages of  the parasite [18], expression was higher in day 8 
gametocytes than in mature gametocytes and asexual blood stages. To assess GFP-Luc 
expression during the parasites development in mosquitoes, Anopheles stephensi were fed 
a blood-meal containing NF54-HGL gametocytes and dissected at various time-points 
post infection (PI) to allow visual inspection of  the mosquito midgut. No fluorescence 
was observed during ookinete formation (24 h PI, data not shown), indicating that GFP 
expression levels may have been under the limit for microscopical detection. From day 
6 PI GFP positive oocysts were easily observable (Supplementary figure S1). Luciferase 
expression was weak during early sporogonic development (2-6 days PI, data not shown), but 
robust signal in low intensity infections (mean oocysts = 1.28, range = 0-7) was detectable 
from day 7 PI onwards (Supplementary figure S2). Uninfected negative control mosquitoes 
showed low levels of  luminescence (n=617; mean RLU=3.2 RLU; standard deviation=1.9 
RLU). Day 8 PI showed a clear separation of  positive and negative mosquitoes and was 
chosen for subsequent assessments of  infection intensity (i.e. number of  oocysts per 
midgut) and prevalence (i.e. percentage of  mosquitoes with oocyst stage infection) based on 
luminescence intensity.
Microscopy and luciferase based assessments of infection and TRA
To confirm that measurements of  luciferase activity can replace manual dissection-based 
oocyst counts, as was previously shown for NF54HT-GFP-Luc [15], 172 experimental 
mosquito feeds (hereafter ‘feeds’) were performed using NF54-HGL gametocyte culture. 
From each feed, separate mosquito samples were assayed by standard microscopy and by 
luminescent SMFA (microscopy, n=2557; luminescence, n=3570). Thirty-two of  these 
feeds were performed as controls allowing for direct comparison of  infection intensity 
and prevalence based on oocyst and luminescence readouts. These were performed either 
without test compounds (0.1% DMSO, n=16) or with control compound DHA that shows 
gametocytocidal activity at high concentration (10 µM DHA, n=16) [13]. Mean oocyst 
counts for control feeds were between zero and 29 oocysts (mean 4.9 oocysts), and had 
a positive linear relationship with mean luminescence intensity (R2=0.86, p<0.0001). 
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Figure 1. A. Schematic of the gene targeting strategy to insert a GFP-Luc reporter gene under control 
of the hsp70 promoter in the pfs47 locus, showing the genomic locus of the wild-type (WT) and gene 
deletion mutants ∆pf47 containing the GFP-luciferase ORF before and after removal of the hdhfr 
resistance marker. P1, P2: primers MWV300 and MWV301, respectively, used for PCR analysis; X (XcmI), 
N (NcoI): restriction sites used for conformation of LR-PCR analysis; pf47: pf47 locus; hrp: histidine 
rich protein; cam: calmodulin; hsp: heat shock protein; hdhfr: human dihydrodrofolate reductase 
coding region; GFP-Luc: GFP-luciferase fusion protein; fcu: cytosine deaminase/uracil phosphoribosyl 
transferase; pbdt: P. berghei dhfr transcription termination region; kb: kilo basepairs. B. Verification of 
the integration site by PCR and restriction digestion. Genomic DNA fragments from the parental NF54 
strain (WT), intermediate transgene NF54-HGL-hDHFR and final transgene NF54-HGL were amplified by 
PCR using primers MWV300 and MWV301 (P1 and P2) and analysed by DNA gel electrophoresis. Where 
indicated, the PCR fragment was subjected to restriction digestion with XcmI/NcoI (X/N) C. Luminescence 
intensity (relative light units, RLU) as a function of cell number. The figure shows a comparison between 
uninfected red blood cells (RBC), immature gametocytes (Day 8 GCT), mature gametocytes (Day 14 GCT) 
and asexual blood stage parasites. D-G. FLP-FRT mediated excision of the selection marker restores 
sensitivity to antifolates. Drug sensitivity analysis of WT, ∆Pf47GFP-luc-hdhfr and ∆Pf47GFP-luc to DHA 
(D), Chloroquine (E), Pyrimethamine (F), and WR99210 (G) in a dose dependent asexual growth inhibition 
assay using pLDH enzyme activity as a readout. Depicted data represents a triplicate measurement and 
was normalized to the MIN (10 µM DHA) and MAX (0.1% DMSO) controls. Error bars indicate standard 
deviations. 
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Similarly, oocyst prevalence was positively associated with luminescence based prevalence 
(R2=0.95, p<0.0001) (Supplementary figure S3). Combining all mosquitoes from control 
feeds, prevalence estimates for all mosquitoes from control feeds were 43.33% (208/480) for 
microscopy, and 49.22% (350/711) for luminescence. 
 To further validate the luminescent SMFA we tested seven compounds from the MMV 
validation box in full dose response in an ‘indirect’ luminescent SMFA format. In the 
indirect assay, gametocytes were incubated with compounds for 24 hours, and mosquitoes 
were fed a blood-meal containing this gametocyte culture/compound mix. Microscopic 
examination of  oocyst densities in midguts and luminescence measurements were 
performed on distinct cohorts of  mosquitoes from the same cage. As shown in figure 2, all 
compounds dose-dependently reduced oocyst formation and luminescence intensity. Data 
were fitted to a Hill equation using Maximum Likelihood Estimation to find the best fit. 
The dose response curves fitted on the microscopy and luminescence data aligned very well 
for artemisone, atovaquone, mefloquine, NPC1161B, pyrimethamine and pyronaridine. 
The curves for lumefantrine appeared to be less well aligned due to a distinct dispersion of  
oocyst counts and RLU values at the highest concentration tested. For all other compounds 
the derived IC50 values differ by no more than 2-3 fold when comparing the two read-outs.
The luminescent SMFA identifies compounds with different modes of TRA
Using only luminescence readouts, we screened 47 established antimalarial compounds 
in the indirect luminescent SMFA format at a 5 µM concentration. Samples of  22-24 
mosquitoes were analysed for each compound (n=46*24; 1*22). The results of  this rapid 
screen are shown in Figure 3A, with TRA (%) calculated using generalised linear mixed 
models (GLMM) from differences in the intensity of  infection between test and vehicle 
(0.1% DMSO) control feeds. Thirty-four compounds had statistically significant TRA 
based on reductions in luminescence intensity; 21/34 with ≥80% TRA [15]. 
 To provide more information on the mechanism of  active compounds, all compounds 
showing ≥80% TRA on the intensity scale in the indirect assay were re-tested, this time 
adding compounds to the blood/gametocyte culture mix immediately prior to mosquito 
feeding (hereafter, the ‘direct’ assay variant). Fourteen compounds had >80% TRA in the 
indirect assay but not in the direct assay, suggesting the absence of  strong activity against the 
parasite life stages occurring in the mosquito gut. Amino alcohol halofantrine, antifolates 
P218, pyrimethamine and chlorproguanil, synthetic dye methylene blue, BC1 inhibitor 
atovaquone, and protein synthesis inhibitor cycloheximide had comparable TRA in the 
indirect and direct SMFA formats, indicating activity against mosquito stage parasites, but 
not excluding the possibility of  concurrent gametocytocidal action. 
 The results of  the indirect and direct assays were compared with previously described 
data [13] showing the effect of  the same 47 compounds at 5 µM in a gametocyte viability 
assay with pLDH readout, and a homogeneous immunoassay detecting the Pfs25 antigen 
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on emerging female gametes (Figure 3B). At a threshold of  ≥80% inhibition, the pLDH 
and gametogenesis assays identified 6/47 and 13/47 compounds respectively as having 
gametocytocidal activity. The activity of  all but one of  the six compounds identified by the 
pLDH assay (napthoquine) was confirmed by the gametogenesis assay, while all hits from 
either viability assay were confirmed in the indirect luminescent SMFA. However, high TRA 
was observed for a number of  compounds where the inhibition assays showed low activity, 
indicating that some compounds had activity only identifiable with transmission as the 
definitive readout. Total false negative rates for the pLDH and gametogenesis assays were 
32% (15/47) and 17% (8/47), respectively. Excluding compounds that blocked transmission 
in the direct luminescent SMFA, which we presumed to have activity downstream of  the 
gametocyte, the SMFA still identified a larger number of  transmission-blocking compounds 
than either gametocytocidal assay, with false negativity rates of  25% (10/40) in the pLDH 
assay and 10% (4/40) in the gametogenesis assay. This is not surprising since the SMFA 
covers a higher biological content than either of  the other two methodologies.
Identification of novel transmission-blocking small molecules
In recent years, a number of  gametocyte assays have been developed that attempt to predict 
gametocyte viability and infectivity based on metabolic activity, reporter gene expression, 
or changes in cell shape or antigen expression [11-13, 19-26]. In an effort coordinated by 
the Bill & Melinda Gates Foundation and the Medicines for Malaria Venture (MMV), a 
number of  these and additional novel assays selected a subset of  compounds from the MMV 
Malaria box as potentially transmission blocking. All of  these molecules kill asexual blood 
stage parasites with submicromolar IC50s (Table 1). Here, we evaluated 18 of  these selected 
compounds in full dose-response experiments using the luminescent SMFA. In order to 
confirm a gametocyte-based mechanism of  action, compounds were washed out following 
incubation with stage V gametocytes to prevent activity against parasite stages emerging 
in the mosquito midgut. Effectiveness of  the washing step was tested by evaluating the 
activity of  pyrimethamine, which has potent activity against the parasite stages that develop 
in the mosquito midgut (Figure 2) but not against gametocytes [27]. Indeed, washing a 
culture of  gametocytes exposed to pyrimethamine restored subsequent oocyst development 
in the mosquito, confirming that this format of  the assay is likely restricted to the analyses 
of  gametocytocidal modes of  actions (Supplementary figure S4). This might however be 
different for more lipophilic drugs, which might be washed out with less efficiency. Sixteen 
out of  the 18 Malaria box compounds tested in this wash-out mode of  the SMFA dose-
dependently reduced oocyst development in the mosquito midgut (Figure 4). Compounds 
MMV665941, MMV667491, MMV019918 and MMV665827 were among the most 
potent transmission-reducing molecules, with IC50 values of  0.04, 0.06, 0.07 and 0.1 µM, 
respectively. To reveal whether these compounds act against the parasite stages that develop 
in the mosquito midgut on top of  their gametocytocidal activity, all compounds were tested 
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Figure 4: Dose response experiments for 18 compounds from the MMV malaria box, assessed in 
the luminescent SMFA in a wash-out assay variant. All compounds were tested in duplicate in two 
independent experiments. The figure shows oocyst intensities relative to vehicle control (0.1% DMSO) 
as a function of concentration for the compounds indicated at the top of the panels. The compounds 
depicted in their molecular structure showed an IC50 < 100 nM in the luminescent SMFA.
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in the direct assay variant at the same maximum concentration as in the wash-out assay 
(10 µM), confirming that 10/18 compounds significantly reduced mosquito oocyst intensity 
Compounds MMV020492 and MMV665882 that did not show gametocytocidal activity 
were equally inactive in the direct SMFA. To further address the mechanism of  action of  
compounds with functional TRA, the SMFA data were compared to data from published 
studies that addressed different aspects of  gametocyte biology (Table 1). MMV019918 
was the only compound consistently showing activity across the different assay formats, 
although IC50 values ranged from 0.07 µM to 0.9 µM, with large differences between the two 
assays that interrogated the ability of  a gametocyte to undergo exflagellation. Conversely, 
MMV007116 and MMV665827 showed potent activity in the SMFA but very low activity 
in the published gametocyte assays, with the exception of  a luciferase reporter assay that 
revealed the effect of  these compounds on gametocyte viability. In general, the luminescent 
SMFA identified more compounds with functional TRA than predicted by each of  the 
individual published gametocyte assay formats.
Discussion
The firefly luciferase expressing parasite line NF54-HGL enables the SMFA to be performed 
for indiscriminate compound screening with a semi-automated luciferase based read-out. 
The results of  the current study demonstrate the versatility of  the SMFA for screening 
compounds with activity against different transmission stages of  the malaria parasite, and 
validate the luminescent assay format in combination with microtiter plate-based processing 
of  mosquitoes for improving the efficiency of  the biological gold-standard for assessing 
Plasmodium transmission in controlled experiments. 
 We presented a screening pipeline for the SMFA that allowed us to investigate drug 
mechanism of  action while retaining transmission as the assay end-point. The indirect 
assay, in which compounds were incubated with gametocytes for 24 hours prior to mosquito 
feeding, represents the simplest and most sensitive screen and the first step in the pipeline 
for screening large compound libraries. The direct assay, in which the compound is added at 
the moment the gametocyte activates to form a gamete, interrogates compound action in the 
mosquito midgut. Pharmacokinetics in the mosquito are largely unknown, but detoxifying 
enzymes may limit the compound’s action in the midgut, restricting the direct SMFA to 
monitoring effects on gametogenesis, ookinete formation and perhaps early sporogony 
[28]. Lastly, the wash-out format of  the SMFA addresses a mode of  action that is likely 
restricted to the gametocyte. High-throughput screening is impossible with the SMFA, but 
the luminescent SMFA represents a significant improvement in the techniques scalability. 
The replacement of  direct oocyst counts with luciferase measurements from homogenised 
mosquitoes in the SMFA was described previously [15] for parasite line NF54HT-GFP-luc 
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[16], but aspects of  the methodology described here differ. The current reporter parasite 
is devoid of  the DHFR selection marker, allowing for precise description of  the effects of  
antifolates including pyrimethamine on oocyst development, and expediting the evaluation 
of  a wide variety of  compound libraries. Mosquito sample sizes were limited to increase 
throughput, and freezing mosquitoes prior to further processing increased flexibility of  
laboratory operations. Furthermore, semi-automated processing of  mosquitoes significantly 
reduced the time needed for assessment of  infection status. In all, the luminescent format for 
individual mosquitoes reduces hands-on time 2-fold in comparison with the microscopical 
readout, which is a tremendous step up from a previously published ‘industrialized’ SMFA 
format [29]. For even further increased throughput, screening in the luminescent SMFA 
may be performed by pooling larger numbers of  mosquitoes, achieving an approximate 
four-fold increase in throughput over the standard microscopical readout if  only infection 
intensity is the desired output [15]. 
 Our data from a large number of  infections indicate that oocyst intensity is a simple 
linear function of  luminescence intensity. This is in keeping with our previous work that 
showed a linear relationship between oocyst counts and luminescence intensity, using a 
different promoter to drive expression of  the reporter gene [15]. Oocysts are an intermediate 
parasite life-stage which even when developing concurrently in a host mosquito may 
differ in size and sporozoite content [30-32]. Whereas microscopy produces discrete 
data, luminescence measurements provide continuous data that reflect actual numbers of  
developing sporozoites, which may be more directly relatable to mosquito infectivity, for 
which oocyst counts are an accepted proxy. An added advantage of  the luminescent assay is 
that it is less subjective than microscopy based assessments of  oocyst numbers. We cannot 
exclude the possibility that in heavily infected mosquitoes, with higher oocyst intensities 
than those reported here, nutrient and space competition may lead to lower per capita 
sporozoite production, resulting in a non-linear relationship between luminescence and 
oocyst intensity and lower luminescence based TRA estimates than would be determined 
from oocyst number alone. Though we advise caution in extrapolating actual oocyst 
number from luminescence values, we believe luminescence based TRA estimates may be 
more accurate than those made using oocyst data. 
 In the direct mode of  the SMFA the compound remains present in the bloodmeal, and 
there is a remote possibility that it interferes with activity of  the luciferase reporter rather 
than with oocyst development. We have been unable to investigate the potential effect of  
compounds interacting with hsp70 expression, as has been observed in other eukaryotes [33], 
or the possibility that compounds may directly inhibit luciferase protein after its production 
[34]. We consider both events highly unlikely to affect the luciferase readout in the current 
SMFA format, as compounds are at latest added to the mosquito bloodmeal 8 days before 
luminescence measurements. Furthermore, analyses of  a subset of  the MMV malaria 
box compounds in a luciferase inhibition assay did not reveal inhibitory activity at the 
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concentrations that reduce oocyst development [22]. The possibility that some compounds 
may effect mosquito metabolism, and by proxy parasite developmental success, can also not 
be excluded. Readouts based on oocyst number may be insensitive to such subtle effects, 
while the more quantitative luminescence readout may not be. Additional experiments 
will be required to elucidate the interaction of  mosquito and parasite fitness in relation to 
compound exposure.
 Apart from oocyst intensity, oocyst prevalence (the proportion of  mosquitoes that develop 
an oocyst-stage infection), is an important parameter determining malaria transmission. 
Whereas inter-experimental variation in control mosquito oocyst burden has no effect on 
TRA expressed as a reduction in oocyst intensity, it heavily influences the outcome based 
on a reduction in oocyst prevalence.[35]. Since our experiments comprised a large set of  
experimental infections that each showed a distinct distribution of  oocyst densities we have, 
therefore, limited our analyses to a comparison of  compound effects on oocyst intensity, as 
this is the only parameter that is directly comparable between experiments. Nevertheless, 
a complete assessment of  the transmission blocking potential of  an antimalarial would 
require a description of  the effects on infection prevalence, preferable at infection intensities 
that mimic those observed in naturally infected mosquitoes [36]. An experimental and 
computational strategy to achieve such an assessment has been implemented in our 
laboratory and will be described elsewhere. 
 Compounds reducing malaria parasite transmission to mosquitoes may kill gametocytes 
directly (gametocytocidal activity), irreversibly impair the parasites ability to develop 
once ingested by the mosquito, or else inhibit gametocyte developmental viability only 
while drug pressure is maintained in the mosquito environment [12]. Because mature 
gametocytes persist at low densities for several weeks after ACT treatment [6], and 
because submicroscopic gametocyte densities may be highly transmissible [37, 38], efforts 
to develop transmission-reducing compounds are focused on identifying activity against 
mature gametocytes [39]. In vitro assays based on markers of  metabolic activity (pLDH 
[13, 19], Alamar Blue reduction [20]) or reporter genes [21, 22, 40] can be used to assess 
the effects of  gametocytocidal compounds but may overlook compounds that manifest 
their action downstream of  the gametocyte. Gametocyte infectivity may be assessed in 
greater detail with gamete formation assays, which can include gametocyte washing steps 
to discriminate between reversible and irreversible compound activity [12, 13, 23]. In vitro 
ookinete formation assays can also be used to identify compounds whose presence in the 
mosquito blood meal inhibits parasite fertilisation [41], but these assays cannot exclude the 
possibility of  compounds reducing ookinete viability or oocyst formation. Assays measuring 
the viability or development of  gametocytes without mosquito feeding are comparatively 
inexpensive and highly scalable, so will continue to be required as a prioritization step in 
the screening pipeline for transmission blocking drugs. The data presented here indicate, 
however, that increased throughput of  in vitro gametocyte assays goes at the cost of  a 
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considerable number of  false negatives. Importantly, as no in vitro assay or combination 
of  assays is able to fully interrogate the effect of  compounds on all parasite developmental 
stages exposed to test compounds, our results underline that the SMFA remains the 
gold standard assessment of  gametocyte infectivity. Our indirect screen of  a varied set 
of  47 antimalarials identified compounds preventing mosquito infection by mechanisms 
targeting any stage of  the parasites sexual development or early sporogony. Assays based on 
parasite metabolic processes (pLDH) and on the expression of  female gamete upregulated 
protein Pfs25 cumulatively failed to identify seven compounds which, incubated with 
cultured gametocytes (NF54-HGL) in the same concentration, caused marked reductions 
in oocyst stage productivity as assessed by the luminescent SMFA. Though we anticipated 
identifying compounds with additional activity downstream of  gamete formation in the 
SMFA, the results of  the direct assay indicate that the pLDH and gamete formation assays 
failed to identify compounds with effects restricted to the gametocyte; three of  the seven 
false negatives had no activity on mosquito stage parasites in the direct SMFA format. 
The effect of  the remaining four compounds may rely on a sporontocidal rather than a 
gametocytocidal activity. In keeping with previous reports of  their sporontocidal activity 
(reviewed in Butcher [42]), pyrimethamine and atovaquone blocked oocyst development but 
were not active in the pLDH and gamete formation assays. Atovaquone has demonstrated 
a long-lasting transmission-blocking effect in ex vivo studies with sera from drug-treated 
volunteers [43], but the effect on transmission in malaria endemic settings has not been 
described in detail. The sporontocidal effect of  pyrimethamine most likely represents a 
class effect of  dihydrofolate reductase (DHFR) inhibitors, as it was also observed for P218 
and chlorproguanil. Proguanil was understandably not active in the SMFA as only its active 
metabolite cycloguanil binds to DHFR [44]. 
 Analyses of  eighteen compounds from the MMV malaria box revealed sixteen compounds 
with functional TRA that were not necessarily identified by individual gametocyte based 
assay formats [12, 24-26]. These 18 compounds were flagged as potential transmission 
blockers by a joint effort coordinated by the Bill and Melinda Gates Foundation and the 
Medicines for Malaria Venture under the ‘Gametocyte Assays for Plasmodium falciparum’ 
program. Under this program, five consortia consisting of  two to five malaria laboratories 
each screened the MMV malaria box in a variety of  gametocyte-based assays. All consortia 
proposed a shortlist of  active molecules for further evaluation in the SMFA. The final 
selection of  18 molecules, governed by MMV, was then based on potency, diversity in 
chemical scaffolds and presumed tractability. As these compounds were expected to act 
at the level of  the gametocyte, we applied a wash-out format to restrict the analysis to the 
sexual blood stage of  the parasite when testing these compounds in the luminescent SMFA. 
For the 18 compounds subjected to this more rigorous investigation, 16 were able to reduce 
onward oocyst development in the mosquito with potencies ranging from 8.6 to 0.04 µM. 
The luminescent SMFA did not reveal TRA for MMV020492, which is in line with its lack 
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of  activity in published gametocyte assays. Equally inactive in the SMFA, MMV020492 
showed a lack of  activity in most published gametocyte assays, with the exception of  a 
luciferase assay that indicated an IC50 of  62 nM. Overall, from a qualitative perspective 
the luciferase assay showed the best agreement with the SMFA, as it identified 14 out of  
the 16 compounds with functional TRA. Assays that interrogate the ability of  a gametocyte 
to form a male or female gamete did not identify MMV000442 as a potential transmission 
reducing compound [12], whereas it showed an IC50 of  590 nM in the SMFA. This 
indicates that gametocyte infectivity is defined by a greater set of  functions than described 
by its sole ability to form a gamete. Quantitatively, neither of  the published gametocyte 
assays correlated particularly well with the SMFA, as IC50 values could vary up to 180-
fold (e.g. MMV007116 SMFA vs gametocyte exflagellation). In addition, the rank order of  
compounds appeared to be different for all assays. This implies that in vitro gametocyte assays 
provide limited guidance for studies aimed at an understanding of  dose in relationship to 
efficacy. Although mouse models have been proposed to determine the efficacious dose for 
blockage of  malaria transmission, these are restricted to P. berghei parasites and have limited 
value for predicting efficacy on human malaria. In addition, P. berghei infection intensities 
are much higher than P. falciparum infection intensities, which leads to an underestimation 
of  TRA when estimated from differences in infection prevalence [35, 45]. 
 Our studies identified four compounds from the malaria box with IC50 values below 100 
nM in the luminescent SMFA. Compounds MMV665827, MMV665941, and MMV667491 
lack structural properties that meet Lipinski’s rule of  five that predicts oral absorption 
of  a candidate drug [46]. Therefore, these compounds are considered tool compounds 
rather than drug-like molecules [47]. Nevertheless, these compounds may have value in 
the identification of  mechanisms underlying transmission-blocking activity, which remain 
poorly understood. Importantly, these molecules have activity against asexual blood stage 
parasites, which opens the possibility of  selecting drug resistant mutants followed by whole 
genome sequencing. This strategy has been successfully employed in the identification of  
PI4K, and eEF2 and confirmation of  DHODH as bonafide drug targets [48-50]. From the 
group of  compounds with potent transmission blocking activity, MMV19918 appears to 
qualify as a drug-like molecule and may, besides serving as a tool in unravelling mechanism 
of  action, act as a starting point for further optimization. This compound appeared 10-fold 
more active in the SMFA as in assays interrogating activity against the asexual blood stages. 
Such a transmission-selective profile was also observed for MMV665941 and MMV667491. 
To the best of  our knowledge these are the first molecules described to date that show 
selectivity towards the transmission stages of  the parasite. Recently, the malaria drug 
development pipeline was enriched with molecules like OZ439, DSM265 and DDD107498, 
which unlike the majority of  marketed antimalarials have activity against the transmission 
stages of  the parasite[51]. However, for all these molecules this activity is at par or less 
potent than the activity observed against asexual blood stage parasites [13, 49, 50, 52]. The 
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observation of  a transmission-selective profile in the study presented here suggests a novel 
mechanism of  action outside the range of  targets described to date. In view of  the need for 
molecules that address a target candidate profile for prevention of  transmission [53], these 
mechanisms and the molecules identified here warrant further investigation.
Conclusion
The results of  the current study demonstrate the sensitivity and flexibility of  the SMFA 
for determining the effect of  small molecules on P. falciparum gametocyte transmission to 
mosquitoes, while validating a method that increases the assays scalability and ease of  
use. Comparison to gametocyte inhibition assays indicates that parasite development in 
the mosquito may be required to ensure assay sensitivity to transmission-blocking small 
molecules. Of  the 18 compounds selected in this analysis based on the results of  previous 
gametocyte assays, our data indicate that 3 compounds have greater activity on transmission 
stage parasites than asexual stage parasites. These molecules may be of  particular interest 
for further drug discovery and elucidation of  novel drug targets.
Methods
Parasites and culture
Asexual blood stages of  all P. falciparum parasite lines were cultured in RPMI 1640 medium 
supplemented with 367 µM hypoxanthine, 25 mM HEPES, 25 mM sodium bicarbonate 
and 10% human type A serum, in a semi-automated system under standard conditions and 
induction of  gametocyte production was performed as previously described [54-56]. 
Generation of NF54-HGL-hDHFR and NF54-HGL parasite lines
The GFP::LUC fusion protein under control of  the hsp70 promoter was stably integrated 
into the genome of  asexual stage NF54 (WT) parasites at the pfs47 locus (PF13_0248) 
by standard double crossover recombination and positive/negative selection [57],[58, 59]. The 
targeting plasmid was based on the gene deletion construct pHHT-FRT-Pf5236 described 
previously [60]. The p52 3’ target region in pHHT-FRT-Pf5236 was replaced by the 3’ pfs47 
target region amplified by PCR using primers MWV257 and MWV259 (primer sequences 
in supplemental Table S1) and introduced in the plasmid by MluI/SacII restriction digestion 
and ligation. The 5’ p52 region was replaced with the 5’pfs47 target region amplified by 
PCR using primers MWV262 and MWV267 and introduced in the plasmid by XmaI/NarI 
restriction digestion and ligation. A reporter gene cassette was constructed by subcloning 
a GFP::LUC fragment from plasmid PL1063 [61] in pCR2.1-BLUNTII-TOPO after AflII/
XbaI restriction digestion. An AgeI restriction site was introduced immediately upstream 
of  the start codon by introducing a PCR fragment amplified with primers MWV252 and 
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MWV253 through KpnI/HpaI restriction digestion and ligation. The promoter region of  the 
hsp70 gene (PF3D7_0818900) was placed upstream of  GFP through sacII/AgeI restriction 
digestion and ligation after amplification with primers MWV198 and MWV200 and 
subcloning in pEGFP-N1 (Clontech laboratories, Mountain view, CA ) through BamHI/
SacII digestion and ligation. The 3’ transcription termination region from the hsp86 gene 
(PF3D7_0708400) was introduced following PCR amplification using primers MWV268 
and MWV271 and XbaI/ApaI restriction digestion and ligation. Finally the reporter cassette 
was introduced in the gene targeting plasmid by KpnI/NgoMIV restriction digestion and 
ligation yielding plasmid pMV163.
 Pfs47 target regions, 5’hsp70 and 3’hsp86 fragments were amplified by PCR amplification 
(Phusion, Finnzymes) from genomic P. falciparum DNA (NF54 strain) and all PCR 
fragments were sequenced after TOPO TA (Invitrogen) sub-cloning. 
 Transfection of  wild type NF54 asexual parasites with DNA construct pMV163 was 
performed as described previously [59] using a Electro Cell Manipulator 600 (BTX, 
Holliston, USA) Double crossover mutants were selected by positive and negative selection 
as described [57], yielding parasite line NF54-HGL-hDHFR. Cloning of  transgenic 
parasites was performed by limiting dilution in 96-well plates as described [62]. Parasites 
in positive wells were transferred to the semi-automated culture system and cultured for 
further phenotype and genotype analyses.
 Removal of  the hdhfr selection marker was next performed by transfection of  the mutants 
with construct pMV-FLPe and selection on blasticidin [60, 63], resulting in parasite line 
NF54-HGL. Integrity of  the transgenes was analysed by PCR using primers MWV300 and 
MWV301 and XcmI/NcoI restriction digestion.
 To confirm functional FRT-mediated excision of  the hDHFR selection marker, 
sensitivity to anti-folates and a number of  non-folate reference compounds were performed 
on NF54 (WT), NF54-HGL-hDHFR, and NF54-HGL using a modified pLDH assay. 
Briefly, non-synchronised asexual parasites (~50% ring stages, 25% trophozoites and 25% 
schizonts) were seeded at a density of  0.5% parasitaemia in 3% haematocrit in a black 
96-well plate in 50 µl of  culture medium, with 50 µl of  diluted test compound. Following 
a 72 hour incubation at 37°C, 98% humidity, 93% N2, 4% CO2 and 3% O2, the increase 
in parasitaemia was assessed using the modified pLDH assay as described previously [13]. 
Assays were performed in triplicate (three serial dilutions for each compound) and all plates 
included triplicate controls to assess minimum (MIN control, 1 µM DHA) and maximum 
(MAX control, 0.1% DMSO) signal. To compare the three different strains data were 
normalized and expressed as the percentage reduction in replication relative to the blocking 
and non-blocking controls.
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GFP fluorescence analysis
The midguts of  mosquitoes fed previously with NF54-HGL gametocyte culture were 
mounted on glass slides in a droplet of  PBS, and GFP expression was visualized and 
photographed on a Leica fluorescence microscope with digital camera.
Standard Membrane Feeding Assays
In the ‘indirect’ mode of  the SMFA, gametocytes were pre-incubated with test and control 
compounds prior to mosquito feeding. To this end, compounds were dissolved in DMSO 
to achieve a stock solution of  10 mM that was serially diluted in DMSO to achieve 
concentrations 1000-fold above the final test concentration. Subsequently, 10 µl of  diluted 
compound in DMSO was added to 990 µl pre-warmed RPMI 1640 medium supplemented 
with 367 µM hypoxanthine, 25 mM HEPES and 25 mM NaHCO3 (‘incomplete medium’). 
40 µl of  this intermediate dilution was added to 360 µl of  parasite culture and incubated 
for 24 hrs at 37°C in Eppendorf  tubes, resulting in 0.1% final DMSO concentration. 
Hereafter, 300 µl of  the gametocyte culture/compound mix was added to 180 µl of  packed 
red blood cells and centrifuged for 20 seconds at 10,000 x g. After carefully aspirating the 
supernatant, 200 µl of  human serum type A was added to the pellet. Finally, 300 µl of  
this mix was immediately injected into an individual membrane covered minifeeder, where 
50 female A. stephensi mosquitoes were allowed to feed for 10 minutes. In the ‘wash-out’ 
mode of  the SMFA, compounds were washed out following preincubation by adding 14 ml 
incomplete medium supplemented with 10% human type A serum (‘complete medium’) 
to the gametocyte suspension, followed by centrifugation (2000 x g) for 7 minutes. The 
supernatant was removed and the gametocytes were washed again with 14 ml of  complete 
medium. The pellet was resuspended in 300 µl of  complete medium and combined with 
180 µl packed red blood cells. All media used for washing were prewarmed to 37°C and the 
subsequent preparation of  the blood meal was as described above. For the ‘direct’ mode 
of  the SMFA, 300 µl parasite culture was added to 180 µl red blood cells, centrifuged for 
20 seconds at 10,000 g and the supernatant was carefully aspirated. Meanwhile, 10 µl of  
compound diluted in incomplete medium was added to 490 µl human serum type A (0.1% 
DMSO final). 200 µl of  this human serum/compound mix was added to the gametocyte 
culture pellet, which was subsequently used for the SMFA as described above. For dose 
response analyses, compounds were diluted in DMSO with subsequent dilution in culture 
medium to a final DMSO concentration of  0.1%. Controls included vehicle (0.1% DMSO) 
and DHA at its approximate IC90 (10 µM). For all assay types, unfed and partially fed 
mosquitoes were removed from the cage after feeding, and fed mosquitoes were maintained 
at 26°C, 80% humidity. Mosquitoes were either dissected and examined for midgut oocysts 
on day 6-8 PI as described [64, 65], or processed in the luciferase activity assay on day 8 PI. 
173
Luminescence SMFA for drug screening
6
Mosquito processing and luciferase assay
To enhance flexibility, and to ensure that individual mosquitoes were safely and efficiently 
transferred from feeding cages to 96-well plates for homogenisation, mosquitoes were 
immobilised at day 8 PI and stored at -20 °C in sealed 15ml falcon tubes for at least 24 
hours and up to 2 weeks, before being processed in the luciferase assay. Upon removal 
from storage at -20 °C mosquitoes were thawed and individually added to wells in 
shallow 96-well plates containing 60 µl PBS with Complete protease inhibitor cocktail 
according to the instructions of  the manufacturer (Roche, Switzerland), and 0.2 gram of  
1.0 mm diameter zirconia beads (Lab Services BV). Plates were next placed in a Mini-
Beadbeater-96 (Biospec, Bartlesville, OK) and rocked for 2*15 seconds, with 1-2 minutes on 
ice between rounds of  homogenisation. Based on visual inspection, this procedure achieved 
a homogenate consistency in line with that achievable using a hand-held pestle rotator as 
described previously [15]. For the individual mosquitoes 45 µl of  homogenised material 
was transferred to wells in a Krystal 2000 black & white 96-well plate (Porvair, United 
Kingdom). Next 45 µl of  Bright-Glo luciferase assay substrate (Promega, Madison, WI) 
was added to each well using a Cybi Selma dispensing station (Cybio, Germany) and the 
plate was incubated for 3 minutes at room temperature. Luciferase activity was measured 
using a Synergy 2 multi-purpose plate reader (Biotek, Winooski, VT). Background was 
determined by measuring uninfected mosquitoes that had undergone the same treatment.
pLDH and Pfs25 assays
Assays were performed as described previously [13].
Data analysis
Statistical analysis was conducted using R (Foundation for Statistical Computing, Vienna, 
Austria), STATA 12 (StataCorp., TX, USA) and GraphPad Prism 5.0 (GraphPad Software 
Inc., CA, USA).
All comparisons of  microscopy and luciferase outcomes were conducted with separate 
groups of  mosquitoes for each measure sampled from the same feeds. Comparisons 
between oocyst and luminescence based measures of  mosquito infection prevalence were 
made with Chi-squared tests with Bonferonni correction. Associations between oocyst and 
luminescence intensity were quantified with linear regression. 95% confidence intervals 
around mean luminescence and oocyst intensity data was calculated by bootstrapping (1000 
repetitions). Luminescence and microscopical TRA estimates were made using generalised 
linear mixed models (GLMMs) [35, 66]. For assessment of  infection prevalence, the cut-off  
for RLU based infection positivity was determined arbitrarily as the mean luminescence 
intensity of  all uninfected controls plus five standard deviations (12.7 RLU), as described 
previously [15]. For gametocyte viability and gametogenesis assays, data were expressed as 
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the percentage effect relative to the MIN and MAX controls [13]. For SMFAs, data were 
expressed relative to the negative (vehicle) controls for oocyst density and oocyst prevalence 
(i.e. the proportion of  infected mosquitoes). IC50 values were calculated by applying a four-
parameter logistic regression model using a Maximum Likelihood Estimation algorithm to 
find the best fit. 
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Selected supplementary material
Figure S1. A. Brightfield micrograph of a section of mosquito midgut with 3 oocysts taken after 
mosquito dissection 6 days PI with NF54-HGL. B. Fluoresence micrograph of the same section of 
mosquito midgut with 3 oocysts taken after mosquito dissection 6 days PI with NF54-HGL.
Figure S2. A. Oocyst intensity in individual mosquitoes from two groups of mosquitoes (A and B) 
infected with NF54-HGL, determined after dissection and standard midgut staining and microscopy 
at day 8 PI. B. Luminescence intensity in individual mosquitoes from the same two mosquito groups 
(A and B), assessed in separate mosquito samples removed from the primary mosquito storage cage at 
day 7, 8, 9 and 12 PI. The dashed line indicates the cut-off calculated statistically from the RLU values of 
all mosquitoes assayed in the current study (8.1 RLU). Prevalence estimates were based on this cut-off.
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Figure S3. A. Relative oocyst and luminesence intensity among mosquitoes sampled from the same 
cages fed blood-meals without the addition of a test compound (16 feeds, 480 mosquitoes) or with the 
addition of DHA (16 feeds, 711 mosquitoes). B. Relative infection prevalence based on the observation 
of oocysts or calculated from luminesence intensity, among mosquitoes sampled from the same cages 
fed blood-meals without the addition of a test compound (16 feeds, 480 mosquitoes) or with the 
addition of DHA (16 feeds, 711 mosquitoes).
Figure S4. Efficacy of the washout protocol. The left panel shows the activity of pyrimethamine in 
the indirect SMFA as reported in Figure 2 of the main manuscript. The right panel shows the activity 
in the wash-out mode of the SMFA, where the compound was washed out prior to mosquito feeding.
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Abstract
Mosquito feeding assays are important in evaluations of  malaria transmission-reducing 
interventions. The proportion of  mosquitoes with midgut oocysts is commonly used as an 
outcome measure, but in natural low intensity infections the effect of  oocyst non-rupture 
on mosquito infectivity is unclear. By identifying ruptured as well as intact oocysts, we 
show that in low intensity P. falciparum infections i) 66.7-96.7% of  infected mosquitoes 
experienced oocyst rupture between 11-21 days post-infection, ii) oocyst rupture led 
invariably to sporozoite release, iii) oocyst rupture led to salivary gland infections in 97.8% 
of  mosquitoes, and iv) 1250 (IQR 313-2400) salivary gland sporozoites were found per 
ruptured oocyst. These data show that infectivity can be predicted with reasonable certainty 
from oocyst prevalence in low intensity infections. High throughput methods for detecting 
infection in whole mosquitoes showed that 18s PCR but not circumsporozoite ELISA gave 
a reliable approximation of  mosquito infection rates on day 7 post-infection. 
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Introduction
Malaria transmission-reducing drugs and vaccines are integral elements of  the research 
agenda for malaria eradication [1]. Progression to a stage where these can be evaluated in 
clinical and community trials will be dependent on the ability of  researchers to determine 
the infectivity of  malaria exposed populations to anopheline vectors of  Plasmodium spp. [2, 
3]. This requires mosquito feeding assays (MFA), wherein groups of  mosquitoes are fed 
the blood of  potentially infective individuals and subsequently examined to confirm the 
establishment of  infection. In preparation for trials with transmission reducing interventions 
(TRI), efforts are being made to standardise MFA [4-9]. Because of  the laboriousness of  
MFAs and the necessity of  large numbers of  mosquito observations for precise estimates 
[8], increasing the scalability of  MFA evaluation has been identified as a research priority 
[5, 6].
 The scalability of  MFA is to an important extent defined by the chosen endpoint. 
During sporogonic development, ingested male and female Plasmodium gametocytes 
quickly activate to form gametes in the mosquito gut. Ookinetes develop from the fusing 
of  gametes, and penetrate the midgut wall forming oocysts under the basal lamina of  the 
midgut epithelium. Upon oocyst rupture, sporozoites are released that migrate to mosquito 
salivary glands rendering the mosquito infective. 
 In the context of  public health the most important measure of  TRI efficacy is a reduction 
in the number of  mosquitoes that become infective after feeding on a treated or vaccinated 
individual [2]. Salivary gland invasion can be detected around day 14 post infection (PI). 
In MFA, examining mosquitoes at an earlier time-point has advantages for mosquito 
husbandry, improves the likelihood of  mosquito survivorship until examination, and 
avoids the direct health hazard that infective mosquitoes form for laboratory personnel. 
The presence or intensity of  oocysts observed on mosquito midguts, which for P. falciparum 
can be reliably detected by microscopy as early as day 6 PI [6], is therefore commonly 
used as an operationally attractive outcome measure that may also be amendable for high 
throughput processing by immunological or molecular methods. However, this requires 
that the detection of  any number of  oocysts should reasonably predict their likelihood 
of  causing mosquito infectivity [2]. At high oocyst intensities such as are achieved 
with cultured gametocytes in the standard membrane feeding assay (SMFA) [8-10], the 
progression from oocyst formation to mosquito infectivity is assumed. In MFA on naturally 
infected individuals, oocyst intensities within the range 1 to 5 are commonly observed 
[11-13], and it is currently not fully understood how these low oocyst densities relate to 
later sporozoite development [8]. Experiments that simultaneously detected intact oocysts 
and salivary gland sporozoites or compared oocysts and sporozoites in separate groups 
of  mosquitoes suggest that not all oocysts contribute effectively to mosquito infectivity 
by releasing sporozoites into the haemocoel [14-17]. The impact of  oocyst arrest in low 
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intensity infections might decrease the reliability of  oocyst prevalence as an indicator of  
infectivity because it could lead to the total failure of  sporozoite release.
 To validate the development of  whole-mosquito approaches to infection detection, we 
report the results of  experimental assessments of  the dynamics of  P. falciparum oocyst-
sporozoite development. Using antibody staining techniques we directly determine the 
extent of  oocyst rupture in low intensity mosquito infections and in the same mosquitoes, 
assess the efficiency of  sporozoite production or invasion of  the salivary glands. The 
suitability of  mosquito infection detection by both circumsporozoite protein (CSP) ELISA 
and P. falciparum specific 18s PCR was determined in comparison with routine microscopy
Results
Achieving low oocyst intensity infections
In line with previous observations [8, 18] oocyst prevalence and intensity were highly related 
(Fig. 1). Gametocyte culture material was diluted with uninfected blood to achieve oocyst 
intensities that are in line with the 1-5 oocysts typically observed in natural P. falciparum 
infections. Infection prevalence (measured at day 7 PI) for the separate experiments (n=30-
104) ranged between 33% and 86.5%, with mean oocyst intensities from 0.57 and 4.7. In 
total 1591 mosquitoes were used in the current study (405 A. stephensi, 1186 A. gambiae). 
Overall median oocyst density in infected mosquitoes was 2 oocysts (IQR 1-5, range 1-10).
Measuring oocyst rupture in low intensity infections
To determine the extent of  oocyst rupture in mosquitoes with a low oocyst intensity, intact 
oocysts were detected among sub-groups of  a single cage of  A. stephensi at days 7 (n=20), 
15 (n=20), 17 (n=20), 21 (n=20), 24 (n=20) and 27 (n=20) PI. The prevalence of  intact 
oocysts on days 7, 15, 17, 21, 24 and 27 was 100% (95% CI 96.4-100%), 45% (95% CI 23.1-
68.5%), 25% (95% CI 8.7-49.1%), 25% (95% CI 8.7-49.1%), 40% (95% CI 19.1-63.9%) 
and 20% (95% CI 5.7-43.7%) respectively (see Fig. S1 in the Supplementary information 
online). Four experiments were subsequently conducted using antibody staining to 
identify ruptured as well as intact oocysts (Fig. 2). In the largest two experiments, oocyst 
prevalence and median intensity were first determined in groups of  30 mosquitoes by 
standard mercurochrome staining at day 7 PI, before a total of  a total of  175 mosquitoes 
were dissected for antibody staining at days 14 and 21 PI (Fig. 3). For experiment 1, oocyst 
prevalence at day 7 PI was 43%, and median oocyst intensity in infected mosquitoes was 1 
(IQR 1-2, range 1-5). In experiment 2, oocyst prevalence at day 7 was 80%, while median 
oocyst intensity for infected mosquitoes was 3 (IQR 1-4.3, range 1-10). No significant 
differences were observed in ruptured oocyst prevalence (the proportion of  mosquitoes 
with ≥ 1 ruptured oocyst) or mean intensity between mosquito groups dissected at day 14 
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or 21 PI, indicating that oocyst rupture after day 14 PI was limited. Rupture and oocyst 
prevalence at all time points are given in Fig. 3. In the two smaller experiments (3&4) 
oocyst prevalence and median intensity were first determined in groups of  30 mosquitoes 
by standard mercurochrome staining at day 7 PI and oocyst rupture was subsequently 
determined between 11-16 days PI, reserving the mosquito carcass for assessments 
of  sporozoite intensity. For experiment 3 (n=98), median oocyst intensity in infected 
mosquitoes was 2 (IQR 1-4, range 1-10), oocyst prevalence at day 7 was 80%, and the 
proportion of  oocyst positive mosquitoes with at least one ruptured oocyst was 84.6% 
(66/78, 95% CI 74.7-91.8%). For experiment 4 (n=39), median oocyst intensity in infected 
mosquitoes was 2 (IQR 1-3, range 1-9), oocyst prevalence at day 7 was 77%, and the 
proportion of  oocyst positive mosquitoes with at least one ruptured oocyst was 96.7% 
(29/30, 95% CI 82.8-99.9%). The prevalence of  oocyst rupture within oocyst positive 
mosquitoes for experiments 1-4 is shown as Supplementary Fig. S2 online. 
Figure 1. Oocyst prevalence and intensity for experimental feeds utilising the NF54 P. falciparum 
strain conducted in the mosquito infectivity unit at RUMC, Nijmegen between 2011 and 2013. 
Each data point represents the mean oocyst intensity and oocyst prevalence in a single group of 
mosquitoes. Criteria for inclusion in these figures were sample size (>10 mosquitoes), parasite strain 
(NF54 strain only) and mosquito species. Data were collected from both experimental and control 
feeds between 6 and 9 days PI. In total 1323 separate experimental feeds comprising 21240 mosquito 
dissections are shown (1233 experimental feeds with A.  stephensi, 90 experimental feeds with 
A. gambiae).
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Taken together, our results show that in mosquitoes where the majority of  infections 
stemmed from 1-3 oocysts, 72% (390/542) of  all oocysts had undergone rupture at 
the time of  observation, while 66.7-96.7% of  infected mosquitoes had at least one 
ruptured oocyst. 
 To examine the efficiency of  sporozoite production and invasion of  the salivary 
glands, groups of  mosquitoes were examined for the detection of  ruptured oocysts and 
quantification of  sporozoites within the mosquito body (excluding the gut) (Fig. 4a) and 
the salivary glands (Fig. 4b). In mosquitoes in which sporozoites were detected in the 
body, a positive correlation between ruptured oocyst number and sporozoite intensity 
was observed (R2=0.61, p<0.0001). Furthermore, all mosquitoes with detectable oocyst 
rupture were sporozoite positive, indicating that rupture will always result in a release 
of  sporozoites into the mosquito haemocoel. In a single mosquito sporozoites were 
detected while no ruptured oocysts were detected by microscopy. It is probable in this 
instance that a ruptured oocyst was mistakenly identified as being intact. Considering all 
mosquitoes with ruptured oocysts, sporozoite intensity in the mosquito body ranged from 
100-44600. Median production was 2000 sporozoites/ruptured oocyst (inter-quartile 
range (IQR) 950-3500). When considering only those cases where a single oocyst was 
found to have ruptured, the median number of  sporozoites observed per oocyst was 2100 
(IQR 1000-3750).
Sporozoite production and invasion of the salivary glands are uniformly 
effective in mosquitoes with low oocyst intensities
To investigate the efficiency of  sporozoite production from ruptured oocysts, the (qualitative) 
presence of  sporozoites released into the haemocoel was determined both by microscopy 
after antibody staining and by PCR in mosquitoes which had undergone midgut dissection 
for oocyst detection. By removing the mosquito midgut for oocyst detection, sporozoite 
detection was restricted to those released from the midgut into the mosquito body. 
Sporozoites were detected in all rupture positive mosquitoes by both microscopy and PCR 
(85/85). No sporozoites were detected in mosquitoes without evidence of  rupture (0/17).
Among the 66 mosquitoes which underwent salivary gland dissection, 45 out of  46 rupture 
positive mosquitoes were also gland positive (97.8%, 95% CI = 88.6-99.9%) (Fig. 4b). In 
another mosquito, 320 sporozoites were found while no ruptured oocysts were detected. 
The relationship between the intensity of  ruptured oocysts and sporozoite intensity in 
the salivary glands was positive, but as for sporozoites in the mosquito body, not clearly 
linear (R2=0.34, p<0.0001). Salivary gland sporozoite intensity ranged from 78-26600. The 
median number of  sporozoites in the glands was 1250 per oocyst (IQR 313-2400). For single 
ruptured oocysts only median sporozoite intensity per oocyst was 1000 (IQR 256.5-2450).
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Figure 2. Classification of oocyst condition. Mosquito midguts were dissected in phosphate buffered 
saline (PBS) and stained using 3SP2-Alexa488 anti-CSP antibodies. After staining, midguts were washed 
twice with PBS for 10 minutes before being sealed under a glass cover slip with Vaseline petroleum jelly. 
All oocysts were identified and assigned a condition by two independent microscopists. Intact oocysts 
were visibly unbroken. Ruptured oocysts and oocyst remnants were visibly broken or degraded. All 
samples were examined within 8 hours of dissection, but sample condition remained stable for a 
number of days (stored at 4°C) prior to dissection for re-examination. Three ruptured and three intact 
oocysts are shown in the figure for demonstrative purposes.
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Oocysts Frequency
0 72
1 39
2 10
3 3
4 0
5 1
Total 125
 
Figure 3. Total oocyst prevalence and prevalence of oocyst rupture. n/N = oocyst positive 
mosquitoes/total number of mosquitoes dissected. Prevalence of oocyst rupture is given as the 
proportion of mosquitoes in which any oocysts were observed to have undergone rupture. Tables 
indicate the range and frequency of oocyst intensities observed in experiment 1 and 2. In experiment 
1, 16/22 (72.7%, 95% CI = 49.8-89.3%) infected mosquitoes had at least one ruptured oocyst at day 14 
PI, while 12/18 (66.7%, 95% CI= 41-86.7%) were rupture positive at day 21 PI. In experiment 2, 30/32 
(93.8%, 95% CI 79.2-99.2%) infected mosquitoes were rupture positive at day 14 PI, while 27/30 (90%, 
95% CI = 73.5-97.9%) were rupture positive at day 21 PI. 
Oocysts Frequency
0 24
1 22
2 21
3 19
4 12
5 6
6 2
7 1
8 2
10 1
Total 110
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Figure 4. The number of sporozoites in the mosquito body or salivary glands, and ruptured 
oocyst intensity in the same mosquitoes. The detection limit for sporozoites detected in a single 
mosquito sample was 78 sporozoites (1 sporozoite observed in 64 Bürker chamber fields / 0.256µl 
homogenate). The Y-axis is split from 1-3000 sporozoites and from 3000-50,000 sporozoites because of 
the heterogeneous distribution of sporozoites within mosquitoes. Data points in red indicate erroneous 
observations (sporozoite +, rupture – or vice versa). A. Y-axis: Sporozoite total calculated from duplicate 
samples of whole homogenised mosquito (excluding gut) stained with 3SP2-Alexa488 conjugate 
antibodies. X-axis: Ruptured oocyst intensity. Median oocyst intensity in infected mosquitoes was 2 
(IQR 1-4, range 1-10). The data point in red is a single mosquito for which 1500 sporozoites were found 
associated with no ruptured oocysts. B. Y-axis: Sporozoite total calculated from duplicate samples of 
homogenised 3SP2-Alexa488 stained salivary glands only. X-axis: Ruptured oocyst intensity. Median 
oocyst intensity in infected mosquitoes was 2 (IQR 1-3, range 1-9). The data points in red are a mosquito 
in which 320 sporozoites were found associated with no ruptured oocysts, and a mosquito in which a 
single ruptured oocyst was found associated with no sporozoites. 
The application of oocyst prevalence as a high throughput read-out 
system
Having demonstrated that at the lowest levels of  oocyst intensity oocyst rupture and 
sporozoite release occurs in the majority of  mosquitoes, we sought to determine the 
utility of  high throughput techniques for the detection of  any mosquito infection at time 
points after which oocyst development may have occurred. Nine experimental feeds were 
conducted. At day 7 PI, 30 mosquitoes were dissected as standard for oocyst detection. 
Separate groups of  mosquitoes were then taken from the same cages at days 7, 10 and 14 PI 
for individual homogenisation. Mosquito homogenate was processed by both CSP ELISA 
and 18s PCR (Table 1). Full details of  these experiments are given in Supplementary Table 
S1 online. In total 796 mosquitoes were tested by both CSP ELISA and 18s PCR. When 
compared to microscopy, ELISA underestimated mosquito infection rates in 100.0% (8/8) 
of  experiments when ELISA was performed on day 7 and in 11.1% (1/9) of  experiments 
when ELISA was performed on day 10. When ELISA was performed on day 14, there 
was no underestimation of  infection rates compared to microscopy and 22.2% (2/9) of  
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experiments had higher mosquito infection estimates by ELISA compared to microscopy 
(Table 1). By contrast, mosquito infection prevalence at day 7 determined by 18s PCR 
and microscopy did not significantly differ in any of  the 8 experiments (experiment 8, 
p=0.054), while at day 10 and 14 PI PCR prevalence was significantly higher than 
microscopy prevalence in 1 and 2 experiments respectively. In the two day 14 experiments 
where prevalence was higher by both ELISA and 18s PCR than by microscopy, differences 
in paired ELISA and PCR measures were non-significant or borderline significant (Day 14 
Experiment 7, p=0.046; Day 14, Experiment 8 p=0.317).
 Relative to positivity by PCR, the sensitivity of  CSP ELISA for the detection of  
P. falciparum in whole homogenised mosquitoes increased from 6.8% at day 7 PI to 61.7% 
at day 10, and 86.7% at day 14 PI. 28/796 mosquitoes (3.5%) were determined as positive 
for CSP but negative for P. falciparum by PCR. ELISA OD values for these mosquitoes 
varied widely above the cut off  for positivity of  OD 0.12 (median OD (IQR) = 0.336 (0.14-
0.91). Of  the 256 mosquitoes determined negative by ELISA but positive by PCR (32.2% of  
total), 64.1% (164/256) were mosquitoes collected on day 7 PI, and 28.5% (73/256) were 
collected at day 10 PI. Agreement values between ELISA and PCR were 40.0% at day 7 
PI (Kappa 0.02, p=0.15), 71.2% at day 10 PI (Kappa 0.45, p>0.0001) and 85.3% at day 14 
PI (Kappa 0.69, p>0.0001). Between paired measures positivity rates by PCR and ELISA 
were significantly different at day 7 (p<0.0001) and 10 PI (p<0.0001) but not at day 14 PI 
(p=0.49). 
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Discussion
The proportion of  mosquitoes that become infective is the most relevant outcome measure 
for assessments of  the human infectious reservoir for malaria and for evaluating the impact 
of  transmission reducing interventions on human infectivity. If  the extent of  oocyst non-
rupture in mosquitoes with low oocyst intensities is not prohibitively high, and if  sporozoite 
release and invasion of  the salivary glands is effective, then the detection of  oocysts, 
regardless of  their density, provides an acceptable estimate of  mosquito infectivity for high 
throughput assessment. In this study we show that the majority of  low density infections 
result in oocyst rupture, sporozoite release and colonisation of  the mosquito salivary glands. 
We further show that PCR but not CSP ELISA may replace microscopy without a loss in 
sensitivity when examining mosquitoes on day 7 post infection.
 The first aim of  the current study was to establish the usefulness of  oocyst prevalence as 
a stand-alone indicator of  infectivity for the evaluation of  MFA. The transition from oocyst 
formation to sporozoite transmission to humans was recently highlighted by Churcher et 
al. as a major gap in our current understanding and limitation to the to the evaluation of  
TRI [8]. The valuable few studies which have investigated the dynamics of  late sporogony 
are summarised by Vaughn et al. [17]. A common observation among these studies is the 
presence of  intact oocysts when most others have ruptured [14-16]. Rates of  oocyst arrest 
have only been recorded in detail for P. vivax by Zollner et al., who estimated that sporozoite 
production reached only 11% of  its theoretical potential by day 18 PI, due to sub-optimal 
productivity by some oocysts or their total failure to release sporozoites [15]. Though non-
rupture of  a proportion of  oocysts is not necessarily relevant where oocyst intensity is high, 
its occurrence in low intensity infections may significantly affect the accuracy of  infectivity 
estimates based on oocyst prevalence alone. By visualising ruptured oocysts, we provide 
direct evidence that in low density infections (median oocysts in infected mosquitoes = 2, 
IQR 1-5) rupture occurs in the majority of  P. falciparum infections. Combining the results of  
4 independent experiments, 85.7% (180/210) of  mosquitoes with low density infections had 
at least one ruptured oocyst when measured between 11-21 days post infection. Our data 
support previous estimates of  the efficiency of  sporozoite production and salivary gland 
invasion by directly relating these measures to the intensity of  oocyst rupture measured in 
the same mosquitoes, showing that infectivity after sporozoite release is almost uniformly 
effective. Following oocyst rupture, sporozoite production appears to be highly effective; 
204 of  the 205 mosquito’s containing ruptured oocysts were also sporozoite positive outside 
the midgut. In the current study, gland invasion was achieved in 45/46 mosquitoes with 
evidence of  oocyst rupture. The one instance where rupture was detected and salivary gland 
sporozoites were not may have arisen because sporozoites from this oocyst may not have 
successfully reached the salivary glands [14, 16], or because rupture occurred so close to the 
time of  dissection that haemocoel traversal was ongoing [19, 20].
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Previous estimates of  the productivity of  Plasmodium oocysts have been restricted either 
because estimates were carried out artificially (excising oocysts from midguts and counting 
the sporozoites within) [21, 22], or because they were based on the observation of  intact 
oocysts without consideration of  the proportion which might fail to rupture [14-16, 23]. In 
the current study, our direct approach to oocyst quantification and classification allowed 
for more precise estimates of  per capita potential and effective sporozoite production. 
For each ruptured oocyst a mean of  2000 sporozoites were found in the mosquito body 
while 1250 were observed in the salivary glands, suggesting that the efficiency of  gland 
invasion is ~60% of  the total number of  sporozoites released. Had oocysts been considered 
irrespective of  their condition, per oocyst sporozoite numbers would have been reduced 
by approximately 28%, to 1440 in the body and 900 in the salivary glands (72% of  all 
oocysts that were observed on mosquito midguts ruptured). Encouragingly, these estimates 
very closely match previous observations in the same species combination (1361 salivary 
gland sporozoites per oocyst, based on data from 33 mosquitoes) [23]. The results of  the 
current study indicate that though the overall efficiency of  sporozoite production, release 
and traversal may be relatively low, the effectiveness is nonetheless extremely high with 
the vast majority of  oocyst-positive mosquitoes eventually becoming sporozoites positive. 
There is no obvious bottleneck preventing the establishment of  salivary gland invasion 
where they are released. 
 As oocyst intensities in the current study were manipulated to exist over a very narrow 
range (>80% 1-3 oocysts, range 1-10), analysis of  the relationship between rupture rates 
and oocyst intensity was not possible. Though it is likely that at high oocyst intensities 
competition for nutrients may inhibit rates of  oocyst maturation and rupture [15, 24, 25], 
we consider it unlikely over the range of  oocyst intensities observed in the current study 
that rupture rates would have decreased significantly with oocyst intensity, especially since 
a second bloodmeal was given to increase availability of  nutrients and better mimic natural 
mosquito feeding frequencies. 
 For evaluations where mosquito infections levels are naturally low, such as for studies 
that aim to determine the human infectious reservoir for malaria or determine the impact 
of  transmission reducing interventions for which the mode of  action is before oocyst 
formation (e.g. gametocytocidal drugs or pre-fertilization and anti-ookinete transmission-
blocking vaccines), we consider oocyst prevalence a reliable, albeit not perfect, indicator of  
mosquito infectiveness. Since the majority of  oocyst positive mosquitoes had at least one 
ruptured oocyst from which sporozoites reached the salivary gland, and as the number of  
sporozoites egested during probing (<100) is considerably less than the number produced 
by single oocysts (1,359-14,000) [21, 22, 26-28] and independent of  total salivary gland 
sporozoite intensity [28], we consider it plausible that infectivity can be predicted with 
reasonable certainty from oocyst prevalence. The modest overestimation of  infectivity 
that is a consequence of  some oocysts not rupturing in low density infections would 
194
be acceptable for the evaluation of  programs aiming to interrupt parasite transmission. 
However, this overestimation may require consideration in studies where direct effects on 
sporozoite development or invasion of  the salivary glands may be responsible for variations 
in the proportion of  mosquitoes that are sporozoite-positive [29].
 Using oocyst prevalence as the sole outcome measure for mosquito feeding assays has 
advantages in terms of  mosquito husbandry, the number of  mosquitoes surviving long 
enough to contribute to read out measures and laboratory safety. As such, the results of  
the current study open the way for the replacement of  microscopy with high throughput 
techniques for oocyst detection to allow for the large number of  mosquito observations 
needed to reliably estimate TRI efficacy [8]. We explored two scalable options: CSP-ELISA 
and 18s PCR. PCR and ELISA have previously been used for the detection of  midgut 
oocysts [24, 30] or salivary gland sporozoites [31-34] in dissected colony and wild caught 
mosquitoes. In the current study, the same homogenate from undissected mosquitoes was 
used for both PCR and CSP-ELISA. CSP-ELISA underestimated mosquito infection rates 
compared to microscopy and PCR, especially at day 7 PI when sporozoite production 
and antigen release from oocysts may have been limited [19]. Several approaches were 
explored for mosquito homogenisation and maximization of  CSP release from midgut 
oocysts including sonication, rapid freeze-thaw cycling, and preparation with various 
detergents. None of  these approaches solved the apparent lack of  CSP release from PCR-
detectable oocysts (data not shown) that precludes the use of  CSP-ELISA as read-out for 
mosquito feeding assays before day 10 PI. In contrast, 18s PCR showed good agreement 
with microscopical oocyst prevalence at all time points. Where statistical differences in 
prevalence were observed these were because of  higher prevalence by PCR, suggesting that 
microscopy may have missed a small number of  (low density) infections. Day 14 CSP-
ELISA results supported PCR estimates in experiments where PCR infection prevalence 
was higher than microscopy prevalence, suggesting that differences in oocyst prevalence 
between samples may also have affected these outcomes. The earliest time point at which 
the whole-mosquito approach to oocyst detection can be applied depends upon the rate 
at which non-established parasites are cleared from the digestive tract of  mosquitoes 
following the infective blood meal. Bell and Ranford-Cartwright estimated using PCR 
based on the amplification of  the MSA-1 gene that Plasmodium DNA can no longer be 
detected in the mosquito body ≥5 days PI [24]. Using the current technique, this creates a 
boundary at 5 days PI after which any Plasmodium in mosquitoes represents an established 
infection. Ookinete specific markers could bring forward this boundary, but to establish the 
utility of  such markers the efficiency of  ookinete-oocyst transition would require further 
investigation; current estimates indicate that in Plasmodium species affecting humans 
population loss during the ookinete-oocyst transition may be between 50-75% [17].
 The results of  the current study validate the use of  oocyst prevalence as an indicator 
of  infectivity. Sensitive PCR based approaches to the detection of  mosquito infection 
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at time points after oocyst formation are capable of  replicating the results of  standard 
microscopical oocyst prevalence assessments.
Methods
Mosquito infections
i) Mosquito rearing and parasite culture
Anopheles stephensi (Sind-Kasur Nijmegen strain) [35] and A. gambiae (Ngousso strain) [36] 
were reared at 30oC and 70-80% humidity, while exposed to a 12/12 hour day/night cycle. 
Direct comparisons of  SMFA experiments using A. stephensi and A. gambiae observed no 
differences between mosquito species in the association between oocyst prevalence and 
oocyst density or estimates of  transmission reduction of  transmission-blocking monoclonal 
antibodies or field sera (Eldering et al., in preparation). For the current experiments, A. 
stephensi mosquitoes were used for all experiments on sporogonic development. The 
experiments on high-throughput assessment of  infected mosquitoes by PCR or ELISA 
used A. gambiae mosquitoes to allow a direct comparison with field-based mosquito feeding 
assays. Mature P. falciparum (NF54) gametocytes (14 day culture, 0.3-0.5% gametocytes, 2% 
haematocrit) were obtained from an automated tipper system and prepared as previously 
described [37, 38]. To achieve low intensity infections for examinations of  oocyst condition 
and sporozoite production, infective blood meals that are routinely used and produce high 
infection prevalence (averaging >70% with oocyst intensities in infected mosquitoes >10) 
were diluted at a ratio of  1:10 with uninfected blood. Dilutions between 1:5 and 1:20 
were used for comparisons of  microscopy, ELISA and PCR for the detection of  infection 
among groups of  mosquitoes, where we aimed for a range of  infection intensities (see 
Supplementary Table S1 online).
ii) Mosquito feeding and dissections
3-5 day old A. stephensi mosquitoes were fed on a glass membrane midi-feeder system 
containing ~1.25ml of  the P. falciparum culture mix [37, 38]. Unfed and partially fed 
mosquitoes were removed after feeding and blood fed females were maintained at 26oC 
and 70-80% humidity. For examinations of  oocyst condition and sporozoite production, 
mosquitoes received an additional uninfected human blood meal between 7 and 10 days PI 
[39]. Routine staining of  midguts was done in 1% mercurochrome. 
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Immunostaining experiments
i) Oocyst prevalence, rupture and sporozoite prevalence at different 
time-points post-infection
To examine oocyst condition and sporozoite prevalence at different time-points PI, the 
midguts of  30 A. stephensi mosquitoes were removed at day 7 PI, stained with mercurochrome, 
and microscopically examined for oocysts prior to rupture. At both days 14 and 21 PI, two 
groups of  mosquitoes were dissected (175 observations total) for oocyst and sporozoite 
examination by antibody staining, ensuring that in each of  the four replicates approximately 
20 positive mosquitoes were examined. At these later time-points midguts were dissected in 
20µl phosphate buffered saline (PBS, pH 7.2), transferred to a fresh drop of  PBS and stained 
using 3SP2-Alexa488 anti-CSP antibodies (1:400) for 30 minutes at room temperature (RT) 
in a humid container. Details of  the 3SP2 antibodies used for oocyst/sporozoite staining 
and CSP ELISA (produced in Nijmegen, Netherlands) have been previously described [28, 
40]. After staining, midguts were washed twice with PBS for 10 minutes before being sealed 
under a glass cover slip with Vaseline petroleum jelly (Unilever, UK). During all dissection 
and washing steps care was taken to avoid artificial oocyst rupture. Intact/degenerated and 
ruptured oocysts were counted using an incident light fluorescence microscope. Mosquito 
carcasses and the PBS from the first dissection step were homogenised in glass grinding 
tubes with 180µl of  PBS. Two lots of  15µl of  homogenate were transferred to a glass slide, 
incubated with 5µl of  3SP2-Alexa488 conjugate (1:400), and left for 30 minutes at RT in 
a humid container. After staining, cover slips were applied with Vaseline and sporozoite 
positivity was determined by examining 50 fields for each sample (100 fields per mosquito) 
using an incident light fluorescence microscope. 
ii) The number of sporozoites released by ruptured oocysts 
To estimate the contribution of  ruptured oocysts to sporozoite intensity in the whole 
mosquito body, the midguts of  98 A. stephensi mosquitoes were dissected and stained 
between days 11-14 PI using 3SP2-Alexa488 antibodies as described above. Mosquitoes 
were collected across four feeding experiments, in which mosquito homogenate was 
transferred to counting chambers (Bürker, Labor Optik, UK) and allowed to settle for 20 
minutes in a humid container before quantification was conducted using an incident light 
fluorescence microscope. 
iii) The number of sporozoites invading the salivary glands following 
oocyst rupture 
To determine the association between oocyst rupture and mosquito infectivity, the midguts 
and salivary glands of  66 A. stephensi mosquitoes were carefully dissected between days 
12-16 PI. Mosquitoes were collected across two feeding experiments. Salivary glands were 
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removed from the mosquito carcass and homogenised in glass grinding tubes with 20µl 
of  3SP2-Alexa488 conjugate (1:400). Sporozoite quantification was then conducted as 
described for body sporozoites. 
High throughput mosquito processing and infection detection
i) Mosquito processing and experimental design
Nine cages of  approximately 160 A. gambiae mosquitoes were infected as described above 
for investigation of  the comparative efficacy of  microscopy, ELISA and PCR in detecting 
mosquito infection prevalence. Alongside standard dissections carried out on a sample of  
mosquitoes at day 7 PI, CSP-ELISA and PCR were performed on each mosquito in groups 
collected from each cage at day 7, 10 and 14 PI. Details of  sample sizes (n=10-44) are in 
Table 1, and full details of  all results are in Supplementary Table S1 online.
ii) CSP-ELISA
CSP ELISA was performed as previously described, with minor modifications [41]. 
Mosquitoes were homogenised in 250ml phosphate buffered saline (PBS pH 7.2) solution 
with 1% sarcosil. Sterilin ELISA plates were coated with 3SP2 (Nijmegen, Netherlands) 
at 5µg/ml, diluted in PBS. Homogenate of  test mosquitoes were analysed in duplicate, 
alongside blank wells (just sample diluent) and a standard curve of  recombinant CSP 
(Gennova, 0.1 µl/ml). A selection of  homogenates from 30 uninfected blood-fed control 
mosquitoes were tested on every plate, so that each sample was tested at least 5 times over 
the course of  the experiment. A cut off  for CSP positivity was determined at an optical 
density (OD) of  0.12, which was the mean OD of  the uninfected mosquitoes plus three 
standard deviations. 
iii) DNA extraction and 18s PCR
Phenol-chloroform DNA extractions were carried out on the 150µl of  mosquito homogenate 
remaining from CSP ELISA as described previously, with minor modifications (23). Briefly, 
Proteinase K was added to each sample of  mosquito homogenate at 20mg/ml, and samples 
were incubated overnight at 55°C. After incubation, samples were briefly spun down and 
a Phenol/Chloroform/Isoamyl alcohol (25:24:1) mix was added to each sample at a ratio 
of  1:1. Samples were mixed vigorously and centrifuged at 10,000g for five minutes. After 
spinning, the aqueous layer was mixed with 250µl of  Isopropanol, and 100 µl of  a mix 
of  3M Sodium Acetate (pH 5.2), Glycogen (10mg/ml), and nuclease free water. Samples 
were then mixed repeatedly during a 15 minute incubation at RT, before centrifugation 
at 13,000g for 30 minutes at 4°C. Supernatant was removed, washed with 1ml of  70% 
Ethanol, and spun again for 5 minutes at 4°C. Ethanol was then removed, and the pellet 
dried and suspended in 20µl of  nuclease free water.
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PCR targeting the small sub-unit ribosomal RNA (ssrRNA) gene of P. falciparum was 
performed as previously described, with minor modifications (24). The volume of  DNA 
used in the nest 1 reaction was increased from 1µl to 5µl, and the volume of  nest 1 template 
used in the nest 2 PCR was adjusted to 2µl. For a more detailed overview of  primer 
sequences, controls and PCR cycling conditions see Baidjoe et al. 2013[42]. N1 and N2 
products were mixed and 10µl was visualized on 1.5% agarose gel by electrophoresis in 
0.5X Tris-acetate-EDTA buffer (0.04 M Tris-acetate and 1 mM EDTA, pH 8.0).
Data analysis
Statistical analysis was conducted using STATA 12 (StataCorp., TX, USA) and GraphPad 
Prism 5.0 (GraphPad Software Inc., CA, USA). In the analyses of  oocyst prevalence and 
condition, and between groups of  mosquitoes analysed by dissection and PCR or ELISA, 
differences in prevalence between groups were tested by Chi-squared test. Differences 
between paired PCR and ELISA positivity values were tested by McNemars’ Chi Square 
test. For agreement between PCR and ELISA carried out on the same mosquitoes, 
sensitivity, specificity, agreement and kappa values were presented using PCR for reference. 
Associations between ruptured oocyst intensity and sporozoite intensity were quantified 
with Spearmans correlation coefficients. Per capita sporozoite production (for both whole 
mosquito and salivary gland specific estimates) was presented as the mean of  the sporozoite 
production per mosquito divided by the number of  ruptured oocysts observed within the 
same mosquito. 
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Selected supplementary material
Figure S1. The prevalence of midgut oocysts in mosquito groups from the same experimental 
feed examined by standard dissection between days 7 and 27 PI. Oocyst prevalence was 
determined by microscopical examination of mercurochrome stained midguts at all time points (n=20 
per time point, n=120 in total). Typically 10-15 mosquitoes per group are dissected as an immediate 
measure of oocyst prevalence and mean intensity during the SMFA. Oocysts identified here are likely to 
have been intact, though the possibility that some may have undergone various degrees of rupture or 
degradation cannot be excluded. Error bars represent 95% confidence intervals (CI). On day 7, median 
oocyst intensity was 2 (IQR 1-2, range 1-6).
200
Figure S2. The prevalence of oocyst rupture in infected mosquitoes. Prevalence of oocyst rupture is 
given as the proportion of mosquitoes in which any oocysts were observed to have undergone rupture. 
Prevalence of intact oocysts is given as the proportion of mosquitoes in which only intact or degenerated 
oocysts were observed. All oocyst examination time-points have been combined within experiments, 
so that experiments 1 and 2 represent the prevalence of oocyst rupture in mosquitoes examined on 
day 14 and 21 PI, and experiment 3 and 4 the prevalence of oocyst rupture in mosquitoes examined 
between 11 and 16 days PI. Details of sample numbers are in the text, and in the legend for Fig. 3. Total 
prevalence of oocyst rupture was 70% (95% CI 53.5-83.4%) in experiment 1, and 91.9% (95% CI 82.2-
97.3%) in experiment 2. 
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Abstract
Background
The infectivity of  Plasmodium gametocytes is typically determined by microscopically 
examining the midguts of  mosquitoes that have taken a blood meal containing potentially 
infectious parasites. Such assessments are required for the development and evaluation 
of  transmission-reducing interventions (TRI) but are limited by subjectivity, technical 
complexity and throughput. The detection of  circumsporozoite protein (CSP) by enzyme-
linked immunosorbent assay (ELISA) and enhanced chemiluminescent slot-blot (ECL-
SB) may be used as objective, scalable alternatives to microscopy for the determination of  
infection prevalence. 
Methods 
To compare the performance of  the CSP ELISA and ECL-SB for the detection of  mosquito 
infection, four groups of  Anopheles stephensi mosquitoes were infected with cultured 
Plasmodium falciparum gametocytes. At day-8, post-infection (PI) parasite status was 
determined by microscopy for a sample of  mosquitoes from each group. At days 8 and 10 
PI, the parasite status of  separate mosquito samples was analysed by both CSP ELISA and 
ECL-SB.
Results 
When mosquito samples were analysed eight days PI, the ECL-SB determined similar 
infection prevalence to microscopy; CSP ELISA lacked the sensitivity to detect CSP in all 
infected mosquitoes at this early time point. When mosquitoes were analysed 48 hours later 
(ten days PI) both assays performed as well as microscopy for infection detection. 
Conclusions
Whilst microscopical examination of  mosquito guts is of  great value when quantification 
of  parasite burden is required, ECL-SB and CSP ELISA are suitable alternatives at day 10 
PI when infection prevalence is the desired endpoint, although CSP ELISA is not suitable 
at day 8 PI. These results are important to groups considering large-scale implementation 
of  TRI. 
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Background
Transmission-reducing interventions (TRIs) that specifically aim to interrupt the 
transmission of  malaria from man to mosquito form important components of  malaria 
control and elimination strategies [1, 2]. The development, targeting and evaluation of  TRIs 
requires robust assessments of  the infectivity of  human malaria infections to mosquitoes 
[3, 4]. Mosquito infection status is typically determined by microscopy following the 
observation of  Plasmodium oocysts in the midgut or sporozoites in the salivary glands [5, 
6]. Oocysts develop on the basal lamina of  the mosquito midgut approximately two days 
after the ingestion of  a blood meal containing infectious gametocytes, and can be visually 
detected by microscopy approximately six days post infection (PI) [5]. Sporozoites develop 
from the budding of  sporoblasts in the developing oocyst, which give rise to hundreds or 
thousands of  sporozoites in an explosive population expansion that starts seven to eight 
days PI [7, 8]. Beyond ten days PI, sporozoites rupture the oocyst capsule and enter the 
haemolymph, beginning their migration to the mosquito salivary glands [7, 9]. Within 8 
hours of  their release, sporozoites must invade the salivary glands or else be broken down 
in the mosquito haemolymph [10]. Sporozoites that succeed in entering the salivary glands 
are detectable from about 11 days PI, and the number in the glands appears to plateau after 
approximately 14 days PI [11] where they remain viable for long periods [12, 13]. Because 
of  this stability and because very few sporozoites are egested during blood feeding [14, 15] 
it is generally accepted that a mosquito with any number of  salivary gland sporozoites is 
infective to humans. 
 The goal of  TRIs is to reduce the proportion of  mosquitoes becoming infectious after 
taking a blood meal on vaccinated or treated individuals [16]. A recent study showed 
that eventual infectivity can be predicted with reasonable certainty from the detection 
of  maturing oocysts in low-intensity infections [11]. With highly trained technicians, 
mosquito dissections can be performed quickly; however, the ability to properly identify 
and quantify developing oocysts is a specialized skill that requires long periods of  training. 
Furthermore, the necessity to screen individual midguts during a limited time-window PI 
limits the throughput of  mosquito feeding assays. It is highly desirable that the endpoint 
for efficacy assessments of  TRIs be unambiguous, flexible with regard to the timing of  
mosquito processing, and usable by non-specialized staff. Screening mosquitoes for oocyst 
stage infections by high throughput immunological or molecular tools may provide an 
alternative to microscopy for processing large volumes of  mosquitoes.
 Circumsporozoite protein (CSP) is a ∼60kD glycosylphosphatidyl-inositol (GPI)-
anchored sporozoite, surface-coat protein with roles in parasite development in oocysts 
[17], traversal of  the haemocoel [18], recognition and binding to the salivary glands [19, 
20], protection after egestion into the human microvasculature [18], and invasion of  human 
hepatocytes [21, 22]. In the mosquito, CSP is abundantly expressed by the developing parasite 
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[23], making the protein an ideal target for immuno-assays. The colorimetric enzyme-
linked immunosorbent assay (ELISA) is commonly used for the detection of  Plasmodium 
CSP in wild-caught mosquitoes [6, 24–26], where salivary gland infection (measured by 
homogenization of  the head or head and thorax) has generally been the endpoint of  interest. 
A positive ELISA test result indicates that mosquitoes ingested infectious parasites more 
than 11 days prior to assessment. If  the ELISA is performed at seven days PI, when oocysts 
are visible by microscopy, CSP expression by developing oocysts is too low for detection 
[11]. The enhanced chemi-luminescent ELISA (ECL ELISA) and slot-blot assays (ECL-SB) 
were designed to overcome these issues of  sensitivity, and are capable of  detecting as little as 
4.4 pg and 1 pg of  recombinant CSP, respectively [27, 28], which could allow for Plasmodium 
detection shortly after the onset of  CSP production during oocyst development.
 Here, two immunoassays, the CSP ELISA and ECL-SB, were evaluated for their ability 
to detect CSP in mosquito homogenates processed from whole mosquito carcasses, by 
comparison to mosquito samples analysed by standard dissection and oocyst enumeration. 
Gametocyte cultures were diluted to ensure parasite burden in test mosquitoes was close to 
the level of  Plasmodium-infected vectors from endemic regions [29, 30], providing groups of  
mosquitoes with controlled, but varying infection prevalence to investigate the performance 
of  the two assays relative to microscopy for the detection of  oocyst-stage infections. Since 
CSP expression increases during oocyst maturation [27, 31], the sensitivity of  the assays 
in longer term infected mosquito specimens that contain a higher amount of  CSP was also 
examined. 
Methods
Infection of Anopheles stephensi mosquitoes with Plasmodium 
falciparum parasites
i) Mosquito rearing: Anopheles stephensi (Sind-Kasur Nijmegen strain) [32] were reared at 30oC 
and 70-80% humidity, while exposed to a 12/12 hour day/night cycle. 
 ii) Parasite culture: Mature Plasmodium falciparum (NF54) gametocytes (14-day culture, 
0.3-0.5% gametocytes, 2% haematocrit) were obtained from an automated tipper system 
and prepared as previously described [33, 34]. To achieve low-intensity infections, infective 
blood meals that are routinely used and produce high infection prevalence (averaging >70% 
with mean oocyst intensities in infected mosquitoes >10) were diluted at a ratio of  1:10 
with uninfected blood.
 iii) Mosquito feeding assays: Four separate batches of  gametocyte material were each fed 
to multiple cages of  mosquitoes (10 cages total). For each cage, approximately 150 three- 
to five-days old Anopheles stephensi mosquitoes were fed on a glass membrane midi-feeder 
system containing ~1.25 ml of  the P. falciparum culture mix [33, 34]. Unfed and partially 
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fed mosquitoes were removed after feeding and blood-fed females were maintained at 26oC 
and 70-80% humidity. 
 iv) Experimental design: After infection, mosquitoes were combined to have four large 
batches of  mosquitoes that allowed examination by microscopy, CSP ELISA and ECL-SB. 
At day 8 PI, 20-30 mosquitoes per batch were examined for oocysts by microscopy. At days 
8 and 10 PI, 36-48 mosquitoes per batch were stored at -20°C in sealed containers until 
analysis by CSP ELISA and ECL-SB. Sample sizes for the two assays were maximised 
based on the availability of  live mosquitoes at the two time points and were kept uniform 
between the two assays. Leftover mosquitoes were killed and discarded. Full details of  
mosquito sample sizes for all assays and groups are in Table 1. 
Microscopy
Routine staining of  midguts for oocyst detection was done in 1% mercurochrome, as 
described previously [11, 33]. All oocyst detection was performed once by expert staff  at 
Radboud UMC, Nijmegen, The Netherlands.
ECL slot-blot
i) Preparation of  whole mosquito homogenates: CSP expression on the developing oocysts was 
determined in lysed whole mosquitoes using a procedure described previously [27]. Briefly, 
individual blood-fed or unfed mosquitoes were placed into single tubes and homogenized 
with a piston in 50 ml of  lysis buffer (1X TBS, 0.5% SDS). The lysates were subsequently 
vortexed for 20 sec and then boiled for 5 min. The insoluble material was pelleted via 
centrifugation and the supernatant was collected and analysed. 
 ii) mAb 2A10: Anti-Pf  CSP mAb 2A10 was generated using a hybridoma cell line acquired 
from the MR4/ATCC, Virginia, USA. A commercial source was used to produce ascites in 
mice and purify antibodies by Protein G affinity chromatography (Harlan Laboratories Inc. 
Madison, WI, USA). mAb 2A10 (1.55 mg/ml) immune-reactivity was characterized in IFA 
using P. falciparum sporozoites and in ELISA and Western Blot using rPf  CSP.
 iii) Performance of  the ECL-SB: This assay was performed using a Minifold 48 slots, 
Whatman apparatus (GE Healthcare Life Sciences, 10447941; Piscataway, NJ, USA) in a 
slightly modified version of  the standard protocol [27]. The ECL-reagents used in this assay 
were purchased as a kit (Life Technologies, Western-StarTM Immunodetection System, 
T1046, Grand Island, NY, USA). Approximately 20 µL of  each sample lysate was loaded 
into each slot-blot well. Sample proteins were allowed to adsorb onto the nitrocellulose 
membrane for one hour and then slots were washed with 500 µl of  deionized water four 
times. The membrane was next blocked at room temperature (RT) in iBlock blocking buffer 
(Applied Biosystems, T2015, Foster City, CA, USA) for one hour before being probed 
with anti-Pf  CSP mAb 2A10 (at 0.31 µg/ml) for an additional hour. The membrane was 
subsequently washed three times (5 min each) in deionized water and three times in iBlock 
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blocking buffer. After the washings, the membrane was incubated with an AP-conjugated 
ECL-goat anti-mouse- IgM+IgG secondary antibody (1:5,000 dilution) for one hour at 
RT and then washed again as described following incubation with mAb 2A10. Before 
development, the membrane was rinsed twice for two minutes with 25 ml of  1X assay buffer 
and bands were visualized by incubating the membrane in 6 ml of  ECL-substrate solution 
at RT for 5 min and exposure to an AR film (Kodak X-OMAT 1000A). 
 iv) ECL slot blot data acquisition and analysis: The band profile on the developed film 
was scanned and analysed using the ImageJ program [35]. The integrated optical density 
(IOD) of  each band was determined by measuring the band intensity in a ‘gated area’. The 
dimensions of  the gated area for IOD determination was kept constant for each band on 
the scanned image. The capacity of  a single blot was 48 mosquito samples, including three 
to five negative controls for the calculation of  CSP positivity. Each blot was developed 
separately. As there were large variations in IOD values between blots (Figure 1), positivity 
determination for test mosquitoes was blot-specific, based on the mean IOD values of  the 
negative controls processed in each blot. As the total number of  mosquitoes processed at 
each time point in groups 2 and 4 exceeded the capacity of  a single blot (48 test mosquitoes 
plus controls), a small number of  test mosquitoes from these groups were processed in 
separate blots (8 and 5 mosquitoes from each time point for groups 2 and 4, respectively), the 
results of  which are shown in Supplementary Figure 1. Cut-off  values for the determination 
of  positive and negative specimens in each run of  the experiment were determined as the 
mean plus two times the standard deviation of  the uninfected mosquito band intensities, as 
described previously [27].
ELISA
i) 3SP2 mAb: Anti-Pf  CSP mAb 3SP2 was generated at Radboud UMC, Nijmegen, The 
Netherlands as described previously [14, 26].
 ii) CSP-ELISA: CSP ELISA was performed as previously described [11]. Mosquitoes 
were homogenized in 250 ml phosphate buffered saline (PBS pH 7.2) solution with 1% 
sarcosil. Sterilin ELISA plates were coated with 3SP2 mAb at 5 µg/ml, diluted in PBS. 
Fifty ml of  mosquito homogenate from all test mosquitoes was analysed in duplicate (100 ml 
total), alongside blank wells (50 ml of  sample diluent) and a standard curve of  recombinant 
CSP (50 µL Gennova, 0.1 µg/ml). A selection of  homogenates from 15 uninfected blood-
fed control mosquitoes were tested on every plate as a visual control, giving OD values 
between 0.06-0.08. OD values were adjusted for plate-to-plate variation by subtracting plate 
blank values. A universal cut-off  for CSP positivity was determined at an optical density 
(OD) of  0.311 using maximum likelihood methods to establish CSP-negative and CSP-
positive Gaussian distributions from the corrected OD values of  all 336 test mosquitoes. 
The cut-off  was set as the mean OD of  the CSP-negative distribution plus three standard 
deviations, as previously described [36, 37].
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Statistical analysis
Statistical significance between ECL Slot-blot and ELISA-based prevalence estimates 
and those measured by microscopic detection after dissection of  mosquito midguts were 
evaluated using the chi-square test for homogeneity. Statistical analysis was conducted in 
GraphPad Prism 5.0 (GraphPad Software Inc, CA, USA), and confidence intervals for 
prevalence estimates were generated using STATA 12 (StataCorp., TX, USA).
Results 
Infection of Anopheles stephensi mosquitoes with Plasmodium 
falciparum gametocyte cultures
Mosquitoes were fed blood meals containing four batches of  gametocytes from P. falciparum 
cultures diluted to generate varying infection rates (Table 1). Parasite burdens and overall 
infection prevalences were estimated after mosquito dissection and oocyst detection and 
counting by microscopy on a subset of  20-30 randomly sampled mosquitoes from each 
group on day 8 PI. Additional paired samples of  36-48 mosquitoes were then removed from 
each of  the four groups on days 8 and 10 PI for processing and assessment in the ECL-SB 
and ELISA (one sample for each day and method). The mosquitoes were randomly selected 
from the cages fed on the same gametocyte material by the same feeders. Since different 
mosquitoes were used for each of  the three assays, some inherent variation in mosquito 
infection rates was expected. Full details of  sample sizes in different test groups for all 
assays are in Table 1. In total, 104 test mosquitoes were analysed by microscopy on day 
8 PI, 336 test mosquitoes were analysed in the ECL-SB on days 8 and 10 PI, and 336 test 
mosquitoes were analysed in the ELISA on days 8 and 10 PI.
Oocyst detection by microscopy
Mean oocyst intensities for groups 1 through 4 were 0.5, 0.9, 6.1 and 7.7 (range 0-22), with 
corresponding oocyst prevalences of  20.8, 40, 70, and 93.3%, respectively, when assessed 
on day 8 PI (Table 1). The percentages of  infected mosquitoes with only a single oocyst 
were 0%, 25%, 11% and 5% respectively for groups 1 through 4.
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Prevalence estimation using ECL-SB
Table 1 shows that at all oocyst intensities and time points the ECL-SB accurately estimated 
oocyst prevalence as detected by microscopy in mosquito samples from the same feed. 
All prevalence estimates were made using a cut-off  threshold of  two standard deviations 
from the mean of  the IOD (integrated optical density) values obtained from ECL-SB from 
uninfected mosquitoes, as described previously [27]. Actual IOD values vary significantly 
between separate assay repeats according to the relative time exposed to X-ray, but positive/
negative determination was consistently robust within experiments (Figure 1). 
Prevalence estimation using ELISA
In line with previous results [11], the ELISA was not sufficiently sensitive to detect CSP 
present in infected mosquitoes at day 8 PI, regardless of  oocyst intensity (Figure 2). 
However, after an additional 48 hours, the ELISA accurately estimated the microscopically 
determined oocyst prevalence at all oocyst intensities. No significant differences were 
observed between prevalence estimates made by ELISA and microscopy (Table 1; p>0.29), 
or between ELISA and ECL-SB compared directly (p≥0.4) for mosquitoes analysed at day 
10 PI.
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Figure 1. ECL-SB integrated optical density values for mosquito homogenate bands exposed 
by X-ray. The capacity of the slot blot apparatus was 48 mosquito homogenates, including three 
to five negative controls for the calculation of CSP positivity. Each blot was developed separately, 
giving rise to the varied IOD values in the figure. Positivity determination was thus blot-specific, 
based on the mean IOD values of the negative controls obtained in each blot. As the total number of 
mosquitoes processed at each time point in groups 2 and 4 exceeded the capacity of a single blot (48 
test mosquitoes plus controls), a small number of test mosquitoes from these groups were processed 
in separate blots (eight and five mosquitoes from each time point for groups 2 and 4, respectively), 
the results of which are shown in Supplementary Figure 1. For clarity, the primary figure shows blots 
containing the majority of mosquitoes from all groups and time points. 
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Figure 2. ELISA OD values for all test and negative control mosquitoes. Plate-specific correction of 
OD values against background reactivity allowed for the calculation of a universal cut-off for positivity, 
which was determined statistically (OD 0.311, shown as the dotted line) [36, 37, 43]. 
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Discussion
This study describes the ability of  two immuno-assays, the CSP-ELISA and ECL-SB, to 
detect low-density mosquito-stage P. falciparum infections based on the detection of  CSP 
in the mosquito carcass. The results suggest that when mosquitoes are assayed ten days 
after ingestion of  an infective blood meal containing gametocytes, infection detection by 
the CSP-ELISA and ECL-SB provide prevalence estimates that are comparable to those 
obtained by microscopy. If  mosquitoes are assayed earlier (8 days PI), only the ECL-SB has 
the sensitivity to accurately estimate true infection prevalence, as compared to microscopy. 
 The results of  the current study corroborate recent data indicating that the ECL-SB can 
detect CSP shortly after its production begins in parallel to the budding out of  sporozoites in 
midgut oocysts [31]. Marginally higher prevalence estimates at day 10 PI compared to day 
8 PI in groups 2 and 3, which contained single oocyst infections (mean oocyst intensity 0.9-
6.1) suggest that some slower developing oocysts in low-intensity infections may be missed 
if  the assay is performed early. The challenges to detecting developing oocysts on day 8 
PI was more pronounced when the colorimetric ELISA was used [11]. A third method, 
the ECL-ELISA, was recently proposed as an enhancement of  the standard colorimetric 
ELISA for the detection of  CSP in whole homogenized mosquito samples [28]. This assay 
is capable of  detecting an amount of  CSP equivalent to that produced by 1.7 oocysts in 
mosquitoes processed at day 8 PI, a significant improvement on the colorimetric ELISA, 
although still possibly incapable of  detecting single oocyst infections at this time point. 
Though our experiments were not powered to investigate the impact of  oocyst intensity 
on assay sensitivity, the similar level of  concordance with microscopy across the range 
of  infection intensities we observed (1-22 oocysts) indicate that both ECL-SB and ELISA 
reliably detected single oocyst infections at day 10PI; the ECL-SB also detecting the vast 
majority at day 8 PI. ECL-SB prevalence estimates were in fact most concordant with 
microscopy in mosquito groups with only 1-4 oocysts (1 & 2), including group 2 where 25% 
of  all infected mosquitoes sampled by microscopy harboured only a single oocyst. This 
indicates that our assays would have great utility for the detection oocysts in Plasmodium 
infected vectors from endemic areas (e.g. mosquitoes infected during direct mosquito 
feeding assays), which are commonly in the 1-5 oocyst range [29, 38].
 In the context of  public health, the prevalence of  mosquitoes that are infectious to humans 
is the most relevant output for determining the efficacy of  TRIs [16, 39]. Oocysts may 
produce many thousands of  sporozoites, the majority capable of  invading and establishing 
themselves in the salivary glands where they await egestion by the blood-feeding mosquito 
into the human dermis [12, 13]. Since mosquitoes egest very few sporozoites when feeding, 
a mosquito with any number of  sporozoites is probably infectious [14, 15]. 
 While the presence of  salivary gland sporozoites marks infectiousness to humans, 
detecting earlier developmental stages may have significant operational benefits. For 
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mosquito-feeding experiments, storage time after feeding is a major concern as mosquito 
mortality may drastically limit sample size for analysis [11, 40, 41]. Early infection detection 
based on oocyst detection is reliable from day 6 PI by microscopy and, although a minority 
of  oocysts may fail to produce sporozoites [9, 11], reliably predicts later sporozoite salivary 
gland infection [11]. Oocysts are thereby detectable before sporozoite proliferation, however, 
the routine microscopical detection of  oocysts has a subjective element and requires highly 
trained microscopists to reliably detect low-density infections. CSP-based assays form an 
attractive alternative to microscopy because of  CSP abundance, and specificity to the oocyst 
and sporozoite stages of  sporogonic development [23]. Though CSP detection necessitates 
mosquito processing at day 8 PI or later [11, 27, 28], the fact of  its detection may be a more 
reliable predictor of  actual mosquito infectivity than the observation of  oocyst capsules or 
presence of  parasite DNA. For the assays in the current study, requirements for mosquito 
processing are modest, and equipment and assay methods relatively low-tech.
 One element that is consistent for ELISA, ECL-SB and other immunological approaches 
to infection detection in whole mosquito homogenates is the method of  mosquito 
homogenization. This has the benefit that mosquitoes may be killed in their cages by removal 
to -20°C freezers, then moved into sealed storage until analysis. Microscopy is constrained 
by strict scheduling based on the dates of  experimental infections, whereas immunological 
and molecular assays may be separated from the schedule of  feeding experiments at the 
convenience of  the operator. 
 Another similarity between the ELISA and the ECL-SB is the relative low cost and 
opportunities to increase throughput, which is beneficial for low-resource settings and for 
settings where the proportion of  infected mosquitoes is low. For the assays performed in 
this study, the estimated cost per mosquito was 0.96 USD for the ECL-SB and <0.1 USD 
for CSP ELISA. For the ECL-SB as performed here, 48 mosquitoes per apparatus can be 
assayed each day. For the ELISA, throughput is even higher and technology and equipment 
are routinely available in most research laboratories. For the CSP ELISA as performed 
here, 96 mosquitoes can be assayed per plate and ten plates can easily be processed by a 
single technician, with assays being completed in a two-day period. 
Conclusions
The results of  this and previous studies indicate that either the ECL-SB or ELISA may 
replace microscopy for infection detection at day 10 PI, and that ECL-SB may do so two 
days earlier with no risk to assay sensitivity. Samples were not tested at day 9 PI, but it is 
possible the ELISA may have performed better at this time point. Availability of  novel 
early midgut stage and trans-midgut stage, non-CSP based biomarkers may further improve 
the sensitivity of  immunological assays for Plasmodium detection in mosquitoes. Efforts to 
develop such assays for trans-midgut stage (days 2-10 PI) Plasmodium detection are underway. 
The ECL-SB’s throughput is dependent on the number of  apparatuses available, while the 
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ELISA’s throughput is essentially only limited by the number of  available technicians. The 
remaining bottleneck to the employment of  either technique for tertiary evaluation of  TRI 
is therefore mosquito processing [42]. A reliable method of  high throughput mosquito 
homogenization involving minimal equipment costs will further enhance the scalability of  
the assays described here.
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Supplementary figure
Supplemental figure S1. ECL-SB integrated optical density values for mosquito homogenate 
bands exposed by x-ray. Mosquitoes processed in separate blots but belonging to the same groups, 
for which cut-offs are different from the majority of mosquitoes in the same groups, are shown in this 
figure. All other details are as for Figure 1.
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Chapter 9
Predicting mosquito infection from gametocyte 
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Abstract
Understanding the association between gametocyte density and human-to-mosquito 
transmission is of  immediate relevance for malaria control efforts. We related female and 
male gametocyte densities to the prevalence and intensity of  mosquito infections in 148 
feeding experiments on naturally infected gametocyte carriers from Mali, Burkina Faso 
and Cameroon. Male-to-female gametocyte ratio is greatest in lower density infections. The 
proportion of  mosquitoes infected is primarily determined by female gametocyte density 
though statistical models indicate transmission is impeded at low gametocyte densities by 
a lack of  male parasites. Improving the precision of  gametocyte quantification simplifies 
the relationship between gametocytaemia and oocyst prevalence which increases rapidly 
before plateauing at higher densities. The mean number of  oocysts per mosquito rises 
quickly with gametocyte density but continues to increase across the range of  gametocyte 
densities examined. The work highlights the importance of  measuring both female and 
male gametocyte density when estimating the human reservoir of  infection.
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Introduction
Mosquitoes must ingest both male and female mature gametocytes to become infected with 
malaria. The shape of  the relationship between gametocyte density and the probability of  
mosquito infection is thought to be complex for Plasmodium falciparum [1-4]; but recent 
evidence has shown that the most comprehensive characterisation of  this relationship 
was conducted using molecular tools that only quantified female gametocyte specific 
Pfs25 mRNA [1][5]. An additional shortcoming of  these previous estimates is that 
female gametocytes were quantified from trendlines with unknown gametocyte sex-ratios, 
potentially affecting assay precision. 
 It is intuitive that gametocyte sex ratio is important in determining transmission efficiency 
[6, 7] but despite evidence that gametocyte sex ratio is adjusted in response to malaria 
developmental bottlenecks [6, 8, 9], there is no direct evidence for its epidemiological 
importance. Since mosquito infections may occur from blood with P. falciparum gametocyte 
densities below the microscopic threshold for detection [1, 10, 11] and gametocyte density 
itself  is an important determinant of  sex ratio [6, 12], sensitive quantification of  male 
and female gametocytes is essential for assessments of  the role of  gametocyte sex ratio 
in natural infections and for reliable estimates of  total gametocyte density. Here, we use 
a new molecular target of  male P. falciparum gametocytes (Pf3D7_1469900 or PfMGET) 
[13] to explore the association between the density of  female and male gametocytes and 
mosquito infection. The relationship between gametocyte density and oocyst intensity is 
also investigated for the first time as recent work has highlighted the importance of  parasite 
intensity in mosquito-to-human transmission [14] and so both the number of  infected 
mosquitoes and their parasite load need to be considered when assessing the human 
reservoir of  infection.
Results
Participant characteristics
Gametocyte carriers were included from Mali (n=71), Burkina Faso (n=64) and Cameroon 
(n=13). P. falciparum parasite prevalence by microscopy ranged from ~40-70% between sites 
[15-18]; sampling occurred in different seasons (Table 1). All sites recruited gametocyte 
carriers prior to antimalarial treatment but used different enrolment criteria. Microscopically 
detected gametocyte carriers were included in 3 studies while one site (Balonghin) included 
submicroscopic gametocyte densities. Total gametocyte densities range from 0.04 to 1164 
gametocytes/µL (Table 1, Figure 1). Gametocyte density estimates by microscopy and qRT-
PCR were correlated in Ouelessebougou (r=0.74), Bobo Dioulasso (r=0.27), Balonghin 
(r=0.56) and Yaoundé (r=0.91) (Figure 1–Figure Supplement 1). Across 148 successful 
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membrane feeding experiments, 16.7% (1297/7757) of  mosquitoes became infected, with 
considerable variation between gametocyte donors and study sites.
Gametocyte sex ratios in natural infections
Female gametocyte densities quantified by Pfs25 quantitative reverse-transcriptase PCR 
(qRT-PCR) and male gametocyte densities by PfMGET qRT-PCR were correlated 
(Figure 1A; Spearman’s rank correlation coefficient = 0.79, p < 0.001). The percentage 
of  gametocytes that were male decreased with increasing total gametocyte densities 
(Figure 1B, p < 0.001 [Kruskal Wallis test]). Conversely there was no evidence for an 
association between proportion of  male gametocytes with asexual parasite density 
(Figure 1C, p = 0.713).
Table 1. Characteristics of gametocyte carriers and mosquito feeding assays
Ouelessebougou, 
Mali 
Bobo 
Dioulasso, 
Burkina Faso
Balonghin, 
Burkina Faso 
Yaoundé, 
Cameroon
Number of experiments 71 19 45 13
Age, median (IRQ) 11 (7-25) 5-15 (range)* 10 (8-13) 9 (6-11)
Asexual parasite prevalence % 
(n/N)
64.8 (46/71) 73.7 (14/19) 73.3 (33/45) 76.9 (10/13)
Asexual parasite density per µL, 
median (IQR)
432 (96-2880) 360 (240-1040) 658 (336-1237) 944 (288-4224)
Gametocyte density per µL, 
median (IQR)
62.8 (31.4-146.8) 19.2 (10.5-26.1) 4.0 (0.6-11.0) 64.4 (11.7-
126.2)
Number of mosquitoes examined 
per experiment, median (IQR)
70 (63-79) 29 (28-30) 40 (35-45) 37 (32-45)
Infectious individuals, % (n/N) 74.7 (53/71) 84.2 (16/19) 22.2 (10/45) 76.9 (10/13)
Infected mosquitoes, % (n/N) 17.0 (842/4960) 39.2 (208/531) 3.5 (63/1783) 38.1 (184/483)
* the age of individual gametocyte donors was not recorded in Bobo Dioulasso; gametocyte carriers 
were recruited from the age range 5-15 years; asexual parasite density was determined by microscopy, 
gametocyte density by quantitative reverse transcriptase PCR. QT-NASBA = Pfs25 mRNA quantitative 
nucleic acid sequence based amplification. 
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Figure 1. Gametocyte density in natural infections. The density of female gametocytes and 
male gametocytes is presented in panel (A) for samples from Ouelessebougou, Mali (red), Yaoundé, 
Cameroon (green), Bobo-Dioulasso, Burkina Faso (blue) and Balonghin, Burkina Faso (purple). 
Female and male gametocyte densities were positively associated (r=0.79, p < 0.001) with the best 
fit relationship shown by the black solid line (grey shaded area showing 95% the confidence interval 
around this line). Coloured horizontal and vertical lines indicate Bayesian credible intervals (CIs) around 
point estimates. The proportion of gametocytes that were male was negatively associated with total 
gametocyte density (B) but not with asexual parasite density (C). All raw data can be found in Figure 
1–Source Data 1 whilst a description of the relationship modelled in (A) is provided in Figure 1–Source 
Data 2. The relationship between gametocyte density as measured by microscopy and PCR is given for 
each site in Figure 1–Figure Supplement 1.
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Infectivity in relation to gametocyte density
The proportion of  mosquitoes developing oocysts is best described by a model that 
incorporates both the number of  female and the number of  male gametocytes (deviance 
information criterion, DIC=451.5). In the best fit model female gametocyte density explains 
most of  the variability with the proportion of  mosquitoes infected increasing rapidly with 
increasing gametocytaemia before saturating at high female gametocyte densities (Figure 
2A). At female gametocyte densities of  200 per µl approximately 40% of  mosquitoes are 
infected. At low gametocyte densities transmission appears to be impeded by a lack of  
male parasites (Figure 2B). The number of  mosquitoes infected is on average lower for 
hosts with fewer than 50 male gametocytes per µl of  blood, with the model predicting that 
male densities <10 per µl reduces the proportion of  infected mosquitoes by 50% (Figure 
2C). Predictions for the proportion of  mosquitoes infected according to the number of  
female and male gametocytes in the blood is given in Figure 2D. Poorer statistical fits 
were observed for statistical models where the proportion of  mosquitoes with oocysts was 
described by either the number of  females alone (DIC=481.3) or total gametocyte density 
(sum of  male and female gametocytes, DIC=501.7). There are considerable differences in 
the relative infectivity between sites. Compared to the Mali data, infectivity was similar in 
the study in Balonghin, Burkina Faso (0.95 times as high; 95% CI 0.1 – 1.4) but 3.65 times 
higher in Bobo Dioulasso, Burkina Faso (95% CI 2.3 – 5.2) and 1.68 times higher in site in 
Yaoundé, Cameroon (95% CI 1.1 – 2.6) (Figure 2–Figure Supplement 1, Figure 2 – Source 
Data 2.). 
Oocyst density in mosquitoes
The distribution of  oocysts between mosquitoes is highly over-dispersed, with some 
mosquitoes harbouring very high oocyst densities. This aggregated distribution is reflected 
in the relationship between proportion of  mosquitoes infected and mean oocyst density 
(Figure 3A). Mean oocyst density increased with increasing gametocyte density and 
continued to increase across the range of  gametocyte densities observed, without evidence 
for a plateau being reached (Figure 3B).
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Figure 3. Associations between mean oocyst density; the proportion of mosquitoes that 
develop oocysts; and gametocyte density. (A) The relationship between mean oocyst density and 
the proportion of mosquitoes that develop oocysts (red = Ouelessebougou, Mali, green = Yaoundé, 
Cameroon, blue = Bobo-Dioulasso, Burkina Faso, purple = Balonghin, Burkina Faso; point size is 
proportional to the number of mosquitoes dissected). A Hill function gave the best fit to these data 
(DIC linear=1310; power = 602; Hill=434). (B) The relationship between total gametocyte density 
and the mean oocyst density in all mosquitoes. The power function gave the best fit to these data 
(DIC linear=1042; hyperbolic=1044; gompertz=1067; power=1036); total gametocyte density gave a 
better fit than only female gametocyte density (DIC = 1061). Horizontal and vertical lines indicate 95% 
Bayesian credible intervals (CIs) around point estimates, solid black line indicates the best-fit model 
with grey shaded area indicates the 95% CI around this line. Like Figure 2A Panel 3B aids clarify by 
scaling model and data to the average infectivity of the largest dataset though the raw data and model 
fits are provided in Figure 3–Figure Supplement 1.
Discussion
We present an improved model to predict mosquito infection from female and male 
gametocyte density estimates. Previous molecular assessments of  P. falciparum gametocyte 
density quantified female specific Pfs25 mRNA then converted this into a measure of  
gametocytes per µL of  blood by reference to standard curve of  mixed-sex gametocytes [1, 
19, 20]. These assessments therefore quantified neither female nor total gametocyte density 
accurately. The current model presents a considerable improvement over previous work 
[1], both by separately quantifying male and female gametocytes using sex-specific mRNA 
markers and standard curves [5] and also by using considerably more accurate estimates 
of  total gametocyte density. Male and female gametocytes were quantified separately using 
automated extraction of  nucleic acids [13]. Manual extraction can result in considerable 
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variation [22] that may have affected the accuracy of  our earlier gametocyte estimates [1]. In 
addition, we used qRT-PCR that has higher precision than the previously used quantitative 
nucleic acid sequence based amplification, QT-NASBA) [21, 22].
 Our analyses show that the relationship between the density of  gametocytes and 
transmission can be adequately described by a simple saturating relationship, and that 
a more complicated curve with two inflection points is not needed [1]. This increase in 
simplicity is likely to be driven by the improved accuracy of  gametocyte density estimates as 
models fit solely to female parasites density had a similar simplified shape. The concurrent 
quantification of  female and male gametocytes leads to an improved estimation of  total 
gametocyte biomass and could explain why models with information on both sexes were 
more accurate. However, evidence indicates that this is unlikely as the model fit to total 
gametocyte density (male plus female) gave a poorer fit than the model where transmission 
was dependent on female density unless there were very low male parasite densities. We 
therefore believe that this work provides direct evidence of  the epidemiological importance 
of  male gametocytes.
 The work confirmed previous evidence that the proportion of  male gametocytes is 
negatively associated with total gametocyte density [6, 12, 23], which may reflect a strategic 
investment in male gametocytes to maximize the likelihood of  transmission in low-density 
infections [6, 24]. The models also indicated that male gametocyte density may become a 
limiting factor for transmission success at low gametocyte densities. These observations are 
in line with in vitro findings with P. falciparum, P. berghei and P. chabaudi where infections 
with a higher proportion of  male gametocytes gave higher transmission success at low 
gametocyte densities but reduced success at higher gametocyte densities [6, 25]. 
 The presented model considerably improved the prediction of  mosquito infection 
rates compared to our previous manuscript [1]. Nevertheless, some level of  uncertainty 
remains, particularly between study sites with several experiments resulting in considerably 
lower mosquito infection rates than predicted based on gametocyte density and sex-ratio. 
There are several plausible reasons for this. Naturally acquired antibody responses to 
gametocyte antigens may reduce transmission efficiency and form a first explanation why 
many mosquitoes may fail to become infected when feeding on some hosts with high-
density gametocyte infections. Whilst immune responses that completely prevent mosquito 
infections are only sporadically detected in naturally exposed populations [26], it is 
plausible that functional transmission reducing immunity has reduced mosquito infection 
rates for a proportion of  gametocyte carriers in our study. Temporal fluctuations in 
transmission reducing immunity [27] may also have contributed to the apparent differences 
in infectivity between study sites that recruited gametocyte carriers at different time-points 
in the season. The site with the highest infectivity in the current study (Bobo Dioulasso), 
recruited individuals in the dry season when the impact of  transmission reducing immunity 
may be lowest [27]. The extent of  between site heterogeneity in transmission should be 
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interpreted with caution since two of  the four sites had <20 study participants. At all sites 
malaria-infected individuals were recruited prior to malaria treatment, making it unlikely 
that drug-induced sterilization of  circulating gametocytes may have affected our analyses. 
Variation in the susceptibility of  the mosquito colonies to parasite genotypes may provide 
a second plausible reason for the imperfect model fit [28]. A third hypothesis could be that 
our quantification of  gametocytes by Pfs25 and PfMGET qRT-PCR may not fully reflect 
gametocyte maturity and infectivity as gametocytes may be detectable in the blood stream 
before [29] and after peak infectivity is reached [20]. Lastly, technical issues related to RNA 
degradation may affect gametocyte quantification and thus yield unreliable low gametocyte 
density estimates [30]. There were no apparent issues in maintaining the essential 
temperature control in the field, during transportation, or following RNA extraction for 
any of  the samples included in this study, nor did the associations between microscopy and 
qRT-PCR gametocyte density estimates indicate (site-specific) RNA degradation that may 
have resulted in underestimations of  true gametocyte densities.
 The study shows that though the prevalence of  mosquitoes with oocysts plateaus at high 
gametocyte densities the average number of  oocysts in those mosquitoes continues to rise, 
as previously reported for P. vivax [31]. Understanding the association between gametocyte 
density and mosquito infection rates is of  immediate relevance for malaria control efforts 
[2, 10]. Here we show that accurate measures of  female and male gametocyte density can 
better predict human-to-mosquito infection, and could be used to assess the infectiousness 
of  human populations.
Methods
Study populations and mosquito feeding experiments
Field samples were collected at four malaria endemic sites. Samples were collected 
prior to treatment and after written informed consent was obtained from participants or 
their guardian(s). Ethical clearance was provided by the National Ethics Committee of  
Cameroon; Ethical Review Committee of  the Ministry of  Health, Burkina Faso; Ethics 
Committee of  the Malaria Research and Training Centre, Bamako; Ethics review committee 
Centre MURAZ; University of  California, San Francisco, and London School of  Hygiene 
& Tropical Medicine. Procedures for Ouelessebougou, Mali are described elsewhere 
[21]. From the trial in Ouelessebougou, baseline samples from microscopically detected 
gametocyte carriers were used. Additional samples were collected from asymptomatic 
microscopically detected gametocyte carriers aged 5-15 years in Bobo Dioulasso in 
Burkina Faso and Yaoundé, Cameroon.  Lastly, a random selection of  samples from a 
xenodiagnostic study in Balonghin in Burkina Faso was used [15]. Samples were eligible 
for selection if  gametocytes were detected by Pfs25 QT-NASBA that has an estimated lower 
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limit of  detection between 0.02-0.1 gametocytes/µL and thus provided data-points at the 
lower range of  gametocyte densities[15]. The same membrane feeding protocol was used at 
all sites: local Anopheles coluzzii colony mosquitoes (Mali, Cameroon and Bobo Dioulasso, 
Burkina Faso) or colony mosquitoes comprising a mixture of  A. coluzzii, A. gambiae s.s. 
and hybrid forms (Balonghin, Burkina Faso) were allowed to feed for 15-20 minutes on 
heparin blood samples until dissection in 1% mercurochrome at day 7 post-feeding and 
oocyst detection by two independent microscopists [32].  For all sites membrane feeding 
and sample collection were performed prior to antimalarial treatment
Molecular analysis of samples from naturally infected gametocyte 
donors
Female gametocytes were quantified by quantitative reverse transcriptase PCR (qRT-PCR) 
targeting female Pfs25 mRNA, as described elsewhere in detail [30] based on established 
protocols [33]. For male gametocytes we used a recently developed qRT-PCR [13] based 
on PfMGET (male gametocyte enriched transcript, Pf3D7_1469900), a transcript that is 
highly enriched in male P. falciparum gametocytes [34]. Primer sequences are provided in 
Table 2. For all qRT-PCR, mRNA was extracted from blood collected in EDTA tubes 
by venipuncture; 100 µL of  whole blood was stored at -80°C in 500µL RNAprotect 
(Qiagen; for Burkina Faso and Cameroon samples) or 900 µL L6 buffer (Severn Biotech, 
Kidderminster, UK; for Mali samples) until automated extraction using a MagNAPure LC 
(Total Nucleic Acid Isolation Kit–High Performance; Roche Applied Science, Indianapolis, 
IN, USA). cDNA was synthesised directly from nucleic acids for the PfMGET assay, for 
which the primers are intron-spanning , and after DNase treatment (RQ1 DNase I Digest 
Kit, Promega) for the Pfs25 assay, using High Capacity cDNA Reverse Transcription Kits 
(Applied Biosystems, Foster City, CA). qRT-PCR results were converted to male and 
female gametocyte densities using standard curves (ten-fold serial dilutions from 106 to 10 
gametocytes/ml) of  separate male and female gametocyte populations that were generated 
using a transgenic parasite line expressing a male specific fluorescence marker [13, 34]. 
The purity of  male and female trendlines was previously confirmed by staining of  sorted 
gametocyte populations using female gametocyte specific anti-Pfg377 antibodies [13, 35]. 
For both Pfs25 and PfMGET qRT-PCR, a threshold for positivity was set at 1 gametocyte 
per sample (0.01/µL).
Table 2. Primer sequences for the Pfs25 female marker, and male marker PfMGET.
Gene target Forward primer Reverse primer
Pfs25 GAAATCCCGTTTCATACGCTTG AGTTTTAACAGGATTGCTTGTATCTAA
PFMGET CGGTCCAAATATAAAATCCTG GTGTTTTTAATGCTGGAGCTG
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Statistical analysis
The statistical methods used here are the same at those in the original paper [1], which we 
briefly recapitulate here. qRT-PCR results are in the form of  cycle-thresholds (TCT, which 
is the number of  cycles it takes for the fluorescence associated with target amplification 
to exceed a defined threshold. The relationship between CT and gametocyte density is 
estimated by fitting a linear regression to CT estimates generated using a sample with 
known gametocyte density (a 10-fold dilution series). Let the observed CT be denoted by y 
then, where β0 and β1 are regression coefficients estimates, x is the (known) parasite density 
from the dilution series and ε represents a normally distributed random error (ε ~ N(0,s2)). 
y = β0 + β1lnx + ε,  (1)
Equation (1) can be rearranged to enable us to estimate gametocyte density from a CT 
measurement. We use a Bayesian hierarchical model to estimate the coefficients β0 and β1. 
These gametocyte density estimates are used to determine the relationship between 
gametocyte density and the proportion of  mosquitoes developing oocysts. Four functional 
forms (linear, power, hyperbolic and Gompertz [1]) were each fit 3 times: on female 
gametocyte density alone; on total gametocyte density; and finally female gametocyte 
density but multiplied by a function accounting for reduced transmission at low male 
densities. Terms allowing for different infectivity at each site were incorporated into the 
models. The algebraic forms of  these models are given in Figure 2-Source Data 2. The 
model quantifying the uncertainty in gametocyte density estimates was fit at the same time 
as the regression determining the relationship between gametocyte density and infectivity 
using Bayesian Markov Chain Monte Carlo methods assuming a Binomial error structure 
for each feeding experiment. Fitting the models simultaneously enabled the uncertainty 
in the gametocyte density estimates to be reflected in the uncertainty of  the shape of  the 
relationship. The models were compared using the DIC with a lower value indicating the 
most parsimonious fit.
 The relationship between gametocyte density and oocyst density was examined in an 
analogous way, with two exceptions: 1) A negative binomial error structure was used to 
describe oocyst counts and 2) The increased complexity of  the model precluded the inclusion 
of  the function accounting for reduced transmission at low male densities, so each functional 
form was only fit twice; on female gametocyte density and total gametocyte density.
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Supplementary materials
Figure 1–Figure Supplement 1. Relationship between total gametocyte densities as measured 
by microscopy or female gametocyte densities quantified by Pfs25 quantitative reverse-
transcriptase PCR. Relationship is shown separately for each of the different sites, be it (A) 
Ouelessebougou, Mali (red), Yaoundé, (B) Bobo-Dioulasso, Burkina Faso (blue), (C) Cameroon (green), 
and (D) Balonghin, Burkina Faso (purple). Black dashed line shows the 1:1 relationship for each site.
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Figure 2–Figure Supplement 2. Relationship between female gametocyte density and the proportion of 
infected mosquitoes for different male gametocyte densities for experiments from Mali (n=71). Points 
are coloured according to gametocyte sex ratio: green >= 16% male, brown < 16% male (16% is the median 
value). At low and intermediate female densities (between 1 and 100 female gametocytes per microlitre), a 
high proportion of males results in higher transmission because a minimum number of males are required for 
successful transmission. But for higher female densities, only a small proportion of males is needed to bring 
the absolute number of males over the threshold for successful transmission, and beyond that extra females 
contribute more to infectivity.
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Figure 1: Source data
Least squares linear regression was used to fit a best fit line for the relationship between 
female gametocyte density and male gametocyte density (on the logarithmic scale).
For simplicity of  presentation, the model displayed in Fig 1A is a simple linear regression 
on all points. The slope is 0.67 (95% CI [0.60, 0.75]) and the intercept is -0.20 (95% CI 
[-0.46, 0.06]) and R2 = 0.69.
 There is no evidence that a quadratic curve fit the data better than a linear relationship 
(p=0.815).
 The fits for individual sites are given below:
Site Slope [95% CI] Intercept [95% CI] R2
Ouelessebougou, Mali 0.44 [0.32, 0.57] 0.56 [0.02, 1.10] 0.41
Bobo Dioulasso, Burkina Faso 0.78 [0.40, 1.15] 0.56 [-0.37, 1.48] 0.53
Balonghin, Burkina Faso 0.80 [0.67, 0.93] -0.68 [-0.94, -0.41] 0.79
Yaoundé, Cameroon 0.82 [0.60, 1.04] -0.02 [-0.87, 0.82] 0.86
Figure 2: Source data
Infectivity was characterised as a function of  gametocyte density using the linear, power, 
hyperbolic and Gompertz functions described in [1]. Each curve was fit 3 times: as a 
function of  total gametocyte density; as a function of  female gametocyte density; and as 
a function of  female and male gametocyte density (female density describing the overall 
shape whilst male gametocyte density allows transmission to be impeded at low densities). 
The full nested equation (extending the notation of  the original manuscript) is given below,
where  is the estimated gametocyte density, be it female parasites (d=f), male parasites 
(d=m) or total gametocytes (sum of  females and males, d=t) and  indicates the restriction 
in transmission imposed by having too few males. The function  determines the 
shape of  the relationship between gametocytes and proportion of  mosquitoes developing 
oocysts. 
 Subscript i indicates the functional form used, be it  where constraining 
different parameters can generate a range of  different shapes (linear  = 1;  = 0), power 
(  = 0), hyperbolic ( > 0, = 1, > 0) or  
which generates a Gompertz (sigmoid-like) function. The variables ,  and 
are indicator variables for whether a subject was from Bobo Dioulasso, Balonghin or 
Cameroon respectively whilst  is a scaling parameter between sites, be it Bobo Dioulasso 
(j=1), Balonghin (j=2) or Cameroon (j=3).
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All models were fit to data provided in Figure 2 – Source Data 1 using methods presented 
in (1) which use the dilution series trendlines to convert PCR CT values (the time taken for 
florescence to reach a threshold value) which is used to estimate gametocyte density.  A full 
list of  the models tested and their fit to data are provided below.
Model fit (Deviance information criteria, DIC)
Total gametocyte 
density (d=t,  τ =1000)
Female gametocyte 
density (d=f, τ =1000)
Female and male 
gametocyte density (d=f)
Linear
(f
α
 (x ̂d’),α2=1, α3=0)
576.0 574.4 566.4
Power
(f
α
 (x ̂d’),α3=0)
501.7 481.3 451.5
Hyperbolic
(f
α
 (x ̂d’),α2=1)
573.0 564.8 +
Gompertz
(f
γ
 (x ̂d’))
557.4 555.7 548.3
+ models with this combination of functions failed to converge and so were discounted.
The model with the lowest DIC is the power function as a function of  female gametocyte 
density multiplied by (1-exp(-a*gm)) is presented in Figure 2A. Estimates and credible 
intervals for the coefficients are given in the table below:
Coefficient Estimate 95% credible interval
τ 0.08573 (0.04229, 0.1967)
α1 0.07108 (0.02295, 0.1746)
α2 0.3021 (0.1602, 0.4751)
β1 2.65 (1.273, 5.174)
β2 -0.04733 (-0.9017, 1.405)
β3 0.6757 (0.06286, 1.582)
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32. Ouédraogo, A.L., et al., A protocol for membrane feeding assays to determine the infectiousness of  P. 
falciparum naturally infected individuals to Anopheles gambiae. MWJ, 2013. 4(16).
33. Wampfler, R., et al., Strategies for Detection of  Plasmodium species Gametocytes. PLoS ONE, 2013. 8(9): p. 
e76316.
34. Lasonder, E., et al., Integrated transcriptomic and proteomic analyses of  P. falciparum gametocytes: molecular 
insight into sex-specific processes and translational repression. Nucleic Acids Research, 2016.
35. Suarez-Cortes, P., et al., Comparative Proteomics and Functional Analysis Reveal a Role of  Plasmodium 
falciparum Osmiophilic Bodies in Malaria Parasite Transmission. Mol Cell Proteomics, 2016. 15(10): p. 
3243-3255.
244
TEN
245
10
Chapter 10
A molecular assay to quantify male and female P. 
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Abstract
Background
Single low dose primaquine (PQ) reduces P. falciparum infectivity before it impacts 
gametocyte density. Here, we examined the effect of  PQ on gametocyte sex-ratio as possible 
explanation for this early sterilizing effect.
Methods
qRT-PCR assays were developed to quantify female gametocytes (targeting Pfs25 mRNA) 
and male gametocytes (targeting Pf3D7_1469900 mRNA) in two randomised trials in 
Kenya and Mali, comparing dihydroartemisinin-piperaquine (DP) alone to DP with PQ. 
Gametocyte sex-ratio was examined in relation to time since treatment and infectivity to 
mosquitoes. 
Results
In Kenya, the median proportion of  male gametocytes was 0.33 at baseline. Seven days 
after treatment, gametocyte density was significantly reduced in the DP-PQ arm relative to 
the DP arm (females=0.05% [IQR 0.0-0.7%] of  baseline, males = 3.4% [IQR 0.4-32.9%] of  
baseline, p<0.001). Twenty-four hours after treatment, gametocyte sex-ratio became male-
biased and was not significantly different between DP or DP-PQ groups. In Mali, there was 
no significant difference in sex-ratio between DP and DP-PQ groups (>0.125mg/kg) 48 
hours after treatment, and gametocyte sex-ratio was not associated with mosquito infection 
rates.
Conclusions
The early sterilising effects of  PQ may not be explained by the preferential clearance of  
male gametocytes and may be due to an effect on gametocyte fitness.
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Introduction
Artemisinin combination therapies (ACT) have contributed substantially to declines in 
the burden of  falciparum malaria in the last 15 years [1], due to their rapid clearance of  
asexual stage parasites and activity against immature gametocytes [2, 3]. ACT reduce the 
post-treatment transmission potential of  parasites from infected humans to mosquitoes 
more than non-artemisinin treatments [4, 5]. However, because of  their incomplete activity 
against mature gametocytes, patients may remain infective to mosquitoes for up to two 
weeks after ACT treatment [6-8]. The only currently available drug able to clear mature 
sexual stage malaria parasites is the 8-aminoquinoline primaquine (PQ) [9] which has 
been used historically for gametocyte clearance as a single dose of  0.75mg base/kg PQ 
in combination with a schizonticide [5, 8-12]. Concerns about haemolysis in individuals 
with glucose 6-dehydrogenase (G6PD) deficiency have contributed to the recent revision 
of  the recommended dose for P. falciparum gametocyte clearance to 0.25mg base/kg. The 
WHO recommend this low dose be provided alongside standard ACT without prior G6PD 
status screening, for the prevention of  P. falciparum transmission in areas with ACT resistant 
parasites, or areas close to elimination [13]. 
 Though the aim of  PQ treatment for P. falciparum is a reduction in gametocyte infectivity, 
there is limited direct evidence on mosquito infection prevalence in individuals treated with 
the currently recommended low dose [9, 14, 15]. In a recent trial where PQ was combined 
with a current ACT, the number of  individuals infecting mosquitoes dropped from 93.3% 
to 6.7% over a time-window when gametocyte prevalence and density appeared unaffected 
by PQ [14]. This pattern appears consistent; a review of  P. falciparum transmission after 
PQ treatment shows that gametocyte infectivity is generally diminished prior to observable 
changes in gametocyte abundance [9]. A so far untested hypothesis is that PQ may 
disproportionally affect male gametocytes and thus sterilize infections while gametocyte 
densities, largely determined by the more abundant female gametocytes [16-19], remain 
stable [20]. In vitro studies with P. berghei show that male gametocytes are more sensitive to 
a range of  antimalarials [21], but PQ requires bio-activation in the liver so in vitro studies 
are not possible. Since post-treatment gametocyte densities are commonly below the 
microscopic threshold for detection, molecular sex-specific gametocyte assays are required 
to test this hypothesis in clinical trials. The only previously published male gametocyte 
marker is insufficiently sensitive to quantify low-density male gametocytes [19].
 Here, we present results from two randomised, controlled trials of  PQ in combination 
with dihydroartemisinin-piperaquine (DP), conducted in Kenya and Mali. Whilst this is 
the first report on the trial in Kenya, gametocyte dynamics and transmission data (but not 
gametocyte sex-ratio) were previously presented for the trial in Mali [14]. In this report, 
we assess the effect of  PQ on gametocyte sex-ratio using quantitative reverse-transcriptase 
PCR (qRT-PCR) with sex-specific RNA markers [19], including a highly sensitive novel 
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male marker selected using sex-specific P. falciparum transcriptomic data (Pf3D7_1469900) 
[22]. Our analysis allowed the first direct assessment of  the effect of  PQ on gametocyte sex 
ratio and subsequent infectivity to mosquitoes. 
Methods
Study design and participants
The Kenyan trial was conducted in Mbita point, western Kenya, between September 2014 
and September 2015. The study area is characterised by moderate malaria transmission [23]. 
During visits to local schools, 5 to 15 year olds providing written consent for screening were 
tested for malaria infection by examination of  100 fields of  a thick blood smear. Participants 
providing written informed consent were eligible if  they were patent gametocyte carriers (1 
gametocyte per 500 WBC in a thick film), 5-15 years of  age, with P. falciparum mono-infection. 
Exclusion criteria were haemoglobin density (Hb) of  <9.5g/dL, asexual parasite density 
of  >200,000 parasites/µL, body mass index (BMI) of  below 16 kg/m2 or above 32kg/m2, 
tympanic temperature of  >39°C, antimalarial treatment taken within 2 days, recent treatment 
with drugs known to be metabolised by the P450 (CYP) 2D enzyme family, history of  adverse 
reaction to study drugs, blood transfusion within 90 days, history or symptoms of  chronic 
illness, or family history of  any condition associated with extended QTc interval. The trial 
protocol received ethical approval from the Kenya Medical Research Institute Ethics Review 
Committee (#439), and the London School of  Hygiene and Tropical Medicine Observational/
Interventional Research Ethics Committee (#7323). 
Procedures
All participants received a three-day course of  dihydroartemisinin-piperaquine (DP; 
Eurartesim, Sigma-Tau, Italy) alone or with a single low dose of  PQ (0.25mg base/kg) on 
the third day of  DP treatment (day 2 of  the trial). Enrolees and trial staff  other than the 
trial pharmacist, who was involved only in randomisation and drug administration, were 
blinded to treatment arm allocation. 
 PQ (Sanofi-Aventis U.S. LLC Bridgewater) was prepared as previously described by 
dissolving crushed 1mg tablets into distilled water and mixing with a taste-masking solution 
to a final concentration of  0.25mg/kg child weight [8, 24]. Participants assigned to the 
placebo arm received the same total volume of  water and masking solution. 
Participants were examined at the study clinic on days 0, 1, 2, 3, 7 and 14 after enrolment. 
Blood samples were taken at all time points except for day 1, either by fingerpick (day 0, day 
2 and day 14) or venipunture (day 3 and day 7). At all sampling points haemoglobin levels 
were quantified by Hemocue photometer (HemoCue AB, Sweden) and asexual parasites 
and gametocytes were enumerated by examination of  a giemsa stained thick film counting 
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against 200 or 500 white blood cells (WBC), respectively, and converted to densities per 
µL assuming 8000 WBC/µL. Two assays were used for gametocyte detection: quantitative 
nucleic acid-based sequence amplification (QT-NASBA) was used to determine gametocyte 
prevalence at enrolment and d2, d3, d7 and d14 following treatment; quantitative reverse-
transcriptase PCR (qRT-PCR) was used for gametocyte quantification [25] and sex-ratio. 
 To validate our sex-specific qRT-PCR assays, we first confirmed the ability to generate 
populations of  male and female gametocytes using a recently published PfDynGFP/
P47mCherry reporter line (supplemental Figures S1-S3). Then, we developed and optimised 
sex-specific qRT-PCR assays amplifying mRNA specific to the Pfs25 (female marker) and 
Pfs230p (male marker) genes [19] and more sensitive male targets (supplemental Table S1). 
Pfs230p also showed limited sensitivity in our preliminary analyses (Supplemental tables 
S2-S3), and in our baseline surveys (gametocytes were undetectable in 9/112 of  baseline 
samples using Pfs230p). We thus designed a new qRT-PCR based on a more abundant 
gene transcript specific to male gametocytes; Pf3D7_1469900 (hereafter PfMGET for male 
gametocyte enriched transcript) [22]. In the supplemental information, we provide details 
of  target selection (Supplemental table S2), the development and validation of  the PfMGET 
qRT-PCR assay (Supplemental tables S3-S6) and details on molecular gametocyte assay 
methodology for the Kenya and Mali trials. Pfs25 and PfMGET assays showed similar 
sensitivity, and a threshold for positivity was set at 1 gametocyte per sample (0.002/µL) for 
both assays. 
 At day 3 and day 7 blood was provided to mosquitoes for direct membrane feeding 
assays, as previously described [26]. Low infectivity (38 oocyst positive mosquitoes out of  
8686 dissected, from 2 individuals in the DP arm) prompted additional feeds (n=32) to be 
conducted with serum replacement at d0, d3 and day 7. Mosquitoes remained uninfected 
in these conditions. Later it was discovered that the A. gambiae s.s. colony was infected with 
Microsporidia spp. which have been shown to inhibit Plasmodium survival in mosquitoes 
[27] and precluded meaningful assessments of  infectivity in this trial.
 To test our findings in an independent dataset, and explore the relationship between 
sex ratio and infectivity, we performed a subsidiary analysis of  blood samples from 
participants of  a single blind, dose-ranging, randomised trial of  DP with PQ conducted 
near Ouelessebougou, Mali [14]. PQ was provided with the first dose of  DP at baseline, 
at doses of  0.0625mg/kg (n=16), 0.125mg/kg (n=16), 0.25mg/kg (n=15), and 0.5mg/kg 
(n=17) (control with DP only, n=16). The main outcomes of  this trial were previously 
reported [14]. For the current study, blood samples were available from baseline and from 
2, 3, 7 and 14 days after the administration of  PQ. Direct membrane feeding assays for the 
assessment of  infectivity to Anopheles gambiae mosquitoes were successfully performed at 
baseline and at days 2 and 7 [14, 26]. 
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Sample size calculations
Sample size calculations were based on the anticipated primary outcome; the prevalence of  
infectivity to mosquitoes in membrane feeding assays. A previous study in the same setting 
showed that 30% of  sub-microscopic gametocyte carriers and 80% of  patent gametocyte 
carriers infected mosquitoes 7 days after DP treatment [7]. Assuming a conservative 
estimate of  30% infection after DP and assuming PQ would reduce this to below 5% [28], 
a sample size of  60 participants per treatment arm, allowing for 10% loss to follow up, 
was considered sufficient to detect this difference in infection rate with 90% power at a 
significance level of  0.05. 
Data Analysis
The primary efficacy endpoint for the Kenyan trial was the mean gametocyte clearance 
time (GCT; i.e. number of  days until gametocytes become undetectable by QT-NASBA 
[24] in the DP-PQ arm compared to the DP arm), calculated using previously presented 
mathematical models that allow clearance time to be extrapolated beyond the period of  
follow-up [29]. Secondary endpoints were the area under the curve (AUC) of  QT-NASBA 
based gametocyte density over time (gametocytes/µL-1 days) [5] using log10 gametocyte 
density in linear regression models with adjustment for baseline gametocyte density, and 
qRT-PCR gametocyte prevalence, density, and sex ratio (proportion of  total gametocytes 
that were male) at days 3 and 7. Stata 12.0 (Stata Corporation, College Station, TX, USA) 
and SAS 9.3 (SAS Institute, Cary, NC, USA) were used for statistical analysis. Baseline 
measures were compared between treatment arms using student’s t-test, Wilcoxon rank-sum 
tests, or chi-squared tests. Differences between treatment arms in gametocyte prevalence 
and (log10 transformed) density after baseline were assessed with linear and logistic models, 
after adjusting for gametocyte density at baseline. Differences in the proportion of  male 
gametocytes between treatment arms were compared with Wilcoxon rank-sum tests 
at baseline, and linear models adjusted for baseline gametocyte density after treatment. 
Proportions within treatment arms were compared to paired baseline measures with 
Wilcoxon signed-rank tests. The accuracy of  gametocyte sex ratio estimates depends on the 
total number of  gametocytes detected. To ensure robust sex ratio estimates, ratio analyses 
were restricted to samples with total qRT-PCR estimated counts of  >16 gametocytes per 
sample [30], resulting in minimum gametocyte/µL thresholds of  0.032 for Kenyan samples, 
and 0.32 for Malian samples.
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Results
5525 children were screened, and 120 gametocyte carriers were enrolled into the Kenyan 
trial (figure 1). 60 were assigned to receive DP with a placebo, and 60 were assigned to 
receive DP-PQ. Four participants in the DP arm and 2 in the DP-PQ arm were lost to 
follow up or excluded from the trial. The lowest Hb concentration recorded during the trial 
was 6.9g/dL, observed in one individual prior to PQ administration who was excluded 
from the trial. Minimum recorded Hb in all other participants was 8.6g/dL.
 Gametocyte density at baseline was not significantly different between treatment arms 
by microscopy (p=0.705), or qRT-PCR (females, p=0.692; males, p=0.784; combined 
males and females, p=0.823) (table 1). The median proportion of  male gametocytes at 
baseline was 0.33 (IQR 0.22-0.49) in the DP arm, and 0.32 (IQR 0.17-0.53) in the DP-PQ 
arm (p=0.547); i.e. a sex ratio of  approximately 1 male to 2 females (table 2).
Gametocytocidal efficacy of low dose PQ
QT-NASBA gametocyte prevalence on day 3 (24 hours after PQ) was 89.3% (50/56) in 
the DP arm and 96.6% (56/58) in the DP-PQ arm (p<0.093) (figure 2, table 2). At day 
7 gametocyte prevalence by QT-NASBA was 85.7% (48/56) in the DP arm, and 37.9% 
(22/58) in the DP-PQ arm (p<0.001). The estimated mean time to gametocyte clearance 
in our selective population with high starting gametocyte densities was 49.2 days (95% 
confidence interval [CI] 30.6-67.9) in the DP arm and 9.8 days (95% CI 7.7-12.0) in the 
DP-PQ arm (p<0.001). For DP, this estimate was based on an extrapolation of  QT-NASBA 
data beyond the duration of  follow-up and should therefore be interpreted with caution.
 All gametocyte density and sex-ratio estimates were based on qRT-PCR. As a consequence 
of  the higher input material for qRT-PCR in the Kenya trial (500 µL of  whole blood for 
extraction, eluted in 10.5 µL water) compared to QT-NASBA (50 µL of  whole blood for 
extraction eluted in 50 µL water), qRT-PCR gametocyte prevalence was considerably 
higher. At day 3, total gametocyte density determined by qRT-PCR was decreased to 
24.81% (IQR 9.54-48.29%) of  its level at baseline in the DP arm, and 35.73% (IQR 14.39-
80.82%) in the DP-PQ arm (p-value after adjustment for baseline density=0.03). By day 7, 
total gametocyte density was decreased to 22.31% (IQR 7.38-78.22%) of  its baseline level in 
the DP arm, and 1.43% (IQR 0.22-8.19%) in the DP-PQ arm (p<0.001). Gametocyte area 
under the curve (AUC) was significantly lower in the DP-PQ arm (p=0.018). 
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Figure 1. Screening and enrolment criteria. DP = Dihydroartemisinin piperaquine, PQ = PQ (0.25mg/kg)
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Table 1: Characteristics of the study population at baseline
Characteristics at baseline DP + Placebo (n=56) DP + 0.25mg/kg PQ (n=58) p value
Demographic and health
 Female % (n/N) 39.3 (22/56) 46.55 (27/58) 0.433
 Age (years) 9.5 (7-11) 10 (7-12) 0.948
 Haemoglobin (g/dL) 11.9 (10.7-13.0) 12.0 (11-12.4) 0.753
Microscopy
 Asexual prevalence (%) 69.09 (38/55) 59.7 (34/57) 0.297
 Asexual density (parasites/μL) 360 (0-1600) 120 (0-800) 0.133
 Gametocyte prevalence (%) 100.0 (55/55) 100.0 (56/56) -
 Gametocyte density (parasites/μL) 32 (16-64) 32 (16-48) 0.705
qRT-PCR
 Total gametocyte prevalence (%) 100.0 (54/54) 100.0 (57/57) -
 Total gametocyte density (parasites/μL) 10.84 (3.06-69.97) 11.87 (4.16-55.80) 0.823
 Male gametocyte prevalence (%) 100.0 (54/54) 100.0 (57/57) -
 Male gametocyte density (parasites/μL) 3.76 (0.78-11.16) 3.09 (0.811-14.14) 0.784
 Female gametocyte prevalence (%) 100.0 (55/55) 100.0 (57/57) -
 Female gametocyte density (parasites/μL) 6.66 (0.85-36.60) 7.64 (1.59-23.92) 0.692
Data are median (IQR) or % (positive/total sample size); - = not calculable; densities are presented for 
all individuals.
Effect of DP and PQ on male and female gametocytes
By day 3 female gametocyte density was decreased to a median of  9.1% (IQR 1.3-33.5%) 
of  its baseline level in the DP arm, and 14.0% (IQR 2.9-65.2%) of  its baseline level in the 
DP-PQ arm (p=0.152) (table 2, figure 3). Male density decreased less substantially over 
the same period (DP = 40.1% (IQR 15.8-86.6%) of  baseline, DP-PQ= 61.8% (IQR 27.7-
191.6%) of  baseline, p=0.035), resulting in male biased sex ratios in both treatment arms 
(DP= 0.70 [IQR 0.47-0.91), DP-PQ=0.68 [0.35-0.93], p=0.625). 
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Figure 2. Gametocyte prevalence and density. A. Gametocyte density determined by microscopy 
at all sampling points, presented as the median, IQR and 10th-90th percentiles of gametocytes per µL 
for gametocyte positive individuals only. For clarity, four data points were not included in the graph; 
3 in the DP only arm at day 0 (576, 608, 686/µL), 1 in the PQ arm at day 0 (1072/µL). B. Gametocyte 
prevalence determined by microscopy or Pfs25 based QT-NASBA, presented as percent positive, with 
95% CI.
At day 7, the density of  gametocytes was significantly reduced in the DP-PQ arm relative to 
the DP arm (females=0.05% [IQR 0.0-0.7%] of  baseline, males = 3.4% [IQR 0.4-32.9%] of  
baseline, p<0.001). In the DP arm, sex ratios were lower than at day 3 but still higher than 
baseline (median proportion male=0.44, IQR 0.26-0.68, p=0.002). Sex ratios among the 
low densities of  gametocytes in the DP-PQ arm were significantly more male biased than 
in the DP arm (median proportion male=0.98, IQR 0.89-1.00, p values <0.001 for matched 
measures at baseline, and group comparison with DP arm).
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Figure 3. qRT-PCR based male and female gametocyte density and proportion male in the 
Kenyan study. A. Proportion of total gametocyte density that are male (males per µL/[males per µL 
females per µL]), presented as individual data points, with the median and interquartile range (IQR). 
Proportion male was only presented or included in analyses if total gametocyte density was estimated 
to be greater than or equal to 16 gametocytes per sample (1 gametocyte/500µL=0.032 gametocytes/
µL). B. Gametocyte density determined by qRT-PCR at baseline (d0), and 24 (d3) or 120 (d7) hours 
after DP/DP-PQ. Female gametocytes were quantified by extrapolating Pfs25 mRNA abundance from 
standard curves of known quantities of female gametocytes, and vice versa. Density is presented as 
median, IQR and 10th-90th percentiles of gametocytes per µL for gametocyte positive individuals only. 
Effect of DP and PQ on gametocyte sex-ratio in relation to infectivity to 
mosquitoes in an independent trial in Mali
Pfs25 qRT-PCR based gametocyte prevalence, density, and infectivity to mosquitoes for the 
trial in Mali have been reported elsewhere [14]. At baseline the median proportion of  male 
gametocytes was 0.15 (IQR 0.09-0.27) overall, and did not differ between any DP-PQ arms 
and the DP arm (p=0.414-0.996) (figure 4). At day 2 (48 hours after PQ administration) 
there was a significant decrease in the proportion of  individuals infecting mosquitoes and 
the proportion of  mosquitoes these individuals infected at all PQ doses of  >0.125mg/kg 
(figure 4). The median proportion of  gametocytes that were male at day 2 was 0.28 (IQR 
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0.14-0.53) in the DP arm. Adjusted for baseline gametocyte density, the proportion of  
male gametocytes was borderline significantly different in the 0.0625mg/kg PQ arm (0.14 
(IQR 0.09-0.27), p=0.052), but not in any higher dose PQ arms (proportion male=0.15-
0.55, p=0.085-0.434). The proportion of  male gametocytes was similar between DP and 
DP-PQ arms at day 3 (p≥0.358), but became highly male biased compared to the DP arm in 
the 0.25 and 0.5mg/kg DP-PQ arms by day 7 (DP=0.29 (IQR 0.24-0.41); 0.25mg/kg=0.80 
(IQR 0.13-0.89), p=0.035; 0.5mg/kg=1.0 (IQR 0.99-1.0), p<0.001). Increasing PQ doses 
reduced the female bias of  gametocytes by day 7 (table S7). Within each treatment arm, the 
proportion of  male gametocytes at day 7 was significantly higher relative to baseline in the 
DP (p=0.016), and DP+PQ dose groups 0.125mg/kg (p=0.033) and 0.5mg/kg (p=0.043), 
but not in in the 0.0625mg/kg (p=0.477) or 0.25mg/kg (p=0.080) dose groups. There was 
no significant difference in the proportion of  male gametocytes between infectious and non-
infectious individuals at baseline (infectious/non-infectious = 55/26, p=0.964), at day 2 
(infectious/non-infectious = 21/57, p=0.531), or at day 7 (infectious/non-infectious = 5/71, 
p=0.244) (figure 5).
Figure 4. Infectiousness to mosquitoes, qRT-PCR based male and female gametocyte density, 
and proportion male in the Malian study. A. Prevalence of infectiousness to mosquitoes among 
the study population in the direct membrane-feeding assay at day 0, 2 and 7. Asterisks (*) indicate 
significantly different infectiousness in logistic regressions relative to control. Mosquito infection was 
determined as the presence of any number of oocysts in the mosquito mid-gut 7 days after feeding. 
B. Proportion of total gametocyte density that are male (males per µL/[males per µL females per µL]), 
presented as individual data points, with the median and interquartile range (IQR). Proportion male 
was only presented or included in analyses if total gametocyte density was estimated to be greater 
than or equal to 16 gametocytes per sample (1 gametocyte/50µL=0.32 gametocytes/µL). Data from 
each dose arm and time point are not included in the graph if proportion male was calculable for 
four or less individuals per arm. Asterisks (*) indicate significantly different proportion male in logistic 
regressions relative to control, adjusted for baseline density C. Gametocyte density determined by 
qRT-PCR at baseline (d0), and 24 (d3) or 120 (d7) hours after DP/DP-PQ. Female gametocytes were 
quantified by extrapolating Pfs25 mRNA abundance from standard curves of known quantities of 
female gametocytes, and vice versa. Density is presented as median, IQR and 10th-90th percentiles of 
gametocytes per µL for gametocyte positive individuals only. Median female gametocyte density was 
calculated from less than 5 individuals in some dose arms at day 7 (0.5mg/kg, n=4), and day 14 (0.5mg/
kg, n=2). Median male gametocyte density was calculated from less than 5 individuals in some dose 
arms at day 14 (0.25mg/kg, n=3; 0.5mg/kg, n=4).
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Figure 5. Proportion of male gametocytes in infectious and non-infectious samples before 
and after treatment in the Malian study. A. Proportion of gametocytes that were male in samples 
taken at baseline from individuals whose whole blood was infectious (=I) or non-infectious (=UI) to 
mosquitoes in the direct membrane feeding assay. Mosquito infection was determined as the presence 
of any number of oocysts in the mosquito mid-gut 7 days after feeding. n = number of individuals for 
which proportion male was calculable, and for which mosquito feeding assays were conducted. B. 
Proportion of gametocytes that were male in samples taken at day 2 (48 hours after first dose of DP in 
both the DP and DP-PQ arms, and only dose of primaquine in DP-PQ arms only) from individuals whose 
whole blood was infectious (=I) or non-infectious (=UI) to mosquitoes in the direct membrane-feeding 
assay. n = number of individuals for which proportion male was calculable, and for which mosquito 
feeding assays were conducted.
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Table 2: Gametocyte measures in the Kenyan study
A. Microscopy and QT-NASBA DP + Placebo (n=56) DP + PQ (n=58) p value
Gametocyte prevalence, % n/N (Microscopy)
 Day 0 100.0 (55/55) 100.0 (56/56) -
 Day 2 44.4 (24/54) 40.0 (22/55) 0.803
 Day 3 44.4 (24/54) 42.9 (24/56) 0.811
 Day 7 29.6 (16/54) 7.1 (4/56) 0.006
 Day 14 9.6 (5/52) 0 (0/56) -
Gametocyte prevalence, % n/N (QT-NASBA)
 Day 0 98.2 (55/56) 98.3 (57/58) 0.980
 Day 2 94.6 (53/56) 98.3 (56/57) 0.334
 Day 3 89.3 (50/56) 96.6 (56/58) 0.093
 Day 7 85.7 (48/56) 37.9 (22/58) <0.001
 Day 14 81.8 (45/55) 8.62 (5/58) <0.001
Gametocyte clearance time/days (95% CI) 49.2 (30.6 - 67.8) 9.8 (7.7 - 12.0) <0.001
Gametocyte AUC/gams/µL-1 days (median, 
IQR)
55.4 (26.9-154.5) 35.4 (12.8-70.1) 0.018
B. Sex specific qRT-PCR
Female gametocyte prevalence, % n/N 
(Pfs25)
 Day 0 100.0 (55/55) 100.0 (57/57) -
 Day 3 92.7 (50/55) 94.7 (51/57) 0.816
 Day 7 88.9 (48/54) 71.4 (33/56) 0.001
Male gametocyte prevalence, % n/N 
(PfMGET)
 Day 0 100.0 (54/54) 100.0 (57/57) -
 Day 3 96.4 (54/56) 96.5 (55/57) 0.931
 Day 7 96.3 (52/54) 96.5 (53/57) 0.465
Total gametocyte prevalence, % (n/N) (Pfs25 
& PfMGET)
 Day 0 100.0 (54/54) 100.0 (57/57) -
 Day 3 96.4 (53/55) 96.5 (55/57) 0.920
 Day 7 96.3 (52/54) 96.4 (52/56) 0.933
Female gametocyte density, gams/µL (Pfs25)
 Day 0 6.650 (0.851-36.599) 7.640 (1.594-23.916) 0.692
 Day 3 0.427 (0.054-2.403) 1.307 (0.111-6.277) 0.152
 Day 7 0.831 (0.080-3.122) 0.003 (0.000-0.055) <0.001
Male gametocyte density, gams/µL (PfMGET)
 Day 0 3.762 (0.778-11.164) 3.084 (0.8114-14.142) 0.784
 Day 3 1.511 (0.303-8.854) 1.920 (0.476-12.387) 0.035
 Day 7 0.870 (0.213-4.749) 0.137 (0.0140-0.600) <0.001
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Total gametocyte density, gams/µL (Pfs25 & 
PfMGET)
 Day 0 10.836 (3.056-69.973) 11.870 (4.157-55.800) 0.823
 Day 3 2.864 (0.495-14.707) 4.167 (1.128-18.080) 0.030
 Day 7 2.509 (0.631-7.136) 0.140 (0.018-0.855) <0.001
Proportion male (median, IQR)
 Day 0 0.338 (0.222-0.493) 0.323 (0.171-0.525) 0.457
 Day 3 0.692 (0.475-0.910) 0.677 (0.345-0.928) 0.634
 Day 7 0.457 (0.278-0.732) 0.979 (0.868-1.000) <0.001
Proportion male (median/IQR) 
≥16 gams/sample only
 Day 0 0.332 (0.222-0.492) 0.323 (0.171-0.525) 0.457
 Day 3 0.700 (0.472-0.911) 0.677 (0.345-0.928) 0.635
 Day 7 0.441 (0.262-0.683) 0.977 (0.891-0.996) <0.001
Data are median (IQR) or % (positive/total sample size), - = not calculable; densities are presented for 
all individuals
Discussion
Our findings support the effectiveness of  a single dose of  PQ (0.25mg/kg) for shortening 
gametocyte carriage following ACT treatment [13]. Our sex-specific qRT-PCR suggests that PQ 
may not preferentially clear male gametocytes. At early time points when PQ has been shown 
to substantially decrease infectiousness to mosquitoes (24-48 hours) [14, 20], the proportion of  
gametocytes that were male was comparable between DP-PQ and DP-only arms.
 Before treatment, there is a non-linear relationship between gametocyte density and 
infectivity to mosquitoes [31-33]. After PQ treatment gametocyte density has no obvious 
relationship with infectivity and infections appear sterilised [14, 20, 24]. White and 
colleagues highlighted this phenomena in historic studies and urged that trials of  PQ 
efficacy based on gametocyte density measures must be interpreted with caution [20]. In a 
recent PQ efficacy trial, it was postulated that because gametocytes were quantified using 
Pfs25 based molecular assays, only female gametocytes were counted, while infections may 
have been sterilised by clearance of  the smaller undetected male population [14]. If  total 
clearance of  one sex was the cause of  PQ’s rapid sterilising effects, a highly sensitive sex-
specific assay would be capable of  predicting post-treatment infectivity. Though we believe 
the assay presented in the current manuscript meets these requirements, our data indicates 
that PQ treatment has a similar effect to ACT treatment in terms of  absolute sex ratio, in the 
days after treatment where infections are sterilised. The extent of  the effect varied between 
the two trials we describe in the current study and may relate to the timing of  PQ and 
Table 2: Continued
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ACT administration, and to the limited sample size of  treatment arms in the Malian trial. 
However, neither trial provides evidence of  the hypothesised increase in female bias after 
PQ treatment; the Kenyan trial indicates male gametocytes may actually be cleared more 
slowly than females by both DP and DP-PQ. Whilst gametocyte sex-ratio is an important 
determinant of  transmissibility and may be associated with gametocyte density, we observed 
no relation between post-treatment gametocyte sex-ratio and infectivity. Collection of  RNA 
samples from a larger number of  gametocyte donors participating in mosquito feeding 
studies conducted prior to drug administration would allow more rigorous assessment of  
gametocyte sex-ratio and its effect on the likelihood of  onward transmission in natural 
infections.
 Our findings do not exclude the possibility that PQ’s sterilising effects are sex-specific. 
The P. berghei based in vitro dual gamete formation assay has shown that male gametocytes 
are more susceptible to a range of  drugs with different modes of  action [21]. The advantage 
of  this system is that its endpoint (exflagellation in males, production of  the translationally 
repressed Pfs25 protein in activated females) is based on gametocytes ability to activate 
(i.e. their fitness) rather than the presence of  their mRNA, which may remain detectable 
in non-functional intact gametocytes. Quantifying gametocytes based on mRNA transcript 
numbers has limitations [34]. We used automated RNA extraction to minimize variation 
in extraction efficiency and assessed mRNA transcript numbers during gametocyte 
maturation. mRNA transcripts of  Pfs25 and PfMGET increased sharply from stage II to 
stage V gametocytes after which we found no evidence for age-dependent transcription 
patterns that may explain our findings of  a faster reduction of  female-specific transcripts 
following treatment (supplemental figure S4). Our findings suggest that the early sterilizing 
effect of  PQ may be a consequence of  a reduced fitness, rather than immediate clearance of  
one or both gametocyte sexes. Delves et al. showed that percent inhibition of  activation by 
dihydroartemisinin was approximately 14x higher for male gametocytes than females [21]. 
Though this appears to conflict with our observation that male gametocytes are cleared 
more slowly by DP-PQ, both observations may be valid if  (male) gametocytes were rendered 
non-functional by DP-PQ but remained in the circulation during sampling. As such, our 
study supports the notion that functional assays (be it gametocyte fitness or infectivity) are 
essential to determine the transmission-blocking properties of  antimalarial drugs. 
 Observations of  microscopy’s insensitivity [6, 35-38] and the significance of  sub-
microscopic gametocyte densities for transmission [39-41] have placed great import on 
quantifying the sub-microscopic gametocyte reservoir. The recent realisation that Pfs25 is 
transcribed specifically, or in far greater abundance in female gametocytes, affects previous 
interpretations of  the Pfs25 readout as measure of  gametocyte density [19] since the 
male component of  gametocyte biomass will have gone largely undetected and thus total 
gametocyte density will have been underestimated. 
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The results of  the current study shed some light on PQ’s early sterilising activity. Determining 
gametocyte sex-ratio may have significant utility for examining the relationship between 
gametocyte density, sex, and infectivity to mosquitoes, and for the assessment of  drugs 
causing clearance of  one sex. However, our findings demonstrate that the preferential 
clearance of  one gametocyte sex does not provide an explanation for the rapid sterilizing 
effect of  PQ. Trials assessing transmission-blocking effects of  drugs like PQ should thus 
continue to rely on functional transmission read-outs such as mosquito feeding assays. 
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Supplementary materials
A. Confirmation of sex-specificity of the transgenic PfDynGFP/
P47mCherry line
The purity of  male and female fractions obtained using the PfDynGFP/P47mCherry line 
was assessed by immune-fluorescence assays (IFA) and microscopy. This line expresses sex-
specific fluorescent markers (GFP integrated under the control of  the male specific Dynein 
heavy chain promoter, mCherry expression controlled by the female specific P47 promoter in 
episomal plasmids), which allow separation of  males and females by fluorescence-activated 
cell sorting (FACS) [1]. A detailed description of  the development of  the reporter line, 
culture conditions, and sorting into sex specific populations by flow cytometry has been 
reported [1]. For the current experiments, conducted at Istituto Superiore di Sanita in Rome, 
Italy, sorting was performed based on GFP signal only. On day 5 following NAG, 4x107 
stage III gametocytes were purified by MACS column, sorted based on GFP expression and 
GFP+ (male gametocytes) and GFP- fractions (female gametocytes) were brought back into 
separate cultures. On day 12, sorted populations had progressed to stage V gametocytes and 
were analysed by IFA using the gametocyte (rabbit anti-Pfg27 [2]) and female gametocyte-
specific antibodies (mouse anti-Pfg377 [3] generated using immunization with recombinant 
Pfg377 [4]) and by microscopy examination of  Giemsa stained smears. IFA analysis show 
that the GFP + fraction was 100% Pfg27+/Pfg377- (Figure S1, Figure S2) and are thus 
males. This was confirmed by examination of  the Giemsa stained smears showing that 
gametocytes exhibit the diagnostic cytoplasmic pink staining (Figure S3). By contrast, the 
GFP- fraction was 83% Pfg27+/Pfg377+ and thus females (Figure S1, S2). Examination of  
the Giemsa stained smears confirms that the vast majority of  these gametocytes exhibit the 
diagnostic cytoplasmic blue staining (FigureS3). A minor fraction the GFP- gametocytes 
(17%) are Pfg27+/Pfg377-. These could be male gcytes from a population of  non-fluorescent 
gametocytes. These results fully support the conclusion that mCherry+/GFP- gametocytes 
are female gametocytes. 
Figure S1. Counts of live 
fluorescent gametocytes in the 
GFP+ and GFP- populations and 
summary of IFA results. A. Counts 
of live fluorescent gametocytes in 
GFP+ and GFP- populations (based 
on FACS sorted parasite material). 
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Figure S2. Representative IFA results
GFP+ gametocytes (100% Pfg27+/Pfg377-)
α-Pfg377 α-Pfg27 merge + Hoechst
GFP- gametocytes (83% Pfg27+/Pfg377+)
α-Pfg377 α-Pfg27 merge + Hoechst
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Figure S3. Giemsa staining of stage V gametocyte populations that were sorted based on GFP 
signal
B. Sex specific qRT-PCR development
Target selection
Sex-specific qRT-PCR assays using primers based on Pfs25 (female marker; PF3D7_1031000) 
and Pfs230p (male marker; PF3D7_0208900) were previously reported [5]. We tested a novel 
male marker, Pf3D7_1469900 (PfMGET), based on a recently published sex-partitioned 
transcriptomic analysis of  P. falciparum gametocytes [1]. We selected this gene based on sex-
specificity, asexual stage over gametocyte ratio, and qRT-PCR performance. Table S1 shows 
the 10 genes most abundantly transcribed in male gametocytes, their abundance in female 
gametocytes, and their ratio in females to males. Furthermore, publically available illumina 
based mRNA sequence libraries (www.plasmodb.org) from seven P. falciparum life stages 
(ring, early trophozoite, late trophozoite, schizont, gametocyte stage II, gametocyte stage 
V, and ookinete) indicates a ratio of  transcript abundance in asexual stages over mature 
gametocytes (in fragments per kilobase per million mapped reads (FPKM); average of  all 
asexual stages/gametocyte stage V) of  0.36 for Pfs230p and 0.07 for PfMGET [6]. Proteins 
aligning to PfMGET were not observed in a recent proteomic analysis of  sex separated stage 
V P. falciparum gametocytes (expressing GFP under the control of  the male specific γ-tubulin 
II promoter), and were detected at very low level in previous proteomic analyses [1, 7]. 
PfMGET was selected for further testing based on evidence of  low transcription in asexual 
stage parasites, high transcript abundance in gametocytes, male gametocyte specificity, and 
on its adaptability to diagnostic qRT-PCR; PfMGET contains introns, which allowed the 
design of  intron spanning primers (Table S2), thereby obviating the necessity for DNase 
treatment that may reduce sensitivity [8].
GFP+ gametocytes (males) GFP- gametocytes (females)                                    
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Table S1. Transcript levels of top 10 male genes. 
Gene ID Old Gene ID Product MG FG
RATIO 
FG/MG
PF3D7_1201600 PFL0080c NIMA related kinase 3 (NEK3) 17813.52 236.63 0.01
Pf3D7_1469900 
(PFMGET)
PF14_0667 conserved Plasmodium protein, 
unknown function
10110.85 208.93 0.02
PF3D7_0406200 PFD0310w sexual stage-specific protein 
precursor (Pfs16)
7991.31 10195.62 1.28
PF3D7_1413200 PF14_0131 conserved Plasmodium protein, 
unknown function
3859.07 362.29 0.09
PF3D7_0422300 PFD1050w alpha tubulin 2 3618.96 89.36 0.02
PF3D7_1311100 PF13_0060 meiosis-specific nuclear structural 
protein 1, putative
2548.67 12.59 0.00
PF3D7_1105100 PF11_0062 histone H2B (H2B) 2426.04 658.45 0.27
PF3D7_0617800 PFF0860c histone H2A (H2A) 2111.91 2573.03 1.22
PF3D7_0726000 28S ribosomal RNA 1616.88 1465.62 0.91
PF3D7_0630800 PFF1495w conserved Plasmodium protein, 
unknown function
1541.28 235.37 0.15
Data are from Table S2 in Lasonder et al. 2016. Values for MG (male gametocytes) and FG (female 
gametocytes) are normalised reads per kilobase per million reads [RPKM]. Ratio is FG RPKM/MG RPKM.
Table S2. Primer sequences for the Pfs25 female marker, and male markers Pfs230P and PfMGET.
Gene target Forward primer Reverse primer
Pfs25 [9] GAAATCCCGTTTCATACGCTTG AGTTTTAACAGGATTGCTTGTATCTAA
Pfs230P [5] CCCAACTAATCGAAGGGATGAA AGTACGTTTAGGAGCATTTTTTGGTAA
PFMGET CGGTCCAAATATAAAATCCTG GTGTTTTTAATGCTGGAGCTG
For preliminary testing of  the new marker, qRT-PCR assays were performed using 
standard curves of  mixed sex NF54 gametocyte mRNA (ten-fold serial dilutions from 106 
to 10 gametocytes/mL). Briefly, NF54 P. falciparum was cultured in the semi-automated 
culture system and started at 5% hematocrit and 0.5% parasitemia [10, 11]. Treatment 
with N-acetyl-glucosamine on day 7 eliminated asexual parasites, and mature stage IV/V 
gametocytes were harvested after 13–15 days, which was confirmed by Giemsa stained 
thin blood films. Gametocyte samples were serially diluted into 50µL blood, and stored 
in 250µL RNAprotect lysis buffer (Qiagen, Hilden, Germany). Total nucleic acid was 
extracted using a MagNAPure LC automatic extractor (Total Nucleic Acid Isolation Kit–
High Performance; Roche Applied Science, Indianapolis, IN, USA) followed by RQ1 
DNaseI digest (Promega, Sunnyvale, CA, USA) and cDNA synthesis (High Capacity 
cDNA Reverse Transcription Kit, Applied Biosystems, Foster City, CA, USA). DNaseI 
digestion was performed for all mixed sex gametocyte samples. qRT-PCR was performed as 
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described previously [12], except that 1µL cDNA was used in the 20µL final reaction mix, 
and primer concentration was reduced to 225nM.
 Despite a probable loss of  sensitivity incurred to the PfMGET assay through DNaseI 
digestion, PfMGET mRNA appeared more abundant than Pfs230p mRNA, reflecting 
evidence of  the transcripts relative abundance per capita [1, 6]. Data from assays conducted 
in parallel on the same material are shown in table S3. The lower CTs for the Pfs25 may 
represent higher transcript copy numbers per parasite, but are also likely the result of  female 
bias in the mixed sex gametocyte culture. 
Table S3. Pfs25, Pfs230p, and PFMGET qRT-PCR, with standard curves of mixed sex NF54 
gametocytes. 
Parasite/stage Quantity (gams/mL) Pfs25 Pfs230p PFMGET
Gametocytes (NF54)
Mixed sex & NAG 
synchronised
10^6 20.72 27.2 24.34
10^5 23.83 29.84 27.03
10^4 26.94 32.19 30.48
10^3 30.14 N/A 32.82
10^2 34.56 N/A 33.74
10^1 34.17 N/A N/A
Data in the table come from assays performed on the same batch of gametocyte material. The data 
represent means of triplicate qRT-PCR CT values, except for Pfs230 which was performed once using 
this material.
NAG   N-acetyl-glucosamine
Gams/mL Gametocytes per mL
Gametocyte specificity
To empirically assess the specificity of  PfMGET mRNA to gametocytes, and determine 
expression at different asexual stages, qRT-PCR assays were performed using standard 
curves of  synchronised NF54 asexual mRNA. Asexual parasites were synchronized by the 
selection of  late trophozoites and schizonts on a 63% percoll density gradient, followed 
by a 5% sorbitol treatment, killing the remaining schizonts after 5 hours, ensuring tight 
synchronization of  parasites within a 5 hour window. Ring stage parasites were harvested 
10, 20, 30 and 40 hours after percoll synchronization respectively. Parasite samples were 
lysed in L6 buffer and extracted immediately or frozen at -80oC until further use. Extraction 
and PCR conditions were the same as for the unsynchronised gametocyte samples, except 
that cDNA input to qRT-PCR was 2 µL.
 Though input to PCR was double for the Pfs230p and PFMGET assays compared to 
Pfs25, transcript became undetectable at similar levels in the Pfs25 and male marker assays 
(threshold for detection generally >10^4) (Table S4).
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Table S4. Standard curves of synchronised asexual stage NF54 P. falciparum. 
Parasite/stage Quantity (gams/mL) Pfs25 Pfs230p PFMGET
Asexuals 10hr 10^6 32.18 32.54 32.66
 10^5 34.91 N/A N/A
 10^4 N/A N/A N/A
Asexuals 20hr 10^6 35.91 N/A 32.47
 10^5 N/A 37.46 34.83
 10^4 N/A N/A N/A
Asexuals 30hr 10^6 31.65 32.50 32.51
 10^5 33.51 32.89 34.23
 10^4 N/A N/A N/A
Asexuals 40hr 10^6 30.04 31.89 32.45
 10^5 34.78 N/A N/A
 10^4 N/A N/A N/A
Data in the table are qRT-PCR CT values.
N/A  mRNA not detectable
Gams/mL Gametocytes per mL
Male/female gametocyte specificity/sensitivity
We then used sorted male and female gametocytes to assess specificity of  our assay. For 
this standard curves of  purified female and male gametocytes (ten-fold serial dilutions from 
106 to 10 gametocytes/mL) were constructed from gametocyte mRNA of  the transgenic 
parasite line PfDynGFP/P47mCherry. [1]. Briefly, NF54 WT and PfDynGFP/P47mCherry 
parasites were cultured in the semi-automated culture system and started at 5% hematocrit 
and 0.5% parasitaemia [10, 11]. Treatment with N-acetyl-glucosamine (NAG) on day 7 
eliminated asexual parasites to harvest mature stage IV/V gametocyte after 13–15 days, 
confirmed by Giemsa stained thin blood films. Gametocytes were concentrated in 37°C 
culture medium, separated from uninfected erythrocytes using a 63% Percoll density 
gradient, and subsequently taken up in a 4°C suspended activation (SA) buffer (10 mM 
Tris, pH 7.3, 170 mM NaCl, 10 mM glucose). Using a Coulter Epics Elite flow cytometer 
(Beckman Coulter) gametocytes were first separated from uninfected red blood cells using 
forward and sideward scatters, and then were sorted based on signal intensity of  the 
fluorescent proteins (green fluorescent protein (GFP) or mCherry). A recent proteomic 
analysis of  a P. falciparum gametocyte strain expressing GFP under the control of  the male 
specific γ-tubulin II promoter confirms the male specificity of  Dynein heavy chain protein 
expression, but indicates shared expression of  P47 in male and female gametocytes [13]. 
The observation that, upon induction of  gamete formation by addition of  xanthurenic acid 
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and a drop of  temperature, exflagellation centers (i.e. male gametes) are produced only by 
GFP+ gametocytes and never by mCherry+/GFP- gametocytes further confirm that GFP 
expression is restricted to male gametocytes (Giulia Siciliano and Pietro Alano, personal 
communication).In the current study, pure male and female specific populations were obtained 
by excluding fluorescence negative and double positive cells. Gametocytes were FACS-
sorted to obtain populations of  GFP+ mCherry- (male gametocytes) and GFP- mCherry+ 
(female gametocytes) gametocytes, which were kept at 4°C in suspended activation (SA) 
buffer. Assessed by fluorescence microscopy, no GFP positive parasites were observed in 
the mCherry+ populations, and no mCherry positive parasites were observed in the GFP+ 
populations (data not shown). FACS purity analysis indicated the single fluorescent cell 
populations were isolated with 99.7% purity. Preliminary testing was conducted with 100 
µL standard curves (table S5).
Table S5. qRT-PCR with Pfs25 and PfMGET and purified male and female gametocyte populations. 
Quantity (gams/
mL)
Batch 1  Batch 2  Batch 3  
PfMGET Pfs25 PfMGET Pfs25 PfMGET Pfs25 PfMGET Pfs25
10^6 19.55 20.42 19.13 21.47 19.89 20.91 27.25 25.17
10^5 23.04 23.56 22.24 24.23 23.05 24.14 30.57 27.78
10^4 26.38 27.12 25.72 27.72 26.98 28.15 N/A 31.55
10^3 29.47 29.58 28.50 31.79 30.92 31.61 N/A N/A
10^2 33.52 33.33 32.84 32.39 33.34 35.29 N/A N/A
10^1 N/A 34.86 N/A N/A 34.74 N/A N/A N/A
Males (GFP+; mCherry-)
Females (GFP-; mCherry+)
Data in the table are qRT-PCR CT values, for three biological replicates of purified male and female 
gametocyte material. Extraction procedures were as for the mixed sex preliminary samples, except 
that sample input to the magNAPure extractor was 100µL and elution was in 100µL of milliQ water.
N/A  mRNA not detectable
Gams/mL Gametocytes per mL
Sex-specific gametocyte standard curves were constructed utilising the separate GFP+, 
mCherry- and GFP-, mCherry+ gametocyte populations. Standard curve volume in blood, 
storage, and extraction procedure matched those of  clinical trial samples in the current 
study. Briefly, mRNA was extracted and eluted in 10.5µL of  water using ZR Whole Blood 
RNA miniprep kit (Zymo Research, Irvine, CA) from blood stored at a ratio of  1 part to 3 
in Blood RNA buffer (Zymo Research, Irvine, CA) at -20 °C. cDNA was synthesised (High 
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Capacity cDNA Reverse Transcription Kit, Applied Biosystems) directly from nucleic acids 
for the PFMGET assay, and after DNase treatment (RQ1 DNaseI, Promega) for the Pfs25 
and Pfs230p assays. The PFMGET assay was also performed using the DNAse digested 
RNA, for comparison. qRT-PCR reactions were conducted as previously described [9], 
except that primer concentrations were reduced to 225 nM and cDNA input into the final 
20 µL reaction mixture was adjusted to 2 µL. The results of  testing using the optimised 
standard curves is shown in Table S6. 
Table S6. qRT-PCR with Pfs25, Pfs230p and PFMGET primers using male (GFP+) and female 
(mCherry+) high volume gametocyte standard curves. 
Extraction material Total NA RNA RNA
Marker PfMGET P230p Pfs25 PFMGET P230p Pfs25
Q
ua
nti
ty
 (g
am
s/
m
L)
10^6 14.43 16.64 19.35 22.05 24.02 25.89 15.53
10^5 17.83 19.69 22.39 25.57 27.63 29.19 20.02
10^4 21.44 23.16 25.99 29.27 30.37 32.94 23.13
10^3 24.98 26.18 29.06 30.75 N/A N/A 26.26
10^2 28.21 29.29 33.1 N/A N/A N/A 30.08
10^1 30.98 33.44 N/A N/A N/A N/A 33.44
Males (GFP+; mCherry-)
Females (GFP-; mCherry+)
Data in the table are single qRT-PCR CT values. Sample input was 500µL. Total NA = Not DNAseI treated, 
RNA = DNAseI treated. Bold = Standard curve and sample preparation for analysis of Kenyan samples (for 
Malian samples, same preparation but lower volume – 50µL to match the sample volume).
N/A  mRNA not detectable
Gams/mL Gametocytes per mL
Removing the DNAse digestion step from RNA preparation for the PfMGET assay 
improved the assays sensitivity notably (increase of  approximately 2 CT’s in all biological 
replicates). The Pfs25 and PfMGET assays detection limits for gametocytes of  their cognate 
sex were <0.01 gametocytes/µL (the lowest gametocyte density used in the standard 
curves), while the detection limit of  the Pfs230p assay for male gametocytes was closer 
to 0.1 gametocytes/µL. When the female and male markers were tested using standard 
curve material from the alternate sex, the sensitivity of  the assays decreased by a factor of  
100-1000 (10^3/10^4 male gametocytes were detectable using the Pfs25 assay, 10^1 were 
detectable using the PfMGET assay, and vice versa for female parasites). The residual Pfs25 
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and 146 transcript detected in standard curve of  the opposite sex indicates either that both 
genes are transcribed in small quantities in gametocytes of  the opposite sex, or that the 
purified standard curves were contaminated by approximately 0.1-1% of  the opposite sex 
(in line with the purity of  the sorting as assessed by FACS purity analysis). As the level 
of  background signal was similar for both Pfs25 and 146, it was deemed unlikely to have 
an effect on the quantification of  either sex or the determination of  sex ratio in mixed sex 
samples. Sex ratio analyses were restricted to samples with total qRT-PCR estimated counts 
of  >16 gametocytes per sample (gametocyte/µL thresholds of  0.032 for Kenyan samples, 
and 0.32 for Malian samples), to improve reliability [14].
 For all clinical trial samples, separate aliquots of  mRNA were processed for the Pfs25/
Pfs230p assays and for the PfMGET assay, as for the standard curve material. Only samples 
and standard curves material retained for the Pfs25/Pfs230p assays were DNAse digested. 
qRT-PCR quantification was performed with matching sex standard curves to ensure that 
male/female specific RNA transcript abundance in field samples could be reliably converted 
to counts of  male or female gametocytes. For the Pfs25 and PfMGET assays a cut off  for 
positivity was set as 1 gametocyte per sample (2 gametocytes per mL/0.002 gametocytes 
per µL).
C. Pfs25 and PfMGET transcript abundance during gametocyte 
maturation
Relating gametocyte transcript numbers to gametocyte densities comes with uncertainties. 
One of  these uncertainties is related to the stability of  the number of  transcripts during 
gametocyte maturation. Figure S5, he figure below, that is now also provided in the 
supporting information presents mRNA transcript counts for Pfs25 and PF_14699000 
(PfMGET) in a time-course experiment. Culturing of  NF54 was done without prior 
gametocyte sex-sorting and female (top panel) and male (bottom panel) transcripts were 
quantified in the same source culture material using Illumina RNAseq with paired reads, 
37bp in length. Transcript counts after normalization for library size are presented for d4 
till d16 after synchronization; stage IV gametocytes were observed on day 5 and stage V 
gametocytes on day 7. These results indicate that for both male and female markers transcript 
abundance is low in stage IIb gametocytes and peaks in stage V gametocytes after which 
transcript numbers appear stable (Pfs25) or may decline at late time-points (PfMGET). It 
is currently unclear whether these patterns in vitro may be directly extrapolated to in vivo 
transcript numbers (as is indicated in the revised discussion section). However, an increase 
in transcript numbers per male gametocyte appears less likely based on these data.
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Figure S4. Transcript stability during gametocyte maturation.
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Summary
Gametocytes are the specialized form of  Plasmodium parasites that are responsible for 
human-to-mosquito transmission of  malaria. Transmission of  gametocytes is highly 
effective, but represents a biomass bottleneck for the parasite that has stimulated interest 
in strategies targeting the transmission stages separately from those responsible for 
clinical disease. Studying targets of  naturally acquired immunity against transmission-
stage parasites may reveal opportunities for novel transmission reducing interventions, 
particularly the development of  a transmission blocking vaccine (TBV). In this review, 
we summarize the current knowledge on immunity against the transmission stages of  
Plasmodium. This includes immune responses against epitopes on the gametocyte-infected 
erythrocyte (GIE) surface during gametocyte development, as well as epitopes present upon 
gametocyte activation in the mosquito midgut. We present an analysis of  historical data 
on transmission reducing immunity (TRI), as analyzed in mosquito feeding assays, and its 
correlation with natural recognition of  sexual stage specific proteins Pfs48/45 and Pfs230. 
Although high antibody titers towards either one of  these proteins is associated with TRI, 
the presence of  additional, novel targets is anticipated. In conclusion, the identification 
of  novel gametocyte-specific targets of  naturally acquired immunity against different 
gametocyte stages could aid in the development of  potential TBV targets and ultimately an 
effective transmission blocking approach.
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Introduction
Malaria remains one of  the largest global health threats, with the greatest burden of  
mortality and morbidity in developing countries of  tropical and sub-tropical regions. Despite 
considerable efforts to control the disease and block its spread, 3.3 billion people remained 
at risk of  contracting malaria in 2010, resulting in an estimated 660,000 deaths [1], primarily 
among young children and women in their first pregnancy. The difficulties in eliminating 
malaria with currently available tools [2] and the emergence of  artemisinin resistance in 
Southeast Asia [3, 4] highlight the need for interventions that specifically aim to reduce the 
transmission of  the parasites responsible for the disease. 
 Gametocytes are the highly specialized form of  Plasmodium parasites that are infectious 
to mosquitoes and thus required for successful transmission from humans to mosquitoes. 
Their formation and infectivity to mosquitoes is presented in Figure 1. P. falciparum 
gametocytes progress through five distinct morphological stages, until they reach the specific 
elongated crescent shape characteristic of  falciparum malaria. Male and female parasites 
are independently differentiated but genetically identical haploid stages that originate 
from asexual precursor stages; current evidence favors a model where one schizont gives 
rise to either male or female gametocytes [5, 6]. The only gametocytes that are observed 
in peripheral blood are sexually committed ring-stage parasites and fully mature stage 
V gametocytes [7, 8]. Intermediate stages II-IV are sequestered mainly in bone marrow 
compartments [9-11]. Although no genomic replication is present in gametocytes and the 
digestion of  hemoglobin ceases after six days of  development, gametocyte-specific mRNA 
is produced and a subset of  transcripts is translationally repressed until gametocytes are 
taken up in the mosquito blood meal and rapidly transform into gametes [12, 13]. The 
reduction in temperature, rise in pH and exposure to xanthurenic acid inside the mosquito 
induces gametogenesis, initiating activation and expression of  stage-specific proteins [14, 
15]. After three rounds of  DNA replication, male gametocytes exflagellate to release eight 
motile microgametes from the host cell that are targeted at the fertilization of  female 
macrogametes [16, 17]. The resulting zygotes elongate to form ookinetes that traverse 
the mosquito midgut and develop into oocysts. Sporozoites then develop within oocysts 
and, approximately 10 days after the blood meal, rupture the oocyst capsule and render 
the mosquito infectious by invading the insect’s salivary glands, completing the cycle of  
transmission [18].
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Figure 1. Maturation and location of P. falciparum transmission stage parasites. Timings are 
given cumulatively as the time since gametocyte formation, or where indicated as time post mosquito 
infection (PI), and as the stage-specific exposure time in brackets.
Transmission of  malaria parasites from humans to mosquitoes is highly effective, with 
infectious humans capable of  giving rise to >100 secondary human infections [19]. 
However, many factors influence the infectivity of  gametocytes, and their transmission 
potential [20, 21]. Gametocyte prevalence and density are highest in infants and young 
children [22], decreasing with age in parallel with cumulative exposure to malaria infection 
and acquired immunity to the parasite’s asexual stages [23, 24]. Though once thought to 
be rare, molecular detection methods have revealed that gametocytes are produced by the 
majority of  infected individuals of  all ages [21, 25-29] and that onward malaria transmission 
is not restricted to microscopically detectable gametocyte densities [30-33]. In addition to 
gametocyte maturity and sex ratio, human immune factors targeting the sexual stages of  the 
parasite also highly influence transmission efficiency [21].
 Here, we review the evidence for naturally occurring human immunity targeted to the 
transmission stages of  Plasmodium parasites, discuss hypotheses for the mechanisms of  this 
immunity, and suggest future research directions that may aid the design of  transmission 
reducing interventions.
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Immune responses to transmission stage parasites
Transmission Reducing Immunity (TRI) can be directed against numerous targets during 
gametocyte formation, maturation and transmission. Within the human host, a humoral 
response targeting parasite-specific epitopes on the gametocyte-infected erythrocyte (GIE) 
surface of  different developmental stages could contribute to a decreased transmission 
capacity. As erythrocytes do not express Major Histocompatibility Complex (MHC) 
molecules and consequently lack organelles required for antigen and MHC class I complex 
processing, presentation to and activation of  CD8+ T cells is thought to play a minor role in 
immune responses to the red blood cell stages of  the parasite, including gametocytes [21]. 
Phagocytosis by monocytes and neutrophils may provide a protective immune mechanism 
against schizont- and merozoite-infected erythrocytes [34, 35], and though there is evidence 
of  early stage GIE phagocytosis in vitro [36], evidence is limited for a functional role in 
vivo [37, 38]. Infected red blood cells may, however, be sensitive to cytokines released 
during general inflammatory responses. During periods of  peak parasitaemia, non-specific 
inflammatory responses may kill both asexual blood stage parasites and circulating 
gametocytes, resulting in substantially reduced infectivity [39, 40]. Clinical immunity to 
human malaria is associated with reduced induction of  cytokines and complementary 
parasite killing factors [40, 41], but there is no evidence that such factors have activity in 
the mosquito midgut. By comparison, there is substantial evidence that naturally acquired 
humoral responses to gametocyte proteins play a role in determining transmission efficiency.
Early stage gametocyte infected erythrocyte surface antigens
Early stage gametocytes of  P. falciparum (stage I-IV) sequester primarily in the bone marrow 
[9]. Previously, it has been assumed that developing gametocytes are not recognized by 
the immune system, but more recent evidence provides a rationale for the existence of  
immunogenic proteins on the GIE surface. Sutherland et al. proposed the involvement of  
immunogenic gametocyte proteins in GIE adhesion to microvasculature, as well as spatial 
and temporal signal transduction, in the human host [42]. For example, parasite sensing of  
signals via host receptors or via non-specific permeability pathways could induce changes 
in the host RBC erythrocyte adhesive phenotype and thus affect the timing of  gametocyte 
release into circulation. In a Thai cohort, naturally acquired antibody responses reduced 
transmission to mosquitoes and distorted the morphology and maturation of  young 
gametocytes [43]. Some of  these plasma antibodies also bound the GIE surface from 
gametocyte stage II onwards, suggesting that host antibodies can target early gametocytes, 
and supporting the need for similar studies in other patient cohorts. Initial studies into 
gametocyte sequestration suggested that gametocytes participate in adhesive interactions 
with host cell receptors, and therefore that adhesins are likely expressed on the GIE 
surface. Adhesive properties of  GIEs to C32 melanoma cells and trHBMEC human bone 
marrow endothelial cells were shown to only partly overlap with those of  asexual parasites, 
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indicating gametocyte-specific sequestration mechanisms [44, 45]. Recent studies detected 
limited adhesion of  gametocytes towards various endothelial cell types [46]. Building on 
recent evidence that gametocytes are enriched in the bone marrow parenchyma [9-11, 47], 
Joice et al. showed that the majority of  bone marrow gametocytes in a cerebral malaria 
patient cohort localized specifically at erythroblastic islands, where young erythroblasts 
develop around a nursing macrophage [9]. Transcriptional data suggests that at least a 
subset of  young gametocytes are in the blood circulation [8] while presence of  asexual 
parasites in the bone marrow parenchyma and formation of  gametocytes in erythroid 
precursor cells in vitro [9, 48] suggests that gametocyte formation could also occur in the 
bone marrow. In either case, potentially immunogenic surface molecules could be involved 
both in the processes of  i) parasite binding to endothelial cells, and ii) erythroblast island 
binding in the bone marrow parenchyma. At the erythroblastic island, gametocyte proteins 
could be involved in binding either to erythroid precursor cells or macrophages. To further 
test these possibilities, binding experiments with different cell types could be performed 
and the ability of  patient sera to inhibit these binding interactions examined. As cytokines 
and other innate immune factors likely influence endothelial permeability, it will be 
important to discern what role antibodies play compared to other immune components 
during both extravasation into and development within the bone marrow. Recent advances 
in distinguishing gametocyte stages in vitro [49, 50] and in flow cytometry assays examining 
antibody binding [51, 52] will enable identification of  early stage gametocyte specific 
immune responses in diverse patient populations. The functionality of  these immune 
responses could then be characterized in different clinical situations and the identity of  
the proteins targeted by early stage gametocyte-specific antibodies defined. Epitopes on 
erythrocytes infected with early stage gametocytes may form attractive novel targets for 
transmission blocking strategies. Functional recognition of  early stage gametocytes could 
be exploited in vaccination strategies that interfere with homing to the bone marrow, 
maturation at this immunoprotective site and/or release of  mature gametocytes into the 
blood stream
Late stage gametocyte infected erythrocyte surface antigens
In the first study of  its kind, Saeed et al. observed naturally acquired humoral immunity 
against fully mature stage V gametocytes in serum samples of  gametocyte-carrying 
Gambian children by flow cytometry [52]. This late GIE surface recognition increased 
with age and was most pronounced in serum samples taken at later time points during the 
infection when mature gametocytes appear in peripheral blood, but was unrelated to anti-
asexual stage humoral immunity. Interestingly, immune responses to GIE were associated 
with decreased gametocyte density, suggesting that this type of  humoral immunity may 
have consequences for gametocyte production or longevity. If  confirmed in other studies, 
these findings hold great promise for the identification of  novel mature gametocyte vaccine 
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targets. These confirmatory studies should take great care in preventing (low levels of) 
activation of  these stage V gametocytes that would result in the accessibility of  gamete 
antigens to which antibody responses may be highly prevalent in endemic settings [53-55]. 
 The identification of  gametocyte-specific epitopes on the GIE surface and their 
function remain to be established. Possible targets include multigene families located in 
the subtelomeric regions, which encode variant surface antigens known for their role in 
sequestration of  asexual parasites and are also expressed in late stage gametocytes. STEVOR 
proteins have been identified as localized at the membrane of  erythrocytes infected with 
late stage gametocytes [56] but a subset of  the variant RIFIN antigens may also be targets 
of  naturally acquired immunity against epitopes on the stage V GIE [57]. Another late stage 
gametocyte specific protein containing binding motifs is pSLAP [58]. Furthermore, the 
existence of  signaling molecules expressed on the GIE and involved in spatial and temporal 
tropism (tropins and circadins) has been hypothesized [42]. 
Human immune responses active against mosquito-stage parasites
Since the majority of  mature gametocytes die within the human host and fail to transmit to 
mosquitoes, proteins that are expressed by gametocytes but are only functional in activated 
gametes and later developmental stages are released and presented to the immune system. 
Indeed, many antigens present on the surface of  these parasite stages (gametes, zygotes, 
ookinetes, oocysts) are already expressed in gametocytes in the human host, in preparation 
for gametogenesis [59]. Immune components that are taken up in the blood meal together 
with the gametocytes can inhibit fertilization in the mosquito midgut [60]. Once gametocytes 
leave the erythrocyte in the mosquito midgut, they are exposed to human cellular and 
humoral immune factors including leukocytes, antibodies and complement. In the avian 
malaria P. gallinaceum, transmission from chickens to mosquitoes was significantly reduced 
after vaccination of  the birds with formalin-treated or irradiated gametes [61-63]. Also in 
the primate malaria P. knowlesi, evidence of  induced TRI was observed upon immunization 
with gametocytes [64]. These animal models revealed for the first time that TRI could 
be induced, and was active against the parasite developmental stages occurring in the 
mosquito. Research into TRI and transmission blocking vaccine (TBV) development has 
since focused on immune responses to the mosquito stages of  parasite development.
Mechanisms of mosquito-stage transmission blocking immunity
Leukocytes are capable of  phagocytizing Plasmodium gametes, though the efficiency 
of  this process appears lower in the mosquito midgut than during in vitro experiments, 
possibly because of  lower temperature and enzymes present in the mosquito midgut [37, 
38]. However, there is little evidence for the direct involvement of  leukocytes in TRI, and 
conflicting evidence for a synergistic effect of  cellular and antibody mediated immunity 
[65, 66].
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Humoral immunity appears to be the dominant mechanism of  natural TRI. The intra-host 
death of  gametocytes that are not successfully transmitted releases a multitude of  epitopes, 
including many present on the surface of  the female macro- or male microgamete upon 
activation within the blood meal of  a mosquito. Humoral immunity remains functional 
within the mosquito midgut and can inhibit transmission through a range of  mechanisms. 
Specific antibodies may inhibit gamete fertilization either by agglutination resulting in 
inhibited gamete mobility, coating the micro- or macrogamete causing reduced cell-cell 
contact, opsonization for immune mediated lysis, or activation of  the complement system 
resulting in gamete lysis [67-70]. Evidence for the dominance of  antibody mediation in TRI 
development comes from its induction by vaccination with whole parasites [62-64] or from 
the activity of  mAb specific to major sexual stage proteins [71]. The threshold at which 
humoral immunity significantly impacts transmission reduction, and the longevity of  these 
responses are currently insufficiently explored.
Assessing immune responses that block mosquito infection
The best standardized method of  determining the presence of  TRI is the standard membrane 
feeding assay (SMFA) in which gametocytes are cultured in vitro and fed to laboratory-
reared mosquitoes [72]. The direct membrane feeding assay (DMFA) is an alternative assay 
applicable in field situations, where gametocytes from naturally infected individuals are fed 
to mosquitoes either in the whole blood of  the donor (to assess infectivity in the presence 
of  other blood components), or after the removal and re-addition of  autologous plasma 
or addition of  plasma from a naive donor (to assess the impact of  plasma components 
on transmission efficiency). These assays are described in detail elsewhere [72-74]. In 
both assays, the transmission reducing activity (TRA) of  test sera/autologous plasma is 
generally determined one week after feeding when oocysts lining the mosquito midgut are 
visible by microscopy [75]. Evidence of  functional TRI has generally been reported when 
the mean number of  oocysts in test mosquitoes is decreased to less than 10% (TRA ≥90%) 
of  that in control mosquitoes (mosquitoes fed the same gametocyte source with control 
serum [SMFA] or naïve plasma [DMFA]), while TRA <50% is considered evidence of  
limited or non-existent TRI [21, 76].
 Advantages of  the DMFA include the assessment of  a multitude of  locally relevant 
strains and more physiological gametocyte densities; however, large variation in these 
experiments does limit its predictive value and correlation with SMFA results. Transmission 
reduction in the DMFA was also correlated with gametocyte carriage, age above 5 years, 
and late season sampling, while it was inversely correlated with gametocyte density [77]. 
Several population-based screens using the DMFA in Cameroon, Kenya and the Gambia 
found that transmission efficiency is enhanced by 14-66% after replacement of  autologous 
plasma with naive control serum [53-55, 77]. Although complete transmission blockage 
is rare, these findings suggest a relatively high prevalence of  functional TRI in endemic 
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populations. However, non-specific factors (e.g. chemicals) present in the serum may 
contribute to the observed effect on TRA, and methodological issues including maintaining 
sample temperature during serum replacement may also affect transmission efficiency 
[78]. Non-specific factors can be excluded in the SMFA, as not only whole serum, but 
also specifically purified antibodies can be added to the infectious blood-meal. Naturally 
acquired transmission-reducing immunity has been detected using the SMFA with 
whole serum and purified IgG [53, 54, 79-81], although the proportion of  individuals 
with reproducible TRI is generally much lower than observed in the DMFA with serum 
replacement. Variations in the intensity of  mosquito infection arising from feeds on natural 
gametocyte carriers or cultured gametocytes make the assay outcomes difficult to compare, 
and may lead to a biological bias, as higher gametocyte density in the SMFA may increase 
epitope availability [82]. Efforts must therefore be made to standardise the conditions of  
the DMFA and SMFA. DMFA experiments require a better parameterization of  inter-assay 
variability and procedural artifacts that may be interpreted as TRI. In turn, the SMFA can 
be optimized to better resemble natural conditions. The incorporation of  multiple strains 
originating from various geographical locations could help avoid false-negative results 
due to sequence variation of  gamete-specific epitopes in endemic strains while the use of  
gametocyte densities representative of  natural mosquito infection rates would improve 
estimation of  the impact of  TRI on the likelihood of  secondary infections [74]. Ideally, 
aiming to more accurately resemble the in vivo situation and avoid exhaustion of  essential 
antibodies by non-specific binding to asexual and immature gametocytes currently present 
in the feeding material, only mature stage V gametocytes with sex ratios comparable to 
natural infections would be fed to mosquitoes. 
 A major drawback of  both assays is their labor intensiveness, as the readout requires the 
dissection and midgut analysis of  minimally 20 mosquitoes per condition after maintaining 
mosquitoes for a week. Recently, the use of  a transgenic parasite line expressing luciferase 
enabled high throughput analysis of  infection rates in mosquito midguts, which is a 
fundamental improvement for performing SMFA at a large scale [83].
Immune targets of transmission blocking immunity
Until the turn of  the century, our understanding of  protein expression during 
P. falciparum sexual development was limited to a selection produced in abundance at the 
onset of  gametocytogensis (Pfg27/25 and Pfs16) [84, 85] or present on the gametocyte/
gamete (Pfs230, Pfs48/45, Pfs41) [71] or zygote/ookinete (Pfs25, Pfs28) [86] surface. 
Many more proteins have now been identified as sexual stage specific [8, 29, 87, 88], with 
the best characterized described in previous reviews [59, 89, 90]. Although Pfs25 specific 
antibody responses have been observed in malaria exposed populations, Pfs25 and Pfs28 
are post-transcriptionally repressed until the parasite’s development in the mosquito midgut 
[59, 91], so it is unlikely that they would elicit functional TRI [92]. Naturally occurring 
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antibody mediated TRI is more likely the result of  exposure to proteins expressed in the 
human parasite stages (so called pre-fertilisation antigens). Pfs230 and Pfs48/45 expression 
is initiated during gametocyte development and proceeds until fertilization of  the micro- 
and macrogametes, with both proteins appearing to have an important role in male 
microgamete fertility [93, 94]. Antibodies specific to both proteins are naturally acquired 
after malaria infection [76, 95], and associated with varying levels of  TRI; 14 studies have 
attempted to correlate TRI measured in MFA with immune recognition of  Pfs230 and 
Pfs48/45, or sub-units thereof  [53, 54, 76, 80, 81, 91, 96-103]. Of  these 14 studies, nine 
determined the presence of  antibody responses to Pfs230 and Pfs48/45 using enzyme-
linked immunosorbent assay (ELISA), and related this data to serum TRA determined in 
the SMFA. Data was available for six studies, allowing a combined analysis of  reactivity to 
these antigens in individuals with and without functional TRI (Table 1). 
 There is growing evidence from studies utilizing recombinant Pfs230 and Pfs48/45 that 
antibody responses to sexual stage antigens are acquired with age [80, 102, 103] in parallel 
with the development of  blood-stage immunity [104]. Evidence for the age relatedness 
of  TRI has been limited by age biased sampling. In the only study that assessed TRI for 
individuals of  all ages, antigen-specific responses increased with age while the functionality 
of  this response appeared to decrease [80]. More research is needed to improve our 
understanding of  the acquisition and maturation of  the TRI response in individuals of  
different ages across a range of  transmission intensities.
 Variability in the efficacy of  sera to inhibit the transmission of  different gametocyte 
isolates from naturally infected individuals suggests strain specific effects [99]. This might 
be due to antigenic variation, although Pfs48/45 and Pfs230 encoding genes show very 
limited variability in coding sequences [103]. Recently, immune sera from individuals in 
Mali were shown to recognize the male gamete protein HAP2, indicating expression by 
gametocytes in the human host. HAP2 specific mAb block transmission to mosquitos in P. 
berghei [105] and P. falciparum [92], but it has yet to be shown if  the presence of  anti-HAP2 
Ab in endemic sera correlates with functional TRI.
 While sera containing antibodies specific to Pfs48/45 or Pfs230 block transmission 
more commonly than sera with no effect on mosquito infection (Pfs48/45: OR 6.62 
(3.61-12.15); Pfs230: OR 4.69 (2.50-8.81), recognition of  these proteins does not predict 
blockage absolutely, nor does it confirm a mechanistic link with TRI. Several studies show 
no association between Ab response to Pfs230 and/or Pfs48/45 and transmission reduction 
[91, 97, 106, 107]. The presence of  TRI in the absence of  Pfs48/45 or Pfs230 specific 
antibodies, and a lack of  TRI in their presence [53, 80, 97, 100-102] suggests that both 
may be partially functional, and that responses to multiple proteins could be necessary to 
elicit transmission inhibition. Combining the data in Table 1, 46.68% (190/407) of  samples 
with <50% TRA recognized either Pfs48/45 or Pfs230, while 30.16% (19/63) of  samples 
with TRA ≥90% recognized neither antigen. To definitively establish the role of  naturally 
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occurring anti-Pfs48/45 and anti-Pfs230 antibodies in the development of  TRI, specific 
antibodies should be affinity purified from immune sera using recombinant antigen and 
tested in the SMFA. 
 The association of  sera transmission enhancement (TE) with anti-gamete immune 
responses has been a long standing discussion among researchers involved in TBV 
development. TE appears to occur naturally in a small proportion of  gametocyte exposed 
individuals [91, 97, 99, 100, 108-110], though at lower frequency [101] (7% TE/48% TR) 
and relative intensity than naturally occuring transmission reduction. The cause of  serum 
TE remains obscure: low antibody titres, from diluted immune sera or anti-gamete mAb 
have been linked with enhanced P. vivax transmission [108-110], and these findings are 
supported by the observation of  enhancment during periods of  low antibody carriage in the 
early and late stages of  P. cynomolgi infection in Macaques [111]. Low titres of  anti-gamete 
antibodies have also been linked with TE for P. falciparum [97, 100, 112], however low titre 
responses to specific gamete and ookinete antigens (Pfs230, Pfs48/45, Pfs25, Pbs21) appear 
non-significantly [100] or not associated [101, 113, 114] with enhanced transmission, 
indicating that TE may be caused by a concurrent response to un-characterized gamete 
antigens, or by other serum factors. Investigating subtle reduction or enhancement of  
mosquito infection rate is made difficult by the SMFA’s inherent variability, but in light of  
its potential impact on the efficacy of  TBVs TE requires further investigation. Antibody 
responses to candidate TBVs provide an incomplete image of  the immune signature of  
natural TRI, and if  involved, these proteins probably represent only part of  a larger range of  
immune responses contributing to TRI. The publishing of  the Plasmodium genome in 2002 
set the course for rapid advances in the fields of  transcriptomics and proteomics. A wealth 
of  studies employing high accuracy mass-spectrometry and mRNA microarrays identified 
proteins expressed specifically in gametocytes [115, 116], male and female gametocytes 
separately [88, 117], gametes, and ookinetes [118, 119]. The results of  studies using P. berghei 
have been reviewed in detail [120]. Recently, high yield purification techniques allowed P. 
falciparum proteomic expression at the blood, early gametocyte, and late gametocyte stages 
to be disentangled, revealing the expression of  >1400 proteins in early gametocytes, and 
>2000 in late gametocytes. Of  these proteins, 1055 appear to be expressed in gametocytes 
but not in trophozoites, with 637 specific to stage IV and V gametocytes [87]. Proteomics 
approaches have confirmed the expression of  known gametocyte surface proteins [121, 
122], and identified hypothetical proteins likely to contain export sequences that may 
indicate surface expression [87]. Combined with analyses which have enabled the ranking 
of  the P. falciparum proteome by the likelihood of  possessing transmembrane domains or 
a glycophosphatidylinositol-anchor (GPI) [123], proteomics enables the prioritization of  
key candidates for involvement in antibody mediated TRI. With high throughput protein 
expression arrays the recognition by immune sera of  thousands of  proteins can now be 
assessed simultaneously [124, 125], and the results, as for previous studies with recombinant 
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Pfs230 and Pfs48/45, correlated to functional TRI measured in mosquito feeding assays. As 
the activity of  many proteins (Pfs230 and Pfs48/45 included) is conformation dependent 
[126, 127], and as high throughput protein expression platforms are currently unable to 
produce tertiary protein structures, such an analysis is unlikely to provide a definitive list 
of  antigens involved in functional TRI. However, it may still reveal new targets with less 
conformation-dependent activity, which would significantly further our understanding of  
TRI development and aid the rational design of  a malaria TBVs.
Transmission blocking vaccines (TBV)
In recent years the development of  the RTS,S malaria vaccine has received significant 
investment, with the results of  a recent Phase 3 cluster randomized trial indicating that 
the vaccine may reduce the number of  severe and un-complicated clinical cases in areas 
of  high transmission [128]. Though highly effective pre-erythrocytic vaccines may be 
classified as vaccines that interrupt malaria transmission (VIMT) by preventing parasite 
multiplication and thereby gametocyte production, the limited longevity and efficacy of  
the response of  RTS,S may be insufficient to significantly affect transmission in all endemic 
settings [128], and antibodies elicited by the vaccine have no direct impact on mosquito 
infection rate [129]. TBV development, reviewed by [89, 90, 130] has remained focused 
on six proteins against which antibodies (monoclonal, or from immunized sera) have been 
empirically shown to inhibit mosquito infection; Plasmodium proteins Pfs25 [86, 131], 
Pfs28 [86], Pfs230 [132], Pfs48/45 [126, 127] and more recently HAP2 [92, 105], and 
mosquito antigen AgAPN-1 [133]. If  responses to pre-fertilisation antigens considered for 
TBV development are dominant effectors of  naturally occurring TRI, vaccination efforts 
with these candidates may be aided by immune boosting from natural parasite exposure 
[134]. More research is required to improve our understanding of  the temporal dynamics of  
sexual stage immunity, but limited evidence that TRI may be short-lived after gametocyte 
exposure [103] highlights the importance of  prioritizing vaccine/adjuvant formulations 
that elicit long-lived immunity. 
 Whilst the advancement of  Pfs25 to clinical trials is promising, examination of  the WHO 
‘Rainbow tables’ for malaria vaccine candidates currently in development makes it clear 
that candidate vaccines targeting transmission stage parasite remain vastly overshadowed 
by the number targeting alternative life cycle stages (pre-erythrocytic and asexual parasites). 
The value of  a sexual stage, transmission blocking vaccine in the campaign to eliminate 
malaria is increasingly acknowledged, and the clinical testing of  candidates other 
than Pfs25 and addition of  novel targets are therefore urgently required. In addition to 
mosquito stage targets able to stimulate immune responses inhibiting parasite fertilization, 
increased focus should be on identifying targets integral to gametocyte development 
in the human host. Recent work providing insight into gametocyte development in the 
bone marrow parenchyma opens up new possibilities for immune responses targeting 
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immature gametocytes while field studies highlight the importance of  responses targeting 
mature gametocytes in inducing TRI. Novel tools to prevent gametocyte maturation and 
longevity could contribute significantly to the interruption of  malaria transmission. A 
better understanding of  naturally occurring TRI and of  the gametocyte’s interaction with 
its human host is fundamental to the development of  new TBV approaches. 
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Abstract
Infection with Plasmodium can elicit antibodies that inhibit parasite survival in the 
mosquito, when they are ingested in an infectious blood meal. Here, we determine the 
transmission-reducing activity (TRA) of  naturally acquired antibodies from 648 malaria-
exposed individuals using lab based mosquito-feeding assays. Transmission inhibition 
is significantly associated with antibody responses to Pfs48/45, Pfs230, and to 43 novel 
gametocyte proteins assessed by protein microarray. In field-based mosquito-feeding assays 
the likelihood and rate of  mosquito infection are significantly lower for individuals reactive 
to Pfs48/45, Pfs230, or to combinations of  the novel TRA associated proteins. We also 
show that naturally acquired purified antibodies against key transmission-blocking epitopes 
of  Pfs48/45 and Pfs230 are mechanistically involved in TRA, while sera depleted of  these 
antibodies retain high-level, complement independent TRA. Our analysis demonstrates 
that host antibody responses to gametocyte proteins are associated with reduced malaria 
transmission efficiency from humans to mosquitoes.
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Introduction
Plasmodium gametocytes develop from their asexual progenitors and are the only malaria 
parasite life-stage infective to mosquitoes. In preparation for their development in the 
mosquito, gametocytes cease to express many proteins involved in the parasites cycle of  
asexual replication, and upregulate others that are involved in sexual development [1, 2]. 
Some of  these have essential roles in mosquito-stage development [3, 4], which culminates 
in the insect becoming infectious to humans. 
 In surveys where mosquitoes were fed directly on the skin or on a blood sample, it 
was noted that some gametocytaemic individuals including those with high gametocyte 
densities were not infectious [5, 6]. This may be associated with naturally acquired 
antibodies that interfere with parasite development within mosquitoes to reduce or prevent 
mosquito infection [7, 8]. The role of  antibodies in determining transmission efficiency 
can be tested in mosquito feeding assays, in which purified antibodies are added to a 
mosquito blood meal that contains gametocytes [9, 10]. Evidence for naturally acquired 
transmission-reducing activity (TRA) is provided if  test antibodies in endemic serum cause 
a reduction in the number of  developing Plasmodium oocysts relative to mosquitoes fed the 
same infectious blood meal without test antibodies. TRA can be experimentally induced 
after immunisation of  animals with inactivated Plasmodium gametocytes or gametes [8, 11]. 
The gametocyte and gamete proteins P48/45 and P230 have been identified as targets of  
transmission blocking monoclonal antibodies (mAb), which act by inhibiting the protein’s 
role in gamete fertilisation in the mosquito gut [3, 4, 12]. Monoclonal antibodies specific to 
the zygote and ookinete proteins P25 and P28 were also shown to block transmission, by 
inhibiting ookinete invasion of  the midgut epithelium [13]. All four have been produced as 
recombinant proteins that can induce antibody-mediated TRA in animal models [13-15]. 
 Because P25 and P28 mRNA is translationally repressed until zygote formation [16], 
antibodies specific to these proteins appear absent in endemic populations [17, 18]. In 
contrast, responses to P48/45 and P230 are commonly observed in naturally infected 
individuals [10, 19, 20]. The presence of  antibodies to Plasmodium falciparum Pfs48/45 
and Pfs230 in endemic sera has been associated with TRA in several, but not all sero-
epidemiological surveys [10, 21-28]. Importantly, many individuals with functional 
TRA do not have measurable antibodies against these two proteins [10, 23, 25, 28-31]. 
Despite these observations, there has been no attempt to demonstrate the contribution of  
naturally acquired α-Pfs48/45 and α-Pfs230 antibodies to transmission inhibition, and little 
investigation of  alternative targets of  natural TRA. The gametocyte proteome has now 
been described in detail [32, 33]. Utilising the protein microarray platform, genome scale 
datasets have been combined with functional and immunological data to provide valuable 
insight into mechanisms and markers of  malaria humoral immunity [34, 35].  
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Here, we aim to investigate the immune signature of  naturally occurring antibody-
mediated TRA, to expand and prioritise antigenic targets for functional characterisation 
as biomarkers, or transmission-blocking vaccine candidates. To this purpose, we utilise 
a protein microarray comprising an inclusive selection of  proteins expressed during 
gametocyte development. We assess antibody responses to these proteins and to correctly 
folded Pfs48/45 [36] and Pfs230 [15] in 648 malaria-exposed individuals from Burkina 
Faso, the Gambia, Cameroon, and from migrants from the Netherlands. Using purified total 
IgG, we assess the functional TRA of  antibodies from the same individuals by determining 
their effect on mosquito infection density in standard membrane-feeding assays (SMFA) 
with cultured P. falciparum gametocytes and Anopheles stephensi mosquitoes. Our analysis 
reveals significant associations between high-level TRA and responses to Pfs48/45, Pfs230 
and 43 novel gametocyte proteins. For a subset of  366 gametocyte positive donors who 
had provided blood samples to Anopheles gambiae s.s. or Anopheles coluzzii mosquitoes in 
field-based membrane-feeding assays, we determine the association of  these antibody 
responses and mosquito infection rates during natural infections. For Pfs48/45 and Pfs230, 
we provide functional data that demonstrate their role in natural TRA. For one of  the 
newly identified proteins (PfGEST) we provide experimental data that does not support its 
functional role in natural TRA.
Results
Antibody responses to gametocyte antigens 
Plasma was collected in epidemiological studies in Burkina Faso [37-41], Cameroon [42, 
43] and the Gambia [24, 44-47] [48], as well as from Dutch migrants who had lived for 
several years in malaria endemic areas and reported repeated malaria episodes (Table 
1). Individuals from malaria endemic areas were all asymptomatic when sampled, and 
were either recruited randomly from the community (n=42), or based on the observation 
of  malaria parasites (n=273) or specifically gametocytes (n=276) in blood smears. For a 
selection of  individuals from malaria-endemic areas (n=498), infectivity to mosquitoes at 
the moment of  sample collection was determined by offering a venous blood sample to An. 
gambiae s.s. or An. coluzzii in a direct membrane feeding assay (DMFA) (Table 1). Dutch 
migrants had no DMFA performed and had either recently returned from extended periods 
in endemic areas (within 6 months after return; n=8) or had returned more than a year 
before sampling (n=49). Those who had returned more than a year before sampling had 
lived in areas with endemic P. falciparum transmission for longer than 15 years, and reported 
between 2 and >80 clinical malaria episodes during that time. 
 Antibody responses to Pfs48/45 (Pfs48/45-10C [36]) and Pfs230 (230CMB[15]) were 
determined by enzyme-linked immunosorbent assay (ELISA) using recombinant, correctly 
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folded proteins. A protein microarray was constructed to assess responses to other 
gametocyte antigens. This array included a total of  315 proteins (Supplementary Data 1) 
that were broken up into 528 overlapping fragments <1000 amino acids in length (overlaps 
of  17 amino acids) for protein expression in an Escherichia coli based in vitro transcription-
translation (IVTT) system [49, 50]. Antigens on the array included proteins previously 
implicated as eliciting TRA after immunisation, proteins involved in early gametocyte 
development as possible markers of  gametocyte exposure [1], markers of  asexual parasite 
exposure [51] and proteins expressed in gametocytes based on recent proteomic analysis 
[52]. To ensure that the array included most potential antibody targets involved in TRA, we 
preferentially included proteins that had transmembrane domains, signal peptides, or GPI 
anchors. Specificity of  proteins to gametocytes was not pre-requisite for inclusion on the array, 
however 228/315 proteins had consensus evidence for enrichment in gametocytes based 
on a recent integration analysis of  11 available proteomics datasets [53] (Supplementary 
Data 1). Among donors from malaria endemic regions, the prevalence and magnitude of  
antibody responses to Pfs48/45 (Pfs48/45-10C [36]) and Pfs230 (230CMB[15]) increased 
with age (Fig. 1 A-D). In contrast, the overall breadth (linear regression [LinR]: p<0.001) 
and magnitude (analysis of  variance [ANOVA]: p<0.001) of  response to antigens on the 
microarray decreased with age (Fig. 1 E-F). The same associations were observed when 
analyses were restricted to donors from Burkina Faso (n=225), the site with the widest age 
range of  donors (Supplementary Fig. 1).  
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Figure 1. Antibody responses to Pfs48/45-10C, Pfs230 and to the microarray proteins with age. 
Antibody responses to correctly folded, recombinant Pfs48/45 and Pfs230 were measured using ELISA, 
with antibody intensity given as the ELISA optical density (OD) values (450nm). Antibody responses to 
microarray proteins are given as the log2-transformed signal intensity (SI) minus the vehicle SI, which 
equates to the log2-fold change over this background. All graphs show only individuals from endemic 
areas (Dutch migrants excluded). Sample size: 0-5 = 131, 5-15 = 366, 15+ = 71. A & C: Bars show the 
seroprevalence of α-Pfs48/45-10C and α-Pfs230 antibodies with age, with Clopper-Pearson confidence 
intervals. B & D: Box plots showing α-Pfs48/45-10C and α-Pfs230 antibody intensity among endemic 
individuals (Dutch migrants excluded) with age. E: Box-plots showing responses to the microarray 
protein targets (n=528). Antibody breadth is the number of proteins reactive above background in 
each individual, within the given groups. F: Magnitude of antibody response to microarray protein 
targets. Each dot represents the average SI of response to each protein target by all individuals 
within given groups. P-values for prevalence data are from likelihood ratio test for differences in 
seroprevalence between all age groups, derived from logistic regression and adjusted for gametocyte 
density. P-values for intensity data and response breadth are from an F test for differences in OD/SI 
between all age groups, derived from linear regression and adjusted for gametocyte density, or from 
ANOVA (for magnitude only). For all box-plots, outliers are shown in black while all data points are 
shown in grey as a bee-swarm.
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Antibody responses associated with transmission-reducing activity 
(TRA)
To assess functional TRA, IgG was purified from the sera of  all 648 individuals and provided to 
An. stephensi mosquitoes together with a blood meal containing cultured NF54 or transgenic 
NF54HT-GFP-Luc gametocytes in standard membrane-feeding assays (SMFA) [9, 54]. If  
the donor IgG caused ≥80% reduction in oocyst formation relative to control mosquitoes 
(TRA ≥80%), the SMFA was repeated with separate gametocyte culture material. In total, 
3.3% (22/648) of  the antibody samples caused replicable TRA of  ≥90% (Table 1). On 
a continuous scale, TRA decreased with age, but was not significantly associated with 
gametocyte density at the point of  sampling (LinR: p=0.269) (Supplementary Fig. 2). 
Because previous gametocyte exposure is associated with TRA [28], comparisons between 
sub-groups were nevertheless adjusted for gametocyte density. Though intermediate TRA 
may be relevant for transmission there are uncertainties about its reliable measurement 
in the SMFA [55, 56]. TRA was therefore dichotomized into ≥90% (high-level TRA) and 
<10% TRA (no TRA) before assessing associations with antibody responses. The group 
without evidence for TRA was refined by excluding individuals without microscopically 
detectable gametocyte densities at the time of  sampling, resulting in 22 individuals with 
high-level TRA activity and 254 individuals who were exposed to gametocytes (and thus 
likely to respond to gametocyte antigens) but showed no evidence for TRA. Using these 
two categories, high-level TRA was significantly more likely in individuals seropositive for 
α-Pfs230 (odds-ratio [OR] from logistic regression [LogR] 7.9 [95% confidence interval [CI] 
2.8-22.8], p<0.001), α-Pfs48/45 (OR 4.4 [95% CI 1.5-12.9], p=0.007), or either antigen (OR 
5.90 [95% CI 2.1-16.7], p=0.001) (Table 2; Supplementary Table 1). Antibody density was 
also higher for Pfs230 (Lin R: p<0.001) and Pfs48/45 (p<0.001) in individuals exhibiting 
high-level TRA (Fig. 2 A & B; Table 2). 
 In addition to Pfs230 and Pfs48/45, the average magnitude of  response to each 
microarray target was also higher in individuals with high-level TRA (students t-test: 
p=0.012) (Fig. 2D), whilst the breadth of  response by each individual was not statistically 
significantly different between individuals with high-level TRA compared to those with 
no evidence of  TRA (LinR: p=0.89) (Fig. 2C). Sixty microarray proteins had statistically 
significantly higher antibody magnitude in individuals with high-level TRA, after p-values 
had been adjusted to control the false discovery rate (FDR) (Fig. 2E) [57]. The inverse, 
higher responses in individuals with no TRA, was not observed (Supplementary Data 2). 
Logistic regression models with FDR controlled p-values showed that antibody prevalence 
to 27 microarray targets was significantly associated with high-level TRA, 25 of  which 
were also significantly more reactive in the analysis of  signal intensity. Because large 
proteins were fragmented on the array, the combined list of  62 novel microarray targets 
with TRA associated antibody responses in either the linear (response intensity) or logistic 
(response prevalence) analysis represented fragments of  43 unique proteins (Table 2). 15 of  
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the 43 proteins with TRA associated responses are conserved unknown proteins. Two are 
known gametocyte/gamete proteins with putative roles in gamete egress; PF3D7_1038400 
(gametocyte specific protein, Pf11-1) and PF3D7_1449000 (gamete surface and sporozoite 
traversal protein/GEST). 
 TRA-associated responses on the array showed only partial overlap with Pfs48/45 
and Pfs230 responses. Individuals with high-level TRA who were seronegative for both 
α-Pfs230 and α-Pfs48/45 (n=10/22), had antibody responses to significantly more TRA 
associated microarray targets (median breadth 11 (out of  62) [interquartile range [IQR] 
3-26]) than gametocyte positive individuals without TRA (n=211; median breadth 4 (out of  
62) [IQR 2-9), Lin R: p=0.018). Responses to some TRA biomarkers were highly prevalent 
in individuals with high-level TRA who lacked significant responses to Pfs45/45 and 
Pfs230 (e.g. Pf11-1 [PF3D7_103840] = 70% [n/N=7/10]; LSA-3 [PF3D7_0220000] = 80% 
[n/N=8/10]). Responses to one target protein mapping to PF3D7_1103800 (CCR4-NOT) 
were present in 60% (n/N=6/10) of  high level TRA α-Pfs48/45 and α-Pfs230 seronegatives, 
while seroprevalence for this target in individuals with no TRA was 10.3% (n/N=26/254) 
(Supplementary Data 3).
 Interestingly, 10 of  the 43 proteins with TRA associated antibody responses are putatively 
exported during early gametogenesis [1]. Though the majority of  these proteins are enriched 
in asexual parasites, their association with TRA may reflect previous observations that 
TR immunity is induced and wanes rapidly after gametocyte exposure [26, 27]. Responses 
to putative markers of  asexual parasite exposure (PF3D7_1036000 [Merozoite surface 
protein 11 [MSP11]), PF3D7_0711700 (erythrocyte membrane protein 1, PfEMP1 [VAR]), 
PF3D7_0731600 (acyl-CoA synthetase [ACS5]), and PF3D7_0423700 (early-transcribed 
membrane protein 4 [ETRAMP4]) [51] were not associated with TRA, either in terms of  
response intensity (Bayes empirical t-test: FDR adjusted p=0.34-0.99) or seroprevalence 
(LogR: FDR adjusted p=1).
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Table 2. TRA associated antibody responses assessed by ELISA or protein microarray
Gene ID Gene description
Seropositivity Signal intensity
Seropositivity 
% (n/N) [TRA 
≥90%)
Seropositivity 
% (n/N) [TRA 
<10%)
OR p-value
Fold 
change SI
p-value
PF3D7_0209000* 6-cysteine protein (P230) 50% (11/22) 10.6% (27/254) 7.9 <0.001 2.5 <0.001
PF3D7_1346700* 6-cysteine protein (P48/45) 40.9% (9/22) 11.4% (29/254) 4.4 0.007 2.1 <0.001
PF3D7_0826100.a E3 ubiquitin-protein ligase, 
putative
59.1% (13/22) 11.8% (30/254) 10.8 <0.001 2.5 <0.001
PF3D7_1103800.a CCR4-NOT transcription complex 
subunit 1, putative (NOT1)
36.4% (8/22) 3.5% (9/254) 15.6 <0.001 1.6 <0.001
PF3D7_0936400 ring-exported protein 4 (REX4) 59.1% (13/22) 15% (38/254) 8.2 0.001 2.2 <0.001
PF3D7_0102200.a ring-infected erythrocyte surface 
antigen (RESA)
50% (11/22) 11% (28/254) 8.1 0.001 2.6 <0.001
PF3D7_1103800.b CCR4-NOT transcription complex 
subunit 1, putative (NOT1)
45.5% (10/22) 10.2% (26/254) 7.3 0.003 1.5 <0.001
PF3D7_1324600 conserved Plasmodium protein, 
unknown function
54.5% (12/22) 16.1% (41/254) 6.2 0.004 1.8 <0.001
PF3D7_1149200.a ring-infected erythrocyte surface 
antigen
45.5% (10/22) 13% (33/254) 5.6 0.012 2.5 <0.001
PF3D7_0322600 conserved Plasmodium protein, 
unknown function
22.7% (5/22) 3.1% (8/254) 9.0 0.019 1.3 <0.001
PF3D7_0826100.b E3 ubiquitin-protein ligase, 
putative
18.2% (4/22) 1.6% (4/254) 13.9 0.019 1.4 <0.001
PF3D7_0930500.a diacylglycerol kinase, putative 
(DGK1)
45.5% (10/22) 15% (38/254) 4.7 0.026 1.7 <0.001
PF3D7_1103800.c CCR4-NOT transcription complex 
subunit 1, putative (NOT1)
36.4% (8/22) 9.8% (25/254) 5.2 0.026 1.5 <0.001
PF3D7_1010700 dolichyl-phosphate-mannose 
protein mannosyltransferase, 
putative
22.7% (5/22) 4.3% (11/254) 6.5 0.044 1.3 <0.001
PF3D7_1038400.a gametocyte-specific protein 
(Pf11-1)
31.8% (7/22) 8.7% (22/254) 4.9 0.044 1.6 <0.001
PF3D7_0505000 conserved Plasmodium 
membrane protein, unknown 
function
22.7% (5/22) 7.1% (18/254) 3.9 0.156 1.6 <0.001
PF3D7_1433200.a conserved Plasmodium protein, 
unknown function
22.7% (5/22) 8.3% (21/254) 3.3 0.246 1.4 <0.001
PF3D7_1360500 guanylyl cyclase beta (GCbeta) 40.9% (9/22) 15% (38/254) 3.9 0.062 1.5 0.001
PF3D7_0102200.b ring-infected erythrocyte surface 
antigen (RESA)
59.1% (13/22) 29.5% (75/254) 3.4 0.093 2.4 0.002
PF3D7_0301700 Plasmodium exported protein, 
unknown function
59.1% (13/22) 18.1% (46/254) 6.5 0.004 2.0 0.004
PF3D7_1212100 peripheral plastid protein 1, 
putative (PPP1)
40.9% (9/22) 16.9% (43/254) 3.4 0.102 1.7 0.004
PF3D7_0731800 alpha/beta hydrolase, putative 
(GEXP08)
40.9% (9/22) 7.5% (19/254) 8.6 0.002 1.6 0.005
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PF3D7_1038400.b gametocyte-specific protein 
(Pf11-1)
63.6% (14/22) 26.8% (68/254) 4.8 0.026 2.0 0.005
PF3D7_0220000 liver stage antigen 3 (LSA3) 81.8% (18/22) 44.5% (113/254) 5.6 0.049 1.9 0.005
PF3D7_0804500.a conserved Plasmodium 
membrane protein, unknown 
function
22.7% (5/22) 4.7% (12/254) 5.9 0.049 1.4 0.005
PF3D7_1107900 mechanosensitive ion channel 
protein
40.9% (9/22) 12.6% (32/254) 4.8 0.028 1.4 0.006
PF3D7_0726400.a conserved Plasmodium 
membrane protein, unknown 
function
45.5% (10/22) 19.7% (50/254) 3.4 0.094 1.5 0.006
PF3D7_0930500.b diacylglycerol kinase, putative 
(DGK1)
31.8% (7/22) 7.9% (20/254) 5.5 0.028 1.4 0.009
PF3D7_0628200 protein kinase PK4 (PK4) 45.5% (10/22) 16.9% (43/254) 4.1 0.049 1.5 0.009
PF3D7_0826100.c E3 ubiquitin-protein ligase, 
putative
45.5% (10/22) 21.7% (55/254) 3.0 0.148 1.7 0.010
PF3D7_1127500 protein disulfide isomerase, 
putative
36.4% (8/22) 16.1% (41/254) 3.0 0.184 1.4 0.010
PF3D7_1314500 cop-coated vesicle membrane 
protein p24 precursor, putative
45.5% (10/22) 23.6% (60/254) 2.7 0.219 1.8 0.010
PF3D7_1038400.c gametocyte-specific protein 
(Pf11-1)
86.4% (19/22) 48% (122/254) 6.9 0.049 2.2 0.011
PF3D7_0922100 ubiquitin-like protein, putative 9.1% (2/22) 0.8% (2/254) 12.6 0.137 1.2 0.012
PF3D7_0702300 sporozoite threonine and 
asparagine-rich protein (STARP)
63.6% (14/22) 42.5% (108/254) 2.4 0.351 1.7 0.012
PF3D7_0523400 DnaJ protein, putative 31.8% (7/22) 10.6% (27/254) 3.9 0.093 1.7 0.013
PF3D7_0305300 conserved Plasmodium 
membrane protein, unknown 
function
36.4% (8/22) 17.3% (44/254) 2.7 0.246 1.7 0.013
PF3D7_0603600 conserved Plasmodium protein, 
unknown function
4.5% (1/22) 0% (0/254) nc nc 1.2 0.013
PF3D7_0306400 FAD-dependent glycerol-3-
phosphate dehydrogenase, 
putative
40.9% (9/22) 17.7% (45/254) 3.2 0.124 1.5 0.014
PF3D7_1433200.b conserved Plasmodium protein, 
unknown function
45.5% (10/22) 20.9% (53/254) 3.2 0.124 1.5 0.014
PF3D7_0726400.b conserved Plasmodium 
membrane protein, unknown 
function
22.7% (5/22) 3.5% (9/254) 8.0 0.026 1.2 0.015
PF3D7_1326500 conserved Plasmodium protein, 
unknown function
18.2% (4/22) 7.9% (20/254) 2.6 0.524 1.4 0.015
PF3D7_0804500.b conserved Plasmodium 
membrane protein, unknown 
function
45.5% (10/22) 18.9% (48/254) 3.6 0.085 1.5 0.016
PF3D7_0830600 Plasmodium exported protein 
(PHISTc), unknown function
40.9% (9/22) 17.7% (45/254) 3.2 0.124 1.7 0.016
PF3D7_0801000 Plasmodium exported protein 
(PHISTc), unknown function
4.5% (1/22) 0.4% (1/254) 12.0 0.422 1.7 0.016
Table 2. Continued
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PF3D7_1021100 conserved Plasmodium protein, 
unknown function
27.3% (6/22) 16.5% (42/254) 1.9 0.799 1.5 0.017
PF3D7_1024800 conserved Plasmodium protein, 
unknown function
40.9% (9/22) 16.5% (42/254) 3.5 0.094 1.5 0.020
PF3D7_0826100.d E3 ubiquitin-protein ligase, 
putative
36.4% (8/22) 18.9% (48/254) 2.5 0.344 1.5 0.021
PF3D7_1149200.b ring-infected erythrocyte surface 
antigen
36.4% (8/22) 22.4% (57/254) 2.0 0.642 1.7 0.024
PF3D7_1306500 MORN repeat protein, putative 31.8% (7/22) 10.2% (26/254) 4.1 0.085 1.3 0.025
PF3D7_0815300 FAD-dependent monooxygenase, 
putative
45.5% (10/22) 26.4% (67/254) 2.3 0.351 1.6 0.026
PF3D7_0726400.c conserved Plasmodium 
membrane protein, unknown 
function
40.9% (9/22) 23.6% (60/254) 2.2 0.422 1.5 0.026
PF3D7_1104700.2 RNA polymerase subunit, 
putative
13.6% (3/22) 0.8% (2/254) 19.9 0.042 1.1 0.028
PF3D7_1143700 conserved Plasmodium protein, 
unknown function
27.3% (6/22) 8.3% (21/254) 4.2 0.094 1.2 0.032
PF3D7_0826100.e E3 ubiquitin-protein ligase, 
putative
36.4% (8/22) 17.7% (45/254) 2.7 0.274 1.5 0.032
PF3D7_0826100.f E3 ubiquitin-protein ligase, 
putative
40.9% (9/22) 22.4% (57/254) 2.4 0.344 1.3 0.032
PF3D7_1449000 gamete egress and sporozoite 
traversal protein, putative (GEST)
22.7% (5/22) 11% (28/254) 2.4 0.532 1.3 0.035
PF3D7_0726400.d conserved Plasmodium 
membrane protein, unknown 
function
31.8% (7/22) 13% (33/254) 3.1 0.183 1.5 0.036
PF3D7_0323100 conserved Plasmodium protein, 
unknown function
36.4% (8/22) 16.9% (43/254) 2.8 0.223 1.5 0.036
PF3D7_0804500.c conserved Plasmodium 
membrane protein, unknown 
function
31.8% (7/22) 5.1% (13/254) 8.7 0.004 1.4 0.043
PF3D7_0826100.g E3 ubiquitin-protein ligase, 
putative
27.3% (6/22) 11.4% (29/254) 2.9 0.274 1.4 0.044
PF3D7_1354200 inositol-polyphosphate 
5-phosphatase, putative (IP5P)
40.9% (9/22) 18.9% (48/254) 3.0 0.168 1.5 0.045
PF3D7_1014300 conserved protein, unknown 
function
27.3% (6/22) 6.7% (17/254) 5.2 0.049 1.2 0.117
PF3D7_1348000 conserved Plasmodium protein, 
unknown function
13.6% (3/22) 1.2% (3/254) 13.2 0.049 1.1 0.310
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Gene ID Proteins, ordered by effect size and significance in the bayes-moderated t-test/linear 
regression analysis, and then by significance in logistic regression. Letters indicate 
cases where multiple protein targets (fragments) mapping to the same proteins are 
associated independently with TRA. 
Fold change SI Absolute fold change in average signal intensity (SI) of response to individual proteins 
by individuals with <10% TRA (gametocyte positive) and ≥90% TRA (1=no change)
Seropositivity Seropositivity was calculated using protein specific cut-offs, calculated using maximum 
likelihoods methods
p-values P-values after Benjamini-Hochberg adjustment to control the rate of false discovery 
below 5%, except for Pfs230 and Pfs48/45 which were assessed independently.
OR Odds-ratio
TR Transmission reduction
* Pfs48/45 and Pfs230 data are from ELISA, with correctly folded proteins. Signal 
intensity comparisons were made by linear regression, seropositivity analysis by 
logistic regression. Fold change SI is the fold change of the mean normalised OD 
between individuals with TRA <10% and >90%. Because these serological assays were 
independent, p values are not controlled for false discovery
Table 2. Continued
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Figure 2. Antibody responses to Pfs48/45-10C, Pfs230 and to the microarray proteins 
with transmission reducing activity (TRA). TRA was categorised as described, to compare 
responses between gametocyte positive individuals with <10% TRA, and individuals with >90% 
TRA. Antibody responses to correctly folded, recombinant Pfs48/45 and Pfs230 were measured 
using ELISA, with antibody intensity given as the ELISA optical density (OD) values (450nm). 
Antibody responses to microarray proteins are given as the log2-transformed signal intensity 
(SI) minus the vehicle SI, which equates to the log2-fold change over this background. A & B: 
Box-plots of α-Pfs48/45-10C and α-Pfs230 antibody intensity with TRA. C: Responses to the 
microarray protein targets (n=528). Antibody breadth is the number of proteins reactive above 
background in each individual, within the given groups. D: Magnitude of antibody response to 
microarray protein targets. Each dot represents the average SI of response to each protein target 
by all individuals within given groups. P values for intensity data and response breadth are from 
an F test for differences in OD/SI between all age groups, derived from linear regression, and 
adjusted for gametocyte density, or from students t-test (for magnitude only). For all box-plots, 
outliers are shown in black while all data points are shown in grey as a bee-swarm. E: Volcano 
plot showing the log2-fold change of the mean signal intensity for TRA as defined above. The 
p-value shown by the dotted line is unadjusted for false discovery. Black circled data points 
are those that remain significant after p-values have been adjusted to control the rate of false 
discovery below 5%, using the Benjamini-Hochberg method.
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TRA and mosquito infection rate in natural infections
Next, we determined whether the immune profile associated with TRA in the SMFA 
was also associated with mosquito infection rates observed in direct-membrane feeding 
experiments. Data on the infectivity of  donor blood samples to mosquitoes at the time of  
plasma donation was available for 494 individuals for whom gametocyte status had been 
assessed by microscopy and TRA assessed in the SMFA. Of  the 128 individuals without 
patent gametocytaemia, 18 (14.1%) were infective to mosquitoes in the DMFA. Of  the 
366 gametocyte positive individuals, 203 (55.5%) infected at least one mosquito, with 
a median mosquito infection rate of  20% (IQR 7.7-42.5%). There was good agreement 
between transmission outcomes in the SMFA using cultured gametocytes and An. stephensi 
mosquitoes, and the field-based DMFA using gametocytes in infected individuals and An. 
gambiae s.s. or An. coluzzii mosquitoes; Individuals with high-level TRA in the SMFA were 
significantly less likely to infect any mosquitoes in the DMFA (LogR: OR 0.23 [95% CI 
0.06-0.79], p=0.020), and more likely to do so at a reduced rate (OR 0.10 [95% CI 0.2-0.61], 
p=0.012). The likelihood of  gametocyte positive individuals infecting any mosquitoes in 
the DMFA was significantly lower if  seropositive for Pfs230 (LogR: OR 0.42 [95% CI 0.22-
0.78], p=0.006), Pfs48/45-10C (OR 0.30 [95% CI 0.16-0.59], p<0.001), or either or both 
antigens (OR 0.33 [95% CI 0.19-0.58], p<0.001) (Fig. 3A). The proportion of  mosquitoes 
that became infected after feeding was also significantly lower for individuals seropositive 
for Pfs230 (LogR: OR 0.36 [95% CI 0.14-0.88], p<0.027), Pfs48/45-10C (OR 0.14 [95% CI 
0.05-0.40], p<0.001) or either or both antigens (OR 0.25 [95% CI 0.11-0.55], p=0.001) (Fig. 
3B). The proportion of  mosquitoes that became infected decreased with increasing Pfs230 
antibody density (LogR: OR for an increase of  0.1 normalised optical density 0.59 [95% 
CI 0.40-0.86], p=0.007) and Pfs48/45-10C antibody density (OR 0.43 [95% CI 0.28-0.66], 
p<0.001). 
 Mosquito infection prevalence was lower in gametocyte positive individuals with 
antibodies recognising more of  the 62 novel protein microarray targets with TRA 
associated antibody responses (Supplementary Fig. 3). Individuals responding to ≥14/62 
microarray proteins (14 being the 75th percentile of  breadth of  response to these targets) 
were significantly less likely to infect mosquitoes (LogR: OR 0.31 [95% CI 0.18-0.51], 
p<0.001), and more likely to do so at a reduced rate (OR 0.21 [95%CI 0.09-0.45]. p<0.001)
(Fig. 3 A & B). After excluding Pfs48/45 or Pfs230 seropositive individuals, infectiousness 
and infection rate remained significantly lower in individuals responding to ≥14 of  the 62 
TRA associated microarray proteins (infectiousness: LogR, OR 0.29 [95% CI 0.16-0.53], 
p<0.001, infection rate: OR 0.23 [95% CI 0.10-0.52], p<0.001).
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Figure 3. Seroprevalence to Pfs48/45, Pfs230, and novel TRA associated microarray 
proteins, and infectiousness in the direct membrane-feeding assay (DMFA). Individuals 
with DMFA data were categorised according to their possession of antibodies specific to: 
Pfs48/45 (positive [+]/negative [-]); Pfs230 (positive [+]/negative [-]); ≥14 of the 61 novel 
microarray proteins with TRA associated antibody responses (15 being the 75th percentile of 
the breadth of response to these microarray targets among the entire sample set); ≥4 of the 
16 novel microarray proteins with TRA associated antibody responses that are also plausible 
targets of antibodies with TRA (4 being the 75th percentile of the breadth of response to these 
microarray targets among the entire sample set). A: Bars show the proportion of infectious 
individuals among seropositive/seronegative gametocytaemic individuals with DMFA data, 
with Clopper-Pearson confidence intervals. n/N =  number of individuals seropositive/total 
number of individuals with DMFA data. P-values are from logistic regression, with adjustment 
for gametocyte density. B: Box-plots show the percentage of mosquitoes that became infected 
after feeding. n/N = the number of mosquitoes feeding on seropositive individuals/the total 
number of mosquitoes feeding on individuals with DMFA data. P-values are from logistic models, 
adjusted for gametocyte density and with host (individual the mosquitoes were feeding upon) 
as a random effect. For all box-plots, outliers are shown as hollow black circles while all data 
points are shown as solid coloured dots.
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Functional involvement of antibodies in TRA
To demonstrate whether naturally-acquired antibodies to Pfs230 or Pfs48/45 were 
causally associated with TRA, we affinity-purified antibodies specific to key transmission-
blocking epitopes of  these proteins and assessed their activity in the SMFA (Table 3). 
These experiments were performed for 6 donors whose IgG showed high-level TRA and 
for whom high volumes of  plasma (≥1mL) were available; 3 of  these donors had ≥10mL 
plasma available, allowing additional testing after 9-fold antibody concentration of  IgG. 
The flow-through of  affinity purification experiments, depleted of  α-Pfs230 and α-Pfs48/45 
antibodies, was also tested in the SMFA to quantify TRA of  antibodies to other target 
antigens. Concentrated back to the original plasma volume, α-Pfs48/45 antibodies of  
one donor independently inhibited transmission (TRA 91.5% [95% CI 86.4-94.7]), while 
α-Pfs230 antibodies of  a different donor had low but statistically significant TRA (TRA 41.1% 
[95% CI 15.5-60.4]). When antibodies were concentrated to nine times their physiological 
concentration (performed for 3 donors with >9mL plasma available), α-Pfs48/45 antibodies 
from one additional individual, and α-Pfs230 antibodies from two additional individuals 
significantly reduced transmission to mosquitoes (Pfs48/45: TRA 81.3%, [95% CI 70.9-
88.0], Pfs230: TRA 94.8% [95% CI 90.2-97.3] & 99.3% [95% 98.6-99.6], Table 3). For all 
individuals the α-Pfs48/45 and α-Pfs230 depleted IgG (containing no antibodies against 
Pfs48-45 epitopes 1-3, or Pfs230 epitope C, confirmed by ELISA) inhibited transmission to 
mosquitoes (Table 3). This activity was complement-independent. 
 To determine the presence of  naturally-acquired antibodies binding to unknown gamete 
surface antigens, we performed surface immuno-fluorescence assays (SIFA) using gametes 
of  a Pfs48/45 knock-out (KO) parasite [3] that does not produce surface retained Pfs230 
[12]. Pfs48/45 and Pfs230 specific antibodies confirmed the absence of  these proteins 
on Pfs48/45 KO gamete surfaces (Fig. 4). The immuno-fluorescence of  gamete surfaces 
observed using total IgG and IgG depleted of  α-Pfs48/45 and α-Pfs230 antibodies from 
naturally exposed individuals therefore reflects recognition of  unknown antigens on the 
gamete surface (Fig. 4, Supplementary Fig. 5A).
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Figure 4. Gamete surface immuno-fluorescence assay (SIFA) using wild-type and Pfs48-45 
KO NF54 gametes, with Pfs48/45 mAb, Pfs230 mAb, and IgG from a malaria exposed serum 
donor. Donor IgG is from donor A in table 3, and was performed using total IgG, and IgG depleted of 
α-Pfs48/45-10c and α-Pfs230CMB Ab. Δ Pfs48/45 = Pfs48/45 KO [3]. BF = Bright-field, FITC = fluorescein 
isothiocyanate. Anti-Pfs48/45 is mAb 45.1, and anti-Pfs230 is mAb 2A2, as described in the methods. 
Scale bar is 20µm.
Antibody responses to a number of  the 43 novel proteins that are associated with TRA 
(Table 2) may be biomarkers of  high prior gametocyte exposure rather than causally related 
to TRA. We thus curated this list of  proteins by excluding genes with known or predicted 
intracellular products, while retaining genes based on evidence for a role in transmission 
reduction or gamete viability, or predicted compatibility with gametocyte/gamete surface 
expression. In addition to Pfs230 and Pfs48/45, 13 novel proteins possess sequence 
characteristics that are compatible with surface expression or have known roles in gamete 
viability (Table 4; Supplementary Data 4 and may thus form biologically plausible targets 
of  transmission-inhibiting antibodies. mAbs specific to Pf11-1, one of  the biomarkers with 
a role in gamete egress, were shown previously to reduce transmission to mosquitoes in 
membrane feeding experiments [58]. Previous data show that the P. berghei homologue of  
another of  our markers, PF3D7_1449000 (PfGEST), shows partial association with gamete 
surfaces and has a clear role in gamete egress [59]. We tested three monoclonal antibodies 
320
(mAb) against PfGEST in the SIFA and SMFA. SIFA with PfGEST mAbs showed no, 
or very limited surface reactivity, indicating that PfGEST is not retained on the gamete 
surface by 20 minutes after erythrocyte egress in P. falciparum (Supplementary Fig. 5B). 
Though two antibodies produced modest TRA in singlicate SMFA experiments at 10 µg/
mL (Generalised linear mixed model (GLMM): maximum 49.3% TRA, 95% CI 31.0-
62.8, p<0.001), this was not replicable and showed no improvement with concentration 
(Supplementary Fig. 4). These data indicate that though naturally acquired PfGEST Ab 
appear to be biomarkers of  TRA, there is no current evidence to support a mechanistic role 
in TRA.
 The 13 potentially surface expressed proteins were represented by 39 targets on the 
microarray, of  which 16 were statistically significantly associated with TRA in the SMFA. 
Though antibody responses to most gametocyte proteins decrease with age, responses to 
these 16 targets shared a pattern more similar to Pfs48/45 and Pfs230; breadth of  response 
to these targets increased with age (p=0.007) while magnitude of  response, though 
highest in older individuals, showed no age-dependent association (Supplementary Fig. 
6). Gametocyte positive individuals recognizing ≥4/16 of  these targets (4 being the 75th 
percentile of  breadth of  response to these targets) showed lower infectiousness (LogR: 
OR 0.36 [95% CI 0.23-0.56], p<0.001) and infection rates (OR 0.32 [95% CI 0.16-0.62, 
p=0.001) in the DMFA (Fig. 3 A & B). These patterns remained significant when Pfs48/45 
or Pfs230 seropositive individuals were excluded (infectiousness: LogR, OR 0.34 [95% CI 
0.20-0.58], p<0.001; infection rate: OR 0.31 [95% CI 0.15-0.64], p=0.001). 
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Discussion
In this study, we assessed antibody-mediated transmission reducing activity (TRA) in 
individuals naturally exposed to P. falciparum and identified associated antibody responses. 
A minority of  samples (3.3%) demonstrated strong and reproducible levels of  TRA in 
controlled in vitro assessments with cultured P. falciparum gametocytes; high-level TRA was 
associated variably with antibody responses to gametocyte antigens Pfs48/45, Pfs230, and 43 
newly described proteins. These antibody responses were associated with reduced mosquito 
infection rates in feeding assays with local mosquito species on infected, gametocytaemic 
individuals. Whilst not all of  the identified antibody responses will be causally involved 
in TRA, we provide the first direct evidence for independent roles of  antibodies specific to 
Pfs48/45 and Pfs230 in naturally acquired TRA. The TRA of  mAb specific to one of  the 
novel TRA biomarkers, PfGEST, indicate that PfGEST antibodies elicited by P. falciparum 
exposure are likely to be non-functional biomarkers of  TRA.
 The transmission of  P. falciparum to mosquitoes is influenced by numerous factors, 
including gametocyte density [60], sex-ratio [61], and human host factors that are currently 
poorly characterised. A direct effect of  naturally acquired antibodies on transmission 
efficiency is suggested by the observation that mosquito infection rates generally increase in 
mosquito feeding experiments on naturally infected gametocyte carriers when autologous 
plasma is replaced by control serum [62]. Antibody responses to Pfs48/45 and Pfs230, 
established target antigens for transmission blocking vaccines [15, 36], are naturally acquired 
upon gametocyte exposure and have previously been statistically associated with TRA 
as measured in the SMFA [10, 21-28]. The strength of  these associations is variable and 
sometimes absent [29]; TRA is often observed in individuals without measurable α-Pfs48/45 
or α-Pfs230 antibodies [10, 23, 25, 28, 30, 31]. We performed SMFA experiments on purified 
IgG samples from 648 malaria-exposed donors and confirm previous associations between 
TRA and α-Pfs48/45 (OR 4.4, 95% CI 1.5-12.9) and α-Pfs230 antibodies (OR 7.9, 95% 
CI 2.8-22.8). Using a unique sample set with transmission data from memDMFA from 
three endemic settings, we further provide the first evidence that α-Pfs48/45 and α-Pfs230 
antibodies are associated with reduced transmission efficiency during natural infections. 
Both the likelihood of  infecting any mosquitoes and the proportion of  infected mosquitoes 
were significantly lower for individuals with α-Pfs48/45 and α-Pfs230 antibodies. For the 
first time, we formally demonstrate that naturally acquired antibodies to these gametocyte 
antigens can independently inhibit mosquito infection after affinity purification.
 Despite the important role of  antibodies to these two pre-fertilization antigens, 45% of  
plasma donors with high-level TRA had no measurable α-Pfs48/45 or α-Pfs230 antibodies, 
and we observed significant levels of  TRA after IgG from a selection of  donors was depleted 
of  α-Pfs48/45 and α-Pfs230 antibodies. Our affinity purification experiments were based on 
the binding of  antibodies to epitopes present in the Pfs48/45-10C and 230-CMB vaccine 
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constructs, since the proteins’ complex conformational structures so far preclude their 
production as full-length proteins. We thus captured the most potent transmission-reducing 
antibodies (Pfs48/45 epitopes 1-3 [21, 22, 36], Pfs230 epitopes within the C region [15]) 
but not necessarily all antibodies to these proteins. Monoclonal antibodies against epitope 
5, which would not bind to the Pfs48/45-10C protein, have been associated with weak TR 
activity [63]. However, given their lower efficacy and the immuno-dominance of  epitopes 
1-3 in naturally immune sera [21] it is highly unlikely that α-Pfs48/45 antibodies to epitopes 
other than epitopes 1-3 would have contributed considerably to TRA. This is also supported 
by the finding that antibodies to epitope 5 are only observed in the presence of  antibodies 
to epitopes 1-3 [21]. Because all known α-Pfs230 antibodies are complement dependent 
[64, 65], whilst TRA in the antibody-depleted fraction is complement independent, a role 
for residual α-Pfs230 antibodies (responsive to epitopes outside the aa. 444-730 region of  
Pfs230 represented by the 230CMB product) is similarly unlikely. Crucially, IgG depleted of  
antibodies to Pfs48/45 epitopes 1-3 recognized surface antigens of  a knockout parasite line 
that fails to express Pfs48/45 and Pfs230, formally demonstrating recognition of  other target 
antigens by immune sera. Our findings of  TRA in the absence of  measurable α-Pfs48/45 or 
α-Pfs230 antibodies, together with persisting recognition of  gametes that do not express these 
two proteins, and functional TRA after depleting IgG of  antibodies to these two targets, thus 
strongly suggest that responses to other antigens may contribute to naturally acquired TRA. 
 Using a protein microarray, we aimed to identify whether responses to other gametocyte 
targets were associated with TRA. This array was enriched for putative gametocyte surface 
antigens but surface expression or gametocyte specificity were not pre-requisites for inclusion 
on the array. Our aim was to determine an immune signature of  TRA that could improve 
our understanding of  transmission efficiency from natural infections. We therefore included 
markers of  gametocyte exposure as well as general markers of  recent malaria infection. 
We observed that responses to 43 proteins were statistically significantly associated with 
high-level antibody-mediated TRA. Responses to these antigens were strongly predictive 
of  transmission efficiency from natural P. falciparum infections with diverse gametocyte 
strains and locally relevant mosquito species. Whilst further studies are needed to assess 
the generalisability of  this signature of  TRA across endemic settings, the strong association 
of  our SMFA-based signature of  TRA with reduced transmission potential during natural 
infections is very promising. Future studies should aim to assess the kinetics of  antibody 
responses to these antigens and their association with TRA using longitudinal cohorts, with 
well-defined clinical, parasitological, and infectivity data. 
 The microarray proteins were produced in an Escherichia coli based in vitro transcription-
translation (IVTT) system. As conformation is not verified for all proteins, those requiring 
post-translational modifications will likely not have been expressed in their native 
conformation. This was exemplified by Pfs48/45 that has a known complex structure [36, 
66] and showed minimal reactivity or discriminative power when printed on the array as an 
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IVTT product (Supplementary Data 2). This apparent disadvantage of  the IVTT system will 
plausibly have affected our results for other conformational proteins, so the list of  proteins in 
Table 3 must be treated as a ‘rule in’ rather than ‘rule out’ selection for proteins associated 
with antibody mediated TRA. 
Among the proteins we identified as having TRA associated antibody responses, 13 novel 
proteins have sequence characteristics suggestive of  surface expression and may be targets 
of  TRA. Previous data indicate that two of  the proteins found to be biomarkers of  TRA in 
our analysis, PfGEST and Pf11-1, were previously shown to have important roles in gamete 
egress from the erythrocyte in mosquitoes [58, 59]. Interestingly, Pf11-1 mAbs are able 
to reduce transmission, possibly by disabling full gamete egress [58]. Our SIFA data with 
humanized mAbs indicate that PfGEST has no clear surface expression in P. falciparum 20 
minutes after activation, which may explain their lack of  replicable TRA in mosquito feeding 
assays compared to similar concentrations of  α-230 specific mAb. As there is only a narrow 
window of  opportunity for α-Pf11-1 and α-PfGEST antibody binding during gamete egress, 
activity against gamete surface proteins with roles in fertilization is a more biologically 
plausible mode of  effective antibody-mediated TRA. Future experiments may identify 
which of  the 13 other TRA associated plausible antibody targets in Table 4 are expressed at 
the gamete surface. Our findings identify the further characterisation of  functional and non-
functional gametocyte antibody responses in individuals with naturally acquired TRA as a 
research priority. Whilst the prevalence of  high-level TRA decreases with age, an opposite 
trend is observed for the magnitude and prevalence of  antibodies to Pfs48/45 and Pfs230 
and to newly identified gametocyte antigens, in spite of  their overall association with TRA 
(Supplementary Fig. 6). A better characterisation of  these antibody responses in relation 
to functional activity is needed and may include a detailed assessment of  antibody isotype, 
affinity and complement-binding activities. 
Regardless of  their functionality, our data indicate that possession of  antibody responses to 
a group of  P. falciparum proteins increases the likelihood of  antibody mediated transmission 
inhibition. Combined with assessment of  α-Pfs48/45 and α-Pfs230, this signature of  TR 
immunity may improve our understanding of  natural malaria transmission dynamics.
Methods
Study participants
Serum was collected from individuals recruited to epidemiological studies in Burkina Faso, 
Cameroon and the Gambia (Table 1), as well as from Dutch migrants with a history of  
residence in P. falciparum malaria endemic regions, who reported having been diagnosed 
with clinical malaria infection. Details of  sample collection and recruitment criteria have 
been published for all samples from individuals living in endemic areas, but are provided 
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here as a summary. Parasitological status was defined by microscopy acknowledging that 
this lacks the sensitivity to detect many low-density infections; i.e. microscopy negative 
samples were not treated as an unexposed control. 
 Cameroon: Samples (n=140) were collected between 2011 and 2015 from individuals aged 
5-16 years, during surveys at primary schools in the Mfou district, 30 km from Yaoundé. 
Data from these individuals has in part been presented previously [42, 43], but the remainder 
were provided by Isabelle Morlais (IRD, Montpelier) without prior publication. Participants 
were primarily P. falciparum gametocyte carriers identified among asymptomatic children 
by microscopical screening. Gametocyte density (median [IQR]=30 [16/80]/µL, among 
gametocyte positives) was calculated against 1000 leukocytes, assuming a density of  8000 
leukocytes per µL.
 Gambia: Samples (n=226) were collected from individuals resident in Farafenni and 
nearby villages, approximately 200 km east of  Banjul, in 1992-1994 [24, 44], 1998 and 1999 
[45], 2001[46, 47], and 2002 [48]. Individuals were aged 1-17 years at the point of  sampling. 
Participants were enrolled if  they were found to be asymptomatically infected with malaria 
parasites, based either on the observation of  gametocytes [24, 44], or asexual parasites [45-
48] by microscopy. Gametocyte density (median [IQR]=63 [10/390]/µL, among gametocyte 
positives) was either calculated by examination of  100 high powered fields, assuming that 1 
gametocyte per field equated to 500/µL (threshold of  5 gametocytes/µL) as in Greenwood 
& Armstrong 1991[67] , or by calculation against 1000 leukocytes, assuming a density of  
8000 leukocytes per µL.
 Burkina Faso: Samples were collected from residents in the villages of  Laye and Dapélogo 
(n=192), approximately 30km northeast and north of  Ouagadougo, in the Central Sudan 
savannah area [37, 40, 41], and from residents of  Soumousso and Dande (n=33), villages 
close to Bobo-dioulasso [38, 39]. The age of  study participants ranged from 1.8-74 years. 
Recruitment was either random [37, 41], or based on the observation of  gametocytes [38-40] 
or asexual parasites [40] by microscopy. Gametocyte density (median [IQR]=64 [32/128]/
µL, among gametocyte positives) was calculated against either 500 or 1000 leukocytes, 
assuming a density of  8000 leukocytes per µL.
 Netherlands: Dutch individuals were recruited by clinical staff  at Radboud university 
medical centre in Nijmegen, the Netherlands, and had either recently returned (<6 months) 
from extended periods in endemic areas (n=8) or had returned more than a year before 
sampling (n=49). Age ranged from 26-84 years. Those who had returned more than a year 
before sampling had lived in areas with endemic P. falciparum transmission for longer than 15 
years and reported between 2 and >80 clinical malaria episodes during that time. For these 
individuals malaria infection history was only available through verbal testimony, whereas 3 
out of  8 of  the recently returned migrants had confirmed recent or current malaria infection. 
Samples were all collected between 1994 and 2014. As detailed previously, sera from some 
of  these expatriates show strong and consistent TRA in the SMFA [68].
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All samples were collected after written informed consent was obtained from participants 
and/or their parent(s) or guardian(s). Ethical clearance was provided by the National Ethics 
Committee of  Cameroon, the Gambian Government/Medical Research Council Joint Ethics 
Committee, the Ethical Review Committee of  the Ministry of  Health of  Burkina Faso and 
the Centre MURAZ ethical review committees, the London School of  Hygiene & Tropical 
Medicine ethics committee and by the Radboud University Medical Center ethical committee.
Sample preparation
For SMFA, IgG was purified from all plasma samples using Protein G HP Spintrap (GE 
Healthcare, GE Uppsala, Sweden), and concentrated to the original serum volume using 
Vivaspin 20 centrifugal concentration columns (Sartorius AG, Goettingen, Germany) 
following the manufacturer’s instructions. Antibody purification was only attempted for 
samples with sufficient serum volume for duplicate SMFAs (180 µL). For the serological 
assays, an additional 30 µL of  serum was retained if  sample volume permitted. Because 
of  the high serum volumes necessary for the antibody depletion/purification experiments, 
these were performed on only six samples with transmission blocking antibodies. Three of  
these six were processed by protein microarray. IgG for depletion/purification was purified 
from 1mL of  serum using protein G high performance affinity columns (HiTrap™ Protein 
G HP 1 mL, GE Healthcare, Uppsala, Sweden), and then adjusted to the original serum 
volume for testing in the specific Pfs48/45 and Pfs230 affinity columns using Vivaspin 
20 centrifugal concentration columns (Sartorius AG, Goettingen, Germany). 300 µL was 
immediately removed for SMFA and serological assays, leaving 700 µL of  total IgG at 
physiological concentration for affinity column purification. Purification was repeated as 
required to allow for antibody eluate concentration.
Direct membrane feeding assay (DMFA)
DMFA was performed during the original studies for 498/579 individuals from endemic 
areas, as described in the separate study protocols using identical glass mini-feeders [54] 
(Coelen Glastechniek, Weldaad, the Netherlands) and the same experimental protocol [69]. 
Of  the 498 individuals with DMFA data, 494 had microscopy based estimates of  asexual 
and gametocyte density; only gametocyte positives (n=366) were used in our DMFA 
analysis. All sites used colonies sourced from eggs caught in local water sources. Colonies 
were of  A. gambiae s.s. (>90%) (The Gambia [24, 44-48]), A. coluzzii (Cameroon [42, 43] 
and Bobo Dioulasso in Burkina Faso [38, 39]) or a comprised a mixture of  A. coluzzii, 
A. gambiae s.s. and hybrid forms (other Burkina Faso sites [37, 40, 41]). Locally adapted 
mosquito colonies from all sites are available upon request. Data presented in the current 
manuscript are the proportion of  infectious individuals and percent of  mosquitoes infected 
with oocysts after feeding on whole blood [69]. 
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Standard membrane feeding assay (SMFA)
Mosquitoes used for the assessment of  antibody TRA in the SMFA were three to five-
day old female An. stephensi (Sind-Kasur Nijmegen strain) [70], which were reared at 
30oC and 70-80% humidity while exposed to a 12 hour day/night cycle. Mature (stage 
IV-V) P. falciparum gametocytes (either NF54[54], or transgenic NF54HT-GFP-Luc [71], 
depending on the preferred read-out) were obtained from an automated tipper system (0.3-
0.5% gametocytes, 2% haematocrit) and prepared with packed red blood cells as previously 
described [9, 54]. Both gametocyte strains can be obtained from the MR4 Malaria Research 
and Reference Reagent Resource Center (https://www.beiresources.org/MR4Home.
aspx). For the preparation of  mosquito blood meals containing test antibodies, 90 µL of  
serum IgG was added to 90 µL of  freeze-dried foetal calf  sera (FCS) and diluted into 35 
µL human serum containing active complement. This antibody/serum mix was added to 
the gametocyte/red blood cell mix to a final volume of  270 µL, and kept at 37˚C until it 
was provided to mosquitoes in the membrane feeding apparatus. Antibodies were therefore 
provided to mosquitoes at approximately 0.66* their physiological concentration (assuming 
a 1:1 plasma/cell ratio). Each SMFA run was performed to test up to 24 antibody samples 
simultaneously, including two control mosquito groups (against which the TRA of  test 
samples was calculated). For control samples 90 µL of  freeze-dried FCS was dissolved in 90 
µL milliQ and added to the same gametocyte/red blood cell mix (270 µL total volume) as 
was used for the other feeds the run.
 Prior to blood feeding, male mosquitoes were separated from females by aspiration. 
Unfed and partially fed female mosquitoes were removed from their resting containers after 
blood feeding. Fully engorged mosquitoes were maintained at 26oC and 70-80% humidity. 
Mosquito infection status was determined differently for the NF54 and NF54HT-GFP-luc 
parasite strains. For experiments with the native NF54 strain, an average of  19.5 mosquitoes 
(range 7-22) were dissected at day 7 post infection (PI). Midguts were stained in 1% 
mercurochrome and oocysts were counted by expert microscopists. For experiments with 
the transgenic NF54HT-GFP-luc strain, mosquitoes were killed on day 8 PI by freezing, 
and 20 were homogenised for each experiment in two pools of  10. Mosquito homogenates 
were well mixed and three samples per pool were assayed for bioluminescence by lysis, and 
addition of  luciferase assay substrate using a Luciferase assay kit (Luciferase assay system 
[E1501], Promega, USA), according to the manufacturer’s instructions and as previously 
described [9]. 
 For experiments with the native NF54 strain, TRA was analysed as the percent difference 
in oocyst number between test and control mosquitoes. For experiments with the transgenic 
NF54HT-GFP-luc strain, TRA was calculated as the average percent difference in 
luminescence intensity for two pools of  10 mosquitoes between test and controls mosquitoes, 
as described [9]. TRA <0% was observed, but was generally within the normal range due to 
natural variation in oocyst intensity between mosquito groups. For individuals with TRA 
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<0%, median TRA was -41.8% (IQR -80.9 - -16.5-). For experiments with replication (e.g. 
the affinity purification experiments) 95% CI around the TRA estimate were calculated 
from luminescence or microscopical readouts for multiple feeds using generalised linear 
mixed models (GLMMs) [72]. Choice of  readout (and therefore of  gametocyte strain) 
varied over the time that the SMFA’s were being performed, and makes no difference to 
the integrity or interpretation of  TRA, only to its efficiency [9]. ≥90% reduction in oocyst/
luminescence intensity in test mosquitoes relative to controls was classified as evidence of  
high-level TRA, which previous data indicate is highly replicable [68]. Samples from all 
individuals with >80% TRA were tested in duplicate to ensure robustness of  the functional 
phenotype and the mean value of  duplicate experiments was used to classify individuals as 
having high level TRA (>90% average reduction) or no evidence of  TRA (<10% average 
reduction).
Recombinant protein production for serological assays
Recombinant, correctly folded proteins were used for antibody depletion/purification 
experiments and for enzyme-linked immunosorbent assays (ELISA). For all assays assessing 
Pfs230 specific antibodies, we used the transmission blocking vaccine candidate 230CMB 
(developed and purified by Fraunhofer USA Center for Molecular Biotechnology), which 
corresponds to amino acids 444-730 of  the Pfs230 protein, and comprises the protein’s pro-
domain and the first of  fourteen cysteine motif  domains [15]. For assays with Pfs48/45, 
two protein constructs were used. For antibody depletion/purification, we used the 
chimeric R0-10C protein [36], which comprises 10 cysteines spanning epitopes 1-3 of  the 
Pfs48/45 C-terminal domain, fused to the GLURP R0 domain [36, 40]. Antibodies specific 
to GLURP R0 have no effect on Plasmodium transmission to mosquitoes (Supplementary 
Table 2) [9]. For non-functional serological assays (ELISA, Microarray), the 10C protein 
was cleaved from the R0-10C as described previously [40].
Monoclonal antibodies
SMFA data using mAb specific to GLURP R0, Pfs48/45 (85RF45.1), Pfs230 (2A2) and 
PfGEST are presented in the Supplementary information. Full details for GLURP R0 
and Pfs48/45 (85RF45.1) mAb production and SMFA is provided in Stone et al. 2014 [9]. 
Details of  Pfs230 mAb production and SMFA are presented in Roeffen et al. 1995 [65]. 
PfGEST mAbs were produced by the Hypothesis-driven Pre-erythrocytic Antigen Target 
Identification Consortium (HPATIC). Briefly, HKL v2.0 KymiceTM containing human 
variable region genes (Kymab) were immunized with recombinant protein expressed in 
the wheat germ cell-free system (CellFree Sciences) adjuvanted with Montanide ISA 720. 
Non-antigen selected splenocytes were sorted into 96 well plates, one cell/well, to generate 
single cell mRNA material (Atreca). Atreca’s Immune Repertoire Capture (IRCTM) provides 
Single-Cell mRNA Barcode-Sequencing with high throughput and accuracy. This platform 
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captured full length sequences, enabling detection of  somatic mutations across the entire 
antibody variable region. Natively paired heavy and light chain IgG variable regions were 
analyzed, and constant region isotype assignments were made which were then produced 
via gene synthesis and recombinant expression as fully human antibodies (LakePharma). 
Three mAbs were tested in duplicate SMFA titration experiments. SMFA was conducted 
according to previously published protocols [9]. In all mAb based SMFA, the endpoint was 
oocyst quantification by manual dissection.
Pfs48/45 and Pfs230 antibody purification
To purify antibodies specific to the Pfs48/45 and Pfs230 proteins from transmission-
reducing sera, affinity columns were created by coupling 1mg of  R0-10C or 230CMB 
to N-hydroxysuccinimide (NHS)-activated high performance affinity chromatography 
columns (HiTrap™ NHS-activated HP 1 mL, GE Healthcare, Uppsala, Sweden); coupling 
efficiency was >80%. 
 For the extraction of  antibodies from human serum, antibodies were extracted first using 
the R0-10C column, and then using the 230CMB column, as follows. The R0-10C column 
was equilibrated with 2mL of  binding buffer (PBS (1x) before 700 µL of  total IgG (at 
physiological concentration, fraction 1 in Table 2) from transmission blocking sera was 
added. The flow-through was collected and the column washed with 12mL of  PBS. 5mL of  
elution buffer (0.15 M NaCl, 0.1 M Glycine/HCL, pH 2.5) was applied to the column for 
the collection for R0-10C specific antibodies. After elution, the purification procedure was 
repeated using the flow-through from the first purification, and the antibody eluates from 
both runs were pooled. The final flow-through and combined antibody eluates (fraction 2 in 
Table 2) were concentrated to 700 µL using Vivaspin 20 centrifugal concentration columns 
(Sartorius AG, Goettingen, Germany). 300 µL of  the flow-through was removed for SMFA 
(fraction 3 in Table 2) and serological assays, and the remaining 400 µL was processed 
over the equilibrated 230CMB column as for the R0-10C column, except that the final flow 
through’s (fraction 5 in Table 2) and eluates (fraction 4 in Table 2) were concentrated to 
400 µL. Depletion of  specific antibody in the flow-throughs of  each column was confirmed 
with ELISA. Antibodies (from eluates or flow-troughs) were processed in the SMFA in 
two biological replicates, as for total IgG with >80% TRA in the larger SMFA screen. For 
3 samples, larger starting volumes were used to allow antibody eluates to be concentrated 
nine times, to examine the effect of  specific concentrated antibody on transmission reducing 
activity.
 The possibility that TRA from the column fractions was due to cytokines or reactive 
ROx/RNOx species, which in circumstances of  inflammatory crisis can inhibit parasite 
development in mosquitoes [73], was excluded both by our use of  protein G binding 
columns for IgG purification for all samples, and our use of  30kDa filters for antibody 
concentration prior to mosquito feeding.
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Surface immuno-fluorescence assays (SIFA)
The Pfs48/45 knock-out (KO) NF54 P. falciparum line was produced and characterised by van 
Dijk et al. [3] and subsequently assessed by Eksi et al. [12]; Eksi et al.  showed that Pfs230 is 
produced but not retained on surface of  Pfs48/45 disruptant gametes. Wild-type (WT) and 
Pfs48/45 KO gametocytes were generated using standard protocols, as described above. Culture 
media Pfs48/45 KO line was supplemented with 2µM pyrimethamine. Briefly, gametocytes 
were allowed to activate at room temperature for 20 minutes (for mAb SIFA) or 1 hour (for 
human IgG SIFA) in the presence of  foetal calf  serum (FCS), and gametes were prepared 
for microscopy by washing with PBS supplemented with 0.5% FCS and 0.05% sodium azide. 
Antibodies were added to gamete preparations in the same PBS/FCS buffer; mAbs at 5µg/ml; 
human IgG/sera at dilutions of  1:20. Secondary antibodies were Alexa Fluor TM 488 goat 
anti-human IgG (H+L), Alexa Fluor TM 488 chicken anti-mouse IgG (H+L), and Alexa Fluor 
TM 488 goat anti-rat IgG (H+L); all were added at dilutions of  1:200. All gamete preparations 
were incubated with secondary antibody at room temperature for 1 hour. 
ELISA
Antibodies specific to the Pfs48/45-10C and Pfs230 (230CMB) proteins were quantified in 
the ELISA exactly as described previously [40]. Optical density (OD) values were normalised 
between assay plates by adjustment relative to a consistent point in the linear portion of  a 
standard curve of  serially diluted highly reactive human sera. Cut-offs for positivity were 
determined from normalised OD values using maximum likelihood methods to define 
Gaussian populations of  low and high responders as described previously [74]. For Dutch 
migrants who had returned from endemic areas ≥1 year before sampling, a seropositivity 
threshold was calculated as the mean + 3 standard deviations of  the averaged normalised OD 
values of  eight naïve European control sera.
Protein microarray
The selection of  proteins to be cloned and printed on the arrays was made primarily 
based on observed expression by stage V P. falciparum gametocytes in a single recent 
proteomic analysis [52]. To ensure that the array included most potential antibody targets, 
we preferentially included proteins that had transmembrane domains, signal peptides, 
or GPI anchors. To ensure that the majority of  proteins that were highly abundant or 
‘specific’ to mature gametocytes were included on the array, we used mass spectrometry 
data from the analysis of  the stage V gametocyte proteome [52], alongside proteomic data 
from purified trophozoites [1] and schizonts (Supplementary Data 5, PRIDE accession 
number: PXD008250) generated in the same laboratory. Gametocyte and asexual stage-
specific expression datasets were generated in relative expression values to compare protein 
abundances (label-free quantitative [LFQ] values) between the stages, which are presented in 
Supplementary Data 1 as a fold change value. 
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We chose to also include proteins that were potential markers of  gametogenesis identified by 
Silvestrini and colleagues [1]. These proteins we identified as being expressed primarily by 
early gametocytes, or shared between stages (proteins for 32/59 were present in the stage V 
database), but some were more abundant in mature gametocytes or other parasite life stages 
(Supplementary Data 1). In addition to these markers, we included four putative markers 
of  asexual parasite exposure: PF3D7_1036000 (Merozoite surface protein 11 [MSP11]), 
PF3D7_0711700 (erythrocyte membrane protein 1, PfEMP1 [VAR]), PF3D7_0731600 
(acyl-CoA synthetase [ACS5]), and PF3D7_0423700 (early-transcribed membrane protein 
4 [ETRAMP4]), based on work by Helb and colleagues [51].
 Details of  the 315 proteins included on the array are given in Supplemental Data 1. 
Proteins with reference sequences longer than 1000 amino-acids were split into multiple 
fragments (overlaps of  at least 17 a.a) for cloning, in vitro protein expression and printing. 
Because the basic criteria for the selection of  proteins for microarray construction was 
based on data generated from a single laboratory, we cross-referenced our protein list 
against a cross-study analysis of  gametocyte specificity [53]. In short, the specificity of  any 
protein for the gametocyte stage was scored by determining how often it had been detected 
across 11 proteomic analyses (listed in Supplementary Data 1: 3 of  gametocytes only, 3 
of  asexual stages only, and 5 of  both asexuals and gametocytes). Proteins were binned 
from low to high abundance and weighted according to the retrieval rates of  proteins in 
two curated lists of  “gold standard” gametocyte and asexual genes, consisting of  genes 
that are known to be specific for either asexual stages (n=45) or gametocytes (n=41). 
High expression of  gametocyte gold standard proteins with concurrent absence of  non-
gametocyte gold standard proteins resulted in a high gametocyte score, calculated from the 
fraction of  retrieved gametocyte genes over retrieved non-gametocyte genes. All scores were 
log transformed and summed over all datasets. Gametocyte scores were categorized using 
the scores’ distribution of  the gametocyte gold standard as follows: Scores above the first 
quartile (9.69) were considered gametocyte specific. Proteins scoring at least as high as the 
lowest scoring gametocyte gold standard representative (-2.46) were considered as enriched 
in gametocytes. Proteins with lower scores are not specific to a certain life stage and have 
some evidence for expression in gametocytes. All proteins scoring lower than the median of  
the asexual gold standard (-18.98) were considered asexual specific. This analysis confirmed 
that 228 of  the 315 proteins had consensus evidence for enrichment in gametocytes (scores 
>-2.46), while 284/315 had conservative evidence for expression in gametocytes (peptides 
present in at least one gametocyte proteomic database, score > -10). 312/315 were present 
in at least one gametocyte proteomic database, giving rise to a score >-18.93. Scores for all 
proteins on the array are included in Supplementary Data 1. To avoid further curation and 
potential bias, no proteins were excluded prior to analysis. 
 Proteins were expressed using an in vitro transcription and translation (IVTT) system, 
the Escherichia coli cell-free Rapid Translation System (RTS) kit (5 Prime, Gaithersburg, 
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MD, USA). A library of  partial or complete CDSs cloned into a T7 expression vector 
pXI has been established at Antigen Discovery, Inc. (ADI, Irvine, CA, USA). This library 
was created through an in vivo recombination cloning process with PCR-amplified CDSs, 
and a complementary linearized expressed vector transformed into chemically competent 
E. coli was amplified by PCR and cloned into pXI vector using a high-throughput PCR 
recombination cloning method described elsewhere [50]. Each expressed protein includes 
a 5’ polyhistidine (HIS) epitope and 3’ hemagglutinin (HA) epitope. After expressing the 
proteins according to manufacturer instructions, translated proteins were printed onto 
nitrocellulose-coated glass AVID slides (Grace Bio-Labs, Inc., Bend, OR, USA) using an 
Omni Grid Accent robotic microarray printer (Digilabs, Inc., Marlborough, MA, USA). 
Each slide contained 8 nitrocellulose “pads” on which the full array was printed, allowing 
eight samples to be probed per slide. Microarray chip printing and protein expression 
were quality checked by probing random slides with anti-HIS and anti-HA monoclonal 
antibodies with fluorescent labelling. Each chip contained 28 IVTT negative control targets 
(for data normalisation), and 48 IgG positive control targets (for quality control).
 For analysis of  antibody reactivity on the protein microarray, serum samples were 
diluted 1:200 in a 3 mg mL-1 E. coli lysate solution in protein arraying buffer (Maine 
Manufacturing, Sanford, ME, USA) and incubated at room temperature for 30 min. Chips 
were rehydrated in blocking buffer for 30 min. Blocking buffer was removed, and chips were 
probed with pre-incubated serum samples using sealed, fitted slide chambers to ensure no 
cross-contamination of  sample between pads. Chips were incubated overnight at 4°C with 
agitation. Chips were washed five times with TBS-0.05% Tween 20, followed by incubation 
with biotin-conjugated goat anti-human IgG (Jackson ImmunoResearch, West Grove, PA, 
USA) diluted 1:200 in blocking buffer at room temperature. Chips were washed three times 
with TBS-0.05% Tween 20, followed by incubation with streptavidin-conjugated SureLight 
P-3 (Columbia Biosciences, Frederick, MD, USA) at room temperature protected from light. 
Chips were washed three times with TBS-0.05% Tween 20, three times with TBS, and once 
with water. Chips were air dried by centrifugation at 1,000 x g for 4 minutes and scanned 
on a GenePix 4300A High-Resolution Microarray Scanner (Molecular Devices, Sunnyvale, 
CA, USA). Target and background intensities were measured using an annotated grid file 
(.GAL). 
 Raw microarray protein target and local background fluorescence intensities, target 
annotations and sample phenotypes were imported and merged in R (Foundation 
for Statistical Computing, Vienna, Austria), where all subsequent procedures were 
performed. Foreground target intensities were corrected for local background using the 
backgroundCorrect function of  the limma package [75]. Next, all corrected values were 
transformed using the base 2 logarithm. The dataset was normalised to remove systematic 
effects by subtracting the median signal intensity of  the IVTT controls for each sample. 
Since the IVTT control targets carry the chip, sample and batch-level systematic effects, 
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but also antibody background reactivity to the IVTT system, this procedure normalises the 
data and provides a relative measure of  the specific antibody binding to the non-specific 
antibody binding to the IVTT controls (a.k.a. background). With the normalised data, a 
value of  0.0 means that the intensity is no different than the background, and a value of  1.0 
indicates a doubling with respect to background. 
Data analysis
Quality control plots were made after each treatment of  the microarray data, which 
included boxplots and density plots of  probe intensity by study sample and probe type. 
Recombinant Pfs230 CMB was printed on the array for comparison to ELISA with the 
same protein, yielding a correlation co-efficient (Spearman’s rank) of  0.44 (p<0.001). A 
universal seropositivity threshold for reactivity to array proteins was established as the 
IVTT background plus 3 standard deviations, which equated to a log2-transformed signal 
intensity threshold of  0.92 (reactivity was therefore defined as approximately twice that 
of  the background). Because high-level transmission-reducing activity was uncommon in 
our sample set (22/649 samples had TRA ≥90%), antigens were defined as ‘reactive’ if  
they elicited seropositive responses in at least 1% of  the study population (≥7 subjects), 
and unreactive antigens were included in all analyses. The universal cut-off  was used only 
for defining proteins as reactive or unreactive, and for depicting antibody breadth for all 
microarray proteins. 
 Statistical analysis was conducted using R (Foundation for Statistical Computing, 
Vienna, Austria) or STATA 12 (StataCorp., TX, USA). The magnitude of  antibody 
reactivity to each antigen on the microarray by individuals in different groups was tested 
by empirical Bayes moderated T-tests [76], and by logistic regression after data binarisation 
using protein specific cut-offs; cut-offs were generated using maximum liklihoods methods 
(which determines the junction between two Gaussian signal distributions for each protein 
that proteins cut off  point for positivity) [74]. For the latter, proteins were dis-included 
from the analyses if  the mixture models failed to stably converge, or had to restart more 
than once. In both the Bayes and logistic models, p-values were adjusted to control the 
false discovery rate below 5% using the Benjamini-Hochberg (BH) method [57], and a 
finding was considered significant for FDR controlled p-values (q-values) less than 0.05. 
For analysis of  TRA on a continuous scale, TRA was used as the log transformed relative 
intensity, to normalise the data and avoid compression at 0%. For clarity, figures presenting 
TRA on a continuous scale present the linear TRA with a base of  0%. Linear models with 
adjustment for gametocyte density (determined by microscopy, and given as gametocytes/
µL) were used to test for differences in continuous variables between groups. Logistic 
models adjusted for gametocyte density were used to test for the association of  binary 
variables between groups, presenting odd-ratios and 95% CI. Differences in the magnitude 
of  response to all proteins by groups of  individuals (in contrast to the Bayes analysis, which 
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compares responses to individual proteins by different groups of  individuals) were assessed 
with t-tests or ANOVA. Differences in mosquito infection prevalence in the DMFA were 
analysed with logistic models adjusted for gametocyte density, while differences in mosquito 
oocyst prevalence were assessed with logistic models, adjusted for gametocyte density and 
with host (individual the mosquitoes were feeding upon) as a random effect. All box-plots 
are standard Tukey’s whisker and box plots, with Tukey’s method for outlier determination. 
All DMFA based analysis was performed on gametocyte positive individuals only. Protein 
domain predictions for proteins with TRA associated responses were made using Inter-pro 
[77] or HhPred protein domain prediction [78].
Data availability
The novel P. falciparum Schizont mass spectrometry proteomics data have been deposited to 
the ProteomeXchange Consortium (http://proteomecentral.proteomexchange.org) via the 
PRIDE partner repository [79] with the dataset identifier PXD008250. The authors declare 
that all other data supporting the findings of  this study are available within the article 
and its Supplementary Information, have been deposited in the DRYAD data depository 
(doi:10.5061/dryad.8bp05), or are available from the authors upon request.
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Supplementary materials
Supplementary figure 1. Antibody responses to the gametocyte protein microarray, with age 
data for Burkina Faso only. Responses by age are for individuals from Burkina Faso only, which was 
the only endemic country with substantial numbers of recruits from all age groups. Antibody breadth 
is the number of proteins reactive above background in each individual. Antibody magnitude is the 
log2-transformed average signal intensity (SI) for each microarray target, minus the vehicle SI. This 
equates to the log2-fold change over background. Responses are shown to each protein target by all 
individuals within given groups. For all box-plots, outliers are shown in black while all data points are 
shown in grey as a bee-swarm.
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Supplementary figure 2. Gametocyte density and transmission reducing activity.   Gametocyte 
density and TRA over age (A & B) are for individuals living in endemic areas only. Gametocyte density is 
shown to 1000 gametocytes/µL in A and D. Values above this limit are excluded from the plots (points 
missing: 0-5=7, 5-15=12, 15+=0), but not the summary statistics for the box-plots (median, IQR). TRA 
on a continuous scale (B & C) is presented as absolute TRA for clarity, but the p values are from simple 
linear regression using log relative infectivity (log[oocysts in treatment mosquitoes/oocysts in control 
mosquitoes]), to normalise the data and avoid compression at zero. All plots and statistical analysis 
with age or gametocyte density include only individuals from endemic areas. Grouped TRA (D) is 
presented for individuals with antibodies causing TRA (TRA) ≥90% vs gametocyte positive individuals 
with antibodies causing TRA <10%, as presented elsewhere. For all box-plots, outliers are shown in 
black while all data points are shown in grey as a bee-swarm.
Supplementary figure 3. Mosquito infection prevalence decreases with breadth of response 
to novel TRA associated protein across all gametocyte densities. Breadth of response to the 61 
novel TRA associated protein targets from the array analysis were binned into quartiles among the 
population with DMFA data (n=366). Box plots show the median, 25th, 75th 5th and 95th percentiles of 
mosquito infection prevalence. For all box-plots, outliers are shown as hollow circles.
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Supplementary figure 4. TRA of mAbs against Pfs48/45, Pfs230, and novel biomarker PfGEST. 
For Pfs230 and PfGEST mAB, TRA was calculated against isotypic negative control mAb (α-CSP). 
Pfs48/45 TRA was calculated using human serum as negative control. Details for Pfs48/45 (85RF45.1) 
mAb production and SMFA is provided in Stone et al. 2014 [9]. Details of Pfs230 mAb production and 
SMFA are presented in Roeffen et al. 1995 [65]. PfGEST mAb were produced by the Hypothesis-driven 
Pre-erythrocytic Antigen Target Identification Consortium (HPATIC) and provided by PATH. SMFA was 
conducted according to previously published protocols [9]. In all mAb based SMFA, the endpoint was 
oocyst quantification by manual dissection. Between 20 and 60 mosquitoes were dissected in each 
experiment. P-values are from a generalised linear mixed model (GLMM), as described previously [72].
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Supplementary figure 5. Gamete surface immuno-fluorescence assay (SIFA) using wild-type and 
Pfs48-45 KO NF54 gametes, with PfGEST mAb and IgG/plasma from a malaria exposed serum 
donor. Donors B and E and naïve donor plasma are described in table 3. SIFA was performed with 
human antibody sources from whole plasma or total IgG depleted of α-Pfs48/45-10c and α-Pfs230CMB 
Ab. Δ Pfs48/45 = Pfs48/45 KO [3]. BF = Bright-field, FITC = fluorescein isothiocyanate. GEST mAbs were a 
mixture of 5µg/mL of all three GEST mAbs described in the methods. Scale bar is 20µm. A. Donor sera, 
B. mAb, with serum for comparison.
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Supplemental figure 6. Figure 1. Antibody responses to Pfs48/45-10C, Pfs230 and to the microarray 
proteins with age, with microarray targets that are plausible antibody targets indicated. Antibody 
responses to conformational, recombinant Pfs48/45 and Pfs230 were measured using ELISA, with 
antibody intensity given as the ELISA optical density (OD) values (450nm), which is normalised between 
assay plates by adjustment relative to a consistent point in the linear portion of a standard curve of 
serially diluted highly reactive human sera. Antibody responses to microarray proteins are given as the 
log2-transformed signal intensity (SI) minus the vehicle SI, which equates to the log2-fold change over this 
background. All graphs show only individuals from endemic areas (Dutch migrants excluded). Sample 
size: 0-5 = 131, 5-15 = 366, 15+ = 71. A & C: Bars show the seroprevalence of α-Pfs48/45-10C and α-Pfs230 
antibodies with age, with Clopper-Pearson confidence intervals. B & D: Box plots showing α-Pfs48/45-
10C and α-Pfs230 antibody intensity with age. E: Box-plots showing responses to the microarray proteins 
(n=528), and the targets which were identified as having characteristics which make surface expression 
or involvement in gamete viability possible (n=16). As indicated in the text, these 16 targets represent 
fragments of 13 unique proteins. Antibody breadth is the number of proteins reactive above background 
in each individual, within the given groups. F: Magnitude of antibody response to microarray proteins 
and plausible Ab targets. Each spot represents the average SI of response to each protein target by all 
individuals within given groups. P-values for prevalence data are from likelihood ratio test for differences 
in seroprevalence between all age groups, derived from logistic regression, and adjusted for gametocyte 
density. P values for intensity data and response breadth are from an F test for differences in OD/SI 
between all age groups, derived from linear regression, and adjusted for gametocyte density, or from 
students t-test (for magnitude only). For all box-plots, outliers are shown with larger black/red dots while 
all data points are shown in grey/red as a bee-swarm of small dots.
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Supplementary table 2. The TRA of GLURP-R0 compared to dilutions of mAb specific to Pfs48/45 
epitope 1 (85RF45.1) and control human serum in the SMFA. Full details of these SMFA experiments 
are in Stone et al. 2014 [9]. 
Treatment
SMFA 1 SMFA 2 SMFA 3
Mean oocysts TRA % Mean oocysts TRA % Mean oocysts TRA %
Control (human serum) 6.8 - 13.3 - 17.9 -
85RF45.1 mAb (0.15µg/ml) 6.3 7.2 11.2 15.8 30.7 -71.4
85RF45.1 mAb  (0.3µg/ml) 2.9 57.0 13.6 -2.5 16.1 10.2
85RF45.1 mAb (0.6µg/ml) 1.4 79.8 7.5 43.7 9.2 48.7
85RF45.1 mAb (1.25µg/ml) 0.1 98.0 1.2 90.7 1.9 89.4
85RF45.1 mAb (2.5µg/ml) 0.1 99.0 0.4 96.7 0.3 98.5
GLURP mAb (2.5µg/ml) 6.9 -2.2 14.1 -6.0 12.1 32.5
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The need to characterise the malaria infectious 
reservoir
The aim of  this thesis was to investigate the effectors of  human malaria infectiousness to 
inform the development and application of  transmission-reducing interventions. Chapter 
2 aimed to develop an operationally attractive tool to identify pockets of  current and 
recent malaria transmission. The work was part of  a larger project based on the concept 
that the infectious reservoir of  malaria might be targeted by proxy, and that interventions 
focused on hotspots of  high prior exposure (and therefore, high infection risk) might reduce 
transmission in the community at large [1, 2]. The theory underlying this is that factors 
like housing quality, local geography, and health seeking behaviour combine with and 
reinforce inequalities in vector exposure [3-5], such that the inhabitants of  defined areas 
suffer disproportionately high incidence of  infection, and sustain transmission to the wider 
community [6, 7]. The work in chapter 2 dealt only with developing tools to enable this 
kind of  population-wide screening, not on its deployment, which was part of  a separate 
trial in Western Kenya in 2012 [8]. The proxy measures of  malaria risk were the presence 
of  current malaria infection, determined by nested PCR based detection of  ribosomal or 
mitochondrial DNA, and cumulative exposure to malaria infection, determined as the 
presence of  antibodies specific to the malaria blood-stage antigens AMA-1 and MSP-1 [9]. 
Both techniques were well known and used but our methodology made their concurrent 
assessment an operationally realistic pre-face to intensive control or elimination [10]. 
We showed that the techniques could be combined efficiently, with no significant loss of  
sensitivity to either the serologic or the molecular outcome. Combining the filter paper 
solute washing and DNA extraction into a single sample processing step meant that the 
ELISA and PCR procedures could be complete within 24 hours, while performing the 
assays on separate samples would require significantly greater pre-processing, roughly 
doubling the time to assay read-out.
 In the absence of  perfect vector controls effective against indoor and outdoor biting 
mosquitoes, reducing the number of  infectious humans is key to reducing transmission. 
Without a policy of  indiscriminate treatment, such as is used in China during elimination 
campaigns [11] and in public health emergencies globally [12], this requires that the 
majority of  infectious individuals should be identified and treated. At its simplest, ensuring 
coverage of  all infectious individuals can be achieved by targeting all infected individuals. 
The molecular techniques in chapter 2 would be well suited to this kind of  surveillance. 
Serology provides an invaluable measure of  population level transmission intensity, and 
such measures are likely to be extremely useful measures of  transmission reducing efficacy 
and elimination. However, accurately identifying the infected population at a single time 
point requires molecular assessment. There are clear benefits to assessing both current 
and historic infection during population surveillance: PCR provides the minimal unit for 
351
Discussion
13
targeting during active case detection, while serology (assessed at the population level) 
provides a measure of  transmission change for program monitoring, and can indicate 
locations or populations with high malaria risk for presumptive control. Since many 
infections may be of  short duration [13], it is also conceivable that many infections are 
missed when screening by PCR whilst a serological ‘footprint’ of  this infection allows a 
more informative assessment of  force of  infection at an individual level. The key to the 
efficiency of  the combined serological and molecular assessments in chapter 2 was the use 
of  finger-prick blood spotted onto filter paper as the source of  antibodies specific to malaria 
parasites, and parasite DNA. Though they are a simple and efficient source of  DNA, the 
use of  dried blood-spots necessitates significant delays between infection detection and 
intervention [14, 15]. High volume, whole blood samples improve sensitivity, but these 
benefits are offset by the complex logistics of  sample storage and transport. A point-of-
care test with equal or higher sensitivity than dried blood spot based PCR is the ideal 
alternative. Loop mediated isothermal amplification (LAMP) meets these requirements; 
it can be used can detect parasites at densities of  as little as 0.3-2.5 parasites per µl [16, 
17], and requires only the tests reagents and a water bath to amplify genus and species 
specific DNA (variously detectable as a visible colour change or one measurable with a 
spectrophotometer) [18]. Conventional RDTs are also in development with comparable 
sensitivity to PCR [19], though the historically low specificity of  these tests may remain a 
limiting factor [14]. 
 Ultra-sensitive diagnostics treat all infected individuals as potentially and equally 
infectious, but in reality, there is likely to be significant heterogeneity in the contribution 
of  different population members to onward transmission. Molecular assessments detecting 
gametocyte specific mRNA (primarily QT-NASBA, amplifying Pfs25 transcripts) have 
shown that the previous assumption that gametocytes are produced by a minority of  
individuals [20] were an artefact of  insensitive diagnosis [21-26]. There may therefore 
be little to gain from targeting transmission-reducing interventions to individuals based 
on gametocyte rather than parasite prevalence. Mosquito infection becomes probable at 
high gametocyte densities, but the lack of  association between gametocyte density and 
infectivity to mosquitoes at lower densities (which are common in natural infections) make 
gametocyte density an unreliable indicator of  infectivity. Intrinsic factors (internal factors 
derived from the parasite or host) may enhance the infectivity of  low-density infections, or 
suppress the infectivity of  high ones, and extrinsic factors (external environmental factors 
effecting the likelihood of  transmission) have similar effects, increasing or annulling the 
possibility of  infectious individuals contributing the mosquito infectious reservoir. With 
our current understanding of  what determines infectiousness and transmission potential, 
assessments of  infectivity are unlikely to have a direct role in control targeting. The later 
chapters of  this thesis focus on understanding and measuring infectiousness at both the 
individual and population level. Understanding heterogeneities in the infectious reservoir 
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would facilitate better control, and may feed into targeted campaigns. For the evaluation 
of  transmission reducing interventions, assessments of  infectivity provide the most direct 
measure of  success. 
The role of mosquito feeding assays in the 
development, targeting, and evaluation of 
transmission reducing interventions
Mosquito feeding assays are the gold standard measure of  human malaria infectivity, but 
they are not discussed in the context of  surveillance and control targeting because of  their 
operational complexity. Nonetheless, xenodiagnostic techniques (traditionally used to 
evaluate the presence of  infectious organisms by studying their transmission to another, 
readily dissectible host) have essential roles in investigative epidemiology (chapter 4), in 
the development of  transmission reducing drug and vaccines in the laboratory (chapters 5, 
6 and 7), and in the evaluation of  these in endemic settings (chapters 8 and 9). 
Delineating infectiousness and transmission potential
Population-wide use of  mosquito feeding assays is uncommon, but becoming more widely 
advocated because of  its uniquely comprehensive readout. Whether or not mosquitoes 
become infected when feeding on an infected host depends on an array of  factors 
(gametocyte density, maturity, parasite strain, human immunity) and feeding assays are 
the only tool currently able to determine whether the host at that given time is capable 
of  successfully infecting mosquitoes and at what rate. Our work in chapter 4 describes 
the various studies that have assessed the infectious reservoir using xenodiagnosis. Our 
conclusion was that assessments cannot only rely on feeding assays conducted across 
transects of  endemic populations, but must incorporate as natural as possible a reflection of  
variation in exposure to mosquitoes. Ultimately, the contact rate between mosquitoes and 
human hosts dictate the transmission potential of  infectious individuals. We questioned 
the dogma that children, being highly gametocytaemic and therefore highly infectious, 
need to be targeted with greater priority than adults to interrupt transmission effectively. 
Not only do previous studies demonstrate that older individuals contribute substantially 
to mosquito infections because of  their demographic abundance [27], we further suggest 
that differential exposure and attractiveness further polarises the contribution of  different 
age groups. What leads from this, practically, is that no age group should be preferentially 
targeted by transmission reducing interventions; children are more infectious and more 
vulnerable to symptomatic infection so require coverage, but older individuals may sustain 
transmission, so interventions must cover the entire infectious population. 
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Rigorous site-specific assessments of  the infectious reservoir are not pre-requisite to local 
elimination (as those in chapter 2 may be). Instead, we suggest that their conduct in a few 
locations with varying patterns and intensity of  transmission, preferably longitudinally, 
could inform elimination programs widely. It is particularly important that these assessments 
be conducted in areas close to elimination, as the data presented in our review and in the 
literature focus on areas with higher endemicity. Mosquito feeding assays conducted on 
this scale may be daunting, but for epidemiological studies (rather than control targeting, 
where this level of  detail may be less important) there are no accurate alternatives. One 
study conducted in southern Tanzania attempted to measure human infectiousness without 
feeding assays, by studying infection rates in mosquitoes that were caught after feeding on 
sleeping individuals [28]. Blood fed-mosquitoes were collected from deliberately ‘holey’ 
bed nets, so that oocysts in the mosquito’s guts could be classified according to their size, 
allowing prediction of  the night (and therefore individual) infectious feeds occurred on. 
Theoretically, these experiments reflect natural infectivity better than feeding assays, 
because mosquito infection was the result of  both human infectiousness and mosquito host 
choice. However, as all study participants were placed under equally poor quality nets, 
normal variations in exposure (as would exist if  the environment were not modulated 
by the study) had no impact on transmission potential. Low and unpredictable mosquito 
feeding rates (and therefore sample sizes) are also likely to be extremely limiting to the 
assays utility. Primarily though, and quite rightly, these techniques would be unjustifiable 
on ethical grounds, even with appropriate treatment of  the exposed individuals. 
 The roles of  age and behaviour-dependent variation in mosquito exposure have thus far 
been ignored in assessments of  the human infectious reservoir for malaria. The simplest 
analysis of  vector exposure would be to use existing data on body size and control coverage 
across age groups to adjust feeding-assay based estimates of  infectiousness. However, the 
relationship between control coverage and age will vary significantly between locations, 
so this post-hoc analysis is imperfect. A better but highly complex analysis would be to 
determine vector exposure for each person during surveillance using human and mosquito 
blood-meal genotyping, such as was used in Peru to demonstrate that adults were more 
often bitten by Aedes aegypti mosquitoes than children in the same houses [29]. A recent 
study by our own group has combined xenodiagnostic surveillance with these individual 
assessments of  biting behaviour. In one area with intense, seasonal transmission in Burkina 
Faso, population adjusted infectivity data showed that children <5 years old were responsible 
for 25.8% of  mosquito infections in the dry season, and 32.9% in the wet season (Bronner 
Goncalves, personal communication). Genotyping data from the same area showed that more 
than 95% of  mosquito blood meals were from individuals >5 years old, meaning that after 
the infectivity data were adjusted for differences in vector exposure, children contributed less 
than 4.4% of  the total number of  infective blood meals. On the other hand, the contribution 
of  older individuals (>15 years) to the pool of  infected mosquitoes increased from 21.7-
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22.1% to 50.3-53.9% after adjustment for exposure. In light of  these data, the ‘infectious 
reservoir’ as it has traditionally been measured is rendered almost irrelevant. As patterns 
of  vector biting behaviour, effective vector exposure and transmission intensity vary widely 
and may change profoundly during the scaling up of  control initiatives, there is a clear 
need for further studies assessing infectivity and transmission potential simultaneously. As 
transmission decreases and residual transmission from outdoor biting mosquitoes becomes 
more important, these studies will have to be adapted to sample indoor and outdoor resting 
mosquitoes if  the infectious reservoir is to be identified accurately. Population or area wide 
vector surveillance is labour intensive, and household level vector exposure is generally 
assessed with traps which sample mosquitoes as they feed and rest inside houses, or as they 
escape to rest outdoors [30]. Mosquitoes that feed and rest outdoors are more challenging to 
sample and target with vector controls, but for elimination it will be important to measure 
exposure to these species because of  their abundance in areas with historically high levels of  
net and insecticide use [31-33]. These difficulties may be circumvented by assessing vector 
exposure serologically. Not only malaria antigens (chapter 2) but also mosquito antigens, 
egested into the bite wound in the saliva, can induce measurable antibody responses in 
exposed humans (chapter 3). [34-40]. For assessment at the population level, salivary 
bioassays could be made highly efficient if  adapted for use with dried blood spots, using the 
methodology described in chapter 2, and have the important advantage that they may be 
developed for the assessment of  both indoor and outdoor biting species. 
Surrogates of mosquito exposure
The mosquito salivary protein gSG6 (Anopheles gambiae salivary gland protein 6) described 
in chapter 3 was initially selected as a biomarker because of  its transcript abundance, small 
size (10kb), specificity to mosquitoes of  the Anopheles genus, specificity to females, and 
the immunogenicity of  its peptides [41-44]. Our work was the first to assess the utility of  
α-gSG6 responses as markers of  heterogeneity in vector exposure at fine spatial scale. A 
key advantage of  the gSG6 assay is that the protein appears to elicit short lived antibodies, 
whose presence parallels short term changes in vector abundance, such as those resulting 
from seasonal fluctuations [42, 45] or vector controls [44]. Though only published in part, 
we studied responses to gSG6 in individuals from Apac, Uganda, an area of  historically 
intense malaria exposure, showing that decreased responses to the salivary protein accurately 
reflected the success of  recent interventions [46]. Since the publication of  our primary 
study, which remains the most detailed concurrent assessment of  antibody responses to 
mosquito saliva in relation to mosquito exposure and prospective malaria risk, several new 
insights in SG6 homologues and resources for future work have become available. Though 
initially thought to be specific to the An. gambiae species complex, SG6 homologues 
have been found in An. funestus, An. stephensi, and An. freeborni. Antibodies specific to 
these proteins cross react, making α-gSG6 antibodies a marker of  exposure to the bites 
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of  afro-tropical malaria vectors, rather than to those of  An. gambiae per se [38]. Following 
the recent publication of  the whole genomes of  16 species of  Anopheles mosquitoes [47], 
specific analyses of  salivary gene conservation among key malaria vectors may provide new 
starting points for the development of  generic and specific bioassays of  vector exposure 
[48], incorporating indoor and outdoor biting species. Future assay development will also 
have to focus on the dynamics of  the bite response. Bite tolerance (lower antibody titre, and 
less severe bite inflammation) has been observed experimentally in response to repeated 
biting by Culex quinquefasciatus [35, 49], and the pattern of  declining gSG6 antibody titre 
with age indicates tolerance also develops to Anopheles saliva. This affects the utility of  the 
gSG6 bioassay, because the magnitude of  response in a child will be different from that of  
an identically exposed adult, or between individuals with the same current but different 
historical biting exposure. The comparability of  responses to different mosquito species 
may also be affected by bite toleration, as different biting frequencies could affect the rate 
at which the responses become tolerated. Interestingly, another Anopheles salivary gland 
protein, cE5, appears to be more immunogenic than gSG6 among all age groups, and shows 
no appreciable decline in response with age [50]. This biomarker may have greater utility 
for assessing the transmission potential of  whole populations. Ideally, its informativeness 
would be assessed in longitudinal studies with frequent household or, in the light of  the 
aforementioned heterogeneity in mosquito exposure, individual-level assessments of  vector 
exposure [30]. Human landing catches may play a role here as a field standard assay for 
assessing indoor as well as outdoor exposure. Though labour intensive, as a proof  of  
concept this would allow the accuracy the salivary biomarker to be set and would provide 
measures of  the entomological inoculation rate against which surrogate biting rates can be 
interpreted.
Mosquito feeding assays as a surveillance tool
A major barrier to the broader use of  feeding assays in surveillance is the time and skill it 
takes to perform the assay reliably. Key to this is the assays readout. It has been assumed that 
because mosquitoes appear to egest very few sporozoites into the bite wound, a mosquito 
with any number of  salivary gland sporozoites is equally infectious [51, 52]. In chapter 
8, we stained the remnants of  ruptured oocysts in the mosquito midgut and carefully 
quantified the sporozoite rate in the same mosquitoes, showing that on average two thousand 
sporozoites were released by each oocyst. Though we showed that there was considerable 
loss between sporozoite release and salivary gland invasion, and that many oocysts actually 
failed to rupture altogether, we demonstrated that the smallest possible level of  infection 
(single oocysts) consistently results in some level of  salivary gland colonisation. These 
results validate the use of  oocyst prevalence as a proxy for infectiousness, which is the basis 
on which chapter 9 was written, which compares methods of  assessing oocyst prevalence at 
the expense of  their actual number, as a rapid read-out of  human infectivity. Very recently, 
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data was published that challenge the initial assumption that all infected mosquitoes are 
equally infectious. In a retrospective analysis of  controlled human and rodent malaria 
infection, Churcher and colleagues show that mosquitoes with heavier sporozoite loads 
cause infection more commonly [53]. Tens of  thousands of  sporozoites may establish in the 
salivary glands, and the small number in the mosquito inoculum (in the region of  tens or 
hundreds) was thought to be due to the mosquito’s thin salivary duct limiting the number 
that can pass through simultaneously [51, 54]. Churcher hypothesises that despite this 
mechanical restraint, variations in the time between biting, sporozoite load and sporozoite 
location may lead to variation in the accumulation of  sporozoites in the salivary duct prior 
to feeding, resulting in varied sporozoite load or infectiousness [53]. These observations 
highlight the importance of  assessing variations in human infectivity; individuals with more 
gametocytes are more likely to infect mosquitoes and infect heavily, and mosquitoes with 
more parasites may transmit more efficiently. In addition to these findings, there are also 
indications that sporozoite strain affects sporozoite infectivity [55]. In short, heterogeneity 
in the human infectious reservoir may have one more layer of  complexity than was 
previously assumed. Though this requires consideration and merits more focused study for 
P. falciparum, it does not necessarily change what is the most appropriate outcome measure 
of  feeding assays. Mosquito infection prevalence rather than the intensity of  their infection 
remains the most epidemiologically relevant metric of  human-mosquito transmission [56, 
57], and the most conservative unit for its targeting. Because of  their strong association, 
infection intensity in mosquitoes with low-level infections may be even be interpretable 
from simpler measures of  oocyst prevalence [58].
The standard membrane-feeding assay
Targeting transmission starts with a robust assay for the development, prioritisation and 
evaluation of  transmission reducing interventions. Though gametocyte infectiousness is 
a biological and therefore inherently variable outcome, it is essential that its assessment 
be standardised, to ensure validity of  comparisons between compounds and vaccines 
during screening, and reproducibility within and between laboratories. As in the field 
based feeding assays in chapters 8 and 9, part of  this standardisation may be achieved 
by making the denominator of  infectiousness objective. In so doing, assay comparability 
is improved, and increases in throughput, which will be essential if  feeding assays are to 
remain in the pipeline for intervention screening, are made possible. In chapters 8 and 
9, this was achieved by disregarding oocyst intensity and instead determining only the 
prevalence of  mosquito infection (and thus, leading from chapter 8, infectiousness), either 
by detection of  parasite DNA using nested PCR or circumsporozoite protein by ELISA 
or chemi-luminescent slot-blot assay. In chapter 5, we developed a scalable standard 
membrane-feeding assay (SMFA) with an objective, luminescence-based endpoint, for the 
assessment of  mosquito infection rate, prevalence, and for the analysis of  transmission 
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reducing activity. Since these publications, several groups have discussed and adopted the 
luminescence SMFA [59-66]. The use of  transgenic parasites eliminates the requirement for 
mosquito dissection, which requires skilled technicians, and is limited by its objectivity and 
speed. The difficulties in scoring oocysts are demonstrated by recent publication in which 
Plasmodium vivax oocysts had to be classified as ‘oocyst like structures’ due to their uncertain 
origin [67]. As the development of  transmission-reducing drugs and vaccines receives wider 
academic attention, it will be increasingly important that new laboratories can efficiently 
detect and quantify mosquito infection, in the field and in the laboratory. Although the 
luminescence SMFA cannot be used to assess infectivity during natural infections, it may 
be used to screen libraries of  sera for their transmission reducing immunity in controlled 
laboratory conditions (chapter 13). This approach could be adopted following the role-out 
of  transmission blocking vaccines in endemic populations [68]. For this purpose, blood 
samples could be taken longitudinally, starting before vaccination and proceeding monthly 
for at least a year, but preferably for multiple transmission seasons for the assessment of  
immune boosting from natural gametocyte exposure. Longitudinal assessment would 
allow antibody half-life to be assessed, with comparison to baseline or, better, to matched 
unvaccinated cohorts, to account for natural seasonal fluctuations in gametocyte exposure 
and transmission reducing immunity.
Transmission blocking drugs
In chapter 7, the luminescence SMFA was adapted for use with a parasite line developed 
in our laboratory that was suited to indiscriminate drug screening (because it lacks the drug 
selectable markers of  the parasite line used in chapter 5). We showed that certain drugs 
have activity that cannot be detected by standard in vitro assays of  gametocytocidal activity, 
and that the broad window of  drug activity that is represented in the output of  the SMFA is 
therefore necessary for some drugs with potent transmission reducing activity. Importantly, 
our assay allows such drug screens to be performed at a rate 2-5 fold greater than would 
be possible with standard microscopical readouts. More than 6 million compounds have 
been tested for their activity against malaria parasites, of  which around 20,000 had notable 
activity [69, 70]. Inevitably, the discovery rate for compounds active against asexual parasites 
has outstripped that for drugs active against transmission stages, because of  the complexity 
of  assessing gametocytocidal or sporontocidal activity [71]. Truly high throughput SMFA 
screening is and will remain out of  reach, because of  the required infrastructure for 
gametocyte culture and insect husbandry. In vitro assessments of  transmission blocking 
compounds can achieve substantial increases in throughout, as demonstrated by a recent 
report in which 13,983 compounds were screened for their gametocytocidal activity, using 
a saponin-lysis based gametocyte visualisation assay [72]. Other in vitro assays, namely 
the dual gamete formation assay [61, 73, 74], interrogate a wider window of  sexual 
developmental pathways against which drugs may be active, and can disentangle the effect 
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of  drugs with permanent and reversible effects. As gametocytocidal activity is a more 
desirable characteristic than activity downstream of  gametocyte activation [75], in vitro 
assays will continue to be the first step in the screening pipeline of  transmission active 
drugs. 
 Primaquine represents a rare case for which most ex vivo screens are incapable of  
demonstrating its activity, which is only apparent after the drugs bio-activation in the liver 
by cytochrome P450 2D6 (CYP 2D6) and other enzymes [76, 77]. The work in chapter 8 
was based on the WHO recommendation that a single dose of  0.25mg base/kg PQ should 
be added to artemisinin combination therapy (ACT) without prior G6PD screening, for 
reducing P. falciparum transmission in areas close to malaria elimination or areas with high 
levels of  ACT resistance [78]. The WHOs prior stance was that 0.75mg base/kg could be 
provided in similar areas with ‘low G6PD risk’ [79]. Our clinical trial in Kenya provided 
valuable support for combining ACT with the recommended low PQ dose to reduce 
gametocyte circulation time, which has until recently been lacking [80]. Unfortunately, 
PQ’s dependence on bio-activation may further complicate its wider adoption as a 
gametocytocide. CYP 2D6 is highly polymorphic. Its allelic variants denote phenotypically 
normal, intermediate or poor substrate metabolism, and primaquine failure (relapse of  P. 
vivax infection) has been linked with CYP 2D6 ‘poor metaboliser’ (PM) status [81]. Though 
studies assessing CYP 2D6 allele frequency are sparse, what data there are indicate that PM 
alleles are uncommon in African populations (6.3%), while intermediate metabolisers (IM) 
are common in Africa and Asia (35-41%) [82]. There are concerns that the frequency of  
PM/IM alleles may affect PQ effectiveness at the recommended low dose [83]. The weight 
based low PQ dose for P. falciparum may therefore need reconsidering, but in in light of  
the drug’s contra-indication in G6PD deficient individuals this will not be simple, and the 
desirability of  alternative transmission blocking drugs is clear.
 Methylene blue has potent gametocytocidal activity at low concentration (10mg/mL), 
and an excellent safety profile [84, 85]. As it is already medically licenced, its adoption is 
limited primarily because of  difficulties producing the drug at scale. The 8-aminoquinline 
Tafenoquine has similar gametocytocidal activity and safety in G6PD deficient individuals 
as PQ [86]. However, in contrast to MB and PQ Tafenoquine has the significant advantage 
of  being long-lasting (2 week half-life) and able to prevent sporogony in mosquitoes that 
ingest the drug up to 4 days after they were infected [87]. Perhaps most exciting is the novel 
Spiroindolone compound KAE609, that was discovered during a high throughput small 
molecule screen [88] and proceeded to show potent schizonticidal and gametocytocidal 
efficacy in vitro, and in the luminescence based SMFA [89]. Phase 1 and 2 trials with 
KAE609 have proceeded successfully, showing clearance times of  P. falciparum and P. 
vivax in excess of  ACT clearance times. Importantly, this efficacy is maintained against 
artemisinin resistant parasite strains [90], and studies show that the biological mechanisms 
of  spiroindolone and artemisinin resistance are distinct [88]. The drug also appears not to 
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stimulate and may even prevent the emergence of  dormant ring stages, which have been 
identified as a potential cause of  recrudescence after artemisinin treatment [91]. The results 
of  clinical trials evaluating the effectiveness of  KAE609 for reducing gametocytaemia 
and transmission to mosquitoes in endemic populations are expected in the near future 
(clinicaltrials.gov: NCT02543086).
 Though the results of  our own trial add to the evidence that gametocytocides like 
primaquine can rapidly reduce the infectiousness of  treated patients, the ability of  such 
drugs to expedite transmission reduction at the population level depends on their coverage 
of  the infectious reservoir. In this respect, the effect of  achieving significant coverage 
with ACTs during mass administrations may overshadow the additional impact of  
gametocytocides [92-94]. Endectocides like ivermectin have a different mode of  action and 
may have larger benefit as supplement to ACTs compared to primaquine [94]. The reason 
for this is that ivermectin has a strong but short-lived effect on mosquito mortality [95] and 
affects the mosquito age structure for several weeks [96-98]. Ivermectin partly circumvents 
the need to achieve near-universal coverage, because of  the frequency of  blood-feeding of  
anophelines during the time ivermectin is active [95, 96, 99-101]. Mathematical models 
suggest that endectocides have great potential as transmission reducing agents, particularly 
in combination with potent schizonticidal and gametocytocidal antimalarials [101].
Could we predict infectiousness without 
xenodiagnosis?
The later chapters of  this thesis aimed to dissect the infective potential of  malaria-infected 
individuals by considering parasite and human factors that might together determine the 
likelihood of  infecting mosquitoes upon exposure.
Gametocytes and molecular markers of infectiousness
Principle among the intrinsic determinants of  infectivity is gametocyte density. Because 
of  their often very low densities, microscopy based surveillance usually fails to detect the 
majority of  gametocyte reservoir. Molecular assays show that sub-microscopic infections 
are often infectious [102], and models indicate their relevance for transmission at the 
population level [103-105]. Gametocyte sex ratio may also be an important determinant 
of  infectiousness but until recently could only be examined by microscopy in high-density 
infections. However, high-density infections only occur in a minority of  population members, 
and sex-ratio is hypothesized to be most important in low-density infections [106]. Low-
tech gametocyte concentration tools (magnet assisted cell sorting) are incompatible with 
microscopy-based sex-ratio assessments, that rely on subtle morphological discrimination 
based primarily on the distribution of  magnetic pigments within the gametocyte [107]. 
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Molecular assays are the only tools theoretically capable of  determining not only gametocyte 
density, but also their sex, maturity, and other parasite factors related to infectivity. 
 In chapters 10 and 11 we presented a novel gametocyte quantification assay, capable of  
determining the density of  both male and female gametocytes over the entire biologically 
plausible range of  infectivity. This plausible range is related to the mosquito blood meal 
size. If  a mosquito ingests anywhere between 2-8µL of  blood while feeding [52, 108], the 
minimum gametocyte density allowing fertilization of  one female by one male gametocyte 
would be 0.25 gametocytes/µL. With heterogeneity in gametocyte densities in blood, 
potentially resulting in clustering of  gametocytes within blood meals [109], the threshold 
of  detection would ideally be lower than this. The detection limit of  our assays was <0.1 
gametocytes/µL. Broadly in line with this this abstract estimate of  plausibility, Churcher 
and colleagues showed using the Pfs25 based QT-NASBA that mosquito infection 
probability decreased linearly below densities of  1 gametocytes/µL [110]. However, 
previous work indicated a puzzling association between gametocyte density and mosquito 
infection rates with a plateau over 1 and up to 200 gametocytes/µL where there was no 
obvious association between density and infection rate. This finding conflicted with smaller 
studies that quantified gametocytes by microscopy and suggested a positive association 
between gametocyte density and the likelihood of  mosquito infection over this density 
range.In chapter 10 we showed that when total gametocyte density is measured accurately, 
combining male and female gametocytes and conducting molecular assays rigorously by 
qRT-PCR in a single laboratory with automated nucleic acid extraction and standardized 
assay conditions, gametocyte density and mosquito infection rate are indeed positively 
correlated over this range, displaying a simple saturating relationship over the range of  
gametocyte densities in our study. Though gametocyte sex ratios unfavorable to fertilization 
success in the mosquito are uncommon, our analysis indicates that in low density infections 
infectivity is lower for a given female gametocyte density when fewer males are present 
(when male: female sex ratio was less than the median, which was approximately 1:5). 
This is in line with previous suggestions based on microscopy that a lower female bias may 
enhance infection probability when gametocytes are sparse [111, 112]. In fact, the best fit 
of  gametocyte density and mosquito infection rate was demonstrated by modelling female 
gametocyte density and infection rate incorporating the estimated infectivity restriction 
imposed by low male densities; this fit was better than both female density alone or total 
gametocyte density. The low sensitivity of  microscopy makes assessments of  gametocyte 
sex-ratio impossible in most natural infections. In all mRNA based assays there is an 
inherent uncertainty in interpreting parasite number from transcript abundance [113]. 
However, ours is the first to quantify male and female gametocytes separately, with similar 
sensitivity, and is therefore the first to allow gametocyte sex-ratio estimation in all infections 
relevant for transmission. Chapter 10 may thus provide the most accurate estimate of  the 
association between gametocyte density and mosquito infection rates to date.
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The PfMGET (Pf3D7_1469900) male marker used in our assay was discovered using 
RNAseq analysis of  pure populations of  male and female gametocytes, separated by the 
detection of  sex-linked fluorescence markers [114]. The gene has no ascribed function at 
present. Interestingly, though PfMGET mRNA was abundant and near uniquely transcribed 
by male gametocytes, proteomic analyses by our own [114] and other groups [115] indicate 
extremely low or non-existent corresponding translation in mature gametocytes. Like Pfs25 
then, the PfMGET protein may only be expressed during or after gametocyte activation, 
indicating a similarly sex-specific function. As we conducted them, the Pfs25 and PfMGET 
assays quantified male and female gametocytes in field samples by extrapolating their 
qRT-PCR signal against known quantities of  the separated male and female gametocyte 
populations. For use with larger numbers of  samples these assays may be conducted 
using readily available, non-transgenic, mixed sex trend-line material, for which male and 
female density have already been calculated. Separate male and female assays are essential 
for estimating sex-ratio in samples with low gametocyte densities, but as an estimate of  
total density the additional uncertainty introduced by having to perform separate mRNA 
quantifications for each sample is not ideal. To more efficiently determine total gametocyte 
density a molecular marker equally transcribed by both male and female gametocytes would 
be extremely useful. Recent transcriptomic analyses of  male and female gametocytes will 
facilitate the search for such markers [114, 116]. Multiplex qRT-PCR assays quantifying 
sex-specific and pan-gametocyte markers, in addition to markers of  maturity, would be the 
ideal molecular assays of  infectiousness. These assays would ideally also be developed for 
Plasmodium species other than P. falciparum.
 In addition to their density and sex ratio, gametocyte strain and maturity provide 
valuable additional measures of  their likely infectivity. Neither were investigated as part 
of  this thesis, but both will have to be considered in assays aiming to predict infectivity 
without xenodiagnosis. Strain specific differences in infectivity are observed in the SMFA, 
and may relate to generic infectivity factors (increased gametocyte formation, or per 
gametocyte fertilisation probability) [117] or other parasite factors interacting with species-
specific mosquito factors e.g. Thioester protein 1 mediated mosquito immunity [118, 119]. 
Variation in gametocyte productivity may also result from human genetic factors, and has 
been linked with haemoglobinopothies including sickle cell trait [120] or tribal genetics 
(densities are lower in the Fulani than in the Mossi tribe in Burkina Faso)[121]. Variations 
in gametocyte productivity affect human infectivity, but not our ability to interpret 
infectivity from estimates of  total gametocyte density. On the other hand, gametocyte 
maturity directly determines per capita gametocyte infectivity [122, 123]. Because immature 
gametocytes sequester, the majority of  those in circulation should be mature, but variations 
the proportion of  newly released stage IV gametocytes and the relative age of  stage V’s 
will affect the likelihood of  successful transmission if  overall densities are low. Molecular 
markers of  early, mid and late gametocytes would enable infections to be characterised 
362
according to maturity, which may explain some deviations from the relationship between 
gametocyte density and mosquito infection rate [26, 124]. Such markers could also adjust 
for the effects of  host clearance efficiency on gametocyte age and infectivity. For example, 
an individual with many gametocytes but rapid gametocyte clearance may consistently 
have a greater proportion of  immature gametocytes, and thus have minimal infectivity 
to mosquitoes, while someone with low clearance rates might have a higher proportion 
of  mature gametocytes, and thus be more infectious. Markers of  gametocyte maturity 
have already proved successful in an analysis of  P. vivax infectivity, in which transcript 
abundance of  the Pfg377 orthologue (female specific and expressed abundantly in mature 
gametocytes and subsequently zygotes) was positively associated with infectiousness in 
field based mosquito feeding assays [125]. Though further candidate markers exist, more 
may be revealed by assessing the transcript and proteomic development of  gametocyte time 
series’ from culture. The same techniques may identify markers responsible for variations 
in infectivity between different gametocyte strains. 
 Ideally, the expression of  infectivity associated parasite factors would be assessed in 
longitudinal studies in areas of  seasonal malaria transmission in which study participants 
are cleared of  all infection, then monitored and sampled regularly during and following the 
transmission season. Gametocyte density, sex ratio, and putative markers of  commitment 
and maturity could then be studied with reference to infectivity assessed by mosquito 
feeding assays conducted at several points after the initiation and treatment of  blood stage 
infection. The molecular tools described in chapters 10 and 11 would allow gametocyte 
density, sex and infectivity to be assessed with unsurpassed detail, and the samples gathered 
would inform the development of  further infectivity associated factors.
Transmission reducing immunity
In addition to gametocyte density and fitness, human immune responses may be a decisive 
factor in determining the likelihood of  onward transmission. Assessment of  transmission 
reducing immune responses may have particular utility as a sero-epidemiological readout 
during surveillance of  populations after the administration of  a transmission blocking vaccine. 
 As discussed extensively in chapter 12’s review, antibody responses to the gametocyte/
gamete proteins Pfs48/45 and Pfs230 do not fully explain the existence of  naturally 
occurring transmission-reducing immunity. Specifically, antibody mediated transmission 
reducing immunity can be present in the absence or presence of  antibodies specific to 
Pfs230 or Pfs48/45 [126]. Previous work has demonstrated statistical associations between 
functional antibody mediated transmission inhibition and antibody prevalence or density to 
Pfs230 and Pfs48/45 [126-135]. Whilst suggestive of  a functional role of  these antibodies in 
transmission reducing immunity, supported by the established potency of  vaccine-induced 
rodent monoclonal antibodies against Pfs48/45 (85RF45.1) and Pfs230 (63F2A2.2a/b), 
formal evidence was never provided. The possibility that these responses parallel other 
363
Discussion
13
jointly or uniquely causal responses had thus far not been excluded. Similar confusion has 
been observed with antibody responses to asexual parasites, where markers of  exposure 
mask the effects of  modulators of  protection from clinical infection [136, 137].
 Our work in chapter 13 makes important steps toward understanding the mechanisms of  
transmission reducing immunity, by definitively proving that antibodies acquired naturally 
to Pfs48/45 and Pfs230 can contribute to the transmission reducing phenotype. Our 
findings also strongly indicate the contribution of  antibodies specific to unknown proteins, 
by showing that sera depleted of  antibodies to key transmission blocking epitopes of  Pfs230 
and Pfs48/45 retained strong, complement independent antibody mediated transmission 
inhibition. Importantly, we show that responses to other gametocyte proteins are associated 
with transmission reducing activity (TRA), as demonstrated by antibody inhibition in 
the SMFA and lower infectiousness to mosquitoes in field based feeding assays. This 
is the first time it has been shown that antibody TRA measured in the SMFA relates to 
infectiousness in field settings. Specifically, individuals responsive to subsets of  the newly 
identified antigens were considerably less likely to infect any mosquitoes (OR 0.37, 95% 
CI 0.24-0.25, p<0.001), and, if  infections, infected far fewer mosquitoes (OR 0.18, 95% CI 
0.24-0.55, p<0.001). Collectively our data are the first to prove the involvement of  specific 
antibodies in transmission-reducing immunity, quantify the impact of  this immunity on 
natural transmission and provide new correlates of  the phenomenon that appear to predict 
transmission potential in multiple endemic settings.
 Of  the six individuals for whom we directly assessed the inhibitory activity of  
different antibody fractions, only one possessed transmission-blocking antibodies against 
Pfs48/45 (epitopes 1, 2 or 3) at sufficient physiological concentration to inhibit mosquito 
transmission. A number of  individuals possessed lower titre responses to Pfs48/45 or 
Pfs230 (CMB region) that blocked after these antibodies had been concentrated. TRA in 
these samples is therefore either due to high titre antibody responses to other proteins (or 
non-protein antigens), or a combination of  lower titre responses to any of  Pfs48/45, Pfs230, 
or other targets. Unfortunately, restrictions in sample volume meant we were unable to say 
whether antibodies specific to the column-bound proteins, when not sufficient to block 
separately, were able to block when combined. The possibility of  cross-antigen synergism 
was therefore not tested, though sero-epidemiological associations indicate such an effect 
may exist [138]. Pfs48/45 is GPI anchored to the gametocyte surface and is retained there 
during gamete activation, while Pfs230 possesses no anchor, and requires interaction with 
Pfs48/45 (probably mediated by the proteins C terminal domain, containing the 6 cysteine 
motifs which characterise the protein family) to be retained on the gametocyte/gamete 
surface [139]. Mutant parasites possessing disruptions in the Pfs230 gene showed reduced 
binding to uninfected erythrocytes, at similar levels to parasites in which both Pfs230 and 
Pfs48/45 were disrupted [140]. Differences in the function and accessibility of  the Pfs48/45 
and Pfs230 epitopes bound by naturally acquired transmission blocking antibodies may alter 
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the functional titre of  antibodies specific to both proteins when they are acting in unison. 
Future studies with high sample volumes, large screening populations, and longitudinal 
gametocyte exposure assessments would provide the necessary reagents for in depth study of  
the functionality of  specific naturally acquired transmission associated antibodies. Another 
approach, becoming more realistic as the scalability of  whole parasite immunisation 
has grown [141], would be to study the dynamics and mechanisms of  induced ‘natural’ 
transmission reducing immunity by inoculating humans with inactivated gametocytes or 
gametes, as was done with non-human animals in the 1970’s and 80’s [142-145].
 The antibody correlates of  transmission reducing immunity identified using our protein 
microarray and library of  transmission blocking sera may themselves be mechanistic in the 
transmission inhibition, or may be non-functional markers of  this immunity. Expression on 
the gamete surface is a logical requirement for a target of  transmission reducing antibodies. 
Though the majority of  the proteins on our microarray possessed transmembrane domains 
or signal peptides, some may be internal and therefore inaccessible to antibody binding 
[146]. The list of  proteins with TRA associated antibody responses provided in Chapter 13 
has therefore been divided into proteins with and without predicted or known features that 
exclude surface expression, to prioritise the candidates for future research. Work is ongoing 
to assess the potential functionality of  the reported antibody responses. At present, proteins 
from our list of  hits are being produced in a wheat germ based cell free system [147, 148], 
and recognition of  them will be confirmed by our library of  sera from transmission-reducing 
individuals. Subsequently, the proteins will be inoculated into rodents with a Montanide gel® 
adjuvant to produce polyclonal antibodies that will be tested in the SMFA later this year. This 
work is being funded by the Malaria Vaccine Initiative (MVI), who registered their interested 
in this avenue of  vaccine discovery. 
 Transmission reducing immunity develops shortly after gametocyte exposure [135], and 
wanes within six months [149]. In humans [133, 150] and non-human animals where individual 
infections have been followed more closely [142-144], there appears to be a close association 
between the development of  transmission reducing immunity and gametocyte density. Some 
of  our correlates of  inhibitory responses may represent biomarkers of  high gametocyte 
density, and not have any mechanistic relevance to the development of  transmission reducing 
immunity. To offset this possibility, comparisons of  antibody association with transmission 
reducing immunity were restricted to gametocyte-exposed individuals, as determined by 
microscopy. Regardless, if  gametocyte exposure increases the likelihood of  developing 
transmission-reducing antibodies, responses associated with gametocyte exposure may predict 
the presence of  mechanistic responses. Our immune signature may therefore have utility as 
a biomarker of  antibody-mediated transmission inhibition that is more inclusive than the 
assessment of  responses to Pfs48/45 or Pfs230 alone. Transmission reducing immunity was 
rare in our study populations, so our correlates require validation in a broader, larger selection 
of  blockers and non-blockers, for whom exposure history and accurate molecular infection 
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data are available. However, it is very encouraging that the correlates or TRA identified from 
a subset of  individuals with high inhibitory activity in the SMFA (n=22) predicted lower 
probability and rate of  mosquito infection in the far larger population of  individuals who 
recognised a high proportion of  these proteins (n=157). This indicates not only that SMFA 
and DMFA are related, but that the DMFA picks up weaker but epidemiologically relevant 
reductions in transmission, which may be predicted by signatures of  antibody response. 
Protein selection for the microarray was based largely on a single proteomic analysis [114] 
and was restricted to only 315 gametocyte enriched proteins, while numerous recent studies 
indicate the presence of  many more gametocyte specific proteins [115, 116, 151, 152]. 
Future work will involve expanded arrays, and larger, longitudinal sample sets, for assessing 
the dynamics and mechanism of  transmission reducing immune responses. This work will 
be conducted in an international collaboration within the framework of  cohorts of  the 
International Centers of  Excellence in Malaria Research (ICEMR).
* * *
As malaria transmission declines, the bridge between persistent low-level transmission and 
elimination becomes increasingly difficult to cross. Malaria elimination has been recently 
achieved with conventional controls and monitoring on islands [153, 154], and in areas of  
the Eastern Mediterranean, were transmission intensity was generally low [155, 156]. As 
transmission and the clinical burden of  malaria decreases in African settings, elimination 
may be made possible or expedited by the detection and treatment of  asymptomatic and 
sub-patent asymptomatic infections. This requires knowledge and surveillance of  the 
infectious reservoir. Direct assessments of  infectivity are essential in understanding relative 
contributions to the infectious reservoir. How infectiousness changes with declining 
transmission between different sections of  the population, and between individuals with 
patent and sub-patent, symptomatic and asymptomatic infections, will guide decisions about 
wider surveillance and intervention. Transmission reduction will result in declining incidence 
of  infection, measurable with sensitive diagnostic surveillance, and reduced rates of  clinical 
disease, which could be assessed passively at health centres [56]. To effect the transmission 
reduction though, the majority of  infectious individuals must be targeted, and in most areas, 
this will require scalable and efficient measures to detect infections and potential infectivity. 
More nuanced surveillance than passive case detection, or periodic surveys with insensitive 
rapid diagnostic tests, has been highlighted as a priority in areas where artemisinin resistant 
parasite strains are endemic, incorporating resistance monitoring to define the asymptomatic 
reservoir of  resistant parasites [14, 157]. If  measures of  infectiousness could be incorporated 
into serological and molecular surveillance, they could efficiently expedite transmission 
reduction.
 The ideal tool for assessing infectiousness would be a rapid, point of  care test that 
determines human gametocyte infectivity and vector biting rate. Given that infectivity is not 
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determined by any single factor, point of  care is probably out of  reach, but a combination of  
multiplex assays with serological and molecular readouts could indicate potential or likely 
infectivity and prioritise areas or demographic groups based on the likelihood of  exposure 
to vectors. Xenodiagnosis could effectively be replaced by accurate estimates of  gametocyte 
density, sex ratio and maturity, combined with a measure of  immune responses known to 
predict or elicit TRI. To determine which infectious individuals are likely to contribute to 
the infectious reservoir, transmission potential could be interpreted from an individual’s 
repertoire and intensity of  antibodies specific to range of  mosquito salivary biomarkers. 
The relevance of  low-density infections will vary between areas or households with different 
exposure to permissive vectors, so such information could be invaluable in areas with 
unpredictable transmission.
Closing remarks
Malaria transmission reduction, through interventions targeted to the infectious reservoir 
of  parasites or the deployment of  drugs and vaccines that reduce infectiousness, has never 
been more relevant. Considerable gains can be achieved with efficacious treatments and 
vector controls, but both of  these at risk from resistance. The discovery of  new drugs like 
spiroindolone KAE609 is encouraging, particularly as this was the direct result of  investment 
in high throughput drug screening. There is hope that the efficacy of  artemisinins can be 
prolonged by combination with new partner drugs like this one, or with multiple drugs, 
including gametocytocides [158]. This does not mean the search for novel treatments 
can stop. ACTs came into wide scale use in in the early 2000’s [159], and resistance was 
observed within 6 years [160]. In February 2017, four individuals separately returned to the 
UK from Angola, Liberia and Uganda, showing reduced parasite clearance times following 
treatment with artemether-lumefantrine [161]. Although these individuals were treated 
outside research settings, leaving some uncertainties about the achieved drug concentrations 
in relation to treatment outcome, the observation is worrying. In the same month, an article 
reported a single malaria case imported to China from Equatorial Guinea, again showing 
slow clearance, but with extended ring stage survival in in vitro drug assays [162]. None of  
these cases showed the degree of  resistance observed in the Greater Mekong region, and 
though the parasite imported to China had a single amino acid switch in the Kelch 13 region, 
genotyping showed it was an African parasite strain. Though few in number, these cases 
may be the first indication that indigenous artemisinin resistance has emerged across the 
African continent.
 As artemisinin stepped into the gap created by chloroquine and sulphadoxine-
pyrimethamine resistance, so the next generation of  treatments must replace artemisinins, or 
with careful planning and containment, be used to maintain their efficacy. To return to Lewis 
Carrol’s Red Queen analogy, this is running to stand still. Resistance to the best available 
insecticides and treatments means that research must focus on finding alternatives, while 
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simultaneously slowing or halting their declining efficacy. If  efforts to achieve sustained 
control require that we run at the parasites pace, then elimination requires that we run twice 
as fast. Conventional malaria control can be highly efficacious, but without a concerted 
effort to achieve elimination, it may simply turn a detectable reservoir of  infection into an 
invisible one [157]. Targeting the infectious reservoir to achieve transmission reduction may 
provide the energy required to eliminate malaria, and doing this first in areas that seed the 
spread of  drug resistance could ensure that elimination remains a feasible goal globally.
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Summary
In spite of  our best efforts, malaria remains a devastating disease. Limiting its impact 
depends on our ability to treat the disease effectively and to kill the parasite’s vector and 
prevent it from biting. Efforts to eliminate the malaria causing Plasmodium parasites require 
that we can detect and understand their infectious reservoir; that is, the people within a 
population who transmit their infections to mosquitoes. Transmission reducing drugs and 
vaccines may also be required to achieve elimination, and translating their success from the 
laboratory to the field requires measures of  Plasmodium’s infectivity to mosquitoes. 
 In Chapter 2 we developed an operationally attractive tool to identify pockets of  current 
and recent malaria transmission, based on the detection of  historical and current malaria 
infection. We showed that detection of  Plasmodium DNA and human antibodies specific 
to the parasite could be extracted and analysed simultaneously, for use in population wide 
surveillance. These techniques are applicable for assessing malaria transmission at the 
population level, and could be used for targeting interventions to areas with high malaria 
exposure where, possibly, the majority of  mosquitoes become infected. 
 Whether or not mosquitoes become infected when feeding on an infected host depends 
on an array of  factors (gametocyte density, maturity, parasite strain, human immunity) and 
feeding assays are the only tool able to determine whether a host is capable of  successfully 
infecting mosquitoes and at what rate. Our work in chapter 4 describes the various studies 
that have assessed the infectious reservoir directly using feeding assays. Our conclusion 
was that such assessments cannot only rely on feeding assays conducted across transects of  
endemic populations, but must incorporate as natural as possible a reflection of  variation in 
exposure to mosquitoes, which determines the transmission potential of  individuals within 
the infectious reservoir.
 Understanding vector exposure is complex, but it may be made simpler by assessing 
vector exposure serologically. Our work in chapter 3 was the first to assess the utility of  
antibody responses to an Anopheles salivary protein, gSG6, as a marker of  heterogeneity 
in vector exposure at fine spatial scale. An assay such as this could be used alongside 
infectivity data from feeding assays, or parasitological readouts, to describe heterogeneity 
in transmission at the population level. 
 A major barrier to the broader use of  feeding assays in surveillance is the time and skill 
it takes to perform the assay reliably. Key to this is the assays readout. In chapters 7 and 
8, we validated the use of  oocyst prevalence as a proxy for infectiousness, and compared 
tools for rapidly assessing mosquito infection as an indicator of  human infectivity in field 
based feeding assays. These feeding assays will be essential for the initial evaluation of  
transmission- focused interventions, but the development of  these interventions starts in 
the laboratory. In chapter 5, we developed a scalable standard membrane-feeding assay 
(SMFA) with an objective, luminescence-based endpoint, for the assessment of  mosquito 
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infection rate and prevalence, and for the analysis of  transmission reducing activity (TRA). 
The use of  transgenic parasites eliminates the requirement for mosquito dissection. In 
chapter 6, the luminescence SMFA was adapted for use with a parasite line developed in 
our laboratory that was suited to indiscriminate drug screening. We showed that certain 
drugs have activity that cannot be detected by standard in vitro assays of  gametocytocidal 
activity, necessitating the retention of  the SMFA in the drug-screening pipeline.
 The later chapters of  this thesis aimed to dissect human infective potential by considering 
parasite and human factors that might together determine the likelihood of  malaria-infected 
individuals infecting mosquitoes when they are bitten. Principle among these is gametocyte 
density. Because of  their often very low densities, microscopy based surveillance usually fails 
to detect the majority of  gametocyte reservoir. Molecular assays show that sub-microscopic 
infections are often infectious, and models indicate their relevance for transmission at 
the population level. In chapters 9 and 10 we used purified transgenic male and female 
gametocytes to develop a novel gametocyte quantification assay, capable of  determining the 
density of  both male and female gametocytes over the entire biologically plausible range 
of  infectivity. In chapter 9 we showed that accurately determined total gametocyte density 
is associated with mosquito infectivity, and that sex-ratio has an important impact on this 
association. In chapter 10, we used the assay to investigate the effect of  a gametocytocidal 
drug, primaquine, in a new clinical trial assessing the effect of  the drug gametocyte 
circulation in Kenyan children. The molecular tools described in chapters 9 and 10 allow 
gametocyte density, sex and infectivity to be assessed with so far unsurpassed detail.
 In addition to gametocyte density and fitness, human immune responses may be 
a decisive factor in determining the likelihood of  onward transmission. Assessment 
of  transmission reducing immune responses may have particular utility as a sero-
epidemiological readout during surveillance of  populations after the administration of  a 
transmission blocking vaccine. As discussed extensively in chapter 11’s review, antibody 
responses to the gametocyte/gamete proteins Pfs48/45 and Pfs230 do not fully explain 
the existence of  naturally occurring transmission-reducing immunity. Specifically, antibody 
mediated transmission reducing immunity can be present in the absence or presence of  
antibodies specific to Pfs230 or Pfs48/45. Our work in chapter 12 makes important steps 
toward understanding the mechanisms of  transmission reducing immunity, by definitively 
proving that antibodies acquired naturally to Pfs48/45 and Pfs230 can contribute to 
the transmission blocking phenotype. We also strongly indicate the contribution of  
antibodies specific to unknown proteins, by showing that sera depleted of  antibodies to key 
transmission blocking epitopes of  Pfs230 and Pfs48/45 retained strong antibody mediated 
TRA. Importantly, we show that antibody responses to other gametocyte proteins bind 
to the surface of  gametes, and are associated with TRA; the latter demonstrated by their 
association with reduced infectivity in both the SMFA with Anopheles stephensi mosquitoes 
and direct membrane feeding assay (DMFA) with Anopheles gambiae mosquitoes. 
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Malaria transmission reduction could be expedited by interventions targeted to the 
infectious reservoir of  parasites or the deployment of  drugs and vaccines that reduce human 
infectiousness. The emergence of  parasite strains resistant to the best available anti-malarial 
drugs makes it urgent that we are better able to detect and deplete the malaria infectious 
reservoir, to prevent the spread of  parasites that threaten malaria control globally. 
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Overzicht
Malaria blijft een ziekte met een enorme ziektelast. Met effectieve medicatie en de 
bestrijding van malariamuggen kunnen we het risico op (ernstige) ziekte voorkomen. 
Pogingen om malaria uit te roeien hebben baat bij een beter inzicht in het infectieuze 
reservoir van malaria; dat wil zeggen: de mensen binnen een populatie die hun infectie 
kunnen doorgeven aan muggen. Transmissiereducerende geneesmiddelen en vaccins 
hebben mogelijk een belangrijke rol bij malaria-eliminatie. Het vertalen van hun succes 
in het laboratorium naar toepassing in het veld vereist methoden om de infectiviteit van 
Plasmodium naar muggen te meten. 
 In hoofdstuk 2 hebben we een operationeel aantrekkelijke methode ontwikkeld om 
haarden van malariatransmissie te identificeren, gebaseerd op het aantonen van historische 
of  huidige malaria-infecties. We hebben laten zien dat Plasmodium -DNA en menselijke, 
voor de parasiet specifieke, antistoffen tegelijkertijd kunnen worden geëxtraheerd en 
geanalyseerd. Deze methode is in het bijzonder geschikt voor het kwantificeren van 
malariatransmissie op populatieniveau. Op deze wijze kan de methode gebruikt worden 
voor de identificatie van gebieden met een hoge malariablootstelling waar gerichte 
interventies kunnen worden ingezet met als doel de transmissie te remmen en te voorkomen 
dat muggen worden geïnfecteerd. 
 Of  muggen geïnfecteerd raken wanneer ze zich voeden op een geïnfecteerde gastheer 
hangt af  van een reeks factoren waaronder gametocytdichtheid, de rijpheid van gametocyten, 
parasitaire stammen en menselijke immuniteit. Voedingsexperimenten waarbij muggen 
onderzocht worden na het nemen van een bloedmaal, vormen de enige betrouwbare 
methoden om te bepalen of  een gastheer in staat is om muggen succesvol te infecteren 
en in welk percentage. Ons werk in hoofdstuk 4 geeft een overzicht van de verschillende 
studies die het infectieuze reservoir direct hebben gekarakteriseerd met behulp van 
voedingsexperimenten. Wij zijn tot de conclusie gekomen dat dergelijke beoordelingen niet 
louter kunnen worden gebaseerd op voedingsexperimenten uitgevoerd in dwarsdoorsneden 
van populaties waar malaria voorkomt, maar een zo natuurlijk mogelijke weerspiegeling 
van variatie in blootstelling aan muggen moet bevatten. Deze muggenblootstelling bepaalt 
in hoge mate het transmissiepotentieel van individuen binnen het infectieuze reservoir.
 Het begrijpen van vectorblootstelling is ingewikkeld, maar het kan eenvoudiger 
worden gemaakt door vectorblootstelling serologisch te bepalen. Ons werk in hoofdstuk 
3 was het eerste om de bruikbaarheid van antilichaamreacties op speekseleiwit (gSG6) 
van een malariamug te onderzoeken als een mogelijke indicator van heterogeniteit in 
vectorblootstelling. Een analyse zoals deze zou, in combinatie met infectiviteitsgegevens 
van voedingsexperimenten, kunnen worden gebruikt om heterogeniteit in transmissie op 
populatieniveau te beschrijven. 
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Belangrijke barrières voor een breder gebruik van voedingsexperimenten zijn de tijd en 
vaardigheid die het kost om de experimenten betrouwbaar uit te voeren. De grootste 
uitdaging hierbij is het aantonen van infecties in de muggen die gebruikt zijn bij de 
experimenten. In hoofdstuk 7 en 8, valideerden wij het gebruik van oocyst-prevalentie als 
een betrouwbare proxy voor het infectieus worden van muggen en vergeleken methoden 
die het mogelijk maken muggenbesmetting snel aan te tonen in voedingsexperimenten. 
Deze voedingsexperimenten zijn essentieel voor de evaluatie van op transmissie gerichte 
interventies; de ontwikkeling van deze interventies begint in het laboratorium. In hoofdstuk 
5, ontwikkelden we een variant op het standaard membraanvoedingsexperiment (standard 
membrane feeding assay; SMFA) dat grotere schaalbaarheid heeft door gebruikmaking van 
een objectief, op luminescentie gebaseerd eindpunt voor de beoordeling van het aantal 
muggeninfecties en de analyse van transmissiereducerende activiteit (TRA). Het gebruik van 
transgene parasieten zorgt ervoor dat dissectie van muggen niet meer nodig is. In hoofdstuk 
6 werd de luminescentie SMFA aangepast voor gebruik met een in ons laboratorium 
ontwikkelde parasietlijn, die geschikt is voor de screening van geneesmiddelen. We hebben 
aangetoond dat bepaalde medicijnen werkzame eigenschappen hebben, die niet eenvoudig 
kunnen worden gedetecteerd door in vitro testen van gametocyt dodende activiteit. De 
SMFA blijft bij geneesmiddelenevaluatie hiermee noodzakelijk.
 De latere hoofdstukken van dit proefschrift hadden als doel het menselijk infectievermogen 
te ontleden door rekening te houden met parasitaire en menselijke factoren die samen 
invloed hebben op de kans dat muggen besmet raken als ze malariageïnfecteerde mensen 
steken. De voornaamste factor hierbij is de gametocytdichtheid. Vanwege hun vaak zeer 
lage dichtheden is het vrijwel onmogelijk om door middel van microscopie het totale 
gametocytenreservoir te detecteren. Moleculaire testen laten zien dat infecties met 
submicroscopische gametocytdichtheden vaak infectieus zijn voor muggen; wiskundige 
modellen tonen daarnaast aan dat deze submicroscopische gametocytdichtheden relevant 
zijn voor de verspreiding van malaria op populatieniveau. In hoofdstuk 9 en 10 gebruikten we 
gezuiverde transgene mannelijke en vrouwelijke gametocyten om een  nieuwe kwantitatieve 
methode voor gametocyten te ontwikkelen, die in staat is de dichtheid van zowel mannelijke 
als vrouwelijke gametocyten te bepalen over het gehele biologisch plausibele bereik van 
infectiviteit. In hoofdstuk 9 hebben we aangetoond dat een nauwkeurig vastgestelde 
gametocytdichtheid sterk geassocieerd is met de kans dat muggen besmet raken en dat de 
geslachtsratio een relevante invloed heeft op deze associatie. In hoofdstuk 10, gebruikten 
we dezelfde methode om het effect van een gametocyt dodend geneesmiddel, primaquine, 
te onderzoeken in een klinisch onderzoek in Keniaanse kinderen. De moleculaire methoden 
die zijn beschreven in hoofdstuk 9 en 10 maken het mogelijk gametocytdichtheid, geslacht 
en infectiviteit in groot detail te bepalen.
 Naast gametocytdichtheid en -rijpheid, kunnen menselijke immuunreacties een 
doorslaggevende factor zijn bij malaria-overdracht naar muggen. De bepaling van 
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menselijke immuunreacties die de transmissie van malaria van mens naar mug remmen is 
van zeer groot belang bij de evaluatie van transmissieblokkerende vaccins. Zoals uitgebreid 
besproken in hoofdstuk 11, kunnen antistofreacties tegen de gametocyten / gameet-eiwitten 
Pfs48 / 45 en Pfs230 slechts ten dele natuurlijke transmissiereducerende immuniteit 
verklaren. Antistof-gemedieerde transmissiereducerende immuniteit kan aanwezig zijn 
in de afwezigheid of  aanwezigheid van antistoffen die specifiek zijn voor de eiwitten 
Pfs230 of  Pfs48 / 45. Ons werk in hoofdstuk 12 boekt een belangrijke stap voorwaarts 
in het begrijpen van de mechanismen van de transmissiereducerende immuniteit. In dit 
werk leveren we definitief  bewijs dat antistoffen voor Pfs48 / 45 en Pfs230, ontwikkeld 
na natuurlijke malariablootstelling, kunnen bijdragen aan het transmissieblokkerende 
fenotype. Ons werk levert sterke aanwijzingen op dat ook antistoffen die specifiek zijn voor 
onbekende eiwitten een rol spelen bij transmissiereducerende immuniteit. We toonden 
aan dat sera waaruit antistoffen tegen de belangrijkste epitopen van Pfs230 en Pfs48 / 
45 waren verwijderd, sterke transmissie-reducerende activiteit behielden. We toonden 
bovendien aan dat onbekende gametocyteiwitten herkend werden en dat deze herkenning 
geassocieerd was met functionele transmissiereducerende immuniteit, zowel in de SMFA 
als in membraanvoeding experimenten die uitgevoerd werden tijdens natuurlijk opgelopen 
malaria-infecties.
 Het terugdringen van de verspreiding van malaria kan versneld worden door interventies 
die specifiek gericht zijn op het infectieuze reservoir van malaria parasieten; bijvoorbeeld 
door de inzet van medicijnen of  vaccins die de menselijke infectiviteit verminderen. 
De opkomst van parasitaire stammen die resistent zijn tegen de beste beschikbare 
antimalariamiddelen, maakt het dringend noodzakelijk dat we het infectieuze reservoir 
voor malaria beter kunnen detecteren en bestrijden, om op deze manier de verspreiding van 
resistente parasieten te voorkomen die de malariacontrole wereldwijd bedreigen. 
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